Title of Invention	"LIPASE INHIBITOR COMPOUNDS"
Abstract	A B S T R A C T Abstract: The subject invention features compounds having the structure:, wherein X is O, S, CH2 or NR5 Y is O or S; R1 is H, substituted or unsubstituted C1C15 alkyl, C1-C15 alkylafyl, -C(O)OR4, -C(O)NR1R5, (I) -CR6R6.OR4,-CR6R6'OC(0)R4, - CR6R6 OC(O)NHR7, -C(O)NR10R11, -C(O)NRSR9, NR8R9, -N(R5)C(O)NHRS, or CH2R4 R2 is a substituted or unsubstituted, straight chain C1-C30 alkyl or branched C3 C30 alkyl, aryl, alkylaryl, arylalkyl, heteroarylalkyl or cycloalkyl, R3 is H or substituted or unsubstituted C1-C6 alkyl or C3-C10 cycloalkyl; R4 is H or a substituted or unsubstituted, straight chain or branched, (C6-C30 alkyl, aryl, CH2 aryl, aryl -C1-C15 alkyl, heteroaryl-C1-C15alkyl or C3-C10 cycloalkyl; R5 is H or a substituted or unsubstituted, straight chain or branched, C6-C30 alkyl, aryl C1-C30alkyl, heteroarylalkyl or cycloalkyl; R6 and R6' are each independently H, substituted or unsubstituted C1-C6 alkyl, dialkyl or C3-C10 cycloalkyl or together form a 3-7 membered ring system; R7 is 11 or substituted or unsubstituted C1 C12 alkyl or C3-C10 cycloalkyl; Rs and R9are each independently H, substituted or unsubstiluted C1-C6 alkyl, C1--C6 alkoxy, C1-C6 alkylaryl, or NR8R? together form a substituted piperazine or piperidine ring or a ilihydro-lH-isoquinoline ring system, or a specific enantiomer thereof, or a specific tautomer, or a pharmaceutically acceptable salt thereof and a method for treating diabetes or obesity by administering a therapeutically effective amount of the compounds of the invention.

Title of Invention

"LIPASE INHIBITOR COMPOUNDS"

Abstract

A B S T R A C T Abstract: The subject invention features compounds having the structure:, wherein X is O, S, CH2 or NR5 Y is O or S; R1 is H, substituted or unsubstituted C1C15 alkyl, C1-C15 alkylafyl, -C(O)OR4, -C(O)NR1R5, (I) -CR6R6.OR4,-CR6R6'OC(0)R4, - CR6R6 OC(O)NHR7, -C(O)NR10R11, -C(O)NRSR9, NR8R9, -N(R5)C(O)NHRS, or CH2R4 R2 is a substituted or unsubstituted, straight chain C1-C30 alkyl or branched C3 C30 alkyl, aryl, alkylaryl, arylalkyl, heteroarylalkyl or cycloalkyl, R3 is H or substituted or unsubstituted C1-C6 alkyl or C3-C10 cycloalkyl; R4 is H or a substituted or unsubstituted, straight chain or branched, (C6-C30 alkyl, aryl, CH2 aryl, aryl -C1-C15 alkyl, heteroaryl-C1-C15alkyl or C3-C10 cycloalkyl; R5 is H or a substituted or unsubstituted, straight chain or branched, C6-C30 alkyl, aryl C1-C30alkyl, heteroarylalkyl or cycloalkyl; R6 and R6' are each independently H, substituted or unsubstituted C1-C6 alkyl, dialkyl or C3-C10 cycloalkyl or together form a 3-7 membered ring system; R7 is 11 or substituted or unsubstituted C1 C12 alkyl or C3-C10 cycloalkyl; Rs and R9are each independently H, substituted or unsubstiluted C1-C6 alkyl, C1--C6 alkoxy, C1-C6 alkylaryl, or NR8R? together form a substituted piperazine or piperidine ring or a ilihydro-lH-isoquinoline ring system, or a specific enantiomer thereof, or a specific tautomer, or a pharmaceutically acceptable salt thereof and a method for treating diabetes or obesity by administering a therapeutically effective amount of the compounds of the invention.

Full Text	PANCREATIC LIPASE INHIBITOR COMPOUNDS. THEIR SYNTHESIS AND USE This application claims priority of U.S. Provisional Application No. 60/342,617, filed December 20, 2001, and U.S. Provisional Application No. 60/357,015, filed February 13, 2002, the entire contents of which are hereby incorporated by reference. Throughout this application, various publications are referenced by full citations. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to those skilled therein as of the date of the invention described and claimed herein. Background of the Invention During the last 20 years, obesity has become an increasingly common problem in the populations of developed countries. The increased incidence of obesity is partly due to the adoption of a westernised diet in many developed countries - which contains many foods with high fat and low fiber concentrations - and partly due to the lifestyle of westernized society. Obesity is known to increase the risk of contracting disorders such as diabetes, cardiovascular disease and hypertension. Pharmacological approaches to the treatment of obesity either try to increase the body's energy expenditure, thereby burning more fat, or reduce the body's energy intake. The latter approach has stimulated the development of a variety of drugs which attempt to reduce the body's ability to absorb fat. These drugs target the enzymes responsible for the digestion of fat in the human digestive cycle. The most important enzymes in the digestion of fat are hydrolytic enzymes. The most significant of these enzymes are lipases, pancreatic lipase in particular. Orlistat, a derivative of lipstatin, a lipase inhibitor, is disclosed as an anti-obesity drug in European Patent Application No. EP129748. Other lipase inhibitors are disclosed in PCT International Publication Nos. WO 00/40569 and WO 00/40247, respectively. Summary of the Invention The subject invention provides a compound having the structure: wherein, X is O, S, CH2 or NR5; Y is O or S; R! is H, substituted or unsubstituted d-Cis alkyl, CrC8 alkylaryl, -C(0)OR4, -C(0)NR4R5, -CReRe-ORA, -CReReOC(O)R4, -CR6R6-OC(O)NHR7l -C(O)NR10Rn, -C(O)NR8R9 NR8R9, -N(R5)C(O)NHR5, or CH2R4; R2 is a substituted or unsubstituted, straight chain CrCao alkyl or branched C3-C30 alkyl, aryl, alkylaryl, arylalkyi, heteroarylalkyl or cycloalkyl; and, R3 is H or substituted or unsubstituted CrCe alkyl or C3-Cio cycloalkyl, wherein R4 is H or a substituted or unsubstituted, straight chain or branched, C6-C30 alkyl, aryl, -CH2-aryl, aryl -CrC3o alkyl, heteroaryl-Ci-C30 alkyl or C3-Cio cycloalkyl; Rs is H or a substituted or unsubstituted, straight chain or branched, Ce-C3o alkyl, aryl Ci-C30alkyl, heteroarylalkyl or cycloalkyl; Re and R6- are each independently H, substituted or unsubstituted d-C6 alkyl, dialkyl or C3-Ci0 cycloalkyl or together form a 3-7 membered ring system; R7 is H or substituted or unsubstituted Ci-Ci2 alkyl or C3- C10 cycloalkyl; and R8 and Rg are each independently H, substituted or unsubstituted d-Ce alkyl, CrC6 alkoxy, CrC6 alkylaryl, or NR8Rg together form a substituted piperazine or piperidine ring or a dihydro-1H-isoquinoline ring system, or a specific enantiomer thereof, or a specific tautomer, or a pharmaceutically acceptable salt thereof. The subject invention also provides a compound having the structure: Q wherein, Rio is H or substituted or unsubstituted Ci-Ci5 alkyl, d-Ci5 alkylaryl, or -C(O)R14, wherein R14 is hydroxyl, or a substituted or unsubstituted CrCso alkyl, alkylamino, dialkylamino, alkoxy, benzyloxy, cycloalkyl, alkylheteroaryl, alkylaryl, or a heterocyclic, heteroaryl or aryl ring; Rn is hydrogen or methyl; R12 is hydrogen or fert-butyl; and Ria is hydrogen or -C(O)ZRi5, wherein Z is CH2, O or N and R15 is substituted or unsubstituted CrCi5 alkyl or aryl. The subject invention also provides a method for treating obesity in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of a compound of the invention so as to thereby treat obesity in the subject. The subject invention also provides a method for treating diabetes in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of a compound of the invention so as to thereby treat diabetes in the subject. The subject invention also provides a method of inhibiting the hydrolytic activity of pancreatic lipase enzymes in a cell, comprising contacting the cell with an amount of a compound of the invention which is effective in inhibiting the hydrolytic activity of pancreatic lipase enzymes. Detailed Description The subject invention provides compounds having the structure: o wherein, X is O, S, CH2 or NR5; YisOorS; RI is H, substituted or unsubstituted CrCi5 alkyl, CrC8 alkylaryl, -C(O)OR4l -C(O)NR4R5, -CR6R6-OR4) -CR6R6'OC(O)R4, -CR6R6'OC(O)NHR7, -C(O)NRioRn, -C(O)NR8R9NR8R9, -N(R5)C(O)NHR5l or CH2R4; R2 is a substituted or unsubstituted, straight chain Ci-C30 alkyl or branched C3-C3o alkyl, aryl, alkylaryl, arylalkyi, heteroarylalkyl or cycloalkyi; and RS is H or substituted or unsubstituted d-Ce alkyl or Cs-Cio cycloalkyi, wherein R4 is H or a substituted or unsubstituted, straight chain or branched, C6-C30 alkyl, aryl, -CH2-aryl, aryl -CrC3oalkyl, heteroaryl-CrCao alkyl or C3-Cio cycloalkyi; R5 is H or a substituted or unsubstituted, straight chain or branched, C6-C3o alkyl, aryl CrC30alkyl, heteroarylalkyl or cycloalkyi; R6 and R6- are each independently H, substituted or unsubstituted CrC6 alkyl, dialkyl or C3-Ci0 cycloalkyi or together form a 3-7 membered ring system; R7 is H or substituted or unsubstituted CrCi?. alkyl or C3- Cio cycloalkyi; and R8 and R9 are each independently H, substituted or unsubstituted CrC6 alkyl, d-Ce alkoxy, CrC6 alkylaryl, or NRaRg together form a substituted piperazine or piperidine ring or a dihydro-1 H-isoquinoline ring system, or a specific enantiomer thereof, or a specific tautomer, or a pharmaceutically acceptable salt thereof. In one embodiment, the compound has the structure: O wherein, X is O, S or NR5; Y is O or S; R1 is H, -C(O)OR4, -C(O)NR4R5, -CR6R6'OR4, -CR6R6'OC(O)R4, -CR6R6OC(O)NHR7, or CHaR-iI Ra is a substituted or unsubstituted, straight chain or branched, C6-C3o alkyl, arylalkyl, heteroarylalkyl or cycloalkyi; and R3 is H or substituted or unsubstituted Ci-C6 alkyl or cycloalkyi, wherein, R4 is H or a substituted or unsubstituted, straight chain or branched, Ce-Cao alkyl, arylalkyl, heteroarylalkyl or cycloalkyi; RS is H or a substituted or unsubstituted, straight chain or branched, C$-C30 alkyl, arylalkyl, heteroarylalkyl or cycloalkyi; Re and R6' are each independently H, substituted or unsubstituted Cr.CB alkyl, dialkyl or cycloalkyi or together form a 3-7 membered ring system; and R7 is H or substituted or unsubstituted CrCi2 alkyl or cycloalkyi. In a further embodiment, the compound has the structure: o wherein, X is O, S or NR5; Ri is H, -C(O)OR4l -C(O)NR4R5, -CR6R6'OR4, -CR6R6OC(O)R4, -CR6R6'OC(O)NHR7, or CH2R4; R2 is a substituted or unsubstituted, straight chain or branched C6-C3o alkyl, arylalkyl, heteroarylalkyl or cycloalkyi; and R3 is H or substituted or unsubstituted CrCe alkyl or cycloalkyi, wherein, R4 is H or a substituted or unsubstituted, straight chain or branched, C6-C30 alkyl, arylalkyl, heteroarylalkyl or cycloalkyi; R5 is H or a substituted or unsubstituted, straight chain or branched, Ce-Cso alkyl, arylalkyl, heteroarylalkyl or cycloalkyi; R6 and R6' are each independently H, substituted or unsubstituted CrC6 alkyl, dialkyi or cycloalkyi or together form a 3-7 membered ring system; and R7 is H or substituted or unsubstituted CrCi2 alkyl or cycloalkyi. In a further embodiment of the above compound, X is O or NR5; R! is -C(O)O-(C6-C30) alkyl, -C(O)NH-(C6-C30) alkyl or -C(0)OCH2(C6H5); R2 is C6-C30 alkyl; and R3 is CrC6 alkyl. In a further embodiment, R3 is H or CH3. In a further embodiment, X is O. In a further embodiment, R3 is methyl. In a further embodiment, X is N. In a further embodiment, R3 is methyl. In a further embodiment, the compound has the structure: o SN XR2 wherein, Y is 0 or S; Ri is H, -(CH2)rCH3> -CH(CH3)2, -CH(CH3)CH2C(CH3)3, -CH(CH3)(CH2)3C(=CH2)CH3, -CH(CH3)(CH2)3C(CH3)2OC(O)CH3, -CH(CH3)[CH2]3C(CH3)20CH3l -CHs(C6H5), -C(O)OH, -C(O)NH(CH2)tCH3l-C(O)O(CH2)uCH3, -C(O)OCH[(CH2)3CH3]2)-C(O)NH(CH2)VCH3, -C(0)N(CH3)2, -C(O)NHCH2(C6H5), -C(0)NHCH2(C5H4N),-C(0)N[(CH2)3CH3]2) -C(0)N[(CH2)5CH3]2, -C(0)N[(CH2)7CH3]2) -C(O)NH(C6Hn), -C(O)(NC4H8N)CH2(C6H5),-C(O)(NC5H9)CH2(C6H5), -C(0)NH(CH2)30(C6H5),-C(O)NHCH[(CH2)3CH3]2, -C(0)NH(CH2)3N(CH3)2,-C(O)NHCH2C(0)OCH2(C6H5), -C(0)N(CH3)CH2(C5H3N[CH3])1-C(0)NH(CH2)2(C5H4N)) -C(0)N(CH2CH3)(CH2)2(C5H4N),-C(0)NHCH2(C4H30), -C(O)(NC4H8N)[CH2]2(NC5H10),-C(O)NHCH2CH(CH3)2) -C(0)NHCH2(C5H4N),-C(0)NHCH2C(CH3)3, -C(O)(NC4H8N)CH2C(O)NHCH(CH3)2,-C(O)(NC9H8)[OCH3]2, -C(0)NHCH2(C6H3[OCH3]2), -C(O)NHCH2(C7H5O2), -C(O)NH(CH2)2O(C6H5),-C(O)NH(CH2)2OCH3, -C(0)NH(CH2)3OCH3, -C(O)NH(CH2)4(C6H5), or -C(0)NH(CH2)3(C6H5); r is an integer from 1 to 15; s is an integer from 0 to 6; t is an integer from 0 to 6; u is an integer from 3 to 8; v is an integer from 5 to 15; XR2 is -(CH2)nCH3, -O(CH2)mCH3) -OCH(CH3)2, -OCH(CH3)(CH2)5CH3, -OCH2CH(CH3)2, -O(CH2)2OCH3) -0(CH2)2OCH2(C6H5), -0(CH2)P(C6H5), -OCH2(C6H4[(CH2)3CH3]), -0(C6H4[(CH2)3CH3]), -O(CH2)2(C6H4[CH3]), -O(CH2)3OCH2(C6H5), -O(CH2)4OCH2(C6H5), -N([CH2]7CH3)C(O)NH(CH2)7CH3, -N([CH2]6CH3)C(O)NH(CH2)6CH3l-NH(CH2)qCH3, -NH(C6H4)0(C6H5), -N(CH3)(CH2)5CH3, -NHCH[(CH2)3CH3]2, -NHCH(CH3)[CH2]5CH3, or -N([CH2]7CH3)2; n is an integer from 6 to 15; m is an integer from 1 to 15; p is an integer from 0 to 6; q is an integer from 6 to 15; and R3 is H, -CH3 or -CH2OCH3. In a further embodiment, the compound has the structure: o _ XR2 wherein, Y is O or S; Ri is H, -(CH2)3CH3) -{CH2)5CH3, -(CH2)6CH3) -(CH2)7CH3, -(CH2)9CH3l -(CH2)nCH3> -CH(CH3)2, -CH(CH3)CH2C(CH3)3, -CH(CH3}(CH2)3C(=CH2)CH3, -CH(CH3)(CH2)3C(CH3)2OC(O)CH3, -CH(CH3}[CH2]3C(CH3)20CH3, -CH2(C6H5), -(CH2)2(C6H5), -(CH2)3(C6H5), -(CH2)4(C6H5), -(CH2)5(C6H5), -C(O)OH, -C(O)NHCH3, -C(O)NHCH2CH3, -C(0)NH(CH2)3CH3l -C(O)OCH2(C6H5), -C(O)O(CH2)SCH3, -C(O)O(CH2)6CH3, •€(0)O(CH2)7CH3l-C(O)OCH[(CH2)3CH3]2, -C(O)NH(CH2)5CH3> -C(O)NH(CH2)7CH3l -C(0)NH(CH2)9CH3, -C(0)NH(CH2)nCH3) -C(0}NH(CH2)i5CH3, -C(0)N(CH3)2l -C(O)NHCH2(C6H5), -C(O)NHCH2(C5H4N),-C(O)N[(CH2)3CH3]2l -C{0)N[(CH2)5CH3]2, -C(0)N[(CH2)7CH3]2, -C(O)NH(CeHn), -C(0)(NC4HBN)CH2{C6H5),-C(0)(NC5H9)CH2(C6H5), -C(O)NH(CH2)3O(C6H5)I-C(0)NHCH[(CH2)3CH3]2l -C(O)NH(CH2)3N(CH3)2)-C(O)NHCH2C(O)OCH2(C6H5), -C(0)N(CH3)CH2(C5H3N[CH3]))-C(0)NH(CH2)2(C5H4N)I -C(O)(NC4H8N)[CH2l2(NC5Hio),-C(0)NHCH2CH(CH3)2l -C(O)NHCH2(C5H4N)!-C(O)NHCH2C(CHS.)3) -C(O)(NC4H8N)CH2C(0)NHCH(CH3)2, -C(O)(NC9H8)[OCH332, -C(O)NHCH2(C6H3[OCH3]2), -C(O)NHCH2(C7H5O2), -C(O)NH(CH2)20(C6H5)1 -C(O)NH(CH2)2OCH3l -C(0)NH(CH2)3OCH3l -C(O)NH(CH2)4(C6H5), or -C(0)NH(CH2)3(C6H5); XR2 is -(CH2)6CH3, -(CH2)i0CH3l -(CH2)i4CH3, -0(CH2)3CH3l -0(CH2)5CH3) -O(CH2)6CH3, -0(CH2)7CH3, -0(CH2)9CH3, -CKCHsOnCHa, -O(CH2)15CH3, -OCH(CH3)2) -OCH(CH3)(CH2)5CH3l -OCH2CH(CH3)2) -O(CH2)2OCH3, -0(CH2)2OCH2(C6H5), -0(CH2)4(C6H5), -O(CH2)3(C6H5), -0(CH2)2(C6H5), -0(CeH5), -OCH2(C6H5), -OCH2(C6H4[(CH2)3CH3]),-0(C6H4[(CH2)3CH3]), -0(CH2)J(C6H4[CH3]),-0(CH2)30CH2(C6H5), -O(CH2)4OCH2(C6H5), -N([CH2]7CH3)C(O)NH(CH2)7CH3> -N([CH2]6CH3)C(0)NH(CH2)6CH3,-NH(CH2)6CH3) -NH(CH2)7CH3l -NH(CH2)nCH3) -NH(CH2)i3CH3, -NH(CH2)i5CH3) -NH(C6H4)0(C6H5), -N(CH3)(CH2)5CH3, -NHCH[(CH2)3CH3]2, -NHCH(CH3)[CH2]5CH3) or -N([CH2]7CH3)2; and R3 is H, -CH3 or -CH2OCH3. In a further embodiment, the compound is selected from the group consisting of: 6-Heptyl-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one; 6-Hexyl-2-octyloxy-thieno[2,3-d][1)3]oxazin-4-one; 2-Octyloxy-6-(1)3l3-trimethyl-butyl)-thieno[2,3-d][1,3]oxazin-4-one; 6-Butyl-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one; 6-Heptyl-2-octylamino-thieno[2,3-d][1,3]oxazin-4-one; 6-Butyl-2-octylamino-thieno[2,3-d][1,3]oxazin-4-one; 6-Benzyl-2-octylamino-thieno[2,3-d][1,3]oxazin-4-one; 6-Heptyl-2-undecyl-thieno[2,3-d][1,3]oxazin-4-one; 6-(5-Methoxy-1,5-dimethyl-hexyl)-2-octyloxy-thieno[2,3-d][1,3]oxazin-4- one; 6-( 1.5-Dimethyl-hex-4-enyl)-2-octyloxy-thieno[2:3-d][1,3]oxazin-4-one; 6-(1,5-Dimethyl-hex-5-enyl)-2-octyloxy-thieno[2,3-d][1,31oxazin-4-one; Trifluoro-acetic acid 1,1-dimethyl-5-(2-octyloxy-4-oxo-4H-thieno[2,3- d][1,3]oxazin-6-yl)-hexyl ester; 2-(2-Benzyloxy-ethoxy)-6-decyl-thieno[2,3-d][1,3]oxazin-4-one; 6-Heptyl-5-methyl-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one; 6-Methyl-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one; 2-Octyloxy-6-phenethyl-thieno[2,3-d][1,3]oxazin-4-one; 2-Octyloxy-6-(3-phenyl-propyl)-thieno[2,3-d][1,3]oxazin-4-one; 2-Octyloxy-6-(4-phenyl-butyl)-thieno[2,3-d][1,3]oxazin-4-one; 2-Octyloxy-6-(5-phenyl-pentyl)-thieno[2,3-d][1,3]oxazin-4-one; 6-Decyl-2-(2-methoxy-ethoxy)-thieno[2,3-d][1,3]oxazin-4-one; 2-(4-Butyl-phenoxy)-6-decyl-thieno[2,3-d][1,3]oxazin-4-one; 2-(3-Benzyloxy-propoxy)-6-decyl-thieno[2,3-d][1,3]oxazin-4-one; 2-(3-Benzyloxy-butyloxy)-6-decyl-thieno[2,3-d][1,3]oxazin-4-one; 6-lsopropyl-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one; 6-Octyl-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one; 6-Dodecyl-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one; 2-Benzyloxy-6-Decyl-thieno[2,3-d][1,3]oxazin-4-one; 2-(4-Butylbenzyloxy)-6-Decyl-thieno[2,3-d][1j3]oxazin-4-one; 6-Decyl-2-(2-p-tolyl-ethoxy)-thieno[2,3-d][1,3]oxazin-4-one; 6-Decyl-2-phenethyloxy-thieno[2,3-d][1,3]oxazin-4-one; 3-Methyl-6-octyl-2-octyloxy-5H-thieno[2,3-b]pyridin-4-one; 2-Butoxy-6-octyl-5H-thieno[2,3-b]pyridin-4-one; 2-Hexyloxy-6-octyl-5H-thieno[2,3-b]pyridin-4-one; 2-Dodecyloxy-6-octyl-5H-thieno[2,3-b]pyridin-4-one; 6-Decyl-2-phenoxy-5H-thieno[2,3-b]pyridinr4-one; 2-Decyloxy-6-octyl-5H-thieno[2,3-b]pyridin-4-one; e-Benzyl^-octyloxythieno^.S-cdll.Sloxazin^-one; 6-Decyl-2-octyloxythienot2,3-d][1,3]oxazin-4-one; 6-Decyl-2-(1 -methylheptyloxy)thieno[2,3-cd[1,3joxazin-4-one; 6-Heptyl-2-(1 -methylheptyloxy)thieno[2,3-c(l[1,3]oxazin-4-one; e-Decyl-2-(4-phenylpropoxy)thieno[2,3-c(\|[1,3]oxazin-4-one; and 6-Decyl-2-(4-phenylbutoxy)thieno[2,3- !3 The subject invention also provides compounds having the structure: o wherein, RIO is H or substituted or unsubstituted CrC15 alkyl, CrC15 alkylaryl, or -C(O)Ri4, wherein R^ is hydroxyl, or a substituted or unsubstituted CrC30 alkyl, alkylamino, dialkylamino, alkoxy, benzyloxy, cycloalkyl, alkylheteroaryl, alkylaryl, or a heterocyclic, heteroaryl or aryl ring; Rn is hydrogen or methyl; Ria is hydrogen or te/t-butyl; and Ria is hydrogen or -C(O)ZR15, wherein Z is CH2, O or N and RIB is substituted or unsubstituted Crds alkyl or aryl. The subject invention also provides a method for treating obesity in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of a compound of the invention so as to thereby treat obesity in the subject. The subject invention also provides a method for treating diabetes in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of a compound of the invention so as to thereby treat diabetes in the subject. The subject invention also provides a method of inhibiting the hydrolytic activity of pancreatic lipase enzymes in a cell, 'comprising contacting the cell with an amount of a compound of the invention which is effective in inhibiting thb hydrolytic activity of pancreatic lipase enzymes. The above method may contact the cell either in vitro or in vivo. The subject invention also provides a pharmaceutical composition comprising the a compound or the invention and a pharmaceutically acceptable carrier. In one embodiment, the pharmaceutical composition is formulated for oral, topical, parenteral, or nasal administration. , The subject invention also provides a process for the manufacture of a pharmaceutical composition comprising admixing a compound of the invention with a pharmaceutically acceptable carrier. The subject invention also provides an article of manufacture comprising packaging material; the above pharmaceutical composition; and , instructions for use of the pharmaceutical composition in the treatment of obesity. The subject invention also provides a process of manufacturing a compound having the structure: N XR2 wherein, X is 0, S, CH2 or NR6; RI is H, substituted or unsubstituted CrCi5alkyl, CrC6 alkylaryl, -C(0)OR4, -C(O)NR4R5, -CR6R6.OR4, -CR6R6.OC(O)R4, -CReR6OC(O)NHR7, -C(O)NR8R9, - -N(R5)C(0)NHR5, or CH2R4; R2 is a substituted or unsubstituted, straight chain CrCso alkyl or branched C3-C30 alkyl, aryl, alkylaryl, arylalkyi, heteroarylalkyi or cycloalkyi; R3 is H or substituted or unsubstituted d-C6 alkyl or cycloalkyi; R4 is H or a substituted or unsubstituted, straight chain or branched, Ce-Cso alkyl, aryl, -CH2-aryl, arylalkyi, heteroarylalkyi or cycloalkyi; R5 is H or a substituted or unsubstituted, straight chain or branched, Ce-Cso alkyl, arylalkyi, heteroarylalkyi or cycloalkyi; R6 and R6* are each independently H, substituted or unsubstituted CrC6 alkyl, dialkyi or cycloalkyi or together form a 3-7 membered ring system; R7 is H or substituted or unsubstituted CrC12 alkyl or cycloalkyi; R8 and R9 are each independently H, substituted or unsubstituted CrC6 alkyl, C-i-Ce alkoxy, d-C6 alkylaryl, or NR8R9 together form a substituted piperazine or piperidine ring or a dihydro-1 H-isoquinoline ring system, comprising (a) reacting o NC and Rin the presence of sulfur, a base and solvent to produce: o H (b) reacting the product of step (a) with 0 c in the presence of a base to produce: (c) reacting the product of step (b) with trifluoroacetic acid (TFA) in the presence of solvent to produce: Q (d) reacting the product of step (c) with SOCI2 in the presence of solvent to produce the compound. In one embodiment of the above process, the base in step (a) is triethyl amine and the solvent is dimethylformamide (DMF). In a further embodiment, the solvent in step (c) is dichloromethane, In a further embodiment, the solvent in step (d) is pyridine:CH2CI2. The subject invention also provides a compound produced by the above process. The subject invention also provides the use of the compounds of the invention for manufacturing a medicament useful for treating obesity in a subject. The subject invention also provides the use of the compounds of the invention for manufacturing a medicament useful for treating diabetes in a subject. The subject invention also provides the use of the compounds of the invention for manufacturing a medicament useful for inhibiting the hydrolytic activity of pancreatic lipase enzymes in a cell. The inhibition of the cell may be effected either in vitro or in vivo. The subject invention also provides the above compounds, wherein any heterocyclic or heteroaryl ring, if present, is a piperazine, piperidine, (1,4)diazepan, pyrazine, pyridine, pyrrolidine, pyrazole, pyrimidine, thiophene, imidazole, azetidine, pyrrole, benzothiazole, benzodioxolane, dithiolane, oxathiine, imidazolidine, quinoline, isoquinoline, dihydroisoquinoline, indole, isoindole, triazaspiro[4.5]decane, morpholine, furan or an isothiazole ring. The subject invention also provides any of the above compounds, wherein any substituent, if present, is halogen, hydroxyl, straight chain (CrC3o)alkyl, branched chain (C3-C30)alkyl, (C3-Ci0)cycloalkyl, straight chatn(Ci C30)alkylcarbonyloxy, branched chain (C3-C3o)alkylcarbonyloxy, arylcarbonyloxy, straight chain(Ci-C3o)alkoxycarbonyloxy, branched chain(C3- C3o)alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, straight chain(d- C3o)alkylcarbonyl, branched chain (C3-C3o)alkylcarbonyl, straight chain (d- C30)alkoxycarbonyl, branched chain (C3-C3o)alkoxycarbonyl, aminocarbonyl, straight chain . (d-CsoJalkylthiocarbonyl, branched chain (C3- C3o)alkylthiocarbonyl, straight chain (C-rC3o)alkoxyl, branched chain (Cr C3o)alkoxyl, phosphate, phosphonato, cyano, amino, straight chain (Cr C3o)alkylamino, branched chain (C3-C30)alkylamino, straight chain (d- C3o)dialkylamino, branched chain (C3-C3o)dialkylamino, arylamino, diarylamino, straight chain (Ci-C30)alkylarylamino, branched chain (Cs-C^alkylarylamino, acylamino, straight chain (CrC3o)alkylcarbonylamino, branched chain (C3- C3o)alkylcarbonylamino, arylcarbonylamino, carbamoyl, ureido, amidino, imino, sulfhydryl, straight chain (Ci-C30)alkylthio, branched chain (C3-C30)alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, azido, 4-10 membered heterocyclyl, straight chain (d- C30)alkylaryl, branched chain (C3-Cx)alkylaryl, benzo(1,3)dioxole, or an aromatic or 5-6 membered heteroaromatic moiety, which substituent may be further substituted by any of the above. The number of carbons when represented as "(CrC30)" or "(C3-C3o)M is intended to mean any incremental whole number between 1 and 3 and 30, e.g. 1, 2, 3, 4, 5 ... or 30. Additional embodiments of the compounds of this invention are described below. Entry structure MW k 0-3.S-1 Ymax % inhibit MP 399.5 CH, H.C 455.6 511.7 -o V 393.6 Crt, 429.! 0.649 485.7 541.8 0.779 H,C CH, 415.E 1.052 451J 0.924 0.286 58.5-60.2 10 rY 423J 1.349 11 PH 339.4 0.547 12 381.5 0.438 47.5-48.0 13 583.8 0.414 14 555.7 0.459 15 450.', 1.548 16 OH, 428.6 1.711 153.5-154.Q 17 414.5 1,74 18 449.7 1.036 18.03% 152.0-152.8 19 :«, p 506.6 0.981 20 450. 0.922 21 H.I 427.6 1.079 22 CH, 365.5 0.537 23 295.4 0.893 24 505.8 1.849 137.1-138.C 25 533.8 1.629 145.0-145.8 26 561.9 1.709 146.3-147.0 •Vv 27 421.6 2.577 28 477; 0.998 29 505.8 0.797 •A* 30 61.9 0.433 31 351.5 0.777 152.5-158 32 , f 393.6 2.447 33 rNH CH, 365.5 0.547 34 ^ H" 428.6 0.864 35 428.6 1.544 148-150 36 449.7 CH, 0.146 0.616 514.7 0.574 0.211 193.5-195 (decomp) p o CO T— CM CD O) CO co CM O> CO CO in CO in CM I-; CD en co O i— T— d r-. cd 01 oi n 06 oco oino CO in in •* CM CM d CO CM 00 in CM coo en8 d in at •>• CO co CO or-. iv CD r-. CO CO CM coq d cq co 47 CM, 449.7 0.191 0.943 48 485.6 0.440 147-149 49 456.6 0.022 50 442.6 0.719 51 CH, H3C 470.6 0.012 52 417.5 1.257 53 517. 0.166 ,CH, 54 393.6 0.702 55 428. 0.754 56 444.6 0.114 57 K,C 0 414.5 0.070 86-88 58 407.6 0.723 173-174.5 59 442.6 0.222 136-138 60 540.8 0.013 61 378.6 0.247 0.460 89-91 62 370.5 0.103 1.901 123.0-124.0 63 336.5 0.074 10.091 93.0-94.0 64 505.7 0.176 3.917 65 ,-CH, 513.7 0.284 0.339 77-80 66 Hfl fiV^O K.C-O" 487.6 1.027 0.118 159.0-163, 67 405.7 0.064 10.973 oil 68 ,CM, 379.6 5.825 0.020 78.94% oil 69 H,o 471.6 1.137 0.112 149-152 70 ,« -^ 457.6 1.999 0.140 71 428.6 0.086 H,C O 14.657 72 395.5 1.102 0.185 H.O-0 73 Y 409.i 0.794 1.594 74 393.6 0.422 0.982 75 n,c 337.5 2.219 0.054 oil 76 H3C 323.5 1.288 0.161 oil 77 371.5 0.392 0.482 oil 78 379.6 1.315 0.126 17.86% oil 79 469.7 69.49% 153-154 80 455.6 66.27% 139-141 81 391.6 66.46% oil 82 491.6 84.90% oil 83 o H.C-0 423.6 36.93% Oil 84 365.5 3.033 0.029 71.26% Oil 85 393.6 96.13% oil 86 421.6 73.58% oil 87 407.6 27.91% 36 88 449.7 74.21% 89 OY"-^—^C c«» 429.5 -14.14% oil 90 421.7 CM. 15.03% oil 91 379.6 12.44% Oil 92 397.6 O CH, oil 93 411.6 oil 94 H.C 365. 83.03% oil 95 337.5 60.26% oil 96 367.5 38-41 97 443.6 oil 98 H,C 441.6 oil 99 H.C 427.6 oil 100 449.7 Oil 101 yo o / 357.5 oil 102 441.6 55-58 10C 385.! oil HO' 1.1. ou 601- 801 901- 9'668 JO I. 9'66e 'HO' 113 429,5 K,C O 114 •0 / Hi 395.5 '-3 "k" and "Ymax" in the above table correspond to values inn the equation appearing on page 159. All compounds listed as oils were oils at room temperature. The language "therapeutically effective amount" of the compounds of the invention, described infra, refers to that amount of a therapeutic compound necessary or sufficient to perform its intended function within a mammal. An effective amount of the therapeutic compound can vary according to factors such as the amount of the causative agent already present in the mammal, the age, sex, and weight of the mammal, and the ability of the therapeutic compounds of the present invention to affect the desired result in the mammal. One of ordinary skill in the art would be able to study the aforementioned factors and make a determination regarding the effective amount of the therapeutic compound without undue experimentation. An in vitro or in vivo assay also can be used to determine an "effective amount" of the, therapeutic compounds described infra. The ordinarily skilled artisan would select an appropriate amount of the therapeutic compound for use in the aforementioned assay or as a therapeutic treatment. A therapeutically effective amount preferably diminishes at least one symptom or effect associated with the disorder being treated by at least about 20%, (more preferably by at least about 40%, even more preferably by at least about 60%, and still more preferably by at least about 80%) relative to untreated subjects. Assays can be designed by one skilled in the art to measure the diminishment of such symptoms and/or effects. Any art recognized assay capable of measuring such parameters are intended to be included as part of this invention. The term "animal" includes any organism with adenosine receptors. Examples of animals include yeast, mammals, reptiles, and birds. It also includes transgenic animals. The term "mammal" is art recognized and is intended to include an animal, more preferably a warm-blooded animal, most preferably cattle, sheep, pigs, horses, dogs, cats, rats, mice, and humans. Mammals susceptible to obesity associated disorders are included as part of this invention. 33 The term "alky!" refers to the radical of saturated aliphatic groups, including straightchain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. In preferred embodiments, a straight chain or branched chain alkyl has 30 or fewer carbon atoms in its backbone (e.g., Ci-C30 for straight chain, C3-C3o for branched chain), and more preferably 20 or fewer. Likewise, preferred cycloalkyls have from 4-10 carbon atoms in their ring structure, and more preferably have 5, 6 or 7 carbons in the ring structure. The term "substituted alkyl", refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. It will be understood by those skilled in the art that the moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate. Cycloalkyls can be further substituted, e.g., with the substituents described above. An "alkylaryl" moiety is an alkyl substituted with an aryl (e.g., phenylmethyl (benzyl)). The term "alkyl" also includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond respectively. The term "aryl" as used herein, refers to the radical of aryl groups, including 5- and 6-membered single-ring aromatic groups that may include from zero to four heteroatoms, for example, benzene, pyrrole, furan, thiophene, imidazole, benzoxazole, benzothiazole, triazole, tetrazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine, and the like. Aryl groups also include polycyclic fused aromatic groups such as naphthy', quinolyi, indolyl, and the like. Those aryl groups having heteroatoms in the ring structure may also be referred to as "aryl heterocycles", "heteroaryls" or ' heteroaromatics". The aromatic ring can be substituted at one or more ring positions with such substituents as described above, as for example, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyioxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyi, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (incUding alkylcarbonylamino, arylcarbonylamino, carbamoyi and ureido), amidino, irruno, sulfhydryl, alkylthio, arylthio, thiocarboxylate, suifates, sulfonato, sulfamoyl, suifonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. Aryl groups can also be fused or bridged with alicyclic or heterocyclic rings which are not aromatic so as to form a polycycle (e.g., tetralin). The terms "alkenyl" and "alkynyl" refer to unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond respectively. For example, the invention contemplates cyano and propargyl groups. Unless the number of carbons is otherwise specified, "lower alky!" as used herein means an alkyl group, as defined above, but having from one to ten carbons, more preferably from one to six carbon atoms in its backbone structure, even more preferably one to three carbon atoms in its backbone structure. Likewise, "lower alkenyl" and "lower alkynyl" have similar chain lengths. The terms "alkoxyalkyl", "polyaminoalkyl" and "thioalkoxyalkyl" refer to alkyl groups, as described above, which further include oxygen, nitrogen or sulfur atoms replacing one or more carbons of the hydrocarbon backbone, e.g., oxygen, nitrogen or sulfur atoms. The terms "poiycyclyl" or "polycyclic radical" refer to the radical of two or more cyclic rings (e.g., cycloalkyls, cycloalkenyls, c.ycloalkynyls, aryls and/or heterocyclyls) in which two or more atoms are common to two adjoining rings, e.g., the rings are "fused rings". Rings that are joined through non-adjacent atoms are termed "bridged" rings. Each of the rings of the polycycle can be substituted with such substituents as described above, as for example, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylarnino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkyl, alkylaryl, or an aromatic or heteroaromatic moiety. The term "heteroatom" as used herein means an atom of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, sulfur and phosphorus. i" The term "heterocycle" or "heterocyclic system" as used herein is intended to mean a stable 5, 6 or 7-membered monocyclic or 7, 8, 9, 10 or 11- membered bicyclic heterocyclic ring which is saturated or partially unsaturated. The terms "carbocyclic" or "heterocyclic" further include spiro compounds, which denote a bicyclic compound in which the two rings have one atom in common and the atom may be carbon or a heteroatom. The term "amino acids" includes naturally and unnaturally occurring amino acids found in proteins such as glycine, alanine, valine, cysteine, leucine, isoleucine, serine, threonine, methionine, glutamic acid, aspartic acid, glutamine, asparagine, lysine, arginine, proline, histidine, phenylalanine, tyrosine, and tryptophan. Amino acid analogs include amino acids with lengthened or shortened side chains or variant side chains with appropriate functional groups. Amino acids also include D and L stereoisomers of an amino acid when the structure of the amino acid admits of stereoisomeric forms. The term "dipeptide" includes two or more amino acids linked together. Preferably, dipeptides are two amino acids linked via a peptide linkage. Particularly preferred dipeptides include, for example, alanine-alanine and glycinealanine. It will be noted that the structure of some of the compounds of this invention includes asymmetric carbon atoms and thus occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. All such isomeric forms of these compounds are expressly included in this invention. Each stereogenic carbon may be of the R or S configuration. It is to be understood accordingly that the isomers arising from such asymmetry (e.g., all enantiomers and diastereomers) are included within the scope of this invention, unless indicated otherwise. Such isomers can be obtained in substantially pure form by classical separation techniques and by stereochemically controlled synthesis. The invention further pertains to pharmaceutical compositions for treating obesity and obesity associated disorders in a mammal. The pharmaceutical composition includes a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. It is to be understood, that all of the compounds described below are included for therapeutic treatment. It is to be further understood that the compounds of the invention can be used alone or in combination with other compounds of the invention or in combination with additional therapeutic compounds, such as antibiotics, antiinflammatories, or anticancer agents, for example. The term "antibiotic" is art recognized and is intended to include those substances produced by growing microorganisms and synthetic derivatives thereof, which eliminate or inhibit growth of pathogens and are selectively toxic to the pathogen while producing minimal or no deleterious effects upon the infected host subject. Suitable examples of antibiotics include, but are not limited to, the principle classes of aminoglycosides, cephalosporins, chloramphenicols, fuscidic acids, macrolides, penicillins, polymixins, tetracyclines and streptomycins. The term "antiinflammatory" is art recognized and is intended to include those agents which act on body mechanisms, without directly antagonizing the causative agent of the inflammation such as glucocorticoids, aspirin, ibuprofen, NSAIDS, etc. The term "anticancer agent" is art recognized and is intended to include those agents which diminish, eradicate, or prevent growth of cancer cells without, preferably, adversely affecting other physiological functions. Representative examples include cisplatin and cyclophosphamide. When the compounds of the present invention are administered as Pharmaceuticals, to humans and mammals, they can be given per se or as a pharmaceutical composition containing, for example, 0.1 to 99.5% (more preferably, 0.5 to 90%) of active ingredient in combination with a pharmaceutically acceptable carrier. The phrase "pharmaceutically acceptable carrier" as used herein means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting a compound(s) of the present invention within or to the subject such that it can performs its intended function. Typically, such compounds are carried or transported from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer solutions; and other non-toxic compatible substances employed in pharmaceutical formulations. As set out above, certain embodiments of the present compounds can contain a basic functional group, such as amino or alkylamino, and are, thus, capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable acids. The term "pharmaceutically acceptable salts" in this respect, refers to the relatively non-toxic,inorganic and organic acid addition salts of compounds of the present invention. These salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or by separately reacting a purified compound of the invention in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed. Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, napthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts and the like. (See, e.g., Berge et al. (1977) "Pharmaceutical Salts", J. Pharm. Sci. 66:1-19). In other cases, the compounds of the present invention may contain one or more acidic functional groups and, thus, are capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable bases. The term "pharmaceutically acceptable salts" in these instances refers to the relatively nontoxic, inorganic and organic base addition salts of compounds of the present invention. These salts can likewise be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form with a suitable base, such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary or tertiary amine. Representative alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium, and aluminum salts and the like. Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like. The term "pharmaceutically acceptable esters" refers to the relatively non-toxic, esterified products of the compounds of the present invention. These esters can be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form or hydroxyl with a suitable esterifying agent. Carboxylic acids can be converted into esters via treatment with an alcohol in the presence of a catalyst. Hydroxyl containing derivatives can be converted into esters via treatment with an esterifying agent such as alkanoyl halides. The term is further intended to include lower hydrocarbon groups capable of being solvated under physiological conditions, e.g., alkyl esters, methyl, ethyl and propyl esters. (See, for example, Berge era/., supra.) The invention further contemplates the use of prodrugs which are converted in vivo to the therapeutic compounds of the invention (see, e.g., R.B. Silverman, 1992, "The Organic Chemistry of Drug Design and Drug Action", Academic Press, Chapter 8). Such prodrugs can be used to alter the biodistribution (e.g., to allow compounds which would not typically enter the reactive site of the protease) or the pharmacokinetics of the therapeutic compound. For example, a carboxylic acid group, can be esterified, e.g., with a methyl group or an ethyl group to yield an ester. When the ester is administered to a subject, the ester is cleaved, enzymatically or non-enzymatically, reductively or hydrolytically, to reveal the anionic group. An anionic group can be esterified with moieties (e.g., acyloxymethyl esters) which are cleaved to reveal an intermediate compound which subsequently decomposes to yield the active compound. In another embodiment, the prodrug is a reduced form of a sulfate or sulfonate, e.g., a thiol, which is oxidized in vivo to the therapeutic compound. Furthermore, an anionic moiety can be esterified to a group which is actively transported in vivo, or which is selectively taken up by target organs. The ester can be selected to allow specific targeting of the therapeutic moieties to particular reactive sites, as described below for carrier moieties. The compounds of the invention may comprise water-soluble prodrugs which are described in WO 99/33815, International Application No. PCT/US98/04595, filed March 9, 1998 and published July 8, 1999. The entire content of WO 99/33815 Is expressly incorporated herein by reference. The water-soluble prodrugs are metabolized in v/Voto an active drug, e.g., by esterase catalyzed hydrolysis. Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions. Examples of pharmaceutically acceptable antioxidants include: water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like. Formulations of the present invention include those suitable for oral, nasal, topical, transdermal, buccal, sublihgual, rectal, vaginal and/or parenteral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred per cent, this amount will range from about 1 per cent to about ninety-nine percent of active ingredient, preferably from about 5 per cent to about 70 per cent, most preferably from about 10 per cent to about 30 per cent. Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present invention with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product. Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient. A compound of the present invention may also be administered as a bolus, electuary or paste. In solid dosage forms of the invention for oral administration (capsules, tablets, pills, dragees, powders, granules and the like), the active ingredient is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; humectants, such as glycerol; disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; solution retarding agents, such as paraffin; absorption accelerators, such as quaternary ammonium compounds; wetting agents, such as, for example, acetyl alcohol and glycerol monostearate; absorbents, such as kaolin and bentonite clay; lubricants, such a talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and coloring agents. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like. A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients. Liquid dosage forms for oral administration of the compounds of the invention include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert dilutents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert clHutents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents. Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agaragar and tragacanth, and mixtures thereof. Formulations of the pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the invention with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound. Formulations of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate. Dosage forms for the topical or transderrnal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants which may be required. The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof. Powders and sprays can contain, in addition to a compound of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium sii'cate? and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane. Transdermal patches have the added advantage of providing controlled delivery of a compound of the present invention to the body. Such dosage forms can be made by dissolving or dispersing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the active compound in a polymer matrix or gel. An appropriate buffer system (e.g., sodium phosphate, sodium acetate or sodium borate) may be added to prevent pH drift under storage conditions. Pharmaceutical compositions of this invention suitable for parenteral administration comprise one or more compounds of the invention in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents. Examples of suitable aqueous and nonaqueous carriers which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin. In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally-administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissue. The preparations of the present invention may be given orally, parenterally, topically, or rectally. They are of course given by forms suitable for each administration route. For example, they are administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories. Oral administration is preferred. The phrases "parenteral administration" and "administered parenterally" as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and ihtrasternal injection and infusion. The phrases "systemic administration," "administered systematically/1 "peripheral administration" and "administered peripherally" as used herein mean the administration of a compound, drug or other material other than directly into the central nervous system, such that it enters the patient's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration. These compounds may be administered to humans and other animals for therapy by any suitable route of administration, including orally, nasally, as by, for example, a spray, rectally, intravaginally, parenterally, intracisternally and topically, as by powders, ointments or drops, including buccally and sublingually. Regardless of the route of administration selected, the compounds of the present invention, which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art. Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient. The selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time.of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts. A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved. In general, a suitable daily dose of a compound of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. Generally, intravenous and subcutaneous doses of the compounds of this invention for a patient, when used for the indicated analgesic effects, will range from about 0.0001 to about 200 mg per kilogram of body weight per day, more preferably from about 0.01 to about 150 mg per kg per day, and still more preferably from about 0.2 to about 140 mg per kg per day. If desired, the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. While it is possible for a compound of the present invention to be administered alone, it is preferable to administer the compound as a pharmaceutical composition. The present invention also pertains to packaged pharmaceutical compositions for treating obesity or obesity associated disorders in a mammal. The packaged pharmaceutical compositions include a container holding a therapeutically effective amount of at least one compound of the invention and instructions for using the compound for treating obesity or an obesity associated disorder in the mammal. The features and details of the invention will now be more particularly described and pointed out in the claims. It is to be understood that the particular embodiments of the invention are shown by way of illustration and not as limitations of the invention. The principle features of this invention can be employed in various embodiments without departing from the scope of the invention. The invention is further illustrated by the following examples which in no way should be construed as being further limiting. The contents of all references, pending patent applications and published patent applications, cited throughout this application, including those referenced in the background section, are hereby incorporated by reference. It should be understood that the models used throughout the examples are accepted models and that the demonstration of efficacy in these models is predictive of efficacy in humans. This invention will be better understood from the Experimental Details which follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described more fully in the claims which follow thereafter. Compounds in the examples are labeled with whole numbers if the compound appears in the table above and as X.Y, where X is the example number and Y is an index starting at 1 in each example, if they do not appear in the above table. •rt Experimental Details All non-aqueous reactions requiring anhydrous conditions were performed under a positive pressure of nitrogen (N£) in oven-dried glassware, which had been cooled under N£. All solvents for anhydrous reactions were purchased from Aldrich. The removal of solvents refers to evaporation in vacua on a rotary evaporator followed by evacuation to constant sample weight ( chromatography were purchased HPLC grade. All reagents employed were of American Chemical Society (ACS) grade or finer. Air sensitive reagents were handled under an atmosphere of dry N2- Where possible all reactions were followed by thin layer chromatography (TLC) and visualized using UV fluorescence, 3% KMnO4 (aqueous) staining, and/or dodecamolybdophosphoric acid. Commercial thin layer and preparative layer chromatography plates were Si250F and SiSOOF, respectively, from J. T. Baker. Flash chromatography was performed using 40 urn 'Baker' silica gel from J. T. Baker. All solvent mixtures are listed as volume ratios. Melting points are uncorrected and were determined on a Mel-Temp II (Laboratory Devices, USA) using open capillary tubes. Mass spectra (MS) were recorded on a Platform 2 Micromass instrument. Nuclear magnetic resonance (NMR) spectra were measured on a Varian 200 instrument in the specified solvent with tetramethylsilane (TMS) as internal standard for 1H NMR. For 13C NMR spectra, the deuterated solvent peak was used as the reference with its position set relative to TMS. LCMS Methods: Method A=LC1 method; Method B=Polar method; Method C=Polar_Short method; Method D=Strong_Nonpolar General Procedure: Amides/Esters a. Route A. The aminothiophene was synthesized using a known protocol (McKibben, B.P., Cartwell, C.H., Castelhano, A.L Tetrahedron Lett. 1999, 40, 5471- 5474). Amide protection with trifluoroacetic anhydride followed by TFA deprotection and treatment with sodium carbonate generates the amino acid. Attempts to deprotect with TFA without amide protection results in decarboxylation. The amino acid was reacted with various acid chlorides, and chloroformates to afford the thienoxazinones in moderate yields (Scheme 1). Scheme 1 BnO^-^ Et2NH, pyr Bn0 Bn° , Sulfur 1)TFA,DCM (70%) DBU.pyr BnO L 95% 20-70% b. Route B.. In general, reacting the f-Bu protected amino acid directly with a chloroformate or an isocyanate followed by TFA deprotection of the M3u ester and treatment with thionyl chloride gives the corresponding thienoxazinones in higher yields (Scheme 2) Scheme 2 BnO 6 g I • o . V^A.,-J 11 3 S^NH. °^ Ll n o S-^MU N r* T /-.^^VTT- or ° A \ / n A; 50-80 % H2,Pd(OH)2 EtOAo (95%) 1) TFA, DCM 1) R,R2YH, EDCI, HOBt, DMAP, DCM (95%) 2) TFA, DCM (95%) CO A(-h (90%) Derivation at the 5-position was achieved through either transesterification of methyl acetoacetate with various alcohols prior to thiophene formation or benzyl deprotection of the diester, followed by EDC coupling with various alcohols and amines to generate esters or amides, respectively. Example 1: General Procedure tor Amino-Thiophene formation 5-Amino-3-methyl-thiophene-2,4-dicarboxylic acid 2-benzyl ester 4-fert-butyl ester. (1.1) To a suspension of benzyl acetoacetate (20.0 g, 104.1 mmol), t-butyl cyanoacetate (14.7 g, 104.1 mmol), sulfur (3.5 g, 109.3 mmol) and pyridine (120 ml) was added diethyl amine dropwise. After 2 days, the "black solution was concentrated under reduced pressure, dissolved in EtaO and filtered through silica. The eluent was then concentrated. Chromatography (silica, 7:1 hexane/EtOAc) yielded 25.58g (71%)of a orange oil which slowly crystallizes upon standing: 1HNMR (CDCI3) 1-58 (s, 9H), 2.70 (s, 3H), 5.27 (s, 2H), 7.38 (m, 5H). 1H NMR was consistent with published data. 5-Amino-3-methyl-thiophene-2,4-dicarboxylic acid 2-heptyl ester 4-fert-butyl ester. (1.2) The same method as for the preparation of 5-amino-3-methyl-thiophene- 2,4-dicarboxylic acid 2-benzyl ester 4-fert-butyl ester was employed. Thus, cyclization of fert-butyl cyanoacetate (10.3 mL, 72.0 mmol), heptyl acetoacetate (13.7 g, 68.0 mrnol), and sulfur (4.4 g, 0.14 mol) in pyridine (80 ml) with added diethylamine (7.1 ml, 68.0 mmol) afforded 18.4 g thiophene (76%) of an oil after column Chromatography (10:1; hexanes:EtOAc): 1H NMR (CDCI3) 8 6.47 (bs, 2H), 4.19 (t, 2H, J= 6.6 Hz), 2.67 (s, 3H), 1.80-1.50 (m, 2H), 1.57 (s, 9H), 1.30 (bs, 8H), 0.89 (t,3H, J=6.6Hz). 5-Amino-3-methyl-thiophene-2,4-dicarboxylic acid 2-octyl ester 4-ferf-butyl ester. (1.3) The same method as for the preparation of 5-amino-3-methyl-thiophene- 2,4-dicarboxylic acid 2-benzyl ester 4-fert-butyl ester was employed. Thus, cyclization of fert-butyl cyanoacetate (6.2 mL, 43.0 mmol), octyl acetoacetate (8.5 g, 41.0 mmol), and sulfur (2.6 g, 82.0 mmol) in pyridine (50 mL) with added diethylamine (4.3 ml, 41.0 mmol) afforded 10.3 g thiophene (68%) of an oil after column chromatography (10:1; hexanes:EtOAc): 1H NMR (CDCI3) 8 6.63 (s, 2H), 4.14 (t, 2H, J= 6.6 Hz), 2.63 (s, 3H), 1.72-1.50 (m, 2H), 1.52 (s, 9H), 1.22 (bs, 10H), 0.83 (t, 3H, J= 6.8 Hz). 13C NMR (CDCI3) 5 165.9, 165.4, 163.0, 147.9, 109.6, 108.0, 81.0, 64.4, 31.7, 29.1, 28.6, 28.4, 25.9, 22.5, 16.2, 14.0. Example 2: General Procedure for Cyclization From Chloroformate and Aminoacid 2-Dodecyloxy-5-methyl-4-oxo-4H-thieno[2,3-c(l[1,3]oxazine-6-carboxylic acid benzyl ester (6) To a stirring solution of 5-amino-3-methyl-thiophene-2,4- dicarboxylic acid 2-benzyl ester (1.00 g, 3.43 mmol) in pyridine (20 ml) was added dodecyl chloroformate (2.80 ml, 2.56 g, 10.3 mmol). The reaction was stirred at 0 SC for 0.5 h, then solvent was removed under reduced pressure. The product was purified by column chromatography (10:1; hexanes:EtOAc) to give 169mg (10%) of a solid: 1H NMR (CDCI3) 8 7.50-7.25 (m, 5H), 5.35 (s, 2H), 4.17 (t, 2H, J = 6.6 Hz), 2.87 (s, 3H), 1.70-1.40 (m, 2H), 1.40-1.00 (m, 18H), 0.88 (t, 3H, J= 6.4 Hz). MS (El): 486.4 (m++H). 5-Methyl-2-octyloxy-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid benzyl ester (5) The same method as for the preparation of 2-dodecyloxy-5- methyl-4-oxo-4H-thieno[2,3-dJ[1,3]oxazine-6-carboxylic acid benzyl. ester was employed: 1H NMR (CDCI3) 8 7.53-7.25 (m, 5H), 5.33 (s, 2H), 4.44 (t, 2H, J= 6.6 Hz), 2.83 (s, 3H), 1.80 (quint, 2H, J = 6.6 Hz), 1.26 (bs, 10H), 0.88 (t, 3H, J = 6.6 Hz). 2-Hexadecyloxy-5-methyl-4-oxo-4H-thienot2,3-d][1,3]oxazine-6-carboxylic acid benzyl ester (7) The same method as for the preparation of 2-dodecyloxy-5-methyl- 4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid benzyl ester was employed: 1H NMR (CDCI3) 5 7.50-7.25 (m, 5H), 5.34 (s, 2H), 4.44 (t, 2H, J= 6.6 Hz), 2.83 (s, 3H), 1.80 (quint, 2H, J= 6.6 Hz), 1.26 (bs, 26H), 0.88 (t, 3H, J = 6.6 Hz). Example 3: General Procedure for Cyclization From Acyl Chloride and Aminoacid 2-Heptyl-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid benzyl ester (1) To a stirring solution of 5-amino-3-methyl-thiophene-2,4-dicarboxylic acid 2-benzyl ester (200 mg, 0.69 mmol) in pyridine (5 mL) was added octanoyi chloride (352 \|j.L, 2.56 g, 10.3 mmol). The reaction was stirred at 0 BC for 0.5 h, then let warm to RT and stirred for 3.5 h. The solvent was removed under reduced pressure. The mixture was diluted in EtOAc, washed with H2O. The organic fraction was dried (MgSO4), and concentrated in vacuo. The product was purified by column chromatography (9:1; hexanes:EtOAc) to give 48 mg (18%) of a solid: ): 1H NMR (CDCla) 6 7.32-7.48 (m, 5H), 5.35 (s, 2H), 2.86 (s, 3H), 2.69 (t, 2H, J = 7.2 Hz), 1.90- 1.70 (m, 2H), 1.45-1.20 (m, 8H), 0.98-0.80 (m, 3H). 5-Methyl-4-oxo-2-pentadecyl-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid benzyl ester (3) The same method as for the preparation of 2-nepty!-5-methyl-4- oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid benzyl ester was employed. Thus, cyclization with hexadecanoyl chloride (476 mL, 2.06 mmol) yielded 56 mg product (16%) after oil after column chromatography (9:1; hexanes:EtOAc): 1HNMR (CDCI3) 6 7.30-7.55 (m, 5H), 5.35 (s, 2H), 2.86 (s, 3H), 2.69 (t, 2H, J = 7.2 Hz), 2.00- 1.70 (m, 2H), 1.50-1.0 (m, 24H), 1.00-0.90 (m, 3H). 2-Undecyl-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid benzyl ester (2) The same method as for the preparation of 2-heptyl-5-methyl-4- oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid benzyl ester was employed. Thus, cyclization with dodecanoyl chloride (476 mL, 2.06 mmol) yielded 77 mg product (24%) after oil after column chromatography (9:1; hexanes:EtOAc): 1H NMR (CDCI3) 5 7.30-7.50 (m, 5H), 5.35 (s, 2H), 2.86 (s, 3H), 2.69 (t, 2H, J = 7.2 Hz), 1.90- 1.70 (m, 2H), 1.50-1.20 (m, 16H), 1.00-0.90 (m, 3H). Example 4: Genera! Procedure for Acylation with Chlorformate of Diester Ph\-o 3-Methoxymethyl-5-octyloxycarbonylamino-thiophene-2,4-dicarboxylic acid 2- benzyl ester 4-ferf-butyl ester. (4.1) To a stirring solution of 5-amino-3- methoxymethyl-thiophene-2,4-dicarboxylic acid 2-benzyl ester 4-fert-butyl ester (1.16 g, 3.06 mmol) in pyridine (15 ml) was added octyl chloroformate (0.9 mL, 886 mg, 4.6 mmol). The reaction was stirred at 0 9C for 1 h, then solvent was removed under reduced pressure. The product was purified by column chromatography (10:1; hexanes:EtOAc) to give 1.27 g (78%) of a solid: 1H NMR (CDCI3) 8 10.51 (s, 1H), 7.32 (m, 5H), 5.12 (s, 2H), 4.19 (t, 2H, J = 6.6 Hz), 3.81 (s, 3H), 3.76 (s, 2H), 1.68 (quint, 2H, J = 6.6 Hz), 1.45 (s, 9H), 1.44-1.21 (m, 10H), 0.89 (t, 3H, J = 5.8 Hz). MS (El): 533.9 (m+). 3-Methyl-5-octyloxycarbonylamino-thiophene-2,4-dicarboxylic acid 4-tert-butyl ester 2-octyl ester. (4.2) The same method as for the preparation of 3- methoxymethyl-5-octyloxycarbonylamino-thiophene-2,4-dicarboxylic acid 2-benzyl ester 4-fert-butyl ester was employed. Thus, acylation with octyl chloroformate (0.171 ml, 168 mg, 0.87 rnmol) afforded 80 mg of a solid (26%) after column chromatography (9:1; hexanes:EtOAc): 1H NMR (CDCIa) 8 10.86 (s, 1H), 4.23 (t, 2H, J = 6.6Hz), 2.67 (s, 3H), 1.80-1.40 (m, 4H), 1.57 (s, 9H), 1.42-1.08 (m, 20H), 0.89 (t, 3H, J = 6.6 Hz). MS (El): 526.0 (m+). 3-Methyl-5-heptyloxycarbonylamino-thiophene-2,4-dicarboxylic acid 4-ferfbutyl ester 2-heptyl ester. (4.3) To a stirring solution of 5-amino-3-methylthiophene- 2,4-dicarboxylic acid 2-heptyl ester 4-tert-butyl ester (5.0 g, 14.0 mmol) and DBU (5.3 ml, 5.4 g, 35.0 mmol) in CH2CI2 (100 mL) was added heptyl chloroformate (5.0 ml, 5,0 g, 28.0 mmol). The reaction was stirred at room temperature for 20 h, and then solvent was removed under reduced pressure. The product was purified by column chromatography (9:1; hexanes:EtOAc) to give 3.1 g (45%) of a solid: 1H NMR (CDCI3) 8 10.86 (s, 1H), 4.23 (t, 2H, J = 6.6Hz), 2.67 (s, 3H), 1.80-1.40 (m, 4H), 1.57 (s, 9H), 1.42-1.08 (m, 16H), 0.89 (t, 3H, J= 6.6 Hz). 5-Benzyloxycarbonylamino-3-methyl-thiophene-2,4-dicarboxyllc acid 4-fertbutyl ester 2-octyi ester. (4.4) The same method as for the preparation of 3- methyl-5-heptyloxycarbonylamino-thiophene-2,4-dicarboxylic acid 4-tert-butyl ester 2-heptyl ester was employed. Thus, acylation with benzyl chloroformate (0.154 mL, 185 mg, 1.1 mmol) afforded 138 mg of a solid (52%) after column chromatography (10:1; hexanes:EtOAc): Mp 65.0-66.0 aC; 1H NMR (CDCI3) 6 10.97 (s, 1H), 7.50- 7.30 (m, 5H), 5.28 (d, 2H, J = 4.8 Hz), 4.23 (t, 2H, J = 6.6 Hz), 2.72 (s, 3H), 1.80- 1.55 (m, 2H), 1.58 (s, 9H), 1.28 (bs, 10H), 0.89 (t, 3H, J= 6.6 Hz). 4-Methyl-2-octyIoxycarbonylamino-thiophene-3-carboxylic acid ethyl ester. (4.5) The same method as for the preparation of 3-methyl-5- heptyioxycarbonylamino-thiophene-2,4-dicarboxylic acid 4-tert-butyl ester 2-heptyl ester was employed. Thus, acylation with octyl chlorofbrmate (1.06 ml, 1.04 g, 5.4 mmol) afforded 254 mg of an oil (28%) after column chromatography (9:1; hexanes:EtOAc): 1H NMR (CDCI3) 6 10.53 (s, 1H), 6.31 (s, 1H), 4.34 (q, 2H, J= 6.8 Hz), 4.12 (t, 2H, J= 6.6 Hz).2.34 (s, 3H), 1.67 (bs, 2H), 1.37 (quint, 3H, J= 6.8 Hz), 1.28 (bs, 10H), 0.88 (t, 3H, J= 6.6 Hz). MS (El): 341.9 (m+). 5-/soPropoxycarbonylamino-3-methyl-thiophene-2,4-dicarboxylic acid 4-fertbutyl ester 2-octyl ester. (4.6) The same method as for the preparation of 3- methyl-5-heptyloxycarbonylamino-thiophene-2,4-dicarboxylic acid 4-fert-butyl ester 2-heptyl ester was employed. Thus, acylation with /so-propy! chloroformate in toluene (0.54 mL, 0.54 mmol) afforded 117 mg of a solid (95%) after column chromatography (9:1; KexanesrEtOAc): 1H NMR (CDCl3) 8 10.82 (s, 1H), 5.30 (s, 1H), 5.08 (sept, 1H, J = 6.2 Hz), 4.23 (t, 2H, J = 6.6 Hz), 2.73 (s, 3H), 1.80-1.60 (m, 2H), 1.60 (s, 9H), 1.34 (d, 6H, J= 6.2 Hz), 1.28 (bs, 10H), 0.88 (t, 3H, J= 6.6 Hz). 5-/so-Butoxycarbonylamino-3-methyl-thiophene-2,4-dicarboxylic acid 4-fertbutyl ester 2-octyl ester. (4.7) The same method as for the preparation of 3- methyl-5-heptyloxycarbonylamino-thiophene-2,4-dicarboxylic acid 4-tert-butyl ester 2-heptyl ester was employed. Thus, acylation with /so-butyl chloroformate (0.07 mL, 74.0 mg, 0.54 mmol) afforded 98 mg of a solid (77%) after column chromatography (9:1; hexanes:EtOAc): 1H NMR (CDCI3) 8 10.86 (s, 1H), 4.23 (t, 2H, J = 6.6 Hz), 4.04 (d, 2H, J = 6.6 Hz), 2.73 (s, 3H), 2.02 (nonet, 1H, J = 6.6 Hz), 1.80-1.50 (m, 2H), 1.06 (s, 9H), 1.28 (bs, 10H), 1.00 (d, 6H, J = 6.6 Hz), 0.88 (t, 3H, J= 6.2 Hz). Example 5: General Procedure for Acylation with Isocyanate of Diester Reaction O H 3-Methyl-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid 4-tert-butyl ester 2- octyl ester. (5.1) To a stirring solution of 5-amino-3-methyl-thiophene-2,4- dicarboxylic acid 2-octyl ester 4-tert-butyl ester (348 mg, 0.94 mmol) and DBU (0.35 mL, 360 mg, 2.4 mmol) in CH2CI2 (10 mL) was added octyl isocyanate (0.166 mL, 146 mg, 0.94 mmol). The reaction was stirred RT for 16 h, and then solvent was removed under reduced pressure. The product was purified by column chromatography (5:1; hexanes:EtOAc) to give 431 mg of a solid (87%): Mp 92.0- 94.0 BC; 1H NMR (CDCI3) 5 12.30 (s, 1H), 8.64 (s, 1H), 5.30 (t, 1H, J= 6.0 Hz), 4.25 (t, 2H, J = 6.4 Hz), 3.29 (q, 2H, J = 6.0 Hz), 2.74 (s, 3H), 1 .90-1 .50 (m, 4H), 1 .61 (s, 9H), 1 .28 (bs, 20H), 0.88 (m, 6H). MS (El): 525.1 (m+). o 3-Methyl-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid 2-benzyl ester 4- fert-butyl ester. (5.2) The same method as for the preparation of 3-methyl-5-(3- octyl-ureido)-thiophene-2,4-dicarboxylic acid 4-fert-butyl ester 2-octyl ester was employed. Thus, acylation with octyl isocyanate (3.83 mL, 3.37 g, 21.7 mmol) afforded 3.42 g of a solid (38%) after column chromatography (9:1; hexanes:EtOAc): Mp 119.0-120.0SC; 1H NMR (CDCI3) 8 11.03 (s, 1H), 7.50-7.20 (m, 5H), 5.27 (s, 2H), 5.03 (vt, 1H), 3.29 (q, 2H, J = 6.6 Hz), 2.71 (s, 3H), 1.63-1.40 (m, 2H), 1.57 (s, 9H), 1.26 (bs, 10H), 0.87 (t, 3H, J- 6.6 Hz). MS (El): 502.8 (m+). o 3-Methyl-5-(3-tetradecyl-ureido)-thiophene-2,4-dicarboxylic acid 2-benzyl ester 4-tert-butyl ester. (5.3) The same method as for the preparation of 3-methyl-5-(3- octyl-ureido)-thiophene-2,4-dicarboxylic acid 4-fert-butyl ester 2-octyl ester was employed. Thus, acylation with tetradecyl isocyanate (0.33 ml, 287 mg, 1.2 mmol) afforded 253 mg of a solid (36%) after column chromatography (9:1; hexanes:EtOAc): Mp 104.5-106.0SC; 1H NMR (CDCI3) 6 11.04 (s, 1H), 7.50-7.20 (m, 5H), 5.27 (S, 2H), 5.14 (t, 1H, J = 6.2 Hz), 3.29 (q, 2H, J = 6.2 Hz), 2.71 (s, 3H), 1.65-1.40 (m, 2H), 1.57 (s, 9H), 1.25 (bs, 22H), 0.88 (t, 3H, J = 6.0 Hz). MS (El): 587.1 (m+). 5-(3-Hexadecyl-ureido)-3-methyl-thiophene-2,4-dicarboxylic acid 2-benzyl ester 4-fert-butyl ester. (5.4) The same method as for the preparation of 3-methyl- 5-(3-octyl-ureido)-thiophene-2,4-dicarbQxylic acid 4-tert-butyl ester 2-octyl ester was employed. Thus, acylation with hexadecyl isocyanate (0.37 mL, 321 mg, 1.2 mmol) afforded 218 mg of a solid (30%) after column chromatography (9:1; hexanes-.EtOAc): Mp 104.0-105.09C; 1H NMR (CDCI3) 8 11.04 (s, 1H), 7.50-7.20 (m, 5H), 5.27 (s, 2H), 5.14 (t, 1H, J = 6.2 Hz), 3.29 (q, 2H, J = 6.2 Hz), 2.71 (s, 3H), 1.65-1.40 (m, 2H), 1.57 (s, 9H), 1.25 (bs, 26H), 0.88 (t, 3H, J= 6.0 Hz). MS (El): 615.1 (m). 5-(3-Dodecyl-ureido)-3-methyl-thiophene-2,4-dicarboxylic acid 2-benzyl ester 4-tert-butyl ester. (5.5) The same method as for the preparation of 3-methyl-5-(3- octyl-ureido)-thiophene-2,4-dicarboxylic acid 4-fert-butyl ester 2-octyl ester was employed. Thus, acylation with decyl isocyanate (0.29 mL, 254 mg, 1.2 mmol) afforded 265 mg of a solid (40%) after column chromatography (9:1; hexanes-.EtOAc): Mp 106.8-108.0SC). 1H NMR (CDCI3) 8 11.04 (s, 1H), 7.45-7.26 (m, 5H), 5.27 (s, 2H), 5.24 (t, 1H, J= 5.6 Hz), 3.28 (q, 2H, J= 6.6 Hz), 2.72 (s, 3H), 1.60-1.40 (m, 2H), 1.57 (s, 9H), 1.25 (bs, 18H), 0.88 (t, 3H, J = 6.4 Hz). MS (El): 559.0 (m+). Example 6: General Procedure TFA Deprotection at C-2 Ph,v-o 3-Methoxymethyl-5-octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2- benzyl ester. (6.1) To a stirring solution of 3-methoxymethyl-5- octyloxycarbonylamino-thiophene-2,4-dicarboxylic acid 2-benzyl ester 4-fert-butyl ester (0.60 mg, 0.11 mmol) in CH2CI2 (1.0 ml) was added TFA (1.0 ml). The reaction was stirred at room temperature for 12 hrs, then solvent was removed under reduced pressure to give a solid. The product was taken on without further purification: 1H NMR (CDCI3) 8 11.98 (s, 1H), 10.09 (s, 1H), 7.45-7.20 (m, 5H), 5.14 (s, 2H), 4.22 (t, 2H, J = 6.6 Hz), 3.85 (s, 3H), 3.82 (s, 2H), 1.70 (quint, 2H, J = 6.6 Hz), 1.28 (bs, 10H), 0.88 (t, 3H, J = 5.6 Hz). o (,0 3-Methoxymethyl-5-octyloxycarbonylamino-thiophene-2,4-dicarboxylic acid 2- octyl ester. (6.2) The same method as for the preparation of 3-methoxymethyl-5- octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester was employed. Thus, deprotection with TFA afforded 64 mg of a solid (68%) aftei column chromatography (5:1; hexanes:EtOAc): 1H NMR (CDCI3) 5 10.56 (s, 1H), 4.27 (t, 2H, J = 6.5 Hz), 4.25 (t, 2H, J = 6.5 Hz), 2.81 (s, 3H), 1.80-1.53 (m, 4H), 1.50-1.15 (m, 20H), 0.89 (t, 3H, J = 6.5 Hz). MS (El): 469.9 (m+). 5-Heptyloxycarbonylamino-3-methoxymethyl-thiophene-2,4-dicarboxylic acid 2-heptyl ester. (6.3) The same method as for the preparation of 3-methoxymethyl- 5-octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester was employed. Thus, deprotection with TFA afforded 2.7 g of a solid (96%) after tritration with hexanes: 1H NMR (CDCI3) 5 10.53 (s, 1H), 4.26 (t, 4H, J = 6.6 Hz), 2.81 (s, 3H), 1.90-1.58 (m, 4H), 1.60-1.12 (m, 16H), 0.89 (t, 3H, J= 6.6 Hz). MS (El): 441.9 (m+). 5-Benzyloxycarbonylamino-3-methyl-thiophene-2,4-dicarboxylic acid 2-octyl ester. (6.4) The same method as for the preparation of 3-methoxymethyl-5- octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester was employed. Thus, deprotection with TFA afforded a solid, which was used without purification: Mp 148.0-149.5 BC; 1H NMR (CDCI3) 8 10.56 (bs, 2H), 7.50-7.30 (m, 5H), 5.30 (d, 2H, J = 4.8 Hz), 4.25 (t, 2H, J = 6.6 Hz), 2.79 (s, 3H), 1.83-1.60 (m, 2H), 1.29 (bs, 10H), 0.89 (t, 3H, J= 6.6 Hz). 0 5-/SD-Propoxycarbonylamino-3-methyl-thiophene-2,4-dicarboxylic acid 2-octyl ester. (6.5) The same method as for the preparation of 3-methoxymethyl-5- octy!oxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester was employed. Thus, deprotection with TFA afforded a solid, which was taken forward without further purification: Mp 152.0-153.0 SC; 1H NMR (CDCI3) 6 10.45 (s, 1H), 5.12 (sept, 1H, J= 6.6 Hz), 4.25 (t, 2H, J = 6.6 Hz), 2.82 (s, 3H), 1.73 (quint, 2H, J = 6.6 Hz), 1.38 (d, 6H, J = 6.6 Hz), 1:28 (bs, 10H), 0.89 (t, 3H, J = 6.6 Hz). o 5-;soButoxycarbonylamino-3-methyl-thiophene-2,4-dicarboxylic acid 2-octyl ester. (6.6) The same method as for the preparation of 3-methoxymethyl-5- octyloxycarbonylamino-thiophene[2;4]dicarboxylic acid 2-benzyl ester was employed. Thus, deprotection with TFA afforded a solid, which was used without purification: 1H NMR (CDCI3) 6 10.53 (bs, 2H), 4.26 (t, 2H, J= 6.2 Hz), 4.08 (d, 2H, J = 6.6 Hz), 2.82 (s, 3H), 2.06 (nonet, 1H, J = 6.6 Hz), 1.71 (quint, 2H, J = 6.6 Hz), 1 .29 (bs, 1 0H), 1 .00 (d, 6H, J = 6.6 Hz), 0.89 (t, 3H, J = 6.6 Hz). o 4-Methyl-5-octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid. (6.7) The same method as for the preparation of 3-methoxymethyl-5- octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester was employed. Thus, deprotection with TFA afforded a solid, which was used without purification: 1H NMR (CDCl3) 6 10.90 (bs, 2H), 5.82-5.62 (m, In), 5.76-5.60 (m, 1H), 3.33 (q, 4H, J = 6.6 Hz), 2.61 (s, 3H), 1.70-1.40 (m, 4H), 1.27 (bs, 20H), 0.88 (m, 6H). 3-Methyl-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid 2-octyl ester. (6.8) The same method as for the preparation of 3-methoxymethyl-5- octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester was employed. Thus, deprotection with TFA afforded a solid, which was used without purification: 1H NMR (CDCl3) 5 12.30 (s, 1H), 10.91 (bs, 2H), 5.30 (t, 1H, J== 6.0 Hz), 4.25 (t, 2H, J = 6.4 Hz), 3.29 (q, 2H, J = 6.0 Hz), 2.74 (s, 3H), 1.90-1.50 (m, 4H), 1.28 (bs, 20H), 0.88 (m, 6H). MS (El): 468.9 (m+). BnNH 5-Ben2ylcarbamoyl-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid. (6.9) The same method as for the preparation of 3-methoxymethy!-5- octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester was employed. Thus, deprotection with TFA afforded a solid, which was used without purification: 1H NMR (CDCI3) 8 11.16 (s, 1H), 7.40-7.10 (m, 5H), 6.19 (t, 1H, J= 5.4 Hz), 4.56 (d, 2H, J = 5A Hz), 3.25 (q, 2H, J = 6.6 Hz), 2.63 (s, 3H), 1.60-1:40 (m, 2H), 1.26 (bs, 10H), 0.86 (t, 3H, J = 6.2 Hz). MS (El): 445.9 (m+). 5-DimethylcarbamoyI-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid. (6.10) The same method as for the preparation of 3-methoxymethyl-5- octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester was employed. Thus, deprotection with TFA afforded a solid, which was used without purification: 1H NMR (CDCI3) 8 10.89 (s, 2H), 5.39 (t, 1H, J= 6.6 Hz), 3.27 (q, 2H, J = 6.6 Hz), 3.05 (s, 6H), 2.28 (s, 3H), 1.65-1.45 (m, 2H), 1.26 (s, 10H), 0.87 (t, 3H, J = 6.2 Hz). MS (El): 383.9 (m+). o O H 3-Methyl-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid 2-benzyl ester. (6.11) The same method as for the preparation of 3-methoxymethyl-5- octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester was employed. Thus, deprotection with TFA afforded a solid, which was used without purification: 1H NMR (CDCU) 5 10.57 (s, 1H), 7.45-7.25 (m, 5H), 5.30 (s, 1H), 4.26 (t, 2H, J= 6.6 Hz), 2.81 (s, 3H), 1.72 (quint, 2H, J= 6.6 Hz), 1.28 (bs, 10H), 0.88 (t, 3H, J=6.6Hz). 4-Methyl-5-octylcarbamoyl-2-(3-tetradecyl-ureido)-thiophene-3-carboxylic acid. (6.12) The same method as for the preparation of 3-methoxymethyl-5- octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester was employed. Thus, deprotection with TFA afforded a solid, which was used without purification. 2-(3-Hexadecyl-ureido)-4-methyl-5-octylcarbamoyl-thiophene-3-carboxylic acid. (6.13) The same method as for the preparation of 3-methoxymethyl-5- octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester was employed. Thus, deprotection with TFA afforded a solid, which was used without purification: MS (El): 580.2 (m""). 2"(3-Dodecyl-ureIdo)-4-methyl-5-octylcarbamoyl-thiophene-3-carboxylic acid. (6.14) The same method as for the preparation of 3-methoxymethyl-5- octyloxycarbonylamino-thiophene[2,4]cicarboxylic acid 2-benzyl ester was employed. Thus, deprotection with TFA afforded a solid, which was used without purification: MS (El): 524.1 (m+). Example 7: Extra TFA Deportection o 3-Methyl-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid. (7.1) To a stirring solution of 3-methyl-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid 4-tert-butyl ester (50.0 mg, 0.13 mmol) in CH2Cl2 (1 ml) was added TFA (1 mL). The reaction was stirred at RT for 2 h, and then solvent was removed under reduced pressure to give a solid. The product was dissolved in EtOAc, washed with sat. NaHCOs (aq.), and brine. The organic layer was dried with MgSO4, filtered, and concentrated under reduced pressure to give 10.0 mg of a solid (22%): 1H NMR (CDCI3) 8 10.45 (bs, 1H), 6.27 (bs, 1H), 5.00 (bs, 1H), 3.50-3.20 (m, 2H), 2.37 (s, 3H), 1.70-1.40 (m, 2H), 1.26 (bs, 10H), 0.88 (t, 3H, J= 6.2 Hz). MS (El): 312.9 (m+-COOH). Example 8: Ethyl Ester Hydrolysis 4-Methyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid. (8.1) To a stirring solution of 4-methyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid ethyl ester (254 mg, 0.74 mmol) in ethanol (2 mL) and THF (2 mL) was added LiOHH2O (31 mg, 0.74 mmol). The reaction was stirred at RT for 5 days, and then solvent was removed under reduced pressure to give a solid. The product was taken on without further purification: 1H NMR (CDCl3) 8 6.02 (s, 1H), 4.07 (t, 2H, J = 6.6 Hz), 2.32 (s, 3H), 1.60-1.40 (m, 2H), 1.27 (bs, 10H), 0.86 (t, 3H, J= 6.6 Hz). Example 9: General Procedure for Hydrogenolysis at C-6 " 5-Methyl-2-octyloxy-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid (11) To a stirring solution of 2-dodecyloxy-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6- carboxylic acid benzyl ester (50 mg, 0.10 mmol) in EtOAc (2 mL) was added 10% Pd/C (5 mg, 10 wt%). The reaction was charged with H2 and stirred at RT for 1 h. The reaction slurry was filtered through a plug of Celite, and the solvent was removed in vacuo. The product was taken on without further purification: 1H NMR (CDCI3) 8 4.47 (t, 2H, J= 6,2 Hz), 4.19 (bs, 1H), 2.85 (s, 3H), 1.80 (quint, 2H, J= 6.2 Hz), 1.27 (bs, 18H), 0.88 (t, 3H, J= 6.6 Hz). MS (El): 395.4 (m+). 3-i\Tiethyi-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid 4-ferf-butyl ester. (9.1) The same method as for the preparation of 2-dodecyloxy-5-methyl-4-oxo-4/-/- thieno[2,3-dl[1,3]oxazine-6-carboxylic acid was employed. Thus, hydrogenolysis afforded a solid, which was used without purification: 1H NMR (CDCIa) 8 11.06 (s, 1H), 5.14 (vt, 1H), 3.30 (q, 2H, J= 6.0 Hz), 2.71 (s, 3H), 1.70-1.40 (m, 2H), 1.59 (s, 9H), 1.27 (bs, 10H), 0.87 (t, 3H, J= 6.6 Hz). MS (El): 412.8 (m+). 5-(3-Dodecyl-ureido)-3-methyl-thiophene-2,4-dicarboxylic acid 4-fert-butyl ester. (9.2) The same method as for the preparation of 2-dodecyloxy-5-methyl-4- oxo^H-thieno^.S-c/ltl.Sloxazine-e-carboxylic acid was employed. Thus, hydrogenolysis afforded 0.198 g of a solid (98%), which was used without purification: Mp 187.0-188.52C; 1H NMR (CDCI3) 8 11.06 (s, 1H), 5.21 (bs, 1H), 3.31 (q, 2H, J= 5.8 Hz), 2.72 (s, 3H), 1.65-1.40 (m, 2H), 1.60 (s, 9H), 1.26 (bs, 18H), 0.88 (t, 3H, J= 6.6 Hz). MS (El): 469.0 (m+). 3-Methyl-5-(3-tetradecyl-ureido)-thiophene-2,4-dicarboxylic acid 4-fert-butyl ester. (9.3) The same method as for the preparation of 2-dodecyloxy-5-methyl-4- oxo-4/:/-thieno[2,3-dl[1,3]oxazine-6-carboxylic acid was employed. Thus, hydrogenolysis afforded 123 mg of a solid (58%), which was used without purification: Mp 176.0-178.09C; 1H NMR (CDCI3) 8 11.06 (s, 1H), 7.35 (t, 1H, J= 6.2 Hz), 5.20 (bs, 1H), 3.30 (q, 2H, J= 6.2 Hz), 2.72 (s, 3H), 1.70-1.45 (m, 2H), 1.59 (s, 9H), 1.25 (bs, 22H), 0.88 (t, 3H, J= 6.6 Hz). MS (El): 497.0 (m). o 5-(3-Hexadecyl-ureido)-3-methyl-thiophene-2,4-dicarboxylic acid 4-fert-butyl ester. (9.4) The same method as for the preparation of 2-dodecyloxy-5-methyl-4- oxo-4/-/-thieno[2,3-d][1,3]oxazine-6-carboxylic acid was employed. Thus, hydrogenolysis afforded a solid, which was used without purification: Mp 187.5- 189.02C; 1H NMR (CDCI3) 5 11.07 (s, 1H), 5.18 (bs, 1H), 3.29 (q, 2H, J= 6.2 Hz), 2.72 (s, 3H), 1.70-1.45 (m, 2H), 1.60 (s, 9H), 1.25 (bs, 26H), 0.88 (t, 3H, J= 6.6 Hz). MS (El): 525.0 (m). Example 10: General Procedure for Amide/Ester Formation at C-6 o 4-Methyl-5-octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid tertbutyl ester. (10.1) To a stirring solution of 3-methyl-5-(3-octyl-ureido)-thiophene- 2,4-dicarboxylic acid 4-fert-butyl ester (185 mg, 0.46 mmol) and octyl amine (0.112 ml, 87.3 mg, 0.69 mmol) in CH2CI2 (10 mL) was added EDO (133 mg, 0.69 mmol) and DMAP (2.8 mg, 0.02 mmol). The reaction was stirred at RT for 16 h, washed with H2O, 0.5N citric acid, sat. NaHCOs, and brine. The organic fraction was dried (MgSC>4), filtered, and concentrated in vacua. The residue was purified by column chromatography (9:1; hexanes:EtOAc) to give 290 mg of a solid (99%): 1H NMR (CDCI3) 8 10.89 (s, 1H), 5.82-5.62 (m, 1H), 5.78-5.60 (m, 1H), 3.33 (q, 4H, J = 6.6 Hz), 2.61 (s, 3H), 1.70-1.40 (m, 4H), 1.55 (s, 9H), 1.27 (bs, 20H), 0.88 (m, 6H). MS (El): 524.1 (m+). BnNH O 5-Benzylcarbamoyl-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid fert-butyl ester. (10.2) The same method as for the preparation of 4-methyl-5- octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid fert-butyl ester was employed. Thus, coupling with benzyl amine (0.061 mL, 60 mg, 0.56 mmol) afforded 202 mg of a solid (99%) after by column chromatography (95:5; CHCI3:MeOH): 1H NMR (CDCI3) 8 10.90 (s, 1H), 7.40-7.20 (m, 5H), 6.05 (t, 1H, J = 5.4 Hz), 5.33 (t, 1H, J - 6.6 Hz), 4.55 (d, 2H, J = 5.4 Hz), 3.26 (q, 2H, J = 6.6 Hz), 2.63 (s, 3H), 1.65-1.40 (m, 2H), 1.56 (s, 9H), 1.26 (bs, 10H), 0.87 (t, 3H, J = 6.2 Hz). MS (El): 502.0 (m+). o 5-Dimethylcarbamoyl-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid ferf-butyl ester. (10.3) The same method as for the preparation of 4-methyl-5- octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid fert-butyl ester was employed. Thus, coupling with a 40% solution of dimethyl amine in HaO (0.063 ml_, 0.56 mmol) afforded 174 mg of a solid (99%) after by column chromatography (95:5; CHCI3:MeOH): 1H NMR (CDCI3) 5 10.78 (s, 1H), 5.39 (t, 1H, J = 6.6 Hz), 3.27 (q, 2H, J= 6.6 Hz), 3.05 (s, 6H), 2.28 (s, 3H), 1.65-1.45 (m, 2H), 1.56 (s, 9H), 1.26 (s, 10H), 0.87 (t, 3H, J= 6.2 Hz). MS (El): 440.0 (m+). 2-(3-Dodecyl-ureido)-4-methyl-5-octylcarbamoyl-thlophene-3-carboxylic acid fert-butyl ester. (10.4) The same method as for the preparation of 4-methyl-5- octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid te/t-butyl ester was employed. Thus, coupling with octyl amine (0.111 mL, 87.0 mg, 0.69 mmol) afforded 205 mg of a solid (81%) after by column chromatography (9:1; hexanes:EtOAc): 1H NMR (CDCI3) 8 10.90 (s, 1H), 5.74 (t, 1H, J = 5.4 Hz), 5.47 (t, 1H, J = 6.2 Hz), 3.32 (vsext, 4H, J = 6.6 Hz), 2.61 (s, 3H), 1.70-1.40 (m, 4H), 1.55 (s, 9H), 1.26 (bs, 28H), 0.88 (t, 6H, J= 6.6 Hz). MS (El): 580.2 (m+). o 4-Wlethyl-5-octylcarbamoyl-2-(3-tetradecyl-ureido)-thiophene-3-carboxylic acid ferf-butyl ester. (10.5) The same method as for the preparation of 4-methyl-5- octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid fert-butyl ester was employed. Thus, coupling with octyl amine (0.112 mL, 87.3 mg, 0.69 mmol) afforded 290 mg of a solid (99%) after by column chromatography (9:1; hexanes:EtOAc): 1H NMR (CDCI3) 8 10.90 (s, 1H), 5.74 (t, 1H, J = 5.4), 5.44 (bs, 1H), 3.33 (vsext, 4H, J= 6.2 Hz), 2.61 (s, 3H), 1.60-1.40 (m, 4H), 1.56 (s, 9H), 1.26 (bs, 32H), 0.88 (t, 6H, J= 6.6 Hz). MS (El): 608.1 (m+). o 2-(3-Hexadecyl-ureido)-4-methyl-5-octylcarbamoyl-thiophene-3-carboxylic acid tert-butyl ester. (10.6) The same method as for the preparation of 4-methyl-5- octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid terf-butyl ester was employed. Thus, coupling with octyl amine (0.080 mL, 62.0 mg, 0.50 mmol) afforded 195 mg of a solid (93% from BnOOC) after by column chromatography (9:1; hexanes:EtOAc): 1H NMR (CDCI3) 8 10.90 (s, 1H), 5.73 (t, 1H, J= 5.4), 5.35 (bs, 1H), 3.33 (vsext, 4H, J= 6.2 Hz), 2.61 (s, 3H), 1.65-1.40 (m, 4H), 1.56 (s, 9H), 1.26 (bs, 36H), 0.88 (t, 6H, J = 6.6 Hz). MS (El): 636.2 (m+). 2-Heptyl-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid hexyl ester (4) The same method as for the preparation of 4-methyl-5-octylcarbamoyl-2- (3-octyl-ureido)-thiophene-3-carboxylic acid fert-butyl ester was employed. Thus, coupling with octyl alcohol (0.125 mL, 1.50 mmol) afforded 20 mg of a solid (21%) after by Prep. TLC (9:1; hexanes:EtOAc): 1H NMR (CDCI3) 5 4.29 (t, 2H, J= 6.6 Hz), 2.84 (s, 3H), 2.87 (t, 2H, J= 7.2 Hz), 2.00-1.60 (m, 4H), 1.15-1.60 (m, 24H), 1.15- 0.70 (m, 6H). Example 11: General Procedure for Cyclization with EDCI Ph, \-0 5-Methoxy-2-octyloxy-4-oxo-4H-thieno[2,3-c/l[1,3]oxazine-6-carboxylic acid benzyl ester (112) To a stirring solution of 3-methoxymethyl-5- octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester (27 mg, 0.056 mmol) in CH2CI2 (1,0 ml) was added EDC (16.0 mg, 0.084 mmol). The reaction was stirred at RT for 16 h, washed with H2O and brine. The organic fraction was dried (MgSO4), filtered, and concentrated in vacua. The residue was purified by column chromatography (5:1; hexanes:EtOAc) to give 7.0 mg of a solid (27%): 1H NMR (CDCI3) 5 7.42-7.27 (m, 5H), 5.16 (s, 2H), 4.38 (t, 2H, J= 6.6 Hz), 3.89 (s, 3H), 3.85 (s, 2H), 1.78 (quint, 2H, J = 6.6 Hz), 1.50-1.10 (m, 10H), 0.89 (t, 3H, J = 6.6 Hz). MS(EI):461.9(m+H+). 5-Methyl-2-octyloxy-4-oxo-4H-thieno[2,3-c/][1,3]oxazine-6-carboxylic acid octyl ester (9) The same method as for the preparation of 5-methoxy-2-octyloxy-4-oxo- 4H-thieno{2,3-d)[1I3]oxazine-6-carboxylic acid benzyl ester was employed. Thus, cyclization afforded 15 mg of a solid (24%) after by column chromatography (9:1; hexanes:EtOAc): Mp 58.5-60.22C; 1H NMR (CDCI3) 5 4.45 (t, 2H, J = 6.6 Hz), 4.29 (t, 2H, J= 6.6 Hz), 2.80 (s, 3H), 1.88-1.70 (m, 4H), 1.29 (bs, 20H), 0.89 (t, 6H, J = 6.6 Hz). MS(EI):451.8(m+). Example 12: General Procedure for Cyclization with SOCI2 5-Methyl-2-heptyloxy-4-oxo-4H-thieno[2,3-dJ[1,3]oxazine-6-carboxylic acid heptyl ester (10) To a stirring solution of 5-heptyloxycarbonylamino-3- methoxymethyl-thiophene-2,4-dicarboxylic acid 2-heptyl ester (2.7 g, 6.1 mmol) in pyridine (65 ml_) was added thionyl chloride (0.88 ml_, 1.4 g, 12.0 mmol). The reaction was stirred RT for 0.5 h, and concentrated in vacuo. The residue was dissolved in CHCI3, washed with H2O, 0.5 N citric acid, sat. NaHC03, and brine. The organic fraction was dried (MgSO4), filtered, and concentrated in vacuo. The residue was purified by column chromatography (20:1; hexanes:EtOAc) to give 2.6 g of a solid (99%): 1H NMR (CDCI3) 6 4.45 (t, 2H, J = 6.6 Hz), 4.29 (t, 2H, J= 6.6 Hz), 2.80 (s, 3H), 1.78 (dquint, 4H, J= 13.2, 6.6 Hz), 1.58-1.18 (bs, 16H), 0.90 (t, 6H, J = 7.0 Hz); 13C NMR (CDCI3) 5 168.9, 162.1, 158.3, 154.0, 144.1, 121.4, 113.9, 71.1, 65.4, 31.6, 31.6, 28.8, 28.7, 28.6, 28.2, 25.9, 25.5, 22.5, 14.6, 14.0; MS (El): 423.9 2-Benzyloxy-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid octyl ester (113) The same method as for the preparation of 5-methyl-2-heptyloxy- 4-oxo-4H-thieno[2,3-c(l[1,3]oxazine-6-carboxylic acid heptyl ester was employed. Thus, cyclization afforded 11.0 mg of a solid (10%) after by column chromatography (20:1; hexanes:EtOAc): 1H NMR (CDCI3) 8 7.55-7.30 (m, 5H), 5.48 (s, 2H), 4.29 (t, 2H, J= 6.6 Hz), 2.82 (s, 3H), 1.75 (quint, 2H, J= 6.6 Hz), 1.29 (bs, 10H), 0.89 (t, 3H, J=6.6Hz). 2-/so-Propoxy-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid octyl ester (12) The same method as for the preparation of 5-methyl-2-heptyloxy-4- oxo-4H-thieno[2,3-cf)[1,3]oxazine-6-carboxylic acid heptyl ester was employed. Thus, cyclization afforded 108 mg of a solid (98%) after by column chromatography (20:1; hexanes:EtOAc): Mp 47.5-48.0sC; 1H NMR (CDCI3) 5 5.31 (sept, 1H, J = 6.2 Hz), 4.29 (t, 2H, J= 6.6 Hz), 2.81 (s, 3H), 1.75 (quint, 2H, J = 6.6 Hz), 1.44 (d, 6H, J = 6.2 Hz), 1.29 (bs, 10H), 0.89 (t, 3H, J = 6.4 Hz); MS (El): 381.9 (m+). 2-/so-Butoxy-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid octyl ester (114) The same method as for the preparation of 5-methyl-2-hepty!oxy- 4-oxo-4H-thieno[2,3-dj[1,3]oxazine-6-carboxylic acid heptyl ester was employed. Thus, cyclization afforded 15 mg of a solid (25%) after by column chromatography (20:1; hexanes:EtOAc): 1H NMR (CDCI3) 6 4.31 (q, 2H, J= 6.6 Hz), 4023 (d, 2H, J = 6.6 Hz), 2.82 (s, 3H), 2.13 (nonet, 1H, J= 6.6 Hz), 1.73 (quint, 2H, J = 6.6 Hz), 1.29 (bs, 10H), 1.03 (d, 6H, J= 6.6 Hz), 0.89 (t, 3H, J= 6.6 Hz); MS (El): 395.9 (m+). 5-Methyl-2-octyloxy-thieno[2,3-d][1,3]oxazln-4-one (23) The same method as for the preparation of 5-methyl-2-heptyloxy-4-oxo-4H-thieno[2,3-o][1,3]oxazine-6- carboxylic acid heptyl ester was employed. Thus, cyclization afforded 44 mg of an oil (20%) after by column chromatography (20:1; hexanes:EtOAc): 1H NMR (CDCI3) 8 6.59 (s, 1H), 4.41 (t, 2H, J = 6.6 Hz), 2.46 (s, 3H), 1.80 (quint, 2H, J = 6.6 Hz), 1.29 (bs, 10H), 0.89 (t, 3H, J= 6.6 Hz); MS (El): 295.9 (m+). 5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid octyl amide (18) The same method as for the preparation of 5-methyl-2-heptyloxy-4- oxo-4/-/-thieno[2,3-d][1,3]oxazine-6-carboxylic acid heptyl ester was employed. Thus, cyclization afforded 106 mg of a solid (52% from 4-methyl-5-octylcarbamoyl-2- (3-octyl-ureido)-thiophene-3-carboxylic acid tert-butyl ester) after by column chromatography (95:5; CHCI3:MeOH): Mp 152.0-152.8SC; 1H NMR (CDCI3) 8 5.70 (bs, 1H), 5.06 (bs, 1H), 3.42 (q, 6H, J = 6.2 Hz), 2.71 (s, 3H), 1.70-1.42 (m, 4H), 1.54 (s, 9H), 1.28 (bs, 20H), 0.89 (t, 6H, J= 6.6 Hz); MS (El): 450.5 (m+1). 5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid octyl ester (20) The same method as for the preparation of 5-methyl-2-heptyloxy-4- oxo-4H-thieno[2,3-c(][1,3]oxazine-6-carboxylic acid heptyl ester was employed. Thus, cyclization afforded 229 mg of a solid (67% from t-Bu ester) after by column chromatography (20:1; hexanes:EtOAc): 1H NMR (CDCI3) 5 5.20 (bs, 1H), 4.26 (t, 2H, J= 6.6 Hz), 3.51-3.40 (m, 2H), 2.78 (s, 3H), 1.85-1.48 (m, 4H), 1.28 (bs, 20H), 1.00-0.80 (m, 6H); MS (El): 451.0 (m+). BnNH 5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid benzylamide (21) The same method as for the preparation of 5-methyl-2- heptyloxy-4-oxo-4H-thieno[2,3-d\|[1,3]oxazine-6-carboxylic acid heptyl ester was employed. Thus, cyclization afforded 75.0 mg of a solid (49% from 3-methyl-5-(3- octyl-ureido)-thiophene-2,4-dicarboxylic acid 4-tert-butyl ester) after by column chromatography (95:5; CHCI3:MeOH): 1H NMR (CDCI3) 6 7.40-7.26 (m, 5H), 6.03 (t, 1H, J= 5.4 Hz), 5.20 (bs, 1H), 4.62 (d, 2H, J= 5.4 Hz), 3.50-3.30 (m, 2H), 2.72 (s, 3H), 1.73-1.43 (m, 2H), 1.28 (bs, 10H), 0.88 (t, 3H, J = 6.6 Hz). MS (El): 427.9 (m+). 5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxa2ine-6-carboxylic acid dimethylamide (22) The same method as for the preparation of 5-methyl-2- heptyloxy-4-oxo-4H-thieno[2,3-c(l[1,3]oxazine-6-carboxylic acid heptyl ester was employed. Thus, cyclization afforded 17.0 mg of a solid (13% from 3-methyl-5-(3- octyl-ureido)-thiophene-2,4-dicarboxylic acid 4-tert-butyl ester) after by column chromatography (1:1 to 1:5; hexanes:EtOAc): 1H NMR (CDCI3) 5 5.22 (bs, 1H), 3.41 (q, 2H, J= 5.4 Hz), 3.08 (s, 6H), 2.41 (s, 3H), 1.62 (quint, 2H, J =6.6 Hz), 1.28 (bs, 10H), 0.88 (t, 3H, J= 6.2 Hz); MS (El): 365.9 (m'+). 5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxyllc acid benzyl ester (16) The same method as for the preparation of 5-methyl-2-heptyloxy- 4-oxo-4H-thieno[2,3-cfl[1l3]oxazine-6-carboxylic acid heptyl ester was employed. Thus, cyclization afforded 108 mg of a solid (63% from 3-methyl-5-(3-octyl-ureido)- thiophene-2,4-dicarboxylic acid 2-benzyl ester 4-tert-butyl ester) after by column chromatography (9:1; hexanes:EtOAc): Mp 153.5-154.05C; 1H NMR (CDCI3) 8 7.50- 7.30 (m, 5H), 5.44 (bs, 1H), 5.32 (s, 2H), 3.42 (q, 2H, J= 6.2 Hz), 2.79 (s, 3H), 1.78- 1.50 (m, 2H), 1.27 (bs, 10H), 0.88 (t, 3H, J = 6.4 Hz); MS (El): 428.9 (m+). 2-Heptylamino-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid benzyl ester (17) The same method as for the preparation of 5-methyl-2-heptyloxy- 4-oxo-4H-thieno[2,3-o(j[1,3]oxazine-6-carboxylic acid heptyl ester was employed. Thus, cyclization afforded 12 mg of a solid; 1H NMR (CDCI3) 8 7.50-7.30 (m, 5H), 5.32 (s, 2H), 5.24 (bs, 1H), 3.42 (q, 2H, J= 6.2 Hz), 2.79 (s, 3H), 1.78-1.50 (m, 2H), 1.27 (bs, 8H), 0.88 (t, 3H, J= 6.4 Hz); MS (El): 414.8 (m+). 2-Dodecylamino-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid octylamide (24) The same method as for the preparation of 5-methyl-2-heptyloxy-4- oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid heptyl ester was employed. Thus, cyclization afforded 56 mg of a solid (32% from 2-(3-decyl-ureido)-4-methyl-5- octylcarbarnoyl-thiophene-3-carboxylic acid ferf-butyl ester) after by column chromatography (9:1 to 5:1; hexanes:EtOAc): Mp 137.1-138.0eC; 1H NMR (CDCI3) 6 5.74 (bs, 1H), 5.30 (bs, 1H), 3.42 (q, 4H, J= 6.6 Hz), 2.71 (s, 3H), 1.75-1.45 (m, 4H), 1.27 (bs, 28H), 0.89 (t, 6H, J= 6.0 Hz); MS (El): 506.1 (m+). 5-Methyl-4-oxo-2-tetradecylamino-4H-thieno[2,3-d]t1,3]oxazine-6-carboxylic acid octylamide (25) The same method as for the preparation of 5-methyl-2- heptyloxy^-oxo^H-thieno^.S-cfJtl.Sloxazine-e-carboxylic acid heptyl ester was employed. Thus, cyclization afforded 25 mg of a solid (19% from 4-methyl-5- octylcarbamoyl-2-(3-tetradecyl-ureido)-thiophene-3-carboxylic acid ferf-butyl ester) after by column chromatography (5:1; hexanes:EtOAc): Mp145.0-145.89C; 1H NMR (CDCla) 6 5.74 (bs, 1H), 5.30 (bs, 1H), 3.42 (q, 4H, J= 6.6 Hz), 2.71 (s, 3H), 1.75- 1.45 (m, 4H), 1.27 (bs, 32H), 0.89 (t, 6H, J = 6.0 Hz); MS (El): 534.1 (m4). 2-Hexadecylamino-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxync acid octylamide (26) The same method as for the preparation of 5-methyl-2- heptyloxy-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid heptyl ester was employed. Thus, cyclization afforded 24 mg of a solid (14% from 2-(3-hexadecylureido)- 4-methyl-5-octylcarbamoyl-thiophene-3-carboxylic acid ferf-butyl ester) after by column chromatography (5:1; hexanes:EtOAc): Mp 146.3-147.OeC; 1H NMR (CDClg) 8 5.74 (bs, 1H), 5.30 (bs, 1H), 3.42 (q, 4H, J = 6.6 Hz), 2.71 (s, 3H), 1.75- 1.45 (m, 4H), 1.27 (bs, 36H), 0.89 (t, 6H, J= 6.0 Hz); MS (El): 562.1 (m+). N H 5-MethyI-4-oxo-2-(4-phenoxy-phenylamino)-4H-thieno[2,3-d][1,3]oxazine-6- carboxylic acid octyl ester (19) The same method as for the preparation of 5- methyl-a-heptyloxy^-oxo^H-thieno^.S-c/in.SJoxazine-e-carboxylic acid heptyl ester was employed. Thus, cyclization afforded a solid, which was purified by recrystalization from EtOAc/Hexanes to give 25 mg of a solid (24%): 1H NMR (CDClg) 6 7.50 (d, 2H, J= 8.8 Hz), 7.25-7.45 (m, 2H), 7.40-6.90 (m, ,5H), 4.27 (t, 2H, J = 6.6 Hz), 2.81 (s, 3H), 1.73 (dt, 2H, J = 6.6 Hz), 1.27 (m, 10H), 0.89 (t, 3H, J = 6.0 Hz). 2-Heptyloxy-5-methyl-4-oxo-4H-thieno[2,3-dJ[1,3]oxazine-6-carboxylic acid benzyl ester (8) The same method as for the preparation of 5-methyl-2-heptyloxy-4- oxo-4H-thieno[2,3-ad[1,3]oxazine-6-carboxylic acid heptyl ester was employed. Thus, cyclization afforded 116 mg of a solid (63%) after by column chromatography (4:1; hexanes:EtOAc): 1H NMR (CDCl3) 6 7.50-7.30 (m, 5H), 5.33 (s, 2H), 4.44 (t, 2H, J = 6.2 Hz), 1.90-1.70 (m, 2H), 1.45-1.15 (m, 10H), 1.00-0.80 (m, 3H). 5-Wlethyl-2-octyloxy-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid octylamlde (15) The same method as for the preparation of 5-methyl-2-heptyloxy-4- oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid heptyl ester was employed. Thus, cyclization afforded 44.0 mg of a solid (44%) after by column chromatography (4:1; hexanes:EtOAc): 1H NMR (CDCI3) 5 5.90-5.70 (m, 1H), 4.43 (t, 2H, J = 6.6 Hz), 3.42 (q, 2H, J = 6.6 Hz), 2.72 (s, 3H), 1.90-1.70 (m, 2H), 1.70-1.50 (m, 2H), 1.50- 1.15 (m, 20H), 0.95-0.80 (m, 6H). Example 13: Carbamate/Urea Intermediates 4-Wlethyl-2-(3-octyl-ureido)-5-[(pyridin-4-ylmethyl)-carbamoyl]-thlophene-3- carboxylic acid tert-butyl ester (13.1) The compound was purified by column chromatography (100% EtOAc) to yield 175 mg (70%) of a white foam.: (70%). 'H NMR (CDCI3, 200MHz) 8 0.86 (m, 3H), 1.25 (brs, 10H), 1.56 (brs, 11H), 2.64 (s, 3H), 3.28 (dt, 2H, J= 6.2Hz, J = 6.6Hz), 4.56 (d, 2H, J= S.BHz), 5.16 (t, 1H, J= 5.4Hz), 6.17 (t, 1H, J= 5.8HZ), 7.24 (d, 2H, J= 5.8Hz), 8.54 (d, 2H, J= 5.8Hz), 10.94 4-Methyl-5-[methyl-(6-methyl-pyridin-2-ylmethyl)-carbamoyl]-2-(3-octyl-ureido)- thiophene-3-carboxylic acid tert-butyl ester (13.2): (84%). 'H NMR (CDCI3, 200MHz) 8 0.87 (m, 3H), 1.25 (brs, 10H), 1.56 (brs, 11H), 2.32 (s, 3H), 2.52 (s, 3H), 3.01 (s, 3H), 3.28 (dt, 2H, J= 6.2Hz, J = 6.6Hz), 4.74 (s, 2H), 4.95 (t, 1H, J= 5.4Hz), 7.03 (d, 2H, J=7.8Hz), 7.55 (t, 1H, J=7.6Hz), 10.75 (s, 1H) 5-[Ethyl-(2-pyridin-2-yl-ethyl)-carbamoyl]-4-methyl-2-(3-octyl-ureido)- thiophene-3-carboxylic acid tert-butyl ester (13.3): (99%). 'H NMR (CDCI3, 200MHz) 8 0.87 (m, 3H), 1.11 (t, 3H, J= 7.0Hz), 1.25 (brs, 10H),.1.56 (brs, 11H), 2.20 (s, 3H), 3.09 (t, 2H, J= 7.0Hz), 3.26 (m, 4H), 3.80 (t, 2H, J= 7.0Hz), 5.08 (t, 1H, J= 5.0HZ), 7.15 (m, 2H), 7.59 (ddd, 1H, J= 7.6Hz, J= 7.6Hz, J= 1.4Hz), 8.51 (d, 1H, J=4.4Hz), 10.76 (S.1H) 5-(Benzyloxycarbonylmethyl-carbamoyl)-4-methyl-2-(3-octyl-ureldo)-thiophene- 3-carboxylic acid tert-butyl ester (13.4): (95%). 1H NMR (CDCI3l 200MHz) 8 0.86 (m, 3H), 1.25 (brs, 10H), 1.58 (brs, 11H), 2.56 (s, 3H), 3.25 (dt, 2H, J= 6.2Hz, J = 6.6Hz), 4.21 (d, 2H, J= 5.4Hz), 5.21 (s, 2H), 5.49 (brs, 1H), 6.51 (t, 1H, J= 5.6Hz), 7.36(8, 5H), 10.71 (s,1H) 5-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinoline-2-carbonyl)-4-methyl-2-(3-octylureido)- thiophene-3-carboxylic acid tert-butyl ester (13.5): (97%). 'H NMR (CDCl3, 200MHz) 8 0.87 (brs, 3H), 1.27 (brs, 10H), 1.57 (s, 11H), 2.30 (s, 3H), 2.83 (t, 2H, J= 5.8Hz), 3.29 (dt, 2H, J= 6.2Hz, J= 6.6Hz), 3.80 (m, 8H), 4.69 (s, 2H), 4.87 (t, 1H, J=5.6Hz), 6.55 (s, 1H), 6.60 (s, 1H), 10.83 (s, 1H) 5-(3,4-Dimethoxy-benzylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophener3- carboxylic acid tert-butyl ester (13.6): (97%). 'H NMR (CDCI3, 200MHz) 5 0.86 (brs, 3H), 1.25 (brs, 10H), 1.56 (s, 11H), 2.63 (s, 3H), 3.25 (dt, 2H, J= 6.2Hz, J= 6.6H2), 3.86 (s, 6H), 4.47 (d, 2H, J= 5.6Hz), 5.05 (t, 1H, J= 5.8Hz), 5.95 (t, 1H, J= S.OHz), 6.84 (m, 3H), 10.90 (s, 1H) 5-(2-Acetylamino-ethylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3- carboxylic acid tert-butyl ester (13.7): (58%). 'H NMR (CDCI3, 200MHz) 8 0.87 (s, 3H), 1.27 (brs, 10H), 1.57 (brs, 11H), 2.04 (s, 3H), 2.60 (s, 3H), 3.29 (dt, 2H, J= 6.2Hz, J= 6.6Hz), 3.50 (m, 4H), 4.90 (brs, 1H), 6.29 (brm, 2H), 10.92 (s, 1H) 5-[4-(lsopropylcarbamoyl-methyl)-piperazine-1-carbonyl]-4-methyl-2-(3-octylureido)- thiophene-3-carboxylic acid tert-butyl ester (13.8): (61%). 'H NMR (CDCI3, 200MHz) 5 0.86 (brs, 3H), 1.10-1.28 (m, 16H), 1.56 (s, 11H), 2.29 (s, 3H), 2.51 (s, 4H), 2.99 (s, 3H), 3.27 (dt, 2H, J= 6.2Hz, J= 6.6Hz), 3.63 (s, 4H), 4.10 (m, 1H), 5.05 (brs, 1H), 6.81 (d, 1H, J= S.OHz), 10.79 (s, 1H) 3-Methyl-5-(3-octyl-thioureido)-thiophene-2,4-dicarboxylic acid 2-benzyl ester 4-tert-butyl ester (13.9): 'H NMR (CDCI3l 200MHz) 6 0.88 (m, 3H), 1.28 (brs, 10H), 1.59 (m, 11H), 2.72 (s, 3H), 3.47 (m, 2H), 5.30 (s, 2H), 6.31 (brs, 1H), 7.36 (m, 5H). 4-Methyl-2-(3-octyl-ureido)-5-[(pyridin-3-yl-methyl)-carbamoyl]-thiophene-3- carboxylic acid tert-butyl ester (13.10). The reaction was passed through a plug of silica gel with ethyl acetate to yield 13.10, 3.42 g (94% crude yield) of an off white solid. 5-[(Furan-2-ylmethyl)-carbamoyl]-4-methyl-2-(3-octyl-ureido)-thiophene-3- carboxylic acid tert-butyl ester (13.11) white solid (97% yield): 'H NMR (CDCI3, 200MHz) 5 0.86 (t, 3H, J= 6.6 Hz), 1.24-1.27 (m, 10H), 1.54 (bs, 11H), 2.61 (s, 3H), 3.26 (dt, 2H, J= 6.4, 5.8 Hz), 4.54 (d, 2H, J= 5.4 Hz), 5.31 (bs, 1H), 6.02 (t, 1H, J = 5.3 Hz), 6.27 (1H, dd, J= 11.4, 3.2 Hz), 6.30, (d, 1H, J = 3.2 Hz), 7.34 (s, 1H), 10.89 (bs, 1H). UC NMR (CDCIa) 6 14.0, 16.0, 22,6, 26.8, 28.4, 29.1, 29.2, 29.9, 31.7, 36.9, 40.8, 82.3, 107.6, 110.4, 112.9, 118.7, 140.5, 142.3, 151.0, 152.7, 153.6, 163.2, 166.4. MS (ES+) 491.95 (M+1), 493.00 (M+2). 4-Wlethyl-2-(3-octyl-ureido)-5-[(2-pyridin-3-yl-ethyl)-carbamoyl]-thiophene-3- carboxylic acid tert-butyl ester (13.12) white solid (73% yield): 'H NMR (CDCI3) 200MHz) 8 0.85 (t, 3H, J= 6.6 Hz), 1.21-1.28 (m, 10H), 1.52 (bs, 11H), 2.54 (s, 3H), 2.89 (t, 2H, J= 6.9 Hz), 3.27 (dt, 2H, J= 6.4, 6.2 Hz), 3.61 (dt, 2H, J= 6.6, 6.2 Hz), 5.69 (bs, 1H), 5.92 (t, 1H, J= 5.9 Hz), 7.23 (dd, 1H, J = 6.2, 5.2 Hz), 7.55, (ddd, 1H, J = 7.6, 1.8, 1.8 Hz), 8.46 (d,1H,J = 4.8 Hz), 8.47(8, 1H), 10.81 (bs, 1H). 13C NMR (CDCI3) 5 14.0, 15.9, 22.6, 26.8, 28.3, 29.1, 29.2, 29.9, 31.7, 33.0, 40.7, 40.9, 82.2, 112.7, 118.9, 123.5, 134.4, 136.3, 139.9, 147.9, 150.1, 152.6, 153.6, 163.7, 166.3. MS (ES+) 516.98 (M+1), 518.05 (M+2). 4-Methyl-2-(3-octyl-ureido)-5-[4-(2-piperidin-1-yl-ethyl)-piperazine-1-carbonyl]- thiophene-3-carboxylic acid tert-butyl ester (13.13) yellow oil (80% yield): 'H. NMR (CDCI3, 200MHz) 5 0.84 (t, 3H, J = 6.4 Hz), 1.22 (bs, 12H), 1.53 (m, 15H), 2.25, (s, 3H), 2.33-2.52 (m, 8H), 3.23 (dt, 2H, J = 6.6, 6.4 Hz), 3.57 (bs, 2H), 5.63 (bs, 1H), 10.73 (bs, 1H). MS (ES+) 592.07 (M+1), 593.13 (M+2). 5-(3-Hexyl-3-methyl-ureido)-3-methyl-thiophene-2,4-dicarboxylic acid 2-benzyl ester 4-tert-butyl ester (13.14). 1H NMR (CDCI3, 200MHz) 8 0.87 (t, 3H, J = 6.4 Hz), 1.25-1.32 (m, 6H), 1.58 (s, 11H), 2.72 (s, 3H), 3.04 (s, 3H), 3.36 (t, 2H, J = 7.7 Hz), 5.26 (s, 2H), 7.27-7.43 (m, 5H), 11.53 (bs, 1H). I3C NMR (CDCI3) 8 13.9, 15.8, 22.5, 26.3, 27.7, 28.3, 31.4, 34.4, 49.3, 65.8, 82.3, 113.1, 115.2, 127.9, 128.4, 136.1, 145.5,153.6,156.6,163.0, 166.7. MS (ES+) 557 (M+68). 5-[3-(1 -Butyl-pentyl)-ureido]-3-methyl-thiophene-2,4-dicarboxylic acid 2-benzyl ester 4-tert-butyl ester (13.15). 'H NMR (CDCI3, 200MHz) 80.86 (t, 6H, J = 6.6 Hz), 1.25-1.31 (m, 12H), 1.55 (s, 9H), 2.70 (s, 3H), 3.58-3.78 (m, 1H), 5.04 (bd, 1H, J = 8.8 Hz), 5.25 (S, 2H), 7.27-7.41 (m, 5H), 10.98 (bs, 1H). "C NMR (CDCI3) 8 13.9, 14.0, 15.8, 22.6, 22.7, 28.0, 28.1, 28.3, 35.1, 35.6, 65.9, 82.3, 112.8, 115.2, 127.9, 128.4,136.1,145.5,153.1,156.3, 163.0,166.4,186.4. MS (ES+) 585 (M+68). 5-(3,3-Dioctyl-ureido)-3-methyl-thiophene-2,4-dicarboxylic acid 2-benzyl ester 81 4-fert-butyl ester (13.16). 'H NMR (CDCI3l 200MHz) 80.87 (t, 6H, J = 6.6 Hz), 1.26-1.30 (m, 20H), 1.58 (bs, 13H), 2.72 (s, 3H), 3.32 (t, 4H, J = 7.7 Hz), 5.25 (s, 2H), 7.28-7.43 (m, 5H), 11.58 (bs, 1H). 13C NMR (CDCI3) 8 14.0, 15.8, 22.6, 26.9, 28.3, 28.5, 29.2, 29.3, 31.8, 47.9, 65.9, 82.3, 113.0, 115.1, 127.9, 128.0, 128.5, 136.1, 145.6, 153.3, 156.7, 163.0, 166.7. 5-lsobutylcarbamoyl-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid tert-butyl ester (13.17). MS (ES): m/z 467.9 [MH+]. 1H NMR (CDCI3, 200 MHz): 8 = 0.83 (m, 9H), 1.26-1.57 (m, 20H), 1.87 (m, 1H, 6.6 Hz), 2.62 (s, 3H), 3.16-3.30 (m, 4H), 5.11 (brs, 1H), 5.64 (m, 1H). 5-(2,2-Dimethyl-propylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3- carboxylic acid tert-butyl ester (13.18). MS (ES): m/z 481.7 [MH+]. 1H NMR (CDCI3, 200 MHz): 5 = 0.83 (m, 9H), 1.26-1.57 (m, 23H), 2.62 (s, 3H), 3.16-3.30 (m, 4H), 5.11 (brs, 1H), 5.64 (m, 1H). 5-[(2,3-Dihydro-benzofuran-5-ylmethyl)-carbamoyl]-4-methyl-2-(3-octyl-ureido)- thiophene-3-carboxylic acid tert-butyl ester (13.19). MS (ES): m/z 543.87 [MH+]. 4-Methyl-2-(3-octyl-ureido)-5-[(pyridin-2-ylmethyl)-carbamoyl]-thiophene-3- carboxylic acid tert-butyl ester (13.20) The same method as for the preparation of 4-methyl-5-octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid tert-butyl ester was employed. Thus, coupling with 2-(aminomethyl)pyridine (31.5 mg, 0.36 mmol) afforded 86.9 mg of a solid (71%) after by column chromatography (EtOAc): 1H NMR (CDCI3) 8 0.87 (m, 3H), 1.45-1.20 (m, 10H), 1.70-1.45 (m, 11H), 2.64 (s, 3H), 3.29 (dt, 4H, J = 6.7, 6.6 Hz), 4.68 (d, 2H, J = 5.8H.Z), 4.91 (m, TH), 7.02 (m, 1H), 7.35-7.10 (m, 1H), 7.65 (t, 1H, J = 8.0Hz), 8.53 (d, 1H, J = 5.0 Hz), 10.92 (s, 1H); MS (El): cal'd 502.86, exp 502.94 (MH+). 4-Methyl-2-(3-octyl-ureido)-5-[(pyridin-3-ylmethyl)-carbamoyl]-thiophene-3- carboxylic acid tert-butyl ester (13.21) The same method as for the preparation of 4-methyl-5-octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid tert-butyl ester was employed. Thus, coupling with 3-(aminomethyl)pyridine (31.5 mg, 0.36 mmol) afforded 93.1 mg of a solid (76%) after by column chromatography (EtOAc): 1H NMR (CDCl3) 5 0.87 (m, 3H), 1.45-1.20 (m, 10H), 1.70-1.45 (m, 11H), 2.65 (s, 3H), 3.29 (dt, 4H, J= 6.7, 6.6 Hz), 4.57 (d, 2H, J = 5.6Hz), 4.89 (m, 1H), 6.05 (t, 1H, J = 7.0, 5.0HZ), 7.68 (d, 1H, J = 7.0Hz), 8.53 (d, 1H, J = 5.0 Hz), 8.58 (s, 1H), 10.92 (s, 1H); MS (El): cal'd 502.86, exp 502.94 (MH+). 5-Dibutylcarbamoyl-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid tert-butyl ester (13.22) The same method as for the preparation of 4-methyl-5- octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid fert-butyl ester was employed. Thus, coupling with dibutylamine (37.6 mg, 0.36 mmol) afforded 56.9 mg of a solid (45%) after by column chromatography (8:2; hexanes:EtOAc): 1H NMR (CDCI8) 5 0.87 (m, 9H), 1.18-1.40 (m, 14H), 1.45-1.68 (m, 15H), 2.23 (s, 3H), 3.20- 3.46 (m, 6H), 5.11 (m, 1H), 10.74 (s, 1H); MS (El): caPd 523.77, exp 524.02 (MH+). 5-(4-Benzyl-piperidine-1-carbonyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3- carboxylic acid tert-butyl ester (13.23): 'H NMR (CDCI3, 200MHz) 8 0.87 (s, 3H), 1.26 (brs, 11H), 1.56 (bra, 15H), 2.27 (s, 3H), 2.54 (d, 2H, J = 6.6Hz), 2.80 (m, 2H), 3.27 (dt, 2H, J = 6.2Hz, J = 6.6Hz), 4.20 (m, 2H), 5.06 (t, 1H, J = 5.2Hz), 7.05-7.30 (m, 5H), 10.77 (s, 1H); MS (ES) 570.1 (M+1) 8 3-Methyl-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid 4-tert-butyl ester 2- (1-butyl-pentyl) ester (13.24): (60%). 'H NMR (CD3OD, 200MHz) 5 0.89 (s, 9H), 1.32 (s, 18H), 1.60 (s, 15H), 2.69 (s, 3H), 3.19 (t, 2H, J = 6.4Hz), 5.00 (p, 1H, J = 6Hz), 10.95 (s, 1H); MS (ES) 539.2 (M+1) 4-Methyl-2-(3-octyl-ureido)-5-(3-phenoxy-propylcarbamoyl)-thiophene-3- carboxylic acid tert-butyl ester (13.25): (55%).'H NMR (CDCI3, 400MHz) 5 0.88 (m, 3H), 1.27 (m, 10H), 1.55 (m, 11H), 2.07 (m, 2H), 2.62 (s, 3H), 3.30 (dt, 2H, J = 5.6Hz, J = 7.2Hz), 3.59 (dt, 2H, J = 5.6Hz, J = 6.4Hz), 4.07 (t, 2H, J = 5.6Hz), 4.82 (brs, 1H), 6.14 (brs, 1H), 6.95 (m, 3H), 7.25 (m, 2H), 10.95 (s, 1H); MS (ES) 545.95 (M) 5-(1-Butyl-pentylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid tert-butyl ester (13.26): (92%). 'H NMR (CDCI3, 200MHz) 8 0.87 (m, 9H), 1.29 (m, 18H), 1.56 (s, 11H), 2.61 (s, 3H), 3.29 (dt, 2H, J = 6.6Hz, J = 6.6Hz), 4.02 (brs, 1H), 5.04 (t, 1H, J = 5.6Hz), 5.40 (d, 1H, J = 8.8Hz), 10.91 (s, 1H) 5-[(Furan-2-ylmethyl)-carbamoyl]-4-methyl-2-(3-octyl-ureido)-thiophene-3- carboxylic acid ferf-butyl ester (13.27): MS (ES+) 491.88 (M+1). 4-Methyl-2-(3-octyl-ureido)-5-(thlazol-2-ylcarbamoyl)-thlophene-3-carboxylic acid ferf-butyl ester (13.28): MS (ES+) 494.84 (M+1). 4-Methyl-2-(3-octyl-ureido)-5-(2-pyridin-3-yl-ethylcarbamoyl)-thiophene-3- carboxylic acid ferf-butyl ester (13.29): MS (ES+) 516.93 (M+1). 4-Methyl-2-(3-octyl-ureido)-5-[4-(2-piperidin-1-yl-ethyl)-piperazine-1-carbonyl]- thiophene-3-carboxylic acid fert-butyl ester (13.30): MS (ES+) 592.04 (M+1). 4-Methyl-2-(3-octyl-ureido)-5-(4-phenyl-plperazine-1-carbonyl)-thlophene-3- carboxylic acid ferf-butyl ester (13.31): MS (ES+) 556.94 (M+1). 5-([1,4']Bipiperidinyl-1'-carbonyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3- carboxylic acid tert-butyl ester (13.32): MS (ES+) 563.01 (M+1). 5-(3-lmidazol-1-yl-propylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3- carboxylic acid terf-butyl ester (13.33): MS (ES+) 519.95 (M+1), 5-Dihexylcarbamoyi-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid tert-butyl ester (13.34): (40%). 1H NMR (CD3CI, 200MHz) 8 0.85 (s, 9H), 1.24 (s, 22H), 1.56 (s, 15H), 2.24 (s, 3H), 3.31 (m, 6H), 4.83 (t, 1H, J = 5.2Hz), 10.76 (S, 1H); MS(ES) 580.21 (M+1) 5-Dioctylcarbamoyl-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid tert-butyl ester (13.35): (65%). 'H NMR (CD3Cl, 200MHz) 8 0.86 (m, 9H), 1.23 (s, 32H), 1.56 (s, 15H), 2.25 (s, 3H), 3.31 (m, 6H), 4.80 (t, 1H, J = 5.6Hz), 10.77 (s, 1H); MS (ES) 637.00 (M+1) 5-Cyclohexylcarbamoyl-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid tert-butyl ester (13.36): (75%). 1H NMR (CD3CI, 200MHz) 8 0.87 (t, 3H, J = 6.4Hz), 1.26 (m, 16H), 1.56 (m, 15H), 2.60 (s, 3H), 3.28 (dt, 2H, J = 6.6Hz, J = 6.2Hz), 3.88 (m, 1H), 4.97 (t, 1H, J = 5.4Hz), 5.57 (d, 1H, J = 7.2Hz), 10.78 (s, 1H); MS (ES) 494.12 (M+1) 5-(4-Benzyl-piperazine-1-carbonyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3- carboxylic acid tert-butyl ester (13.37): (72%). 'H NMR (CD3CI, 200MHz) 80.87 (m, 3H), 1.26 (brs, 10H), 1.56 (brs, 11H), 2.28 (s, 3H), 2.44 (brs, 4H), 3.27 (dt, 2H, J = 6.6Hz, J = 6.6Hz), 3.52 (s, 2H), 3.60 (brs, 4H), 4.88 (t, 1H, J = 5.0Hz), 7.30 (brs, 5H), 10.78 (s, 1H); MS (ES) 571.16 (M--1) 4-Methyl-2-(3-octyl-ureido)-5-[(pyridin-3-ylmethyl)-carbamoyl]-thiophene-3- carboxylic acid tert-butyl ester (13.38). The crude solid was then flashed through a plug of silica gel with ethyl acetate to yield 13.38, 3.84g (98% crude yield) of a tan solid. 5-(3-DimethyIamino-propylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3- carboxylic acid tert-butyl ester (13.39): MS (ES+) 496.95 (M+1). 3-Methyl-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid 2-benzyl ester 4- lerf-butyl ester (13.40). Mp 11 9.0-1 20.09C; 1H NMR (CDCI3) 8 11.03 (s, 1H), 7.50- 7.20 (m, 5H), 5.27 (s, 2H), 5.03 (vt, 1H), 3.29 (q, 2H, J = 6.6 Hz), 2.71 (s, 3H), 1.63- 1.40 (m, 2H), 1.57 (s, 9H), 1.26 (bs, 10H), 0.87 (t, 3H, J = 6.6 Hz). MS (El): 502.8 3-Methyl-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid 4-ferf-butyl ester 2- octyl ester (13.41) Mp 92.0-94.0 eC; 1H NMR (CDCI3) 6 12.30 (s, 1H), 8.64 (s, 1H), 5.30 (t, 1H, J = 6.0 Hz), 4.25 (t, 2H, J = 6.4 Hz), 3.29 (q, 2H, J = 6.0 Hz), 2.74 (s, 3H), 1.90-1.50 (m, 4H), 1.61 (s, 9H), 1.28 (bs, 20H), 0.88 (m, 6H). MS (El): 525.1 4-Methyl-5-octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid fertbiityl ester (13.42). 1H NMR (CDCI3) 8 10.89 (s, 1H), 5.82-5.62 (m, 1H), 5.78-5.60 (m, 1H), 3.33 (q, 4H, J = 6.6 Hz), 2.61 (s, 3H), 1.70-1.40 (m, 4H), 1.55 (s, 9H), 1.27 (bs, 20H), 0.88 (m, 6H). MS (El): 524.1 (m+). 4-Methyl-2-(3-octyl-ureido)-5-(4-phenyl-butylcarbamoyl)-thiophene-3-carboxylic acid tert-butyl ester (13.43): 'H NMR (CDCI3l 200MHz) 8 0.87 (m, 3H), 1.21-1.43 (m, 10H), 1.57 (s, 15H), 2.60 (m, 5H), 3.24-3.43 (m, 4H), 5.22 (brs, 1H), 5.70 (t, 1H, J = 5.0HZ), 7.25 (m, 5H), 10.90 (s, 1 H). 4-Methyl-2-(3-octyl-ureido)-5-(3-phenyl-propylcarbamoyl)-thiophene-3- carboxylic acid tert-butyl ester (13.44) 'H NMR (CDCI3l 200MHz) 8 0.87 (m, 3H), 1.21-1.45 (m, 10H), 1.57 (s, 11H), 1.89 (tt, 2H, J = 7.4Hz, J = 7.6Hz), 2.65 (m, 5H), 3.24-3.45 (m, 4H), 5.14 (brs, 1H), 5.73 (t, 1H, J = 5.2Hz), 7.17-7.31 (m, 5H), 10.90 4-Methyl-2-(3-octyl-ureido)-5-(2-phenoxy-ethylcarbamoyl)-thiophene-3- carboxylic acid tert-butyl ester (13.45): 'H NMR (CDCl3, 200MHz) 8 0.87 (m, 3H), 1.22-1.49 (m, 10H), 1.56 (s, 11H), 2.61 (s, 3H), 3.28 (dt, 2H, J = 6.2Hz, J = 6.6Hz), 3.78 (dt, 2H, J = 5.2Hz, J = 5.4Hz), 4.09 (t,'2H, J = 5.2Hz), 5.08 (t, 1H, J = S.OHz), 6.21 (t, 1 H, J = 5.4HZ), 6.29 (m, 3H), 7.28 (m, 2H), 1 0.91 (s, 1 H). 5-(2-Methoxy-ethylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3- carboxylic acid tert-butyl ester (13.46): 'H NMR (CDCI3, 200MHz) 8 0.87 (m, 3H), 1.27-1.45 (m, 10H), 1.57 (brs, 11H), 2.60 (s, 3H), 3.24-3.37 (m, 5H), 3.54 (m, 4H), 5.05 (t, 1H, J = 5.2Hz), 6.12 (brs, 1H), 10.88 (s, 1H). 5-(3-Methoxy-propylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3- carboxylic acid tert-butyl ester (13.47): 'H NMR (CDCI3, 200MHz) 8 0.87 (m, 3H), 1.21-1.49 (m, 10H), 1.57 (brs, 11H), 1.83 (tt, 2H, J = 5.8Hz, J = 6.2Hz), 2.60 (s, 3H), 3.24-3.35 (m, 5H), 3.49 (m, 4H), 5.13 (t, 1H, J = 5.6Hz), 6.31 (t, 1H, J = 5.6Hz), 10.90(s, 5-((Benzo(1,3)dioxol-5-ylmethyl)-carbamoyl)-4-methyl-2-(3-octyl-ureido)- thiophene-3-carboxyHc acid tert-butyl ester (13.48): 'H NMR (CDCI3, 200MHz) 8 0.87 (m, 3H), 1.26-1.43 (brs, 10H), 1.57 (brs, 11H), 2.63 (s, 3H), 3.27 (dt, 2H, J= 6.2HZ, J= 6.6HZ), 4.44 (d, 2H, J = 5.6Hz), 4.92 (t, 1H, J = 5.6Hz), 5.94 (s, 2H), 6.76 (s, 2H), 6.81 (s, 1H), 10.91 (s, 1H). 3-Methyl-5-(1-methylheptyloxycarbonylamino)thiophene-2,4-dicarboxylic acid 2-benzyl ester 4-tert-butyl ester (13.49) Light brownish oil in 82% yield as mixture of two rotatmers (2:1 ratio). 'H NMR (CDCI3, 200MHz): 8 7.35-7.40 (m, 5H), 6.49 (brs, 1H), 5.25 and 5.28 (s, 2H), 4.70-4.80 and 4.80-5.05 (m, 1H), 2.68 and 2.73 (s, 3H), 1.50-1.61 (m, 9H), 1.20-1.40 (m, 8H), 0.87(m, 3H). 3-Methyl-5-[3-(1-methylheptyl)ureido]thiophene-2,4-dicarboxylic acid 2-benzyl ester 4-fert-butyl ester (13.50) Light yellow oil in 99% yield as mixture of two rotatmers. 'H NMR (CDCIS, 200MHz): 5 11.00 (brs, 1H), 7.29-7.43 (m, 5H), 5.24 and 5.26 (s, 2H), 4.60 and 4.68 (brs, 1H), 3.80-3.95 (brs, 1H), 3.45-3.90 (m, 1H), 2.65 and 2.70 (s, 3H), 1.55 and 1.57 (s, 9H), 1.40-1.50(m, 2H), 1.20-1.40 (m, 8H), 1.17 (d, 2H, J = 6.6Hz), 1.09(d, 1H, J= 6.2HZ), 0.80-0.95(m, 3H). Example 14: Acid Intermediates 4-Methyl-2-(3-octyl-ureido)-5-[(pyridin-4-ylmethyl)-carbamoyl]-thiophene-3- carboxylic acid (14.1): (99%). 'H NMR (CD3OD, 200MHz) 8 0.86 (m, 3H), 1.25 (brs, 10H), 1.56 (m, 2H), 2.64 (s, 3H), 3.28 (m, 2H), 4.56 (d, 2H, J= 5.8Hz) 7.24 (d, 2H, J= 5.8HZ), 8.54 (d, 2H, J= 5.8Hz) 4-Methyl-5-[methyl-(6-methyl-pyridin-2-ylmethyl)-carbamoyl]-2-(3-octyl-ureido)- thiophene-3-carboxylic acid (14.2): (99%). 'H NMR (CD3OD, 200MHz) 6 0.86 (m, 3H), 1.28 (brs, 10H), 1.50 (brs, 2H), 2.38 (s, 3H), 2.50 (s, 3H), 3.04 (s, 3H), 3.17 (brs, 2H), 4.74 (s, 2H), 7.15 (m, 2H), 7.55 (t, 1 H, J= 7.6Hz) 5-[Ethyl-(2'pyridin-2-yl-ethyl)-carbamoyl]-4-methyl-2-(3-octyl-ureido)- thiophene-3-carboxylic acid (14.3): (99%). 'H NMR (CD3OD, 200MHz) 8 0.85 (m, 3H), 1.20 (brs, 13H), 1.49 (brs, 2H), 2.20 (s, 3H), 3.19 (m, 4H), 3.41 (m, 2H), 3.83 (brs, 2H), 7.38 (m, 2H), 7.84 (t, 1 H, J= 7.2Hz), 8.49 (d, 1 H, J= 3.6Hz) 5-(Benzyloxycarbonylmethyl-carbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene- 3-carboxylic acid (14.4): (99%). 1H NMR (CD3OD, 200MHz) 6 0.86 (m, 3H). 1.28 (brs, 10H), 1.50 (brs, 2H), 2.57 (s, 3H), 3.18 (m, 2H), 4.09 (s, 2H), 7.31 (brs, 5H) 3-Methyl-5-(3-octyl-thioureido)-thiophene-2,4-dicarboxylic acid 2-benzyl ester (14.5): (99%). 'H NMR (CD3OD, 200MHz) 8 0.89 (brs, 3H), 1.29 (brs, 10H), 1.61 (brs, 2H), 2.74 (s, 3H), 3.48 (brs, 2H), 5.29 (s, 2H), 7.38 (m, 5H). 4-Wlethyl-2-(3-octyl-ureido)-5-[(pyridin-3-yl-methyl)-carbamoyI]-thiophene-3- carboxylic acid (14.6) Thiophene (3.42 g, 6.8 mmol) was dissolved in 40 mL CH2CI2. Trifluoroacetic acid (10 mL) was added slowly and the reaction was stirred for 4h at rt. The reaction was concentrated in-vacuo. The residue was dissolved in methanol and saturated NaHCO3 was added until pH~7. The solution was concentrated in vacuo and then resuspended in hot ethyl acetate. The insoluble salts were filtered and the filtrate was concentrated in vacuo to yield 14.6, 2.19 g (72% crude yield) of a tan solid. 5-[(Furan-2-yl-methyl)-carbamoyl]-4-methyl-2-(3-octyl-ureido)-thiophene-3- carboxylic acid (14.7) white solid (73% yield): 'H NMR (CD3OD, 200MHz) 8 0.90 (t, 3H, J= 6.4 Hz), 1.30-1.39 (m, 10H), 1.50-1.60 (m, 2H), 2.56 (s, 3H), 3.20 (t, 2H, J = 6.9 Hz), 4.49 (s, 2H), 6.27 (1H, d, J = 3.0 Hz), 6.35 (dd, 1H, J = 3.2, 1.8 Hz), 7.34 (d, 1H, J =1.8 Hz). MS (ES+) 435.76 (M+1), 436.66 (M+2). 4-Methyl-2-(3-octyl-ureido)-5-[(2-pyridin-3-yl-ethyl)-carbamoyl]-thiophene-3- carboxylic acid (14.8) light pink solid (100% yield): 'H NMR (CD3OD, 200MHz) 8 0.90 (t, 3H, J= 9.9 Hz), 1.32 (bs, 10H), 1.51-1.60 (m, 2H), 2.58 (s, 3H), 2.96 (t, 2H, J = 7.0 Hz), 3.20 (t, 2H, J = 6.7 Hz), 3.59 (t, 2H, J = 7.0 Hz), 7.39 (dd, 1 H, J = 7.8, 4.8 Hz), 7.78 (d, 1H, J=7.8 Hz), 8.39 (d, 1H, J=4.8 Hz), 8.46 (s, 1H). MS (ES-) 458.92 (M-1). 4-Methyl-2-(3-octyl-ureido)-5-[4-(2-piperidin-1-yl-ethyl)-piperazine-1-carbonyl]- thiophene-3-carboxylic acid (14.9) peach solid (80% yield): MS (ES-) 534.04 (M- 1). 5-(3-Hexyl-3-methyl-ureido)-3-methyl-thiophene-2,4-dicarboxyi«c ackti 2-benzyl ester (14.10) light pink solid (100% yield): 'H NMR (CDCI3, 200MHz) 8 0.87 (t, 3H, J = 6.4 Hz), 1.25-1.31 (m, 6H), 1.58-1.62 (m, 2H), 2.78 (s, 3H), 3.05 (s, 3H), 3.36 (t, 13C 2H, J = 7.5 Hz), 5.29 (s, 2H), 7.29-7.44 (m, 5H), 10.39 (bs, 1H), 11.18 (bs, 1H). NMR (CDCI3) 5 13.9, 15.4, 22.4, 26.3, 27.7, 31.4, 34.7, 49.7, 66.4, 110.8, 116.4, 127.9, 128.1, 128.5, 135.7, 146.1, 153.5, 158.6, 162.9, 171.3. MS (ES+) 432.74 (M+1). 5-(3,3-Dioctyl-ureido)-3-methyl-thiophene-2,4-dicarboxylic acid 2-benzyl ester (14.11) light pink solid (84% yield): 1H NMR (CDCI3, 200MHz) 6 0.86 (t, 6H, J = 6.6 Hz), 1.26-1.30 (m, 20H), 1.63 (bs, 4H), 2.80 (s, 3H), 3.33 (t, 4H, J = 7.0 Hz), 5.28 (s, 2H), 7.30-7.43 (m, 5H), 11.20 (s, 1H), 11.92 (bs, 1H). 5-lsobutylcarbamoyl-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid (14.12). MS (ES): m/z411.8 [MH+]. 5-(2,2-Dimethyl-propylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3- carboxylic acid (14.13). MS (ES): m/z 425.8 [MH+]. 1H NMR (CDCI3) 200 MHz): D = 1.26-1.57 (m, 23H), 2.62 (s, 3H), 3.16-3.30 (m, 4H), 5.11 (brs, 1H), 5.64 (m, 1H). O 4-Methyl-2-(3-octyl-ureido)-5-[(pyridin-2-ylmethyl)-carbamoyl]-thiophene-3- carboxylic acid (14.14) The same method as for the preparation of 3- methoxymethyl-5-octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester was employed. Thus, deprotection with TFA afforded a solid, which was used without purification: 1H NMR (CDCI3 + 1 drop of CD3OD) 8 0.86 (m, 3H), 1.32-1.20 (m, 10H), 1.60-1.32 (m, 2H), 2.59 (s, 3H), 3.22 (dt, 4H, J= 6.7, 6.6 Hz), 4.76 (s, 2H), 7.40-7.15 (m, 2H), 7.76 (t, 1H, J = 7.9Hz), 8.53 (d, 1H, J = 5.0 Hz). 4-Methyl-2-(3-octyl-ureido)-5-[(pyridin-3-ylmethyl)-carbamoyl]-thiophene-3- carboxylic acid (14.15) The same method as for the preparation of 3- methoxymethyl-5-octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester was employed. Thus, deprotection with TFA afforded a solid, which was used without purification: 1H NMR (CDCI3+1 drop of CD3OD) 8 0.82 (m, 3H), 1.45-1.20 (m, 10H), 1.70-1.45 (m, 2H), 2.02 (m, 3H), 2.92 (m, 2H), 4.39 (m, 1H), 7.11 (m, 1H), 7.55 (m, 1H), 8.31 (m, 1H), 8.49 (m, 1H). 5-(4-Benzyl-piperidine-1-carbonyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3- carboxylic acid (14.16): (100%). 'H NMR (CD3OD, 200MHz) 8 0. 87 (s, 3H), 1.26 (brs, 11H), 1.56 (brs, 6H), 2.27 (s, 3H), 2.54 (d, 2H, J = 6.6Hz), 2.90 (m, 2H), 3.27 (t, 2H, J = 6.6Hz), 4.20 (brs, 2H), 7.05-7.30 (rn, 5H) 3-Methyl-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid 2-(1-butyl-pentyl) ester (14.17): (95%). 1H NMR (CD3OD, 400MHz) 8 0.89 (m, 9H), 1.33 (m, 18H), 1.50-1.70 (m, 6H), 2.73 (s, 3H), 3.19 (t, 2H, J = 6.6Hz), 5.02 (m, 1H) 5-(1-Butyl-pentylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thlophene-3-carboxylic acid (14.18): (100%). 'H NMR (CDCI3, 200MHz) S 0.87 (m, 9H), 1.29 (m, 18H), 1.56 (s, 6H), 2.52 (s, 3H), 3.35 (t, 2H, J = 6.6Hz), 3.90 (brs, 1H) 4-Methyl-2-(3-octyl-ureido)-5-(3-phenoxy-propylcarbamoyl)-thiophene-3- carboxylic acid (14.19): (100%). 1H NMR (CD3OD, 200MHz) 8 0.89 (m, 3H), 1.32 (s, 10H), 1.55 (brs, 2H), 2.06 (tt, 2H, J = 6.0Hz, J = 6.0Hz), 2.55 (s, 3H), 3.19 (t, 2H, J = 7.0Hz), 3.51 (t, 2H, J = 6.8Hz), 6.90 (m, 3H), 7.24 (m, 2H). 4-Methyl-2-(3-octyl-ureido)-5-(pyridin-3-ylmethyl)-carbamoyl)-thiophene-3- carboxyllc acid (14.20):. 14.20,110 mg (100% crude yield) of a tan solid. 5-(3-Dimethylamino-propylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3- carboxylic acid (14.21): MS (ES-) 438.70 (M-1). 5-[(Furan-2-ylmethyl)-carbamoyl]-4-methyl-2-(3-octyl-ureido)-thiophene-3- carboxylic acid (14.22): MS (ES-) 434.03 (M-1). 4-Methyl-2-(3-octyl-ureido)-5-(thiazol-2-ylcarbamoyl)-thiophene-3-carboxylic acid (14.23): MS (ES-) 436.23 (M-1). 4-Methyl-2-(3-octyl-ureido)-5-(2-pyridin-3-yl-ethylcarbamoyl)-thiophene-3- carboxylic acid (14.24): MS (ES-) 459.03(M-1). 4-Methyl-2-(3-octyl-ureido)-5-[4-(2-piperidin-1-yl-ethyl)-piperazine-1-carbonyl]- thiophene-3-carboxylic acid (14.25): MS (ES-) 534.20 (M-1). 4-Methyl-2-(3-octyl-ureido)-5-(4-phenyl-piperazine-1-carbonyl)-thiophene-3- carboxylic acid (14.26): MS (ES-) 499.03 (M-1). 5-([1,4']Bipiperidinyl-1'-carbonyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3- carboxylic acid (14.27): MS (ES-) 505.08 (M-1). 5-(3-lmida2ol-1-yl-propylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3- carboxylic acid (14.28): MS (ES-) 462.09 (M-1). 3-Methyl-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid 4-fert-butyl ester (14.29) 1H NMR (CDCI3) 8 11.06 (s, 1H), 5.14 (vt, 1H), 3.30 (q, 2H, J= 6.0 Hz), 2.71 (s, 3H), 1.70-1.40 (m, 2H), 1.59 (s, 9H), 1.27 (bs, 10H), 0.87 (t, 3H, J= 6.6 Hz). MS (El): 412.8 (m+). 2-Dodecyloxy-5-methyl-4-oxo-4W-thieno[2,3-cf][1,3]oxazine-6-carboxylic acid (14.30) 1H NMR (CDCIa) 6 4.47 (t, 2H, J= 6.2 Hz), 4.19 (bs, 1H), 2.85 (s, 3H), 1.80 (quint, 2H, J= 6.2 Hz), 1.27 (bs, 18H), 0.88 (t, 3H, J= 6.6 Hz). MS (Ei): 395.4 (m+). 4-Methyl-5-octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid (14.31) 1H NMR (CDCh) 8 10.90 (bs, 2H), 5.82-5.62 (m, 1H), 5.78-5.60 (m, 1H), 3.33 (q, 4H, J = 6.6 Hz), 2.61 (s, 3H), 1.70-1.40 (m, 4H), 1.27 (bs, 20H), 0.88 (m, 6H). 3-Methoxymethyl-5-octvioxycarbonylamino-thiophene[2,4]dicarboxylic acid 2- benzyl ester (14.32) 1H NMR (CDCI3) 8 11.98 (s, 1H), 10.09 (s, 1H), 7.45-7.20 (m, 5H), 5.14 (s, 2H), 4.22 (t, 2H, J = 6.6 Hz), 3.85 (s, 3H), 3.82 (s, 2H), 1.70 (quint, 2H, J = 6.6 Hz), 1.28 (bs, 10H), 0.88 (t, 3H, J = 5.6 Hz). 5-(4-(lsopropylcarbamoyl-methyl)-piperazine-1-carbonyl)-4-methyl-2-(3-octylureido)- thiophene-3-carboxylic acid (14.33): 'H NMR (CDCI3) 200MHz) 8 0.89 (brs, 3H), 1.15-1.34 (m, 16H), 1.56 (m, 2H), 2.37 (s, 3H), 3.05-3.49 (m, 10H), 3.95 (m, 1H). 5-((Benzo(1,3)dioxol-5-ylrr,ethyl)-carbamoyl)-4-methyl-2-(3-octyl-ureido)- thiophene-3-carboxylic acid (14.34): 'H NMR (CDCI3, 200MHz) 8 0.86 (m, 3H), .1.32-1.45 (m, 10H), 1.53 (rr, 2H), 2.56 (s, 3H), 3.19 (m,2H), 4.4 (d, 2H, J = 6.0Hz), 5.91 (s, 2H), 6.80 (m, 3H). 5-(3,4-Dlmethoxy-benzylcarbamoyl)-4-methylT2-(3-octyl-ureido)-thiophene-3- carboxylic acid (14.35): 'H NMR (CDCI3, 200MHz) 8 0.88 (brs, 3H), 1.31-1.45 (m, 10H), 1.56 (m, 2H), 2.56 (s, SH), 3.18 (dt, 2H, J= 6.2Hz, J= 6.6Hz), 3.80 (s, 3H), 3.82 (s, 3H), 4.43 (s, 2H), 6.89 (s, 2H), 6.97 (s, 1H). S-te^-Dimethoxy-S^-dihydro-IH-isoquinoline^-carbonylH-methyl^-ta-octylureido)- thiophene-3-carboxylic acid (14.36): 'H NMR (CDCI3l 200MHz) 8 0.89 (m, 3H), 1.31-1.45 (m, 10H), 1 51 (brs, 2H), 2.31 (s, 3H), 2.85 (t, 2H, J = 6.0Hz), 3.18 (t, 2H, J = 7.0Hz), 3.79 (m, 8H), 6.71 (s, 1H), 6.74 (s,1H). 4-Methyl-2-(3-octyl-ureido)-5-(4-phenyl-butylcarbamoyl)-thiophene-3-carboxylic acid (14.37): 'H NMR (CDCI3) 200MHz) 8 0.89 (brs, 3H), 1.26-1.45 (m, 10H), 1.59 (m, 6H), 2.54 (s, 3H), 2.65 (t, 2H, J = 7.0Hz)', 3.19 (m, 4H), 7.21 (m, 5H). 4-Methyl-2-(3-octyl-ureldo)-5-(3-phenyl-propylcarbamoyl)-thiophene-3- carboxylic acid (14.38): 'H NMR (CDCI3, 200MHz) 8 0.89 (m, 3H), 1.25-1.45 (m, 10H), 1.57 (brs, 2H), 1.89 (tt, 2H, J = 7.4Hz, J = 7.6Hz), 2.55 (s, 3H), 3.17-3.39 (m, 4H), 7.23 (m, 5H). 4-Methyl-2-(3-octyl-ureido)-5-(2-phenoxy-ethylcarbamoyl)-thiophene-3- carboxylic acid (14.39): 'H NMR (CDCI3, 200MHz) 8 0.87 (m, 3H), 1.25-1.41 (m, 10H), 1.56 (brs, 2H), 2.56 (s, 3H), 3.19 (dt, 2H, J = 6.2Hz, J = 6.6Hz), 3.71 (dt, 2H, J = 5.2HZ, J = 5.4Hz), 4.12 (t, 2H, J = 5.2Hz), 6.95 (m, 3H), 7.25 (m, 2H). 5-(2-Methoxy-ethylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3- carboxylic acid (14.40): 'H NMR (CDCI3l 200MHz) 5 0.89 (brs, 3H), 1.25-1.43 (m, 10H), 1.53 (m, 2H), 2.56 (s, 3H), 3.19 (t, 2H, J =7.0Hz), 3.37 (s, 3H), 3.51 (m, 4H). 5-(3-Methoxy-propylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3- carboxylic acid (14.41): 'H NMR (CDCI3, 200MHz) 8 0.89 (brs, 3H), 1.27-1.44 (m, 10H), 1.51 (brs, 2H), 1.84 (tt, 2H, J = 6.2Hz, J = 6.6Hz), 2.56 (s, 3H), 3.19 (t, 2H, J = 7.0Hz), 3.34 (s, 3H), 3.39 (t, 2H, J = 7.0Hz), 3.49 (t, 2H, J = 6.2Hz). 0 O 5-Methyl-2-(1-methyiheptyloxy)-4-pxo-4H-thieno[2,3-c/Ioxa2ine-6-carboxylic acid benzyl ester (14.42) Light yellow oil in 32% yield. 'HNMR (CDCI3, 200MHz): 8 10.70 (brs, 1H), 8.31 (brs, 2H), 7.29-7.43 (m, 5H), 5.27 (S, 2H), 3.45-3.90 (m, 1H), 2.75 (s, 3H), 1.40-1.60(m, 2H), 1.10-1.40 (m, 11H), 0.85 (t, 3H, J=6.6Hz). 3-Methyl-5-[3-(1-methylheptyl)ureido]thiophene-2,4-dicarboxylic acid 2-benzyl ester (14.43) Light brownish solid in 99% yield. 'HNMR (CDCI3, 200MHz): 8 10.52 (s, 1H), 9.00(brs, 1H), 7.35-7.39 (m, 5H), 5.28 (s, 2H), 4.70-5.05 (m, 1H), 2.79 (s, 3H), 1.42-1.62(m, 2H), 1.10-1.40 (m, 8H), 0.87(t, 3H, J= 6.6Hz), MS (ES) [M'-l] 444.96. 5-(4-Benzyl-piperazine-1-carbonyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3- carboxylic acid (37) 1H NMR (DMSO, 200MHz) 8 0.83 (brm, 3H), 1.18-1.41 (brm, 12H), 2.26 (s, 3H), 2.33 (brs, 4H), 2.99 (dt, 2H, J = 5.8Hz, J = 5.8Hz), 3.29 (s, 2H), 3.43 (brm, 4H), 7.21-7.41 (m, 5H) Example 15: Thienoxazinones [(5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carbonyl)- amino]-acetic acid benzyl ester (48): 'H NMR (CDCI3) 200MHz) 6 0.88 (m, 3H), 1.30 (brs, 10H), 1.61 (m, 2H), 2.74 (s, 3H), 3.42 (dt, 2H, J= 6.2Hz, J= 7.0Hz), 4.25 (d, 2H, J= 5.0Hz), 5.08 (brs, 1H), 5.23 (s, 2H), 6.29 (brs, 1H), 7.37 (s, 5H) O 5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid (pyridin-4-ylmethyl)-amide (55): (15%). 'H NMR (CDCI3, 200MHz) 5 0.88 (brs, 3H), 1.25 (brs, 10H), 1.55 (brs, 2H), 2.75 (s, 3H), 3.38 (dt, 2H, J= 6.4Hz, J= 6.6Hz), 4.60 (d, 2H, J= 5.8Hz), 6.17 (s, 1H), 7.24 (s, 2H), 8.54 (d, 2H, J= 5.8Hz) 5-iv"iethyi-2-ociyiamhio-4-oxo-4K-thieno[2,3-d][1,3]oxazine-6-carboxylic acid methyl-(6-methyl-pyridin-2-ylmethyl)-amide (49): (20%). 'H NMR (CDCI3, 200MHz) 5 0.86 (m, 3H), 1.26 (brs, 10H), 1.58 (m, 2H), 2.45 (s, 3H), 2.52 (s, 3H), 3.06 (s, 3H), 3.38 (dt, 2H, J= 6.4Hz, J= 6.6Hz), 4.73 (s, 2H), 5.28 (brs, 1H), 7.05 (d, 2H, J= 7.6Hz), 7.56 (t, 1H, J= 7.8Hz) 5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxyllc acid ethyl-(2-pyridin-2-yl-ethyl)-amide (51): (58%). 'H NMR (CDCI3, 200MHz) 5 0.87 (m, 3H), 1.14 (t, 3H, J= 7.0Hz), 1.26 (brs, 10H), 1.59 (m, 2H), 2.31 (s, 3H), 3.10 (t, 2H, J= 7.0HZ), 3.38 (dt, 4H, J= 6.2Hz, J= 7.0Hz), 3.84 (t, 2H, J= 7.6Hz), 5.26 (brs, 1H), 7.14 (m, 2H), 7:59 (ddd, 1H, J= 7.4Hz, J= 7.6Hz, J= 1.6Hz), 8.52 (d, 1H, J= 4.4HZ) 5-Methyl-2-octy!amino-4-oxo-4H-thieno[2,3-d][1,3]thiazlne-6-carboxylic acid benzyl ester (56): 'H NMR (CD3OD, 200MHz) 6 0.87 (brs, 3H), 1.27 (brs, 10H), 1.61 (m, 2H), 2.82 (s, 3H), 3.45 (dt, 2H, J= 6.2Hz, J= 6.6Hz), 5.31 (s, 2H), 5.42 (brs, 1H), 7.35 (m,5H) 2-(Hexyl-methyl-amino)-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6- carboxylic acid benzyl ester (57): 'H NMR (CDCI3, 200MHz) 5 0.89 (t, 3H, J= 6.6 Hz), 1.30 (bs, 6H), 1.58-1.64 (m, 2H), 2.77 (s, 3H), 3.11 (s, 3H), 3.47-3.50 (m, 2H), 5.29 (s, 2H), 7.30-7.44 (m, 5H). MS (ES+) 414.70 (M+1). 2-(1-Butyl-pentylamino)-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6- carboxylic acid benzyl ester (59). 'H NMR (CDCI3, 200MHz) 8 0.89 (t, 6H, J = 6.4 Hz), 1.22-1.40 (bs, 8H), 1.48-1.66 (m, 4H), 2.79 (s, 3H), 3.90-4.00 (m, 1H), 5.32 (s, 2H), 5.77 (d, J= 8.4 Hz), 7.31-7.45 (m, 5H). 0 2-Dioctylamino-5-methyl-4-oxo-4H-thleno[2,3-d][1,3]oxazine-6-carboxylic acid benzyl ester (60) 'H NMR (CDCI3, 200MHz) 8 0.88 (t, 6H, J = 6.6 Hz), 1.26-1.37 (m, 20H), 1.58-1.64 (m, 4H), 2.79 (s, 3H), 3.39-3.53 (m, 4H), 5.31 (s, 2H), 7.29-7.45 (m, 5H).oo \—/ \_N 0 0 5-Methyl-2-octylamino-6-[4-(2-piperidm-1-yl-ethyl)-piperazine-1-carbonyllthleno[ 2,3-d][1,3]oxazin-4-one (53) MS (ES): m/z 517.9 [MH+]. 1H NMR (CDCI3, 200 MHz): 5 = 0.87-1.59 (m, 9H), 1.18-1.59 (m, 14H), 2.54 (s, 3H), 2.23-2.51 (rff, 4H), 3.34 (dt, 2H, J = 7 Hz), 3.61 (m, 3H), 5.21 (brs, 1H) 5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid (furan-2-ylmethyl)-amide (52) MS (ES): nVz417.3 [MH+]. 1H NMR (CDCI3, 200 MHz): 5 = 1.18-1.41 (m, 14H), 2.67 (s, 3H), 3.43 (t, 2H, J = 8.4 Hz), 4.48 (m, 2H, J = 5.6 Hz), 5.12 (brs, 1H), 6.02-6.57 (m, 3H). 5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxyIic acid (2- pyridin-3-yl-cthyl)-amide (50) MS (ES): m/z 443.5 [MH+]. 1H NMR (CDCI3, 200 MHz): 8 = 1.25-1.68 (m, 14H), 2.60 (s, 3H), 2.99 (t, 2H, J = 7.4 Hz), 3.39 (dt, 2H, J = 6.6 Hz), 5.25 (brs, 1H), 5.77 (s, 1H), 7.25 (m, 2H), 7.61 (d, 1H, J = 19.4 Hz), 8.51 (m, 1H). 5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid isobutyl-amide (54). MS (ES): m/z 393.8 [MH+]. 1H NMR (CDCIs, 200 MHz): 6 = 0.84-0.88 (m, 20H), 0.95-0.99(d, 6H, ), 1.41 (m, 14H), 2.67 (s, 3H), 3.43 (t, 2H, J = 8.4 Hz), 4.48 (m, 2H, J = 5.6 Hz), 5.12 (brs, 1H). 5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-dl[1,3]oxazine-6-carboxylic acid (2,2-dimethyl-propyl-amide (58). MS (ES): m/z 407.86 [MH+]. 1H NMR (CDCI3, 200 MHz): 8 = 0.84-0.93 (m, 14H), 0.96 (s, 9H), 2.72 (s, 3H), 3.24 (s, 2H), 3.42 (m, 2H, J = 6.2 Hz), 5.12 (brs, 1H), 5.76 (brs, 1H). 5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid dibutylamide (36). The same method as for the preparation of 5-methyl-2- heptyloxy-4-oxo-4H-thieno[2,3-c(][1,3]oxazine-6-carboxylic acid heptyl ester was employed. Thus, cyclization afforded 20 mg of a solid after column chromatography (7:3; hexanes:EtOAc) (40% from tert-butyl ester): 1H NMR (CDCI3) 5 0.88 (m, 9H), 1.18-1.40 (m, 14H), 1.45-1.68 (m, 6H), 2.37 (s, 3H), 3.30-3.46 (rn, 6H), 5.19 (br s, 1H); MS (El): caPd 449.66, exp 449.95 (MH+). 5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid (pyridin-3-ylmethyl)amide (35). The same method as for the preparation of 5- methyl-2-heptyloxy-4-oxo-4H-thieno[2,3-afl[1,3]oxazine-6-carboxylic acid heptyl ester was employed. Thus, cyclization afforded 46 mg of a solid (36.6% from tert-butyl ester) after tritration: 1H NMR (CDCI3) 6 0.87 (m, 3H), 1.42-1.20 (m, 10H), 1.68-1.45 (m, 2H), 2.72 (s, 3H), 3.41 (dt, 4H, J= 6.7, 6.6 Hz), 4.62 (d, 2H, J = 6.0Hz), 5.15 (m, fOt) 1H), 6.07 (m, 1H), 7.38-7.20 (m, 1H), 7.70 (d, 1H, J = 8.6Hz), 8.65-8.52 (m, 2H); (El): cal'd 428.56, exp 428.88 (MH+). 5-Methyl-2-octyIamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid (pyridin-2-ylmethyl)amide (34). The same method as for the preparation of 5- methyl-2-heptyloxy-4-oxo-4H-thieno[2,3-ad[1,3]oxazine-6-carboxylic acid heptyl ester was employed. Thus, cyclization afforded 46 mg of a solid (36.6% from tert-butyl ester) after tritration: 1H NMR (CDCI3) 6 0.87 (m, 3H), 1.45-1.20 (m, 10H), 1.80-1.50 (m, 2H), 2.79 (s, 3H), 3.41 (dt, 4H, J= 6.7, 6.6 Hz), 4.72 (d, 2H, J = 4.4Hz), 5.25 (m, 1H), 7.45-7.18 (m, 2H), 7.69 (t, 1H, J = 7.6Hz), 8.55 (d, 1H, J = 4.6 Hz); MS (El): cal'd 428.56, exp 428.88 (MH+). 6-(4-Ben2yl-piperidine-1-carbonyl)-5-methyl-2-octylamino-thieno[2,3- d][1,3]oxazin-4-one (43) 1H NMR (CDCIs, 200MHz) 6 0.88 (brs, 3H), 1.27 (brs, 11H), 1.54-1.70 (m, 6H), 2.40 (s, 3H), 2.57 (d, 2H, J = 7'.OHz), 2.86 (m, 2H), 3.40 (dt,. 2H, J = 6.4Hz, J = 6.4Hz), 4.20 (brs, 2H), 5.09 (s, 1H), 7.11-7.35 (m, 5H); MS (ES) 496.69 (M+1). fet 5-Methyl-2-octyIamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid 1 - butyl-pentyl ester (39): (73%). 'H NMR (CDCI3, 200MHz) 6 0.89 (s, 9H), 1.31 (s, 18H), 1.61 (m, 6H), 2.78 (s, 3H), 3.42 (dt, 2H, J = 6.2Hz, J = 6.6Hz), 5.00-5.20 (m, 2H); MS(ES) 465.67 (M+1) 5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid (1 - butyl-pentyl)-amide (45): (28%). 'H NMR (CDCI3, 200MHz) 5 0.87 (m, 9H), 1.29 (m, 18H), 1.56 (s, 2H), 2.65 (s, 3H), 3.40 (dt, 2H, J = 6.6Hz, J = 6.6Hz), 4.02 (brs, 1H), 5.04 (brs, 1H), 5.40 (d, 1H, J = 8.8Hz); MS (ES) 464.6 (M+1) -octyl 5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid (3- phenoxy-propyl)-amide (44): (22%). 'H NMR (CDCI3, 200MHz) 6 0.88 (m, 3H), 1.27 (m, 10H), 1.55 (m, 2H), 2.07 (m, 2H), 2.62 (s, 3H), 3.40 (dt, 2H, J = 5.6Hz, J = 7.2Hz), 3.65 (dt, 2H, J = 5.6Hz, J = 6.4Hz), 4.12 (t, 2H, J = 5.6Hz), 5.05 (brs, 1H), 6.30 (brs, 1H), 6.95 (m, 3H), 7.25 (m, 2H); MS (ES) 471.81 (M+1) 5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid cyclohexylamide (38): (21%). 'H NMR (CDCIa, 400MHz) 8 0.87 (s, 3H), 1.26 (m, 16H), 1.56 (m, 6H), 2.60 (s, 3H), 3.40 (dt, 2H, J = 6.6Hz, J = 6.2Hz), 3.88 (m, 1H), 5.07 (brs, 1H), 5.57 (d, 1H, J = 7.2Hz); MS (ES) 420.12 (M+1) 5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid dioctylamide (41): (61%). 'H NMR (CDCI3l 400MHz) 6 0.87 (m, 9H), 1.25 (brs, 30H), 1.58 (m, 6H), 2.38 (s, 3H), 3.39 (m, 6H), 5.12 (brs, 1H); MS (ES) 562.15 (M+1) 103 5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid dihexylamide (42): (56%). 1H NMR (CDCI3l 400MHz) 8 0.87 (m, 9H), 1.27 (brs, 22H), 1.56 (m, 6H), 2.38 (s, 3H), 3.40 (m, 6H), 5.05 (brs, 1H); MS (ES) 506.03 (M+1). O 6-(4-Benzyl-piperazine-1-carbonyl)-5-methyl-2-octylamino-thieno[2,3- d][1,3]oxazin-4-one (40): (67%). 1H NMR (CD3CI, 200MHz) 8 0.87 (t, 3H, J = 5Hz), 1.27 (brs, 10H), 1.58 (brs, 2H), 2.40 (s, 3H), 2.46 (t, 4H, J = 4.8Hz), 3.39 (dt, 2H, J = 6.6Hz, J = 6.6Hz), 3.52 (s, 2H), 3.62 (brs, 4H), 5.19 (brs, 1H), 7.30 (s, 5H); MS (ES) 497.11 (M+1) 5-Methyl-2-octyiamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid methylamide (31): (70%, off-white solid). 'H NMR (CDCI3, 200MHz) 8 0.88 (m, 3H), 1.25-1.4 (m), 1.59-1.65 (m), 2.71 (s, 3H), 2.99 (d, 3H (J=5.2)), 3.41 (q, 2H, J=7 Hz), 5.32 (bs, 1H), 5.76 (bs, 1H). MS (ES+) 351.93 (M+1), 352.99 (M+2). 5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxyIic acid ethylamide (33): (off-white solid). 'H NMR (CDCI3, 200MHz) 6 0.88 (t, 3H, J=6.5 Hz), 1.21-1.31 (m, 13H), 1.59-1.65 (m, 2H), 2.71 (s, 3H), 3.36-3.53 (m, 4H), 5.27 (bs, 1H), 5.72 (bs, 1H). MS (ES+) 365.95 (M+1), 367.01 (M+2). 5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid butylamide (32): (off-white solid). 1H NMR (CDCI3, 200MHz) 8 0.85-1.00 (m, 6H), 1.28-1.50 (m, 12H), 1.53-1.63 (m, 4H), 2.70 (s, 3H), 3.41-3.43 (m, 4H), 5.53 (bs, 1H), 5.78 (bs, 1H). MS (ES+) 393.98 (M+1), 395.05(M+2). 5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid hexylamide (27): (off-white solid). 'H NMR (CDCI3, 200MHz) 6 0.88-0.89 (m, 6H), 1.27-1.32 (m, 16H), 1.61 (bs, 4H), 2.70 (s, 3H), 3.41 (2xdt, 4H), 5.44 (bs, 1H), 5.76 (bs, 1H). MS (ES+) 422.05 (M+1), 423.13 (M+2). 5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid decylamide (28): (off-white solid). 'H NMR (CDCI3\| 200MHz) 5 0.85-0.88 (m, 6H), 1.26-1.31 (m, 24H), 1.61 (bs, 4H), 2.70 (s, 3H), 3.41 (2xdt, 4H), 5.27 (bs, 1H), 5.73 (bs, 1H). MS (ES+) 478.08 (M+1), 479.10 (M+2). 5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid dodecylamide (29): (off-white solid). 'H NMR (CDCI3, 200MHz) 8 0.85-0.91 (m, 6H), 1.26-1.31 (m, 24H), 1.61 (bs, 4H), 2.70 (s, 3H), 3.41 (2xdt, 4H), 5.30 (bs, 1H), 5.73 (bs, 1H). MS (ES+) 506.14 (M+1), 507.14 (M+2). 5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid hexadecylamide (30): (off-white solid). 'H NMR (CDCI3, 200MHz) 6 0.84-0.91 (m, 6H), 1.26-1.32 (m, 34H), 1.61 (bs, 4H), 2.70 (s, 3H), 3.41 (2xdt, 4H), 5.21 (bs, 1H), 5.72 (bs, 1H). MS (ES+) 562.19 (M+1), 563.22 (M+2). J-00 6-(6,7"Dimethoxy-3,4-dihydro-1H-isoquinoline-2-carbonyl)-5-methyl-2- octylamino-thieno(2,3-d)(1,3)oxazln-4-one (65): 1H NMR (CDCI3, 200MHz) 5 0.88 (brs, 3H), 1.28-1.45 (m, 10H), 1.62 (m, 2H), 2.43 (s, 3H), 2.85 (t, 2H, J = 5.6Hz), 3.41 (dt, 2H, J = 6.6Hz, J = 6.6Hz), 3.84 (m, 8H), 4.69 (s, 2H), 5.20 (brs, 1H), 6.56 (s, 1H), 6.63 (s,1H). 5-Methyl-2-octylamino-4-oxo-4H-thieno(2,3-d)(1,3)oxazine-6-carboxylic acid (2- (3,4-dimethoxy-phenyl)-methyl)-amldc (66): !H NMR (CDCI3, 200MHz) 6 0.88 (brs, 3H), 1.28-1.43 (m, 10H), 1.59 (m, 2H), 2.71 (s, 3H), 3.41 (dt, 2H, J = 6.6Hz, J = 6.6Hz), 3.88 (s, 6H), 4.55 (d, 2H, J = 5.4Hz), 5.10 (brs, 1H), 5.96 (brs, 1H), 6.88 (m, 3H). N-lsopropyl-2-(4-(5-methyl-2-octylamino-4-oxo-4H-thieno(2J3-d)(1,3)oxazine-6- carbonyl)-piperazin-1-yl)-acetamide (64): 'H NMR (CDCI3, 200MHz) 8 0.88 (m, 3H), 1.28-1.45 (m, 16H), 1T,60 (m, 2H), 2.41 (s, 3H), 2.54 (m, 4H), 3.25 (s, 2H), 3.40 (dt, 2H, J = 6.6Hz, J = 6.6Hz), 3.59 (m, 4H), 4.61 (m, 1H), 5.08 (brs, 1H). O 5-Methyl-2-octylamlno-4-oxo-4H-thieno(2,3-d)(1,3)oxazine-6-carboxy!ic acid (2- benzo(1,3)dioxol-5-yl-methyl)-amide (69): 'H NMR (CDCI3> 200MHz) 6 0.88 (t, 3H, J = 7.0Hz), 1.27-1.45 (m, 10H), 1.60 (m, 2H), 2.71 (s, 3H), 3.44 (dt, 2H, J = 6.4Hz, J = 6.4Hz), 4.51 (d, 2H, J = 5.6Hz), 5.08 (brs, 1H), 5.96 (s, 3H), 6.79 (m, 3H). 0 5-Methyl-2-octylamino-4-oxo-4H-thieno(2,3-d)(1,3)oxazine-6-carboxylic acid (2- phenoxy-ethyl)-amlde (70): 'H NMR (CDCI3, 200MHz) 8 0.88 (t, 3H, J = 7.0Hz), 1.27-1.42 (m, 10H), 1.60 (m, 2H), 2.72 (s, 3H), 3.41 (dt, 2H, J = 6.6Hz, J = 6.6Hz), 3.84 (dt, 2H, J = 5.0HZ, J = 5.2Hz), 4.15 (t, 2H, J = 5.0Hz), 5.08 (brs, 1H), 6.25 (brs, 1H),6.93(m, 3H), 7.30 (m, 2H). 0 5-Methyl-2-octylamino-4-oxo-4H-thieno(2,3-d)(1,3)oxazine-6-carboxylic acid (2- methoxy-ethyl)-amide (72): 'H NMR (CDCI3, 200MHz) 8 0.88 (t, 3H, J = 6.8Hz), 1.28-1.45 (m, 10H), 1.61 (m, 2H), 2.71 (s, 3H), 3.93 (m, 5H), 3.58 (m, 4H), 5.08 (brs, 1H), 6.15 (brs, 1H). 5-Methyl-2-octylamino-4-oxo-4H-thieno(2,3-d)(1,3)oxazine-6-carboxylic acid (3- methoxy-propyl)-amide (73): 'H NMR (CDCI3( 200MHz) 6 0.88 (t, 3H, J = 6.8Hz), 1.28-1.44 (m, 10H), 1.61 (m, 2H), 1.87 (tt, 2H, J = 5.8Hz, J = 6.0Hz), 2.70 (s, 3H), 3.40 (m, 5H), 3.57 (m, 4H), 5.09 (brs, 1H), 6.77 (brs, 1H). 5-Methyl-2-octylamino-4-oxo-4H-thieno(2,3-d)(1,3)oxazlne-6-carboxyllc acid (4- phenyl-butyl)-amide (79): 'H NMR (CDCI3, 200MHz) 8 0.88 (t, 3H, J = 6.6Hz), 1.28-1.45 (m, 10H), 1.66 (m, 6H), 2.69 (m, 5H), 3.43 (m, 4H), 5.07 (brs, 1H), 5.68 (brs, 1H), 7.20 (m,5H). 5-Methyl-2-octylamino-4-oxo-4H-thieno(2,3-d)(1,3)oxazine-6-carboxylic acid (3- phenyl-propyl)-amide (80): 'H NMR (CDCI3, 200MHz) 8 0.88 (t, 3H, J = 6.6Hz), 1.27-1.44 (m, 10H), 1.58 (m, 2H), 1.96 (tt, 2H, J = 7.0Hz, J = 7.4Hz), 2.72 (m, 5H), 3.43 (m, 4H), 5.71 (brs, 1 H), 7.22 (m, 5H). 1C13 o N O 5-Methyl-2-(1 -methyl heptyloxy)-4-oxo-4H-thieno[2,3-cf\|[1,3]oxazine-B-carboxyUc acid benzyl ester (89) Light yellow oil in 22% yield. 'H NMR (CDCIj, 200MHz): 6 7.31-7.50 (m, 5H), 5.34 (s, 2H), 5.18 (tq, 1H, J = 6.2, 6.2Hz), 2.82 (s, 3H), 1.58-1.83(m, 2H), 1.40(d, 3H, J = 6.2Hz), 1.10-1.34 (m, 8H), 0.88 (t, 3H, J=6.6Hz). O O H 5-Methyl-2-(1-methylheptylamino)-4-oxo-4H-thleno[2,3-cQ[1,3]oxazine-6- carboxylic acid benzyl ester (71) Light yellow oil in 40% yield. 'H NMR (CDCI,, 200MHz): 8 7.31-7.43 (m, 5H), 5.32 (s, 2H), 5.13 (d, 1H, J = 6.2Hz), 4.00 (m, 1H), 2.79 (s, 3H), 1.42-1.62(m, 2H), 1.10-1.40 (m, 8H), 0.87 (t, 3H, J = 6.6Hz). MS (ES) [M++1] 429.10. ooi 2-(1,3-Dioctyl-ureido)-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid benzyl ester (13): 1H NMR (CDCI3, 200MHz): 8 9.25 (m, -1H), 7.31-7.43 (m, 5H), 5.32 (s, 2H), 3.99 (m, 2H), 3.35 (dt, 2H, J= 5.6, 5.6 Hz), 2.83 (s, 3H), 1.70-1.5 (m, 4H), 1.50-1.20 (m, 20H), 0.87 (m, 6H, J= 6.6Hz). MS (ES) [M++1] 583.99. 2-(1,3-Diheptyl-ureido)-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6- carboxylic acid benzyl ester (14): 'H NMR (CDCI,, 200MHz): 6 9.25 (m, 1H), 7.31- 7.43 (m, 5H), 5.32 (s, 2H), 3.99 (m, 2H), 3.35 (dt, 2H, J = 5.6, 5.6 Hz), 2.83 (s, 3H), 1.70-1.5 (m, 4H), 1.50-1.20 (m, 16H), 0.87 (m, 6H, J = 6.6Hz). MS (ES) [M++1] 555.97. 114- 5-Methyl-3-octyl-1H-thieno[2,3-d]pyrimidine-2,4-dione-6-carboxylic acid octylamide (47): Compound 18 (100 mg, 0.22 mmol) was dissolved in 1.8 mL absolute ethanol. Sodium ethoxide (21% by wt in ethanol, 1.1 ml, 2.9 mmol) was added and the solution was refluxed for 1h. Once cooled to room temperature, the solution was poured into 10 ml of a 1N HCI solution. The resultant precipitate was filtered to provide 47 (116 mg) as an off-white solid (100% yield). 'H NMR (CDCI3, 200MHz) 6 0.87 (m, 6H), 1.27-1.32 (m, 20H), 1.54-1.70 (m, 4H), 2.78 (s, 3H), 3.44 (dt, 2H, J = 7.0, 6.2 Hz), 3.97 (t, 2H, J = 7.7 Hz), 5.86 (t, 1H, J = 5.4 Hz), 10.39 (s, 1H). Example 16; Procedure for reduction of carboxylic acid: 5-Hydroxymethyl-4- methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid tert-butyl ester (2) 3- Methyl-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid 4-tert-butyl ester (1.0g, 2.40 mmol) was dissolved in 25 mL of CH2CI2 and 0.25 ml_ of DMF. Thionyl chloride added as a 2M solution in CH2CI2 (1.2 ml, 2.4 mmol) and the reaction was stirred for 2h. The reaction was rotovaped to a white solid, which was dissolved in 20 mL of dioxane. Sodium borohydride (910 mg, 24.0 mmol) added and the reaction stirred for 2h. The reaction was poured into 100 mL of H2O and extracted with EtOAc. The organic layer was washed with 1N HCI (aq), H2O, dried with MgSO4) and the solvent rotovaped off. The residue was recrystalized from EtOAc/Hexanes to give 600 mg of the title compound.: (62%). 1H NMR (CDCI3, 200MHz) 8 0.87 (m, 3H), 1.26 (brs, 10H), 1.57 (brs, 11H), 2.30 (s, 3H), 3.28 (dt, 2H, J= 6.2Hz, J = 6.6Hz), 4.64 (s, 2H), 4.74 (t, 2H, J = 5.6Hz), 10.77 (s, 1H) Scheme 3 OH oxalyl chloride DMSO, NEt3 CH2CI2 -78aC-»rt S, NEt3 DMF rt 2 days rNH, \| SOCI2 OH pyr:CH2CI2 -R1 or NHRbase, CH2CI2 X .R' Example 17: Aldehyde Intermediates For a general procedure to synthesize non-commercial aldehydes 17.1-17.4 see Yoshisuke, Tsuda et al, Chem. Pharm. Bull. 1991, 39(1), 18-22 4-Phenyi-butyraldehyde (17.1) clear liquid (860 mg, 87% yield) 'H NMR (CDCI3, 200MHz) 6 1.99 (tt, 2H, J= 7.8, 7.4Hz), 2.45 (dt, 2H, J= 7.0, 1.2Hz), 2.67 (t, 2H, J-. 7.4Hz), 7.26 (m, 5H), 9.76 (t, 1H, J= 1.4Hz). 115 5-Phenyl-pentanal (17.2) clear liquid (470 mg, 48% yield) 'H NMR (CDCI3, 200MHz) 6 1.67 (m, 4H), 2.45 (dt, 2H, J = 4.8, 1.8Hz), 2.64 (brs, 2H), 7.25 (m, 5H), 9.75 (t, 1H, J=1.8Hz). 6-Phenyl-hexanal (17.3) pale yellow oil (2.49 g, 84% yield) 1H NMR (CDCI3, 200MHz) 5 1.20-1.43(m, 4H), 1.44-1.76(m, 4H), 2.41 (dt, 2H, J=7.0, 7.6 Hz), 2.60(t, 2H, J = 7.2 Hz), 7.06-7.35(m, 5H), 9.75(t, 1H, J = 1.8 Hz); MS (ES) No ionization and no LC was found 5-Phenyl-heptanal (17.4) pale yellow oil (401 mg, 81% yield) 1H NMR (CDCI3, 200MHz) 6 1.20-1.50(m, 2H), 1.50-1.80(m, 4H), 2.41 (dt, 2H, J = 7.0, 7.4 Hz), 2.61 (t, 2H, J = 7.4 Hz), 7.00-7.20(m, 5H), 9.75(t, 1H, 2 Hz), MS (ES) No ionization and no LC was found. Example 18: Aminothlophenes 2-Amino-5-methyl-thiophene-3-carboxylic acid tert-butyl ester (18.1): 1H NMR (CDCIs) 51.54 (s, 9H), 2.24 (s, 3H), 5.65 (br d, 2H), 7.25 (s, 1H); MS (El): cal'd 213.70,exp213.96(MH+). 2-Amino-5-heptyl-thiophene-3-carboxyllc acid fert-butyl ester (18.2) yellow oil (5.808 g, 46% yield): 0.88 (t, 3H, J = 6.4 Hz), 1.24-1.32 (m, 8H), 1.54-1.57 (m, 11H), 2.56 (t, 2H, J = 7.5 Hz), 5.69 (bs, 2H), 6.56 (s, 1H). MS (ES+) 297. For a general procedure to synthesize 2-amino-5-alkyl-thiophene-3-carboxylic acid tert-butyl esters from aldehydes, see Tinney, F. J.; et al. J. Med. Chem. 1981, 24, 878-882. 2-Amino-5-butyl-thiophene-3-carboxylic acid ferf-butyl ester (18.3) yellow oil (372 mg, 41% yield): 'H NMR (CDCI3, 200MHz) 6 0.91 (t, 3H, J= 7.1 Hz), 1.26-1.41 (m, 4H), 1.53 (bs, 9H), 2.56 (t, 2H, J = 7.3 Hz), 5.77 (bs, 2H), 6.56 (t, 1H, J= 1.1 Hz). "C NMR (CDCI3, 50MHz) 8 13.7, 22.0, 28.4, 29.3, 33.2, 79.7, 107.7,121.8,126.3, 160.4,164.9. MS (ES+) 340.4 (M+1). NH. 2-Amino-5-decyl-thiophene-3-carboxylic acid tert-butyl ester (18.4) yellow oil (11.32 g, 79% yield): 'H NMR (CDCI3, 400MHz) 8 0 88 (t, 3H, J = 6.8 Hz), 1.26-1.30 (m, 14H), 1.52-1.55 (m, 11H), 2.56 (t, 2H, J = 7.4 Hz), 5.68 (bs, 2H), 6.56 (s, 1H). 2-Arnino-5-benzyl-thiophene-3-carboxylic acid fert-butyl ester (18.5) yellow oil (520 mg, 51% yield): 'H NMR (CDCI3, 200MHz) 6 1.53 (s, 9H), 3.89 (s, 2H), 5.71 (bs, 2H), 6.66 (t, 1H, J= 1.1 Hz), 7.16-7.33 (m, 5H). 13C NMR (CDCI3, 50MHz) 5 28.4, 35.9, 79.9, 107.8, 123.4, 124.7, 126.5, 128.4, 128.5, 140.0, 161.3, 164.9. MS (ES+) 289.9 (M+1). 2-Amino-5-(1,3,3-trlmethyl-butyl)-thiophene-3-carboxylic acid fert-butyl ester (18.6) yellow oil (846 mg, 79% yield): 'H NMR (CDCI3, 200MHz) 8 0.89 (s, 9H), 1.22 (d, 3H, J = 7.0 Hz), 1.39 (dd, 1 H, J = 13.8, 4.6 Hz), 1.54 (s, 9H), 1.59 (dd, 1 H, J = 14.0, 7.0 Hz), 2.80-2.96 (m, 1H), 5.67 (bs, 2H), 6.55 (s, 1H). 2-Amino-5-(5-methoxy-1,5-dimethyl-hexyl)-thiophene-3-carboxylic acid tertbutyl ester (18.7) yellow oil (2.328 g, 80% yield): 'H NMR (CDCI3, 200MHz) 8 1.12 (s, 6H), 1.22 (d, 3H, J= 6.8 Hz), 1.22-1.54 (m, 18H), 2.74 (dq, 1H, J= 7.0, 6.2 Hz), 3.16 (s, 3H), 5.70 (bs, 2H), 6.57 (s, 1H). MS (ES+) 341.93 (M+1). £16 2-Amino-5-(1,5-dimethyl-hex-4-enyl)-thiophene-3-carboxylic acid fert-butyl ester (18.8) yellow oil (2.029 mg, 77% yield): 'H NMR (CDCl3, 200MHz) 5 1.21 (d, 3H, J = 6.6 Hz), 1.51-1.54 (m, 11 H), 1.57 (s, 3H), 1.68 (s, 3H), 1.96 (dt, 2H, J = 7.2, 7.0 Hz), 2.75 (tq, 1H, J = 7.0, 6.6 Hz), 5.08 (t, 1H, J= 6.4 Hz), 5.69 (bs, 2H), 6.56 (s, 1H). MS (ES+) 309.9 (M+1). 2-Amino-5-phenethyl-thiophene-3-carboxylic acid fe/t-butyl ester (18.9) yellow solid (1.5 g, 85% yield) 1H NMR (CDCI3) 200MHz) 8 1.53 (s, 9H), 2.88 (s, 4H), 5.70 (s, 2H), 6.59 (S, 1H), 7.26 (m, 5H) 2-Amino-5-(3-phenyl-propyl)-thiophene-3-carboxyllc acid ferf-butyl ester (18.10) yellow oil (440 mg, 48% yield) 1H NMR (CDCI3, 200MHz) 8 1.54 (s, 9H), 1.90 (tt, 2H, J= 7.8,7.2Hz), 2.62 (m, 4H), 5.70 (s, 2H), 6.58 (s, 1H), 7.26 (m, 5H) 2-Amino-5-(4-phenyl-butyl)-thiophene-3-carboxylic acid fert-butyl ester (18.11) yellow oil (1.22 g, 67% yield) 'H NMR (CDCI3l 200MHz) 8 0.88 (bt, 2H, J= 6.6 Hz), 1.16-1.31 (m, 2H), 1.54 (s, 9H), 1.57-1.74 (m, 2H), 2.52-2.70 (m, 2H), 5.69(bs, 2H), 6.56 (t, 1H, J= 1.2 Hz), 7.11-7.22 (m, 3H), 7.22-7.34 (m, 2H); MS (ES) No lonization (M+1), ^method D) = 9.11min. 2-Amino-5-(5-phenyl-pentyl)-thiophene-3-carboxylic acid ferf-butyl ester (18.12) yellow oil (638 mg, 36% yield) 1H NMR (CDCI3, 200MHz) 8 1.21-1.50 (m, 2H), 1.50- 1.76 (m, 14H), 2.44-2.72 (m, 4H), 5.69(bs, 2H), 6.56 (t, 1H, J= 1.2 Hz), 7.07-7.37 (m, 5H); MS (ES) No lonization (M+1), t^method D)= No LC trace observed 2-Amino-5-butyl-thiophene-3-carboxylic acid tert-butyl ester (18.13): 1H NMR (CDCI3, 200 MHz): 8 = 0.91 (t, J = 7.1 Hz, 3H), 1.10-1.80 (m, 13H), 2.56 (td, J = 0.8, 7.4 Hz, 2H), 5.68 (brs, 2H), 6.56 (t, J = 1.1 Hz, 1H). 2-Amino-5-isopropyl-thiophene-3-carboxylic acid tert-butyl ester (18.14): 1H NMR (CDCI3, 200 MHz): 8 = 1.23 (dd, J = 2.2, 6.8 Hz, 6H), 1.54 (s, 9H), 2.78-3.02 (m, 1H), 5.68 (brs, 2H), 6.57 (d, J = 1.2 Hz, 1H). 2-Amino-5-octyl-thiophene-3-carboxylic acid tert-butyl ester (18.15): 1H NMR (CDCI3, 200 MHz): 8 = 0.88 (t, J = 6.6 Hz, 3H), 1.14-1.43 (m, 10H), 1.44-1.68 (m, 11H), 2.56 (t, J = 7.1 Hz, 2H), 5.67 (bra, 2H), 6.56 (s, 1H). 2-Amino-5-dodecyl-thiophene-3-carboxylic acid tert-butyl ester (18.16): 1H NMR (CDCI3, 200 MHz): 8 = 0.88 (t, J = 6.6 Hz, 3H), 1.16-1.42 (m, 18H), 1.46-1.68 (m, 11 H), 2.55 (t, J = 7.5 Hz, 2H), 5.68 (brs, 2H), 6.55 (t, J = 1.2 Hz, 1 H). 2-Amino-5-heptyl-4-methyl-thiophene-3-carboxylic acid tert-butyl ester (18.17): 9.561 g (61%). 1H NMR (CDCI3, 200 MHz): 8 0.87 (t, J = 6.6 Hz, 3H), 1.16-1.40 (m, 10H, 1.55 (s, 9H), 2.12 (s, 3H), 2.41 (t, J = 7.4 Hz, 2H). 2-Amino-5-octyl-4-methyl-thiophene-3-carboxylic acid tert-butyl ester (18.18): 10.202 g (63%). 1H NMR (CDCI3, 200 MHz): 8 0.87 (t, J = 6.8 Hz, 3H), 1.20-1.38 (m, 12 H), 1.55 (s, 9H), 2.12 (s, 3H), 2.41 (t, J = 7.2 Hz, 2H). 113 2-Amino-6-benzylthiophene-3-carboxylic acid f-butyl ester (18.19) Light yellow oil in 62% yield. 'H NMR (CDCI3, 200MHz): 6 7.18-7.38 (m, 5H), 6.66 (t, 1H, J= 1.0Hz), 5.70 (brs, 2H), 3.90 (s, 2H), 1 .54(s, 9H). H S" ^NH2 2-Amino-6-decylthiophene-3-carboxylic acid f-butyl ester (18.20) Dark brownish oil in 74% yield. 'H NMR (CDCI3> 200MHz): 5 6.56 (t, 1H, J= 1.2Hz), 5.68 (brs, 2H), 2.56 (dt, 2H, 7.6, 1.2Hz), 1.54(s, 9H), 1.20-1.40 (m, 8H), 0.89 (t, 3H, J = 7.6Hz). 2-Amino-6-hexylthiophene-3-carboxylic acid f-butyl ester (18.21) Dark brownish oil in 99% yield. 'H NMR (CDCI,, 200MHz): S 6.56 (t, 1H, J= 1.2Hz), 5.68 (brs, 2H), 2.55 (dt, 2H, J = 8.0, 1.2Hz), 1.54(s, 9H), 1.20-1.40 (m, 16HO, 0.88 (t, 3H, J = 7.0Hz). Example 19: Carbamate/Urea Intermediates 5-Heptyl-4-methyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid tertbutyl ester (19.1): 1H NMR (CDCI3) 50.83-0.92 (m, 6H), 1.20-1.40 (m, 18H), 1.50- 1.60 (m, 11H), 1.64-1.72 (m, 2H), 2.20 (s, 3H), 2.62 (t, 2H, J = 7.6 Hz), 4.19 (t, 2H, J = 7.2 Hz); MS (El): cal'd 467.72, exp, did not ionize. 5-Methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid tert-butyl ester (19.2): 1H NMR (CDCIa) 80.87 (t, 3H, J = 7.2 Hz), 1.20-1.42 (m, 10H), 1.45-1.68 (m, 11H), 2.32 (s, 3H), 3.27 (dt, 2H, J = 7.2, 7.2 Hz), 4.79 (m, 1H), 6.70 (s, 1H), 10.2 (br s, 1H); MS (El): cal'd 368.5, exp 368.87 (MH+). 5-Methyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid tert-butyl ester (19.3): 1H NMR (CDCI3) 80.88 (t, 3H, J = 7.2 Hz), 1.20-1.42 (m, 10H), 1.55 (s, 9H), 1.62-1.72 (m, 2H), 2.34 (s, 3H), 4.19 (t, 2H, J = 6.8 Hz), 6.74 (s, 1H), 10.12 (br s, 1H); MS (El): cal'd 369.5, exp,.did not ionize. General Procedure for urea formation (19.4-19.6): 5-Heptyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid fe/t-butyl ester (19.4) Amino-thiophene 18.2 (200 mg, 0.67 mmol) was dissolved in 3 ml_ CH2Cl2 and cooled to 0 SC. Under N2 atmosphere, DBU (0.25 ml, 1.68 mmol) was added slowly followed by octyl isocyanate (104mg, 0.67mmol). The reaction slowly warmed to rt and was stirred at room temperature for 5h. The reaction was then diluted with 20 mL CHaCIa and washed with 1N HCI and brine. The organic solution was then dried with MgSCXj and concentrated in vacua. The crude mixture purified by silica gel chromatography (15:1 hexanes: ethyl acetate) to yield 19.4, 73 mg (24% yield) of an off-white solid: 1H NMR (CDCI3, 200MHz) 8 0.88 (t, 6H, J = 6.4 Hz), 1.27-1.29 (m, 18H), 1.54-1.58 (m, 13H), 2.64 (t, 2H, J = 7.5 Hz), 3.26 (dt, 2H, J = 7.0, 5.8 Hz), 4.85 (t, 1H, J = 5.7 Hz), 6.69 (s, 1H), 10.25 (s, 1H). MS (ES+) 453.1 (M+1). O 5-Butyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid ferf-butyl ester (19.5) offwhite solid (353 mg, 59% yield): 'H NMR (CDCI3, 200MHz) 8 0.87 (t, 3H, J = 7.1 Hz), 0.90 (t, 3H, J= 7.1 Hz), 1.25-1.41 (m, 12H), 1.53-1.64 (m, 13H), 2.64 (t, 2H, J = 7.5 Hz), 3.27 (dt, 2H, J = 7.0, 6.2 Hz), 5.29 (t, 1H, J ~ 5.7 Hz), 6.69 (s, 1H), 10.27 (bs, 1H). 13C NMR (CDCIs, 50MHz) 8 1.3.7, 14.0, 22.1, 22.6, 26.8, 28.3, 29.1, 29.2, 29.3, 30.0, 31.7, 33.4, 40.8, 80.7, 110.7, 119.8, 133.0, 149.9, 153.7, 165.6. 5-Benzyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid ferf-butyl ester (19.6) pale yellow solid (394 mg, 49% yield): 'H NMR (CDCI3, 200MHz) 8 0.87 (t, 3H, J = 6.4 Hz), 1.27 (bs, 10H), 1.54 (s, 11H), 3.25 (dt, 2H, J = 7.0, 5.8 Hz), 3.97 (s, 2H), 4.88 (t, 1H, J= 5.6 Hz), 6.48 (t, 1H, J= 1.0 Hz), 7.16-7.32 (m, 5H), 10.26 (bs, 1H). General procedure for amide and carbamate formation (19.7-19.17): 2-Dodecanoylamino-5-heptyl-thiophene-3-carboxylic acid tert-butyl ester (19.7) Amino-thiophene 18.2 (171 mg, 0.57 mmol) was dissolved in 3 ml_ CHaCIa and 2 ml pyridine. Under N2 atmosphere, lauroyl chloride (126mg, 0.57mmol) was added and the reaction was stirred at room temperature for 6h. The reaction was then diluted with 10 mL CH2CI2 and washed with water, 5% citric acid, and brine. The organic solution was then dried with MgS04 and concentrated in vacua. The crude mixture purified by silica gel chromatography (40:1 hexanes: ethyl acetate) to yield 19.7,175 mg (63% yield) of a yellow oil: 'H NMR (CDCI3, 200MHz) 8 0.87 (t, 6H, J = 6.4 Hz), 1.25-1.44 (m, 24H), 1.51-1.73 (m, 13H), 2.45 (t, 2H, J=7.5 Hz), 2.67 (t, 2H, J=7.5 Hz), 6.77 (s, 1H), 10.94 (bs, 1H). 13C NMR (CDCI3, 50MHz) 8 14.0, 14.1, 22.5, 22.6, 25.3, 28.3, 28.9, 29.0, 29.1, 29.2, 29.3, 29.4, 29.5, 29.6, 31.3, 31.7, 31.9, 36.7, 81.2, 113.3, 120.1, 134.8,146.3, 165.1, 169.9. 2-Octyloxycarbonylamino-5-(1.3,3-trimethyl-butyl)-thiophene-3-carboxylic acid fert-butyl ester (19.8) yellow oil (185 mg, 34% yield): 'H NMR (CDCI3, 200MHz) 8 0.85-0.91 (m, 12H), 1.26-1.76 (m, 26H), 2.90-3.03 (m, 1H), 4.20 (t, 2H, J= 6.8 Hz), 6.73 (s, 1H), 10.15 (bs, 1H). 13C NMR (CDCI3, 50MHz) 8 14.0, 22.6, 25.8, 26.3, 28.3, 28.8, 29.1, 29.2, 29.8, 31.2, 31.8, 32.0, 52.6, 66.3, 81.2, 112.3, 118.9, 142.1, 147.7, 153.3,164.9. 5-(5-Methoxy-1,5-methyl-hexyl)-2-octyloxycarbonylamino-thiophene-3- carboxyiic acid fert-butyl ester (19.9) pale yellow oil: 'H NMR (CDCI3> 200MHz) 5 0.89 (t, 3H, J= 6.4 Hz), 1.11 (s, 6H), 1.26-1.48 (m, 19H), 1.50-1.71 (m, 11H), 2.74 (dq, 1H, J = 7.0, 7.0 Hz), 3.15 (s, 3H), 4.20 (t, 2H, J= 6.6 Hz), 6.74 (s, 1H), 10.17 (s, 1H). "C NMR (CDCI3l 50MHz) 8 14.0, 21.5, 22.5, 22.6, 24.9, 25.7, 28.2, 28.7, 29.1, 31.7, 35.1, 39.3, 39.5, 48.9, 60.2, 66.2, 74.3, 81.. 1, 112.2, 119.3, 139.7, 147.9, 153.1, 164.8. CT 0 5-(1,5-Dimethyl-hex-4-enyl)-2-octyloxycarbonylamino-thiophene-3-carboxylic acid terf-butyl ester (19.10) brown oil (630 mg, 90% yield): 1H NMR (CDCI3, 200MHz) 8 0.89 (t, 3H, J = 6.6 Hz), 1.26-1.42 (m, 13H), 1.55-1.73 (m, 19H), 1.96 (dt, 2H, J = 7.8, 7.2 Hz), 2.86 (tq, 1H, J = 7.2, 6.6 Hz), 4.20 (t, 3H, J= 6.6 Hz), 5.08 (t, 1H, J= 7.2 Hz), 6.74 (s, 1H), 10.16 (bs, 1H). H 2-Octyloxycarbonylamino-5-phenethyl-thiophene-3-carboxylic acid ferf-butyl ester (19.11) white solid (740 mg, 98% yield) 'H NMR (CDCI3, 200MHz) 8 0.88 (t, 3H, J= 6.6Hz), 1.28 (brs, 10H), 1.56 (s, 9H), 1.68 (m, 2H), 2.96 (s, 4H), 4.20 (t, 2H, J = 6.6Hz), 6.75 (s, 1H), 7.26 (m, 5H), 10.15 (s, 1H) 2-Octyioxycarbonylamino-5-(3-phenyl-propyi)-ihiophene-3-carboxyiic aciu ierfbutyl ester (19.12) yellow oil (270 mg, 90% yield) 'H NMR (CDCI3, 200MHz) 8 0.88 (t, 3H, J= 6.6Hz), 1.28 (brs, 10H), 1.64 (brs, 11H), 1.97 (tt, 2H, J = 7.8, 7.2Hz), 2.69 (m, 4H), 4.20 (t, 2H, J= 6.6 Hz), 6.76 (s, 1H), 7.26 (m, 5H), 10.15 (s, 1H) 2-Octyloxycarbonylamino-5-(4-phenyl-butyl)-thiophene-3-carboxylic acid tertbutyl ester (19.13) clear colorless oil (401 mg, 88% yield) 1H NMR (CDCI3, 200MHz) 8 0.88 (bt, 3H, J = 6.2 Hz), 1.15-1.42 (m, 11H), 1.56 (s, 9H), 1.61-1.80 (m, 6H), 2.52-2.80 (m, 4H), 4.20 (t, 2H, J = 6.6 Hz), 6.74 (s, 1H), 7.09-7.35 (m, 5H), 10.15 (s, 1H); MS (ES) no ionization or LC was observed. 2-Octyloxycarbonylamino-5-(5-phenyl-pentyl)-thiophene-3-carboxylic acid tertbutyl ester (19.14) clear/colorless oil (331 mg, 75% yield) 1H NMR (CDCI3, 200MHz), 8 0.88 (bt, 3H, J= 6.2 Hz), 1.20-1.50 (m, 14H), 1.50-1.75 (m, 15H), 2.50- 2.75 (m, 4H), 4.19 (t, 2H, J = 7.0 Hz), 6.74 (t, 1H, J = 1.0 Hz), 7.08-7.36 (m, 5H); MS (ES) No LC trace and no ionization came out. 5-Decyl-2-(2-methoxy-ethoxycarbonylamino)-thiophene-3-carboxylic acid tertbutyl ester (19.15) pale yellow oil (307 mg, 76% yield) 1H NMR (CDCI3, 200MHz) 8 0.88 (bt, 3H, J = 6.2 Hz), 1.16-1.43 (m, 14H), 1.55 (s, 9H), 1.57-1.73 (m, 2H), 2.66 (t, 2H, J = 7.8 Hz), 3.41 (s, 3H), 3.58-3.70 (m, 2H), 4.25-4.44 (m, 2H), 6.74 (s, 1H), 10.27 (bs, 1H); MS (ES) 442.64 (M+1), t^method D) = 12.91min. 2-(4-Butyl-phenoxycarbonylamino)-5-decyl-thiophene-3-carboxylic acid tertbutyl ester (19.16) Amino thiophene 18.4 ( 300 mg, 0.92 mmol) was dissolved in anhydrous THF (4 ml_). Under a nitrogen atmosphere was added 4-nitrophenyl chloroformate (184 mg, 0.92 mmol) and was stirred overnight at room temperature. Without any isolation of the 4-nitrophenyl carbamate intermediate the sodium salt of 4-butyl phenol (200 mg, 1.26 mmol) was dropwise added to the solution of the intermediate and was stirred at room temperature for 2 hours followed by heating to 40 BC for an additional hour. The sodium salt of the phenol was prepared by dissolving 4-butyl phenol (174 mg, 1.16 mmol) in anhydrous THF (3 mL) and cooling to 0 SC. Then NaH(60% dispersion in mineral oil) (45 mg, 1.16 mmol) was added to reaction mixture and stirred at 0 BC for Vfe hour and was used as stated above. The reaction mixture was partitioned between CHCI3 and H20 and separated. The H20 layer was extracted again with CHCI3 (3x) and separated. The combined CHCI, layers was washed with 2M NaOH (1x), 1M HCI (1x), brine (1x) and dried with Na2SO4 filtered and concentrated resulting in 490 mg of a dark orange oil. The crude material was further purified by flash silica chromatography (2% EtOAc in Hexanes) which resulted in 241 mg of a yellow oil (50% yield). 1H NMR (CDCI3, 200MHz) 8 0.83-0.93 (m, 6H), 1.19-1.45 (m, 18H), 1.47-1.72 (m, 14H), 2.55-2.75 (m, 4H), 6.80 (s, 1H), 7.11 (d, 2H, J=8.8Hz), 7.19 (d, 2H, J = 8.8Hz), 10.58 (s, 1H). 5-Decyl-2-(4-phenyl-butoxycarbonylamino)-thiophene-3-carboxylic acid tertbutyl ester (19.17) pale yellow oil (241 mg, 89% yield) 1H NMR (CDCI3, 200MHz) 5 0.88 (t, 3H, J = 6.6 Hz), 1.26-1.38 (m, 14H), 1.56-1.70 (m, 11H), 1.99 (tt, 2H, J = 12.6, 6.2 Hz), 2.66 (t, 2H, J = 7.5 Hz), 3.58 (t, 2H, J = 6.2 Hz), 4.34 (t, 2H, J = 6.2 Hz), 4.50 (s, 2H), 6.75 (s, 1H), 7.24-7.34 (m, 5H), 10.16 (s, 1H). UC NMR (CDCI3, 50MHz) 8 14.04, 22.60, 28.26, 28.97, 29.19, 29.23, 29.27, 29.45, 29.48, 29.51, 31.25, 31.82, 63.35, 66.35, 72.96, 81.09, 112.53, 120.60, 127.48, 127.53, 128.28, 133.87,138.21, 147.97, 152.97, 164.77. Example 20: Tert-butyl Ester Intermediates 5-Butyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid tert-butyl ester (20.1): 1H NMR (CDCI3, 200 MHz): 8 = 0.80-1.00 (m, 6H), 1.18-1.49 (m, 12H), 1.50-1.79 (m, 13H), 2.67 (t, J = 7.3 Hz, 2H), 4.19 (t, J = 6.6 Hz, 2H), 6.74 (t, J = 0.9 Hz, 1H), 10.14 (brs, 1H). 5-lsopropyl-2-octyloxycarbonylamJno-thlophene-3-carboxylic acid tert-butyl ester (20.2): 1H NMR (CDCI3, 200 MHz): 8 = 0.88 (t, J = 6.6 Hz, 3H), 1.16-1.46 (m, 16H), 1.50-1.76 (m, 11H), 2.90-3.16 (m, 1H), 4.20 (t, J = 6.6 Hz, 2H), 6.75 (d, J = 1.0Hz, 1H), 10.15 (brs, 1H). cr o 5-Octyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid tert-butyl ester (20.3): 1H NMR (CDCI3, 200 MHz): 6 = 0.79-0.98 (m, 6H), 1.18-1.46 (m, 20H), 1.51-1.78 (m, 13H), 2.66 (td, J = 0.8, 7.5 Hz, 2H), 4.19 (t, J = 6.6 Hz, 2H), 6.74 (t, J = 1.1 Hz, 1H), 10.14 (brs, 1H). CT O 5-Dodecyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid tert-butyl ester (20.4): 1H NMR (CDCI3, 200 MHz): 6 = 0.80-0.98 (m, 6H), 1.15-1.46 (m, 28H), 1.52-1.78 (m, 13H), 2.66 (t, J = 7.3 Hz, 2H), 4.20 (t, J = 6.8 Hz, 2H), 6.74 (s, 1H), 10.14 (brs, 1H). 2-Benzyloxycarbonylamino-5-decyi-thiophene-3-carboxylic acid tert-butyl ester (20.5): 1H NMR (CDCI3, 200 MHz): 8 = 0.88 (t, J = 6.4 Hz, 3H), 1.18-1.42 (m, 14H), 1.48-1.72 (rn, 11H), 2.66 (t, J = 7.5 Hz, 2H), 5.24 (s, 2H), 6.74 (s, 1H), 7.31-7.47 (m, 5H), 10.25 (brs, 1H). General procedure for the preparation of tert-butyl esters 20.6-20.8 from aminothiophene 18.4 and the corresponding commercially available alcohols: To a solution of 4-butylbenzyl alcohol (0.30 mL, 1.76 mmol) in CH2Cl2 (10 ml) was added saturated NaHC03 (10 ml) and then diphosgene (0.25 ml, 2.07 mmol) dropwise. The mixture was allowed to stir vigorously at ambient temperature for 45 min, and aminothiophene 18.4 (283 mg, 0.83 mmol) was added in one portion. After stirring vigorously for 2 h, the reaction mixture was diluted with EtaO (100 ml), and the organic layer was washed with saturated NaHCOs (2x20 mL), and brine (40 mL). The organic layer was dried over Na2S04 and then filtered. The filtrate was concentrated and the resulting residue was purified by flash column chromatography (40:1 Hexanes/EtOAc) to give tert-butyl ester 20.6 as a light yellow oil (416 mg, 95%). 2-(4-Butylbenzyloxycarbonylamino)-5-decyl-thiophene-3-carboxylic acid tertbutyl ester (20.6): 1H NMR (CDCI3, 200 MHz): 6 = 0.82-1.00 (m, 6H). 1.18-1.46 (m, 16H), 1.48-1.72 (m, 13H), 2.54-2.73 (m, 4H), 5.20 (s, 2H), 6.73 (s, 1H), 7.13- 7.38 (m,4H), 10.23 (brs, 1H). 5-Decyl-2-(2-p-tolyl-ethoxycarbonylamino)-thiophei'ie-3-carboxyi!c acid tertbutyl ester (20.7): 1H NMR (CDCI3, 200 MHz): 8 = 0.88 (t, J = 6.4 Hz, 3H), 1.17- 139 1.42 (m, 14H), 1.49-1.72 (m, 11H), 2.32 (s, 3H), 2.66 (t, J = 7.3 Hz, 2H), 2.96 (t, J = 7.1 Hz, 2H), 4.39 (t, J = 7.3 Hz, 2H), 6.74 (s, 1H), 7.08-7.19 (m, 4H), 10.14 (brs, 1H). 0 0 5-Decyl-2-phenethyloxycarbonylamino-thiophene-3-carboxylic acid tert-butyl ester (20.8): 1H NMR (CDCI3, 200 MHz): 5 = 0.88 (t, J = 6.4 Hz, 3H), 1.18-1.42 (m, 14H), 1.50-1.72 (m, 11H), 2.66 (t, J = 7.3 Hz, 2H), 3.01 (t, J = 7.5 Hz, 2H), 4.42 (t, J = 7.3 Hz, 2H), 6.74 (s, 1H), 7.18-7.40 (m, 5H), 10.15 (brs, 1H). O 4-Methyl-5-octyl-2-octyloxycarbonylamino-th1ophene-3-carboxylic acid tertbutyl ester (20.9): 2.35 g (33%). 1H NMR (CDCI3, 200 MHz): 6 0.87 (t, J = 6.6 Hz, 3H), 0.88 (t, J = 7.6 Hz, 3H), 1.30-1.72 (m, 24H), 1.57 (s, 9H), 2.20 (s, 3H), 2.61 (t, J = 7.8 Hz, 2H), 4.18 (t, J = 6.6 Hz, 2H), 10.26 (s, 1H); 13C NMR (CDCI3, 75 MHz): 6 12.3, 12.9, 20.9, 24.0, 24.1, 25.4, 26.7, 27.1, 27.3, 27.4, 27.5, 27.6, 29.6, 30.1, 30.1, 64.5, 79.7, 111.2, 126.2, 127.1, 146.7, 151.5, 164.0. 2-Butyloxycarbonylamino-5-octyl-th!ophene-3-carboxylic acid tert-butyl ester (20.10): 693 mg (92%). 1H NMR (CDCI3> 200 MHz): 8 0.83 (t, J = 6.6 Hz, 3H), 0.94 (t, J =7.0 Hz, 3H), 1.20-1.48 (m, 12H), 1.55 (s, 9H), 1.52-1.75 (m, 4H), 2.65 (t, J = 7.0 Hz, 2H), 4.20 (t, J = 6.6 Hz, 2H), 6.73 (s, 1H), 10.14 (s 1H). 2-Hexyloxycarbonylamino-5-octyl-thiophene-3-carboxylic acid tert-butyl ester (20.11): 760 mg (98%). 1H NMR (CDCI3, 200 MHz): 80.87 (t, J = 6.6 Hz, 3H), 0.89 (t, J = 6.6 Hz, 3H), 1.18-1.44 (m, 14H), 1.55 (s, 9H), 1.54-1.76 (m, 4H), 2.65 (t, J = 7.0 Hz, 2H), 4.19 (t, J = 6.6 Hz, 2H), 6.73 (s, 1H), 10.14 (s, 1H). 2-Dodecy!oxycarbonylamino-5-octyl-thiophene-3-carboxylic acid tert-butyl ester (20.12): 831 mg (88%). 1H NMR (CDCI3) 200 MHz): 8 0.87 (t, J = 6.6 Hz, 6H), 1.051-.50 (m, 28H), 1.55 (s, 9H), 1.50-1.75 (m, 4H), 2.65 (t, J = 7.2 Hz, 2H), 4.19 (t, J = 6.6 Hz, 2H), 6.73 (t, J = 1.2 Hz, 1H), 10.14 (s, 1H). 5-Decyl-2-phenyloxycarbonylamino-thiophene-3-carboxylic acid tert-butyl ester (20.13): 696 mg (84%). 1H NMR (CDCI3, 200 MHz): 80.88 (t, J = 7.0 Hz, 3H), 1.20-1.36 (m, 14H), 1.52-1.66 (m, 2H), 1.59 (s, 9H), 2.67 (dt, J = 7.4, 1.2 Hz, 2H), 6.78 (t, J = 1.2 Hz, 1H), 7.14-7.48 (m, 5H), 10.55 (s, 1H). 2-Decyloxycarbonylamino-5-octyl-thiophene-3-carboxylic acid ferf-butyl ester (20.14): 863 mg (91%). 1H NMR (CDCI3) 200 MHz): 5 0.87 (t, J = 6.6 Hz, 6H), 1.14- 1.44 (m, 24H), 1.55 (s, 9H), 1.52-1.76 (m, 4H), 2.65 (t, J = 7.2 Hz, 2H), 4.19 (t, J = 6.6 Hz, 2H), 6.73 (s, 1H), 10.14 (s, 1H). CT O 6-Benzyl-2-octyloxycarbonylamino)thiophene-3-carboxylic acid f-butyl ester (20.15) Light yellow oil in 77% yield. 'H NMR (CDCI3> 200MHz): 5 10.16 (s, 1H), 7.20-7.40 (m, 5H), 6.82 (s, 1H), 4.17 (t, 2H, J= 6.6Hz), 3.99 (s, 2H), 1.64(q, 2H, J= 6.6Hz), 1.55(s, 9H), 1.10-1.50 (m, 10H), 0.88(t,3H, J=6.6Hz). 6-Hexyl-2-(octyloxycarbonylamino)thiophene-3-carboxylic acid f-butyl ester (20.16) Light yellow oil in 86% yield. 1H NMR (CDCI3, 200MHz): 8 10.14 (brs, 1H), 6.74 (s, 1H), 4.19 (t, 2H, J = 6.6Hz), 2.66 (t, 2H, J = 7.6Hz), 1.60-1.75(m, 2H), 1.56 (s, 9H), 1.10-1.40 (m, 18H), 0.80- 0.95(m, 6H). CT O 6-Decyl-2-(octyloxycarbonylamino)thiophene-3-carboxylic acid f-butyl ester (20.17) Light yellow oil in 99% yield. 'H NMR (CDCI3, 200MHz): 8 10.14 (brs, 1H), 6.74 (s, 1H), 4.19 (t, 2H, J = 6.6Hz), 2.66 (t, 2H, J = 8.0Hz), 1.60-1.75(m, 2H), 1.56 (s, 9H), 1.08-1.40 (m, 26H), 0.80- 0.95(m, 6H). O O 6-Decyl-2-(1-methylheptyloxycarbonylamino)thiophene-3-carboxylic acid tbutyl ester (20.18) Light yellow oil in 99% yield. 'H NMR (CDCI3, 200MHz): 8 10.10 (brs, 1H), 6.73 (s, 1H), 4.82-5.00 (m, 1H), 2.65 (t, 2H, J = 7.4Hz), 1.50-1.83(m, 15H), 1.08-1.50 (m, 23H), 0.80-1.00(m, 6H). 6-Heptyl-2-(1-methylheptyloxycarbonylamino)thiophene-3-carboxylic acid rbutyl ester (20.19) Light yellow oil in 78% yield. 133 'H NMR (CDCI,, 200MHz): 6 10.01 (brs, 1H), 6.73 (s, 1H), 4.80-5.00 (m, 1H), 2.65 (t, 2H, J= 7.4Hz), 1.50-1.83(m, 13H), 1.08-1.50 (m, 17H), 0.80-1.00 (m, 6H). 5-Decyl-2-(4-phenylbutoxycarbonylamino)thiophene-3-carboxylic acid f-butyl ester (20.20) Light brownish oil in 99% yield. 1H NMR (CDCI3, 400MHz): 5 10.12 (s, 1H), 7.26-7.31 (m, 2H), 7.19-7.26 (m, 3H), 6.75 (s, 1H), 4.23 (t, 2H, J = 6.4Hz), 2.73 (t, 2H, J= 7.6Hz), 2.66 (t, 2H, J= 7.2Hz), 1.98- 2.07(m, 2H), 1.59-1.65(m, 2H), 1.52-1.57 (m, 11H), 1.26-1.30 (m, 12H), 0.88(t, 3H, J = 6.4Hz). 5-Decyl-2-(4-phenylbutoxycarbonylamino)thiophene-3-carboxylic acid f-butyl ester (20.21) Light brownish oil in 98% yield. 'H NMR (CDCI3I 400MHz): 5 10.11 (s, 1H), 7.26-7.31 (m, 2H), 7.18-7.26 (m, 3H), 6.74 (S, 1H), 4.26 (brs, 2H), 2.67-2.70 (m, 4H), 1.70-1.80(m, 4H), 1.50-1.70(m, 11H), 1.18-1.40 (m, 16H), 0.88(t, 3H, J = 6.8Hz). Example 21: Acid Intermediates 5-Heptyl-4-methyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid (21.1): May contain -10% other isomer; 1H NMR (CDCI3) 6 0.82-0.94 (m, 6H), 1.20-1.46 (m, 18H), 1.50-1.66 (m, 2H), 1.66-1.80 (m, 2H), 2.28 (s, 3H), 2.64 (t, 2H, J = 7.2 Hz), 4.22 (t, 2H, J = 7.0 Hz). There was another peak at 2.79 (t, J = 7.0 Hz), which may be from other isomer; MS (El): cal'd 411.61, exp, did not ionize. 5-Methyl-2-octyloxycarbonylamino-th!ophene-3-carboxylic acid (21.2): 1H NMR (CDCI3) 80.88 (t, 3H, J = 7.2 Hz), 1:20-1.45 (m, 10H), 1.65-1.75 (m, 2H), 2.37 (s, 3H), 4.23 (t, 2H, J = 6.8 Hz), 6.84 (s, 1H), 9.89 (s, 1H); MS (El): cal'd 313.41, exp. 5-Heptyl-2-(3-octyl-ureldo)-thiophene-3-carboxylic acid (21.3) tan solid (51 mg, 80% yield): 'H NMR (CDCI3, 200MHz) 8 0.87 (t, 6H, J = 5.7 Hz), 1.26 (bs, 18H), 1.54-1.61 (m, 4H), 2.63 (t, 2H, J = 7.5 Hz), 3.26 (dt, 2H, J = 7.0, 7.0 Hz), 5.95 (bs, 1H), 6.77 (s, 1H), 10.10 (s, 1H), 11.36 (bs, 1H). "C NMR (CDCIg, 50MHz) 5 14.0, 22.6, 26.8, 29.0, 29.2, 29.3, 29.4, 29.7, 31.1, 31.7, 31.8, 41.0, 88.4, 108.9, 119.6, 134.2,151.9, 154.1,169.9. 5-Butyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid (21.4) purple oil (308 mg, 100% yield): 'H NMR (CDCI3> 200MHz) 6 0.87 (t, 6H, J= 5.7 Hz), 1.26 (bs, 18H), 1.54-1.61 (m, 4H), 2.63 (t, 2H, J = 7.5 Hz), 3.26 (dt, 2H, J = 7.0, 7.0 Hz), 5.95 (bs, 1 H), 6.77 (s, 1 H), 10.10 (s, 1 H), 11.36 (bs, 1 H). 5-Benzyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid (21.5) tan solid (450 mg): 'H NMR (CDCIg, 200MHz) 5 0.87 (t, 3H, J= 6.4 Hz), 1.26 (bs, 10H), 1.51 (tt, 2H, J = 12.2, 6.5 Hz), 3.21 (dt, 2H, J= 6.6, 6.0 Hz), 3.96 (s, 2H), 6.33 (bs, 1H), 6.82 (s, 1H), 7.14-7.32 (m, 5H), 10.16 (bs,1H). 8 NH 2-Dodecanoylamino-5-heptyl-thiophene-3-carboxylic acid (21.6) dark brown solid (185 mg, 100% yield): 'H NMR (CDCI3, 200MHz) 6 0.85-0.90 (m, 6H), 1.26- 1.40 (m, 24H), 1.54-1.79 (m, 4H), 2.52 (t, 2H, J = 7.5 Hz), 2.71 (t, 2H, J = 7.5 Hz), 6.91 (s, 1 H), 10.53 (bs, 1 H), 10.75 (s, 1 H). MS (ES-) 421.86 (M-1). 5-Heptyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid (21.7) pale yellow solid (76 mg, 54% yield): 'H NMR'(CDCI3, 200MHz) 8 0.85-0.91 (m, 6H), 1.30 (bs, 18H), 1.58-1.75 (m, 4H), 2.69 (t, 2H, J = 7.5 Hz), 4.24 (t, 2H, J = 6.6 Hz), 6.86 (s, 1H), 9.90 (s, 1H). MS (ES-) 395.93 (M-1). O 2-Octyloxycarbonylamino-5-(1,3,3-trimethyl-butyl)-thiophene-3-carboxylic acid (21.8) waxy tan solid (190 mg, 100% yield): 'H NMR (CDCI3, 200MHz) 6 0.88-0.89 (m, 12H), 1.28-1.76 (m, 17H), 2.90-3.09 (m, 1H), 4.24 (t, 2H, J= 6.6 Hz), 6.87 (s, 1H), 9.85 (S, 1H), 10.34 (bs, 1H). 2-(2-BenzyIoxy-ethoxycarbonylamino)-5-decyl-thiophene-3-carboxylic acid (21.9) tan solid (142 mg): 'H NMR (CDCI3, 200MHz) 8 0.89 (t, 3H, J = 6.5 Hz), 1.23- 1.27 (m, 14H), 1.58-1.69 (m, 2H), 2.69 (t, 2H, J = 7.3 Hz), 3.76 (t, 2H, J = 4.6 Hz), 4.43 (t, 2H, J = 4.6 Hz), 4.61 (s, 2H), 6.88 (s, 1H), 7.28-7.38 (m, 5H), 9.99 (s, 1H), 10.48. (bs, 1 H). MS (ES-) 460.06 (M-1). 2-Octyloxycarbonylamino-5-phenethyl-thiophene-3-carboxylic acid (21.10) white solid (203 mg, 97% yield): 1H NMR (CDCI3, 200MHz) 8 0.88 (t, 3H, J= 6.8Hz), 1.28 (brs, 10H), 2.98 (s, 4H), 4.23 (t, 2H, J= 7.0Hz), 6.84 (s, 1H), 7.22 (m, 5H), 9.96 13? 0 2-Octyloxycarbonylamino-5-(3-phenyl-propyl)-thiophene-3-carboxylic acid (21.11) yellow solid (175 mg, 99% yield): 'H NMR (CDCI3, 200MHz) 8 0.88 (t, 3H, J = 6.8Hz), 1.28 (brs, 10H), 1.68 (m, 2H), 1.98 (tt, 2H, J= 7.8Hz, 7.2Hz), 4.23 (t, 2H, J = 7.0HZ), 6.87 (s, 1H), 7.26 (m, 5H), 9.93 (1H) o 2-Octyloxycarbonylamino-5-(4-phenyl-butyl)-thiophene-3-carboxylic acid (21.12) white waxy solid (303 mg, 92% yield): 1H NMR (CD3OD, 400MHz) § 0.90 (bt, 3H, J= 6.8 Hz), 1.21-1.48 (m, 12H), 1.57-1.76 (m, 6H), 2.57-2.77 (m, 4H), 4.20 (t, 2H, J = 6.4 Hz), 6.82 (s, 1H), 7.08-7.32 (m, 5H). MS (ES) 430.35 (M-1), tfi(method D) = 7.74min 2-Octyloxycarbonylamino-5-(5-phenyl-pentyl)-thiophene-3-carboxylic acid (21.13) off-white solid (331 mg, 90% yield): 1H NMR (CD3OD, 400MHz) 6 0.90 (bt, 3H, J = 6.4 Hz), 1.23-1.45 (m, 14H), 1.58-1.75 (m, 6H), 2.59 (t, 2H, J = 7.6 Hz), 2.68 (t, 2H, J = 7.2 Hz), 4.20 (t, 2H, 6.8 Hz), 6.81 (bs, 1H), 7.07-7.18 (m, 3H), 7.19- 7.27 (m, 2H). MS (ES) 443.58 (M-1), tn(method D) = 8.58min 5-Decyl-2-(2-methoxy-ethoxycarbonylamino)-thiophene-3-carboxylic acid (21.14) off-white solid (256 mg, 95% yield): 1H NMR (CDCI3, 200MHz) 8 0.88 (bt, 3H, J = 6.2 Hz), 1.11-1.44 (m, 14H), 1.47-1.73 (m, 2H), 2.69 (t, 2H, J = 7.8 Hz), 3.43 (s, 3H), 3.62-3.75 (m, 2H), 4.31-4.47 (m, 2H), 6.86 (s, 1H), 10.00 (s, 1H). MS (ES) 384.52 (M-1), t^method D) = 6.28min. 2-(4-Butyl-phenoxycarbonylamino)-5-decyl-thiophene-3-carboxylic acid (21.15) tan solid (214 mg, 97% yield) 'H NMR (CD3OD, 400 MHz) 8 0.891 (bt, 3H, J = 6.8 Hz), 0.949 (t, 3H, J= 7.2 Hz), 1.21-1.43 (m, 16H), 1.54-1.71 (m, 4H), 2.63 (t, 2H, J = 7.6 Hz), 2.70 (t, 2H, J= 7.2 Hz), 6.87 (s, 1H), 7.12 (d, 2H, J= 8.4 Hz), 7.23 (d, 2H, J= 8.8 Hz); MS (ES) no ionization (M-1), tR(method D) = no peak 2-(3-phenoxy-propoxycarbonylamlno)-5-decyl-thiophene-3-carboxylic acid (21.16) off-white solid (137 mg, 80% yield): 1H NMR (CDCI3l 200MHz) 8 0.88 (t, 3H, J= 6.4 Hz), 1.26-1.38 (m, 14H), 1.64 (tt, 2H, J= 12.4, 7.0 Hz), 2.02 (tt, 2H, J= 12.4, 6.2 Hz), 2.68 (t, 2H, J = 7.3 Hz), 3.60 (t, 2H, J = 6.2 Hz), 4.37 (t, 2H, J = 6.2 Hz), 4.53 (s, 2H), 6.87 (s, 1H), 7.25-7.34 (m, 5H), 9.88 (s, 1H), 10.85 (bs, 1H). 2-(4-Benzyloxy-butoxycarbonylamino)-5-decyl-thiophene-3-carboxylic acid (21.17) off-white solid (55 mg, 55% yield): 1H NMR (CDCI3, 200MHz) 8 0.88 (t, 3H, J = 6.3 Hz), 1.26-1.38 (m, 14H), 1.61-1.82 (m, 6H), 2.68 (t, 2H, J= 7.4 Hz), 3.53 (t, 2H, J = 5.8 Hz), 4.27 (t, 2H, J = 5.8 Hz), 4.50 (s, 2H), 6.86 (s, 1H), 7.25-7.33 (m, 5H), 9.92(s, 1H). 5-Pentyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid (21.18): 1H NMR (CDCI3, 200 MHz): 8 = 0.78-1.02 (m, 6H), 1.14-1.50 (m, 12H), 1.52-1.82 (m, 4H), 2.69 (t, J = 7.5 Hz, 2H), 4.23 (t, J = 6.8 Hz, 2H), 6.59 (s, 1H), 9.88(brs, 1H). 5-lsopropyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid (21.19): 1H NMR (CDCI3, 200 MHz): 8 = 0.88 (t, J = 6.4 Hz, 3H), 1.16-1.50 (m, 16H), 1.60-1.82 (m, 2H), 2.90-3.18 (m, 1H), 4.24 (t, J = 6.8 Hz, 2H), 6.87 (d, J = 1.2 Hz, 1H), 9.81 (brs, 1H), 9.86 (brs, 1H). O 5-Octyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid (21.20): 1H NMR (CDCI3, 200 MHz): 6 = 0.78-1.00 (m, 6H), 1.12-1.49 (m, 20H), 1.54-1.82 (m, 4H), 2.68 (t, J = 7.3 Hz, 2H), 4.23 (t, J = 6.6 Hz, 2H), 6.86 (s, 1H), 9.89 (brs, 1H). 5-Dodecyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid (21.21): 1H NMR (CDCI3, 200 MHz): 8 = 0.78-0.96 (m, 6H), 1.12-1.46 (m, 28H), 1.52-1.78 (m, 4H), 2.68 (t, J = 7.3 Hz, 2H), 4.23 (t, J = 6.8 Hz, 2H), 6.85 (s, 1H), 9.90 (brs, 1H). 2-Benzyloxycarbonylamino-5-decyl-thlophene-3-carboxylic acid (21.22): 1H NMR (CDCI3, 200 MHz): 6 = 0.88 (t, J = 6.4 Hz, 3H), 1.14-1.44 (m, 14H), 1.50-1.74 (m, 2H), 2.68 (t, J = 7.1 Hz, 2H), 5.26 (s, 2H), 6.85 (s, 1H), 7.33-7.49 (m, 5H), 9.95 (brs, 1H). 2-(4-Butylbenzyloxycarbonylamino)-5-decyl-thiophene-3-carboxylic acid (21.23): 1H NMR (CDCI3, 200 MHz): 8 = 0.78-1.02 (m, 6H), 1.10-1.46 (m, 16H), 1.48-1.76 (m, 4H), 2.52-2.80 (m, 4H), 5.23 (s, 2H), 6.84 (s, 1H), 7.13-7.40 (m, 4H), 9.93 (brs, 1H). cr o' 5-Decyl-2-(2-p-tolyl-ethoxycarbonylamino)-thiophene-3-carboxylic acid (21.24): 1H NMR (CDCIa, 200 MHz): 8 = 0.88 (t, J = 6.4 Hz, 3H), 1.16-1.46 (m, 14H), 1.52- 1.78 (m, 2H), 2.33 (s, 3H), 2.69 (t, J = 7.5 Hz, 2H), 3.00 (t, J = 7.3 Hz, 2H), 4.43 (t, J = 7.3 Hz, 2H), 6.87 (s, 1H), 7.08-7.22 (m, 4H), 9.91 (brs, 1H). H ( T O 5-Decyl-2-phenethyloxycarbonylamino-thiophene-3-carboxylic acid (21.25): 1H NMR (CDCI3, 200 MHz): 8 = 0.88 (t, J = 6.4 Hz, 3H), 1.16-1.46 (m, 14H), 1.52-1.76 (m, 2H), 2.69 (t, J = 7.3 Hz, 2H), 3.05 (t, J = 7.3 Hz, 2H), 4.46 (t, J = 7.5 Hz, 2H), 6.87 (s, 1H), 7.18-7.42 (m, 5H), 9.92 (brs, 1H). 4-Methyl-5-octyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid (21.26): 520 mg (69%). 1H NMR (CDCI3, 200 MHz): S 0.87 (t, J = 6.6 Hz, 6H), 1.16-1.62 (m, 24), 2.28 (s, 3H), 2.64 (t, J = 7.2 Hz, 2H), 4.18 (t, J = 6.6 Hz, 2H), 10.26 (s, 1H). o 2-Butyloxycarbonylamino-5-octyl-thiophene-3-carboxylic acid (21.27): 366 mg (67%). 1H NMR (CDCIs, 200 MHz): 6 0.87 (t, J = 6.6 Hz, 3H), 0.96 (t, J = 7.4 Hz, 3H), 1.14-1.82 (m, 16H), 2.67 (t, J = 7.4 Hz, 2H), 4.24 (t, J = 6.6 Hz, 2H), 6.85 (s, 1H), 9.89(8, 1H). 2-Hexyloxycarbonylamino-5-octyl-thiophene-3-carboxyiic acid (21.28): 395 mg (60%). 1H NMR (CDCI3, 200 MHz): 8 0.87 (t, J = 7.0 Hz, 3H), 0.90 (t, J = 6.4 Hz, 3H), 1.12-1.52 (m, 16H), 1.50-1.82 (m, 4H), 2.68 (t, J = 7.2 Hz, 2H), 4.23 (t, J = 7.0 Hz, 2H), 6.68 (s, 1H), 9.88 (s, 1H). 2-Dodecyloxycarbonylamlno-5-octyl-thiophene-3-carboxylic acid (21.29): 541 mg (80%). 1H NMR (CDCIg, 200 MHz): 5 0.87 (t, J = 6.4 Hz, 6H), 1.12-1.50 (m, 28H), 1.50-1.80 (m, 4H), 2.68 (t, J = 7.4 Hz, 2H), 4.23 (t, J = 6.6 Hz, 2H), 6.85 (s, 1H), 9.89 (s, 1H). cr o 5-Decyl-2-phenyloxycarbonylamino-thiophene-3-carboxylic acid (21.30): 469 mg (80%). 1H NMR (CDCI3) 200 MHz): 50.87 (t, J = 6.6 Hz, 3H), 1.18-1.44 (m, 14H), 1.54-1.76 (m, 2H), 2.70 (t, J = 7.2 Hz, 2H), 6.91 (s, 2H), 7.17-7.48 (m, 5H), 10.27 (s,1H). Cr 0 2-Decyloxycarbonylamino-5-octyl-thiophene-3-carboxylic acid (21.31): 603 mg (86%). 1H NMR (CDCI3, 200 MHz): 8 0.87 (t, J = 6.2 Hz, 6H), 1.32-1.50 (m, 24H), 1.52-1.82 (m, 4H), 2.67 (t, J = 7.4 Hz, 2H), 4.23 (t, J = 6.6 Hz, 2H), 6.85 (s, 1H), 9.89 (S.1H). 6-Benzyl-2-octyloxycarbonylamino)thiophene-3-carboxylic acid (21.32) Light yellow solid in 100% yield. 'H NMR (CDCI3, 200MHz): 5 9.86 (s, 1H), 7.22-7.34 (m, 5H), 7.00(brs, 1H), 6.87 (t, 1H, J= 1.0HZ), 4.21 (t, 2H, J= 6.6Hz), 4.01 (s, 2H), 1.67(q, 2H, J = 7.0Hz), 1.15- 1.45 (m, 10H), 0.88(t, 3H, J = 7.0Hz). 6-Hexyl-2-(octyloxycarbonylamino)thiophene-3-carboxylic acid (21.33) Light yellow oil in 74% yield. 'H NMR (CDCI3, 200MHz): 5 10.87 (brs, 1H), 9.83 (s, 1H), 6.86 (s, 1H), 4.24 (t, 2H, J = 6.6Hz), 2.68 (t, 2H, J = 7.2Hz), 1.60-1.80(m, 4H), 1.10-1.45 (m, 20H), 0.80-0.95(m, 6H). 6-Decyl-2-(octyloxycarbonylamino)thiophene-3-carboxylic acid (21.34) Light yellow solid in 100% yield. 'H NMR (CDCI3, 200MHz): 5 9.89 (brs, 1H), 8.00 (brs, 1H), 6.85 (s, 1H), 4.23 (t, 2H, J = 6.6Hz), 2.68 (t, 2H, J = 7.0Hz), 1.60-1.80(m, 4H), 1.08-1.40 (m, 24H), 0.80-0.95(m, 6H). 6-Decyl-2-(1-methylheptyloxycarbonylamino)thiophene-3-carboxylic (21.35) Light yellow solid in 98% yield. acid 'H NMR (CDCI,, 200MHz): 6 9.80 (brs, 1H), 8.24(brs, 1H), 6.73 (s, 1H), 4.82-5.00 (m, 1H), 2.65 (t, 2H, J = 7.4Hz), 1.50-1.83(m, 15H), 1.08-1.50 (m, 23H), 0.80-1.00(m, 6H). ( T O acid 6-Heptyl-2-(1-methylheptyloxycarbonylamino)thiophene-3-carboxylic (21.36) Light yellow oil in 100% yield. 'H NMR (CDCI3> 200MHz): 5 9.80 (brs, 1H), 8.24(brs, 1H), 6.85 (s, 1H), 4.90-5.00 (m, 1H), 2.68 (t, 2H, J = 7.6Hz), 1.50-1.83(m, 4H), 1.08-1.50 (m, 20H), 0.80-1.00 (m, 6H). O O 5-Decyl-2-(4-phenylpropoxycarbonylamino)thiophene-3-carboxylic acid (21.37) Light brownish solid in 100% yield. 'H NMR (CDCI,, 400MHz): 5 10.4 (brs, 1H), 9.88 (s, 1H), 7.26-7.31 (m, 2H), 7.18-7.21 (m, 3H), 6.87 (s, 1H), 4.27 (t, 2H, J= 6.4Hz), 2.74 (t, 2H, J = S.OHz), 2.68 (t, 2H, J = 7.6Hz), 2.02-2.07(m, 2H), 1.59-1.66(m, 2H), 1.18-1.40 (m, 14H), 0.88 (t, 3H, J = 6.0Hz). 5-Decyl-2-(4-phenylbutoxycarbonylamino)thiophene-3-carboxylic acid (21.38) Light brownish solid in 100% yield. !H NMR (CDCI3, 400MHz): 8 12.0 (brs, 1H), 9.90 (s, 1H), 7.26-7.31 (m, 2H), 7.17-7.21 (m, 3H), 6.87 (s, 1H), 4.26 (t, 2H, J= 6.4Hz), 2.67-2.70 (m, 4H), 1.70-1.80(m, 4H), 1.50-1.70(m, 2H), 1.18-1.40 (m, 16H), 0.88(t, 3H, J = 6.8Hz). Example 22: Thienoxazinones 6-Heptyl-5-methyl-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one (74) (May contain -10% other isomer); Mp 29-31 SC; 1H NMR (CDCI3) 6 0.82-0.96 (m, 6H), 1.20-1.50 (m, 18H), 1.50-1.68 (m, 2H), 1.68-1.86 (m, 2H), 2.36 (s, 3H), 2.70 (t, 2H, J = 6.8 Hz), 4.38 (t, 2H, J = 6.6 Hz) Another peak at 2.83 (t, J = 6.7 Hz), which may be from other isomer; MS (El): cal'd 393.59, exp, did not ionize. 6-Methyl-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one (22.1): 1H NMR (CDCI3) 80.88 (t, 3H, J = 7.2 Hz), 1.20-1.45 (m, 10H), 1.55 (s, 9H), 1.70-1.84 (m, 2H), 2.46 (s, 3H), 4.39 (t, 2H, J = 6.6 Hz), 6.93 (s, 1H); MS (El): cal'd 295.5, exp. 6-Heptyl-2-octylamino-thieno[2,3-d][1,3]oxazin-4-one (61): off-white solid (38 mg, 801% yield): 'H NMR (CDCI3, 200MHz) 5 0.87 (t, 6H, J = 6.4 Hz), 1.27-1.30 (m, 18H), 1.58-1.67 (m, 4H), 2.71 (t, 2H, J= 7.3 Hz), 3.38 (dt, 2H, J= 7.0, 6.2 Hz), 5.45 (68,11-0,6.84(8,1^. 6-Butyl-2-octylamino-thieno[2,3-d][1,3]oxazin-4-one (63): off-white solid (162 mg, 55% yield): mp 93.0-94.0 eC. 'H NMR (CDCI3, 200MHz) 5 0.88 (t, 3H, J= 6.4 Hz), 0.93 (t, 3H, J = 7.3 Hz), 1.27-1.48 (m, 12H), 1.56-1.71 (m, 4H), 2.72 (t, 2H, J = 7.5 Hz), 3.39 (dt, 2H, J = 7.0, 6.2 Hz), 5.73 (bs, 1H), 6.§5 (t, 1H, J= 1.1 Hz). MS (ES+) 337.23 (M+1). 6-Benzyl-2-octylamino-thieno[2,3-d][1,3]oxazin-4-one (62): off-white solid (182 mg, 55% 2-step yield): mp 123.0-124.0 BC. 'H NMR (CDCI3, 200MHz) 6 0.87 (t, 3H, J= 6.4 Hz), 1.26-1.28 (m, 10H), 1.51 (tt, 2H, J= 13.6, 6.5 Hz), 3.36 (dt, 2H, J = 7.0, 6.6 Hz), 4.02 (s, 2H), 5.81 (bs, 1H), 6.85 (s, 1H), 7.20-7.35 (m, 5H). MS (ES+) 371.18 (M+1). 6-Heptyl-2-undecyl-thieno[2,3-d][1,3]oxazin-4-one (67): yellow oil (97 mg, 55% yield): 'H NMR (CDCI3, 200MHz) 5 0.85-0.91 (m, 6H), 1.26-1.32 (m, 24H), 1.66- 1.83 (m, 4H), 2.69 (t, 2H, J= 7.7 Hz), 2.82 (t, 2H, J= 7.5 Hz), 7.06 (s, 1H). 13C NMR (CDCI3, 50MHz) 8 14.0, 14.1, 22.5, 22.6, 26.2, 28.8, 28.9, 29.0, 29.2, 29.3, 29.4, 29.5, 30.4, 31.0, 31.7, 31.9, 34.7, 117.8, 118.6, 144.3, 155.6, 162.2, 165.2. 6-Heptyl-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one (68): yellow oil (36 mg, 50% yield): 1H NMR (CDCI3, 200MHz) 8 0.85-0.93 (m, 6H), 1.29-1.48 (m, 18H), 1.61- 1.87 (m, 4H), 2.77 (t, 2H, J = 7.5 Hz), 4.41 (t, 2H, J = 6.6 Hz), 6.97 (t, 1H, J = 1.1 Hz). 2-Octyloxy-6-(1,3,3-trimethyl-butyl)-thIeno[2,3-d][1,3]oxazin-4-one (78): colorless oil (92 mg, 51% yield): 'H NMR (CDCI3, 200MHz) 8 0.88-0.89 (m, 12H), 1.30-1.83 (m, 17H), 3.04-3.13 (m, 1H), 4.41 (t, 2H, J = 6.6 Hz), 6.98 (s, 1H). "C NMR (CDCI3, 50MHz) 8 14.0, 22.6, 25.6, 26.2, 28.3, 29.1, 29.8, 31.3, 31.7, 32.8, 52.6, 70.5, 113.2, 116.5, 149.4,154.5,156.9,165.3. MS (ES+) 380.01 (M+1). (83): pale yellow oil (3 mg): 'H NMR (CDCI3, 200MHz) 8 0.89 (t, 3H, J = 6.6 Hz), 1.11 (s, 6H), 1.26-1.67 (m, 19H), 1.77 (dt, 2H, J= 7.0, 6.6 Hz), 2.96 (dq, 1H, J = 7.2, 7.0 Hz), 3.15 (S, 3H), 4.40 (t, 2H, J^ 6.6 Hz), 6.98 (s, 1H). MS (ES+) 424.03 (M+1). 6-(1,5-Dimethyl-hex-4-enyl)-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one and 6- (1,5-Dimethyl-hex-5-enyl)-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one (2:1 mixture of isomers) (81): colorless oil (16 mg): MS (ES+) 391.95, 391.97 (M+1). O Trifluoro-acetic acid 1,1-dimethyl-5-(2-octyloxy-4-oxo-4H-thieno[2,3- d][1,3]oxazin-6-yl)-hexyl ester (82): colorless oil (61 mg): 'H NMR (CDCI3, 200MHz) 8 0.89 (t, 3H, J= 6.6 Hz), 1.26-1.69 (m, 8H), 1.76-1.88 (m, 4H), 2.97 (dq, 1H, J = 7.0, 6.8 Hz), 4.41 (t, 2H, J = 6.6 Hz), 6.98 (s, 1H). "C NMR (CDCI3, 100MHz) 8 14.2, 21.5, 22.7, 22.8, 25.7, 25.8, 28.5, 29.3, 31.9, 35.8, 38.7, 40.3, 70.8, 89.1, 113.6, 114.6 (q, CF3, J = 285.9 Hz), 117.3, 117.4, 146.8, 154.7, 156.4 (q, COCF3, J= 40.9 Hz), 157.3, 165.8. MS (ES+) 505.93 (M+1). 2-(2-Benzyloxy-ethoxy)-6-decy1-thieno[2,3-d][1,3]oxazin-4-one (97): yellow oil (68 mg, 50% yield): 'H NMR (CDCI3, 400MHz) 8 0.88 (t, 3H, J= 6.8 Hz), 1.26-1.32 (m, 14H), 1.66 (tt, 2H, J = 14, 7.6 Hz), 2.76 (t, 2H, J = 7.6 Hz), 3.81 (t, 2H, J = 4.4 Hz), 4.57 (t, 2H, J = 4.6 Hz), 4.60 (s, 2H), 6.95 (s, 1H), 7.25-7.34 (m, 5H). 13C NMR (CDCI3l 100MHz) 5 14.0, 22.6, 28.8, 29.2, 29.3, 29.4, 29.5, 30.2, 30.9, 31.8, 67.1, 69.3, 73.3, 113.7, 118.2, 127.6, 127.7, 128.4, 137.6, 141.3, 154.2, 156.7, 165.2. 490 2-Octyloxy-6-phenethyl-thieno[2,3-d][1,3]oxazin-4-one (103): clear oil (84 mg, 88% yield) 'H NMR (CDCI3l 200MHz) 8 0.89 (t, 3h, J = 6.8Hz), 1.28-1.43 (m, 10H), 1.79 (tt, 2H, J = 7.6Hz, J = 7.2Hz), 2.98 (t, 2H, J = 7.2Hz), 3.10 (t, 2H, J = 7.6Hz), 4.39 (t, 2H, J = 6.8Hz), 6.95 (s, 1H), 7.17-7.31 (m, 5H). 2-Octyloxy-6-(3-phenyl-propyl)-thieno[2,3-d][1,3]oxazin-4-one (104): white solid (72 mg, 75% yield) 'H NMR (CDCI3, 200MHz) 80.88 (t, 3H, J = 6.6Hz), 1.21-1.50 (m, 10H), 1.79 (tt, 2H, J = 7.0Hz, J = 6.6Hz), 2.01 (tt, 2H, J = 7.8Hz, J = 7.2Hz), 2.69 (t, 2H, J = 7.6Hz), 2.80 (t, 2H, J = 7.2Hz), 4.40 (t, 2H, J = 6.6Hz), 6.98 (s, 1H), 7.16- 7.35 (m, 5H). 2-Octyloxy-6-(4-phenyl-butyl)-thieno[2,3-d][1,3]oxazin-4-one (92): pale yellow oil (218 mg, 78% yield) 'H NMR (CDCI3, 200MHz) 8 0.887 (bt, 3H, 6.2 Hz), 1.08-1.52 (m, 10H), 1.60-1.90 (m, 6H), 2.54-2.72 (m, 2H), 2.72-2.88 (m, 2H), 4.40 (t, 2H, J = 6.6 Hz), 6.95 (s, 1H), 7.09-7.38 (m, 5H); MS (ES) 414.59 (M+1), tn(method D) = 9.71 min. 131 2-Octyloxy-6-(5-phenyl-pentyl)-thieno[2,3-d][1,3]oxazin-4-one (93): Pale yellow oil (223 mg, 94% yield) 1H NMR (CDCI3, 200MHz) 8 0.887 (bt, 3H, J = 6.2 Hz), 1.20-1.50 (m, 12H), 1.57-1.88 (m, 6H), 2.61 (t, 2H, J = 7,4 Hz), 2.76 (t, 2H, J = 6.8 Hz), 4.40 ( t, 2H, J = 6.6 Hz), 6.95 (t, 1H, J = 1 Hz), 7.08-7.35 (m, 5H); MS (ES) 428.62 (M+1), tfl(method D) = 10.69min. 6-Decyl-2-(2-methoxy-ethoxy)-thieno[2,3-d][1,3]oxazin-4-one (96): off-white waxy solid (195 mg, 83% yield); m.p. = 38-41 SC; 1H NMR (CDCI3, 200MHz) 8 0.879 (bt, 3H, J = 6.2 Hz), 1.06-1.43 (m, 14H), 1.52-1.78 (m, 2H), 2.76 (t, 3H, J= 7.0 Hz), 3.43 (s, 3H), 3.62-3.82 (m, 2H), 4.44-4.64 (m, 2H), 6.96 (s, 1H); MS (ES) 368.52 (M+1), tfl(method D) = S.OOmin. 2-(4-Butyl-phenoxy)-6-decyl-thieno[2,3-d][1,3]oxazin-4-one (102): light yellow solid (145 mg, 79% yield); m.p. = 55-58 SC; 1H NMR (CDCI,, 400 MHz) 8 0.878 (t, 3H, J= 6.0 Hz), 0.946 (t, 3H, J = 7.6 Hz), 1.18-1.45 (m, 18H), 1.55-1.71 (m, 4H), 2.64 (t, 2H, J = 7.6 Hz), 2.76 (t, 2H, J = 7.6 Hz), 6.99 (s, 1H), 7.15 (d, 2H, J = 8.4 Hz), 7.24 (d, 2H, J= 8.4 Hz); MS (ES) 442.64 (M+1), t, (method D) = 12.19min. o 2-(3-Benzyloxy-propoxy)-6-decyI-thieno[2,3-d][1,3]oxazin-4-one (109): colorless oil (115 mg, 87% yield): 'H NMR (CDCI3, 200 MHz) 8 0.88 (t, 3H, J= 6.6 Hz), 1.26- 1.38 (m, 14H), 1.67 (tt, 2H, J= 14.4, 7.4 Hz), 2.09 (tt, 2H, J= 12.4, 6.2 Hz), 2.76 (t, 2H, J= 7.4 Hz), 3.62 (t, 2H, J = 6.2 Hz), 4.51 (s, 2H), 4.53 (t, 2H, J= 6.4 Hz), 6.96 (t, 1H, J = 1.1 Hz), 7.24-7.33 (m, 5H). "C NMR (CDCI3, 100MHz) 5 14.04, 22.61, 28.78, 28.83, 29.22, 29.23, 29.44, 29.50, 30.25, 30.90, 31.82, 65.93, 67.46, 73.06, 113.59,118.14,127.60,128.31, 133.09,141.18,154.30, 156.73, 165.54. 2-(3-Benzyloxy-butyloxy)-6-decyl-thieno[2,3-d][1,3]oxazin-4-one (111): colorless oil (19 mg, 36% yield): 'H NMR (CDCI3, 200 MHz) 8 0.88 (t, 3H, J = 6.4 Hz), 1.26- 1.38 (m, 14H), 1.63-1.99 (m, 14H), 2.76 (t, 2H, J= 7.7 Hz), 3.54 (t, 2H, J= 6.2 Hz), 4.44 (t, 2H, J= 6.2 Hz), 4.51 (s, 2H), 3.96 (t, 1H, J= 1.0 Hz), 7.28-7.35 (m, 5H). N o 6-Butyl-2-octyloxy-thleno[2,3-d][1,3]oxazln-4-one (75): MS (ES/SIR): m/z 338.49 [MH4]. 1H NMR (CDCI3, 200 MHz): 8 = 0.78-1.03 (m, 6H), 1.15-1.53 (m, 12H), 1.54-1.90 (m, 4H), 2.77 (t, J = 7.5 Hz, 2H), 4.40 (t, J = 6.6 Hz, 2H), 6.96 (t, J = 0.8 Hz, 1H). 6-lsopropy!-2-octy!oxy-thieno[2,3-d][1,3]oxazin-4-one (76): MS (ES/SIR): m/z 324.46 [MH4]. 1H NMR (CDCI3, 200 MHz): 8 = 0.88 (t, J = 6.6 Hz, 3H), 1.18-1.52 (m, 16H), 1.70-1.88 (m, 2H), 2.98-3.22 (m, 1H), 4.40 (t, J = 6.6 Hz, 2H), 6.98 (d, J = 1.0 Hz, 1H). 6-Octyl-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one (85): 1H NMR (CDCI3, 200 MHz): 6 = 0.80-1.00 (m, 6H), 1.12-1.52 (m, 20H), 1.57-1.90 (m, 4H), 2.76 (td, J 1.0, 7.6 Hz, 2H), 4.40 (t, J = 6.6 Hz, 2H), 6.95 (t, J = 1.1 Hz, 1H). N O 6-Dodecyl-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one (88): 1H NMR (CDCI3> 200 MHz): 5 = 0.80-0.98 (m, 6H), 1.16-1.52 (m, 28H), 1.58-1.88 (m, 4H), 2.76 (t, J = 7.2 Hz, 2H), 4.40 (t, J = 6.6 Hz, 2H), 6.95 (s, 1H). 2-Benzyloxy-6-Decyl-thieno[2,3-d][1,3]oxazin-4-one (105): MS (ES/SIR): m/z 400.56 [MH+].1H NMR (CDCI3, 400 MHz): 8 = 0.88 (t, J = 6.8 Hz, 3H), 1.17-1.42 (m, 14H), 1.67 (quint., J = 7.4 Hz, 2H), 2.77 (t, J = 7.1 Hz, 2H), 5.44 (s, 2H), 6.96 (s, 1H), 7.33-7.49 (m, 5H). 15 2-(4-Butylbenzyloxy)-6-Decyl-thieno[2,3-d][1,3]oxazin-4-one (106): 1H NMR (CDCI3, 200 MHz): 8 = 0.78-1.02 (m, 6H), 1.12-1.47 (m, 16H), 1.50-1.77 (m, 4H), 2.62 (t, J = 7.5 Hz, 2H), 2.77 (t, J = 7.6 Hz, 2H), 5.40 (s, 2H), 6.96 (s, 1H), 7.20 (d, J = 8.0 Hz, 2H), 7.36 (d, J = 8.2 Hz, 2H). 6-Decyl-2-(2-p-tolyl-ethoxyHhieno[2,3-d][1,3]oxazin-4-one (107): 1H NMR (CDCI3) 200 MHz): 8 = 0.88 (t, J = 6.6 Hz, 3H), 1.14-1.46 (m, 14H), 1.56-1.78 (m, 2H), 2.32 (s, 3H), 2.76 (t, J = 7.4 Hz, 2H), 3.06 (t, J = 7.0 Hz, 2H), 4.58 (t, J = 7.0 Hz, 2H), 6.95 (t, J = 1.1 Hz, 1H), 7.07-7.22 (m, 4H). 6-Decyl-2-phenethyloxy-thieno[2,3-d][1,3]oxazin-4-one (108): 1H NMR (CDCI3, 200 MHz): 8 = 0.88 (t, J = 6.4 Hz, 3H), 1.14-1.46 (m, 14H), 1.56-1.76 (m, 2H), 2.76 (t, J = 7.2 Hz, 2H), 3.11 (t, J = 7.0 Hz, 2H), 4.60 (t, J = 7.0 Hz, 2H), 6.95 (s, 1H), 7.18-7.42 (m,5H). 455 3-Methyl-6-octyl-2-octyloxy-5H-thieno[2,3-b]pyridin-4-one (87): 51 mg (60%). m.p. 369C. 1H NMR (CDCI3, 200 MHz): 8 0.88 (t, J = 6.6 Hz, 6HO, 1.10-1.94 (m, 24H), 2.35 (s, 3H), 2.69 (t, J = 7.2 Hz, 2H), 4.38 (t, J = 7.0 Hz, 2H); 13C NMR (CDCI3, 75 MHz): 5 11.1, 12.3, 20.9, 23.9, 25.7, 26.6, 27.3, 27.4, 27.5, 27.6, 29.4, 30.0, 30.1, 68.6, 11.5, 126.9, 132.0, 153.1, 155.1, 162.9. 2-Butoxy-6-octyl-5H-thieno[2,3-b]pyridin-4-one (95): 265 mg (93%). 1H NMR (CDCI3, 200 MHz): 8 0.86 (t, J = 6.6 Hz, 3H), 0.96 (t, J = 7.2 Hz, 3H), 1.14-1.88 (m,16H), 2.74 (t, J = 7.4 Hz, 2H), 4.39 (t, J = 6.6 Hz, 2H), 6.93 (s, 1H); 13C NMR (CDCI3, 75 MHz): S 11.9, 12.3, 17.2, 20.9, 27.2, 27.4, 27.5, 28.6, 29.2, 30.1, 68.5, 101.9, 116.5, 139.4, 152.7, 155.2, 164.0; MS (SIR): 338.48 (M+1). 2-Hexyloxy-6-octyl-5H-thieno[2,3-b]pyridin-4-one (94): 312 mg (94%). 1H NMR (CDCI3, 200 MHz): 8 0.86 (t, J = 6.6 Hz, 3H), 0.89 (t, J = 6.6 Hz, 3H), 1.15-1.54 (m, 16H), 1.54-1.88 (m, 4H), 2.74 (t, J = 7.0 Hz, 2H), 4.38 (t, J = 6.6 Hz, 2H), 6.94 (t, J = 1.2 Hz, 1H); 13C NMR (CDCI3, 75 MHz): 8 12.2, 12.3, 20.8, 20.9, 23.6, 26.6, 27.2, 27.4, 27.5, 28.6, 29.2, 29.6, 30.1, 68.8, 101.9, 116.5, 139.4, 152.7, 155.2, 164.0; MS (SIR): 366.55 (M+1). 2-Dodecyloxy-6-octyl-5H-thieno[2,3-b]pyridin-4-one (100): 322 mg (91%). 1H NMR (CDCI3, 200 MHz): 8 0.87 (t, J = 6.2 Hz, 6H), 1.04-1.52 (m, 28H), 1.52-1.90 (m, 4H), 2.75 (t, J = 7.0 Hz, 2H), 4.38 (t, J = 6.5 Hz, 2H), 6.94 (s, 1H); 13C NMR (CDCI3) 75 MHz): 8 12.3, 12.4, 20.9, 21.0, 23.9, 26.6, 27.2, 27.4, 27.5, 27.6, 27.7, 27.8, 27.9, 28.6, 29.2, 30.1, 30.2, 68.8, 11.9, 116.5, 139.4, 152.7, 155.2, 164.0; MS (SIR): 450.71 (M+1). 6-Decyl-2-phenoxy-5H-thieno[2,3-b]pyridin-4-onc (101): 322 mg (86%). 1H NMR (CDCI3, 200 MHz): 8 0.87 (t, J = 6.6 Hz, 3H), 1.15-1.45 (m, 14H), 1.55-1.75 (m, 2H), 2.75 (t, J = 7.0 Hz, 2H), 7.0 (t, J = 1 Hz, 1H), 7.22-7.51 (m, 5H); 13C NMR (CDCl3, 75 MHz): 8 12.4, 21.0, 27.2, 27.5, 27.6, 27.6, 27.8, 28.6, 29.2, 30.2, 97.7, 97.7, 102.5, 116.5, 119.4, 124.9, 128.0, 140.7, 149.5, 152.3, 154.5, 163.1; MS (SIR): 358.48 (M+1). 2-Decyloxy-6-octyl-5H-th!eno[2,3-b]pyridin-4-one (110): 313 mg (69%). 1H NMR (CDCIa, 200 MHz): 8 0.85 (t, J = 6.4 Hz, 6H), 1.16-1.50 (m, 24H), 1.50-1.88 (m, 4H), 2.74 (t, J = 6.8 Hz, 2H), 4.38 (t, J = 6.6 Hz, 2H), 6,93 (s, 1H); 13C NMR (CDCI3, 75 MHz): 8 12.3, 20.9, 20.9, 23.9, 26.6, 27.2, 27.4, 27.5, 27.6, 27.7, 27.8, 28.6, 29.2, 30.1, 30.1, 68.8, 111.9,116.5, 139.3, 152.6,155.2,164.0. 6-Benzyl-2-octyloxythieno[2,3-dl[1,3]oxazin-4-one (77) Light yellow oil in 53% yield. 'H NMR (CDCI3, 200MHz): 5 7.20-7.40 (m, 5H), 6.98 (t, iH, J= 1.0Hz), 4.38 (t, 2H, J =. 6.6Hz), 4.09 (s, 2H), 1.76(q, 2H, J= 7.2Hz), 1.10-1.50 (m, 10H), 0.88 (t, 3H, J = 7.0Hz). MS (ES) [M+l] 372.51. 6-Hexyl-2-octyloxythieno[2,3-cQ[1,3]oxazin-4-one (84) Light yellow oil in 30% yield. 'H NMR (CDCI3, 200MHz): S 6.94 (s, 1H), 4.39 (t, 2H, J = 6.6Hz), 2.76 (t, 2H, J = 7.2Hz), 1.76(q, 2H, J = 7.4Hz), 1.64 (q, 2H, J = 7.6Hz), 1.08-1.50 (m, 14H), 0.80- 0.95 (m, 6H). MS (ES) [M++l] 366.55. O 6-Decyl-2-octyloxythieno[2,3-c/][1,3]oxazin-4-one (86) Light yellow oil in 50% yield. 'H NMR (CDCI3) 200MHz): 5 6.94 (s, 1H), 4.39 (t, 2H, J = 6.6Hz), 2.76 (t, 2H, J = 7.2HZ), 1.76(q, 2H, J = 7.4Hz), 1.64 (q, 2H, J = 7.6Hz), 1.08-1.50 (m, 20H), 0.80- 0.95 (m, 6H). MS (ES) [M++l] 422.56 6-Decyl-2-(1-methylheptyloxy)thieno[2,3-d][1,3]oxazin-4-one(90) Light yellow oil in 22% yield. !H NMR (CDCI3, 200MHz): 5 6.96 (s, 1H), 5.13 (tq, 1H, J= 5.8, 6.2Hz), 2.76 (t, 2H, J = 7.6Hz), 1.58-1.83(m, 4H), 1.08-1.50 (m, 26H), 0.80-1.00 (m, 6H). MS (ES) [M++l] 380.57. 6-Heptyl-2-(1-methylheptyloxy)thieno[2,3-cq[1,3]oxazin-4-one(91) Light yellow oil in 28% yield. 'H NMR (CDCI3, 200MHz): 6 6.96 (s, 1H), 5.13 (tq, 1H, J= 6.2, 6.6Hz), 2.76 (t, 2H, J = 7.6Hz), 1.58-1.83(171, 4H), 1.08-1.50 (m, 20H), 0.80-1.00 (m, 6H). MS (ES) [M++l] 422.65 6-Decyl-2-(4-phenylpropoxy)thieno[2,3-d][1,3]oxazin-4-one (99) Light yellow oil in 28% yield. 'H NMR (CDCL, 200MHz): 5 7.17-7.38 (m, 5H), 6.96 (s, 1H), 4.42 (t, 2H, J= 6.6Hz), 2.72-2.85 (m, 4H), 2.05-2.20(m, 2H), 1.50-1.75(m, 2H), 1.20-1.40 (m, 16H), 0.88(t, 3H, J= 6.6Hz). MS (ES) [M++l] 428.62. 6-Decyl-2-(4-phenylbutoxy)thieno[2,3-d][1,3]oxazin-4-one (98) Light yellow oil in 25% yield. 1H NMR (CDCI3, 200MHz): 8 7.10-7.38 (m, 5H), 6.96 (s, 1H), 4.42 (t, 2H, J= 6.4Hz), 2.60-2.80 (m, 4H), 1.75-1.83(m, 4H), 1.50-1.70(m, 2H), 1.18-1.40 (m, 16H), 0.88(t, 3H, J = 6.4Hz). Example 23; Pancreatic lipase assay The use of a pancreatic lipase assay has been described in the literature (Hadvary, P. et al. Biochem. J. (1988) 256: 357-361; Hadvary, P. et al. Biochem. J. (1991) 266:2021-2027). Pancreatic lipase activity was measured using a 718 Stat Titrino (Brinkmann) programmed to maintain a pH of 8.0 using 0.1 N NaOH. The substrate mixture (pH 8) contained 1 mM taurochenodeoxycholate (Sigma), 9 mM taurodeoxycholate (Sigma), 0.1 mM cholesterol (Sigma), 1 mM phosphatidylcholine (Sigma), 1.5% BSA, 2 mM Tris base, 100 mM NaCI, 10 mM CaCI2, and 3% triolein (Sigma). The mixture (5 mL) was emulsified via sonication at room temperature, and added to the titration vessel with rapid stirring. The Stat Titrino was turned on and lipase (7.0 nM type VI-S porcine pancreatic lipase (Sigma) dissolved in PBS) was added to the vessel. After 10 min, inhibitor (700 nM dissolved in 100% DMSO) was added and the reaction continued for an additional 12.5 min. The k values were determined for the 12.5 min after the addition of the inhibitor using a one phase exponential association equation, Y=Ymax(1-exp(-k*X)), k values for lipase alone were 0.0004 ± 0.0001 sec. The k values for compounds disclosed herein are >0.0004 ± 0.0001 sec. Equivalents Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, many equivalents to specific embodiments of the invention described specifically herein. Such equivalents are intended to be encompassed in the scope of the following claims. WE CLAIM: 1. A compound having the structure: (Formula Removed) wherein, X is O, S, or CH2; Y is O or S; R1 is H, substituted CI-C15 alkyl, unsubstituted C2-C15 alkyl, C1-C8 alkylaryl, -C(0)OR4, -C(0)NR,R,, -CR„R„ OR,,, -CR6R6 OC(0)R4, CR6R6OC(0)NHR7, -QCONR8R9, NR8R9, -N(R5)C(0)NHR5, or CH9R4; R2 is a substituted or unsubstituted, straight chainC1-C30 alkyl or branched C3-C30 alkyl, aryl, alkylaryl, arylalkyi, hclcroarylalkyi or cycloalkyl; and R3 is H, -CH3, -CI I2OCI l3 or C,-CK, cycloalkyl, wherein R4 is H or a substituted or unsubstituted, straight chain or branched, C6-C30 alkyl, aryl, -CII2-aryl, aryl -C\|-C«> alkyl, heteroaryl-C1-C30alkyl or C3-C10 cycloalkyl; R5 is H or a substituted or unsubstituted, straight chain or branched, C6-C30 alkyl, aryl C1-C30 alkyl, heteroarylalkyl or cycloalkyl; R6 and R6' are each independently H, substituted or unsubstituted C1-C6 alkyl, dialkyl or C3-C10 cycloalkyl or together form a 3-7 membered cycloalkyl or aryl group; R7 is H or substituted or unsubstituted C1-C12 alkyl or C3-C10 cycloalkyl; and Rg and R9 are each independently H, substituted or unsubstituted C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylaryl, or NR8R9 together form a substituted piperazine or piperidine ring or a dihydro-lH-isoquinoline ring system, or a specific enantiomer thereof, or a specific tautomer, or a pharmaceutically acceptable salt thereof. 2.The compound as claimed in claim 1, having the structure: (Structure Removed) wherein, XisOorS; R1 is H, -C(0)OR4, -C'(0)NR„Rs, -( R„R()OR,, -C R„R(,-OC(0)R4, -CR6R6-OC(0)NHR7, or CH2R4; R2 is a substituted or unsubstiluled, straight chain or branched C6-C30 alkyl, arylalkyl, heteroarylalkyl or cycloalkyl; and R3 is H, -CH3, -CH2OH3, or C3-C10 cycloalkyl, wherein, R4 is H or a substituted or unsubstiluled, straight chain or branched, C6-C30 alkyl, arylalkyl, heteroarylalkyl or cycloalkyl; R5 is H or a substituted or unsubstiluled, straight chain or branched, C6-C30 alkyl, arylalkyl, heteroarylalkyl or cycloalkyl; R6 and R6' are each independently H, substituted or unsubstituted C1-C6 alkyl, dialkyl or cycloalkyl or together form a 3-7 membered cycloalkyl or aryl group; and R7 is H or substituted or unsubstituted C1-C12 alkyl or cycloalkyl. 3.The compound as claimed in claim 2, wherein X is O; R1 is -C(0)0-(C6-C30) alkyl, -C(0)NH-(C6-C30) alkyl or -C(0)OCH2(C6H5); R2 is C6-C30 alkyl; and (Structure Removed) The compound as claimed in claim 2, wherein R3 is H or -CH3. 5. The compound as claimed in claims 3 or 4, wherein X is O. 6.The compound as claimed in claims 3 to 5, wherein R3 is methyl. 7. The compound as claimed in claim 1, having the structure: (Structure Removed) wherein, Y is O or S; R, is 1-1, -(CH2)rCH3, -CH(CH3)2, -CH(CH3)CH2C(CH3),, -CH(CH3)(CH2)3C(=CH2)CI I3, -CH(CH)(CH2)3C(CH3)20C(0)CH3, -CH(CH3)[CH2]3C(CH3)2OCH3, -CHS(C6H5), -C(0)OH, -C(0)NH(CH2)tCH3,-C(0)0(CH2)uCH3, -C(0)OCH[(CH2)3CH3]2,-C(0)NH(CH2)vCH3, -C(0)N(CH3)2, -C(0)NHCH2(C6H5), -C(0)NHCH2(C5H4N),-C(0)N[(CH2)3CH3]2, -C(0)N[(CH2)5CH3]2, -C(0)N[(CH2)7CH3]2, -C(0)NH(C6Hn), -C(0)(NC4HgN)CH2(C6H5),-C(0)(NC5H9)CH2(C6H5), -C(0)NH(CH2)30(C6H5))-C(0)NHCH[(CH2)3CH3]2, -C(0)NH(CH2)3N(CH3)2,-C(0)NHCH2C(0)OCH2(C6H5), -e(0)N(CH3)CH2(C5H3N[CH3]),-C(0)NH(CH2)2(C5H4N), -C(0)N(CH2CH3)(CH2)2(C5H4N),-C(0)NHCH2(C4H30), -C(0)(NC4H8N)[CH2]2(NC5H10),-C(0)NHCH2CH(CH3)2, -C(0)NHCH2(C5H4N),-C(0)NHCH2C(CH3)3, -C(0)(NC4H8N)CH2C(0)NHCH(CH3)2,-C(0)(NC9H8)[OCH3]2, -C(0)NHCH2(C6H3[OCH3]2), -C(0)NHCH2(C7H502), -C(0)NH(CH2)20(C6H5),-C(0)NH(CH2)20CH3) -C(0)NH(CH2)3OCH3, -C(0)NH(CH2)4(C6H5), or -C(0)NH(CH2)3(CH5); r is an integer from 1 to 15; s is an integer from 0 to 6; t is an integer from 0 to 6; u is an integer from 3 to 8; v is an integer from 5 to 15; XR2 is -(CH2)nCH3 -O(CH2)mCH3, -OCH(CH3)2 -OCH(CH3)(CH2)5CH3 -OCH2;CH(CH3)2, -O(CH2) 2 OCH3.. -0(CH2)20CH2(C6H5), -0(C'I l2)n(C6H5), -OC'H3(C6H4](CH2)3CH3), -0(CH4\|(CH2)3CH3]), -0(CH2)2(6H4](CH3])), -0(CH2)3OCH2(C6H5) or -0(CH2)4OCH2(C6H5); n is an integer from 6 to 15; m is an integer from 1 to 15; p is an integer from 0 to 6; and R3 is H, -CH3 or -CH2OCH3. 8. The compound as claimed in claim 7, having the structure: (Structure Removed) wherein, Y is O or S; R, is H, -(CH2)3CH3, -(CH,)SCH3, -(CH2)6CH3, -(CH2)7CH3, -(CH2)9CH3, -(CH2),,CH3, -CH(CH3)2, -CH(CH3)CH2C(CH3)3, -CH(CH3)(CH2)3C(=CH2)CH3, -CH(CH3)(CH2)3C(CH3)20C(0)CH3, -CH(CH3)[CH2l3C(CH3)20CH3, -CH2(C6H5), -(CH2)2(C6H5), -(CH2)3(C6H5), -(CH2)4(C6H5), -(CH2)5(C6H5), -C(0)OH, -C(0)NHCH3, -C(0)NHCH2CH3, -C(0)NH(CH2)3CH3, -C(0)OCH2(C6H5), -C(0)0(CH2)5CH3, -C(0)0(CH2)6CH3) -C(0)0(CH2)7CH3, -C(0)OCH[(CH2)3CH3]2, -C(0)NH(CH2)5CH3, -C(0)NH(CH2)7CH3, -C(0)NH(CH2)9CH3, -C(0)NH(CH2)i 1CH3, -C(0)NH(CH2)\|5CH3, -C(0)N(CH3)2, -C(0)NHCH2(C6H5), -C(0)NHCH2(C5H4N),-C(0)N[(CH2)3CH3]2, -C(0)N[(CH2)5CH3]2, -C(0)N[(CH2)7CH3]2, -C(0)NH(C6H„), -C(0)(NC4H8N)CH2(C6H5),-C(0)(NC5H9)CH2(C6H5), -C(0)NH(CH2)30(C6H5),-C(0)NHCH[(CH2)3CH3]2, -C(0)NH(CH2)3N(CH3)2,-C(0)NHCH2C(0)OCH2(C6H5), -C(0)N(CH3)CH2(C5H3N[CH3]),-C(0)NH(CH2)2(C5H4N), -C(0)N(CH2CH3)(CH2)2(C5H4N),-C(0)NHCH2(C4H30), -C(0)(NC4H8N)[CH2]2(NC5H,o), -C(0)NHCH2CH(CH3)2, -C(0)NHCH2(C5H4N),-C(0)NHCH2C(CH3)3, -C(0)(NC4H8N)CH2C(0)NHCH(CH3)2,-C(0)(NC9H8)[OCH3]2, -C(0)NHCH2(C6H3[OCH3]2),-C(0)NHCH2(C7H502), 2-Octyloxy-6-(3-phenyl-propyl)-thieno[2,3-d][ 1,3]oxazin-4-one; 2-Octyloxy-6-(4-phenyl-butyl)-thieno[2,3-d][ 1,3]oxazin-4-one; 2-Octyioxy-6-(5-phenyl-pentyI)-thieno[2,3-d][l,3]oxazin-4-one; 6-Decyl-2-(2-methoxy-ethoxy)-thieno[2,3-d][ 1,3]oxazin-4-one; 2-(4-Butyl-phenoxy)-6-decyl-thieno[2,3-d\|[l,3]oxazin-4-one; 2-(3-Benzyloxy-propoxy)-6-decyl-thieno[2,3-d \|[ 1,3 joxazin-4-one; 2-(3-Benzyloxy-butyloxy)-6-decyl-thieno(2,3-d II1,3 \|oxazin-4-onc; 6-Isopropyl-2-octyloxy-thieno[2,3-d \|[ 1,3 \|oxazin-4-onc; 6-Octyl-2-octyloxy-thieno[2,3-d\|\| 1,3 \|oxa/.in-4-one; 6-Dodecyl-2-octyloxy-thieno[2,3-d \|\| 1,3 \|oxazin-4-one; 2-Benzyloxy-6-Decyl-thieno[2,3-d \|\| 1,3 \|oxazin-4-one; 2-(4-Butylbenzyloxy)-6-Decyl-lhicno[2,3-d\|l 1,3\|oxazin-4-one; 6-Decyl-2-(2-p-tolyl-ethoxy)-thienol2,3-d\|[I,3]oxazin-4-one; 6-Decy 1-2-phenethy loxy-th ieno( 2,3 -d \| [ 1,3 joxazin-4-one; 3-Methyl-6-octyl-2-octyloxy-5U-thieno[2,3-b]pyridin-4-one; 2-Butoxy-6-octyl-5H-thieno[2,3-b\|pyridin-4-one; 2-Hexyloxy-6-octyl-5H-thieno[2,3-b\|pyridin-4-one; 2-Dodecyloxy-6-octyl-5H-thieno[2,3-b]pyridin-4-one; 6-Decyl-2-phenoxy-5H-thieno[2,3-b]pyridin-4-one; 2-Decyloxy-6-octyl-5H-thieno[2,3-b]pyridin-4-one; 6-Benzyl-2-octyloxythieno[2,3-t/][l,3]oxazin-4-one; 6-Decyl-2-octyloxythieno[2,3-d][l,3]oxazin-4-one; 6-Decyl-2-(l-methylheptyloxy)thieno[2,3-d][l,3]oxazin-4-one; 6-Heptyl-2-( 1 -methylheptyloxy)thieno[2,3-d][l ,3]oxazin-4-one; 6-Decyl-2-(4-phenylpropoxy)thieno[2,3-t/][l,3]oxazin-4-one; and 6-Decyl-2-(4-phenylbutoxy)thieno[2,3-c/][l,3]oxazin-4-one. 10. A compound having the structure: (Structure Removed) wherein, Y is O; XR2is -N([CH2]7CH,)C(0)NI I(CH2)7CH3, -N([CH2J6CH3)C(0)NH(CH3)()CH3, -NH(CH2)qCH3, -NH(C6H4)0(C6H5), -N(CH3)(CH2)5CH3, -NHCH[(CH2)3CH3]2, -NHCH(CH3)[CH2]5CH3, or -N([CH2]7CH3)2; q is an integer from 6 to 15; Ri is H, substituted C1-C15 alkyl, or unsubstituted C2-C15 alkyl, C1-C8 alkylaryl, -C(0)OR4, -C(0)NR4R5, -CR6R6OR4, -CR6R60C(0)R4, CR6R60C(0)NHR7, -C(0)NRgR9NR8R9, -N(R5)C(0)NHR5, or CH2R4; R3 is H, -CH3, -CH2OCH3 or C3-C10 cycloalkyl, wherein R4 is H or a substituted or unsubstituted, straight chain or branched, C6-C30 alkyl, aryl, -CH2-aryl, aryl -C1-C30 alkyl, heteroaryl-C1-C30alkyl or C3-C10 cycloalkyl; R6 and R6- are each independently H, substituted or unsubstituted C1-C6 alkyl, dialkyl or C3-C10 cycloalkyl or together form a 3-7 membered cycloalkyl or aryl group; R7 is H or substituted or unsubstituted C1-C12 alkyl or C3-C10 cycloalkyl; and R8 and R9 are each independently H, substituted or unsubstituted C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylaryl, or NR8R9 together form a substituted piperazine or piperidine ring or a dihydro-1 H-isoquinoline ring system, or a specific enantiomer thereof, or a specific tautomer, or a pharmaceuticaliy acceptable salt thereof. 11. The compound as claimed in claim 10 having the structure: (Structure Removed) wherein, R1 is H, -(CH2)rCH3, -CH(CH3)2, -CH(CH3)CH2C(CH,)3, -CH(CH3)(CH2)3C(=CH2)CH3, -CH(CH3)(CH2)3C(CH3)2OC(0)CH3, -CH(CH3)[CH2J3C(CH3)2OCH3, -CHs(C6H5), -C(0)OH, -C(0)NH(CH2)tCH3, -C(0)0(CH2)uCH3, -C(0)OCH[(CH2)3CH3]2, -C(0)NH(CH2)vCH3, -C(0)N(CH3)2, -C(0)NHCH2(C6H5), -C(0)NHCH2(C5H4N), -C(0)N[(CH2)3CH3]2, -C(0)N[(CH2)5CH3]2, -C(0)N[(CH2)7CH3]2, -C(0)NH(C6Hn), -C(0)(NC4H8N)CH2(C6H5), -C(0)(NC5H9)CH2(C6H5), -C(0)NH(CH2)30(C6H5), -C(0)NHCH[(CH2)3CH3]2, -C(0)NH(CH2)3N(CH3)2, -C(0)NHCH2C(0)OCH2(C6H5), -C(0)N(CH3)CH2(C5H3N[CH3]), -C(0)NH(CH2)2(C5H4N), -C(0)N(CH2CH3)(CH2)2(C5H4N), -C(0)NHCH2(C4H30)7 -C(O)(NC4H8N)[CH2]2(NC5H10), -C(0)NHCH2CH(CH3)2, -C(0)NHCH2(C5H4N), -C(0)NHCH2C(CH3)3, -C(0)(NC4H8N)CH2C(0)NHCH(CH3)2, -C(0)(NC9Hg)[OCH,]2, -C(0)NHCH2(C6H3[OCI I3I2), -C(0)NHCH2(C7Hs02), -C(0)NH(CH2)20(C6H5), -C(0)NH(CH2)2OCH3, -C(0)NH(CH2)3OCH3, -C(0)NH(CH2)4(C6H5), or -C(0)NH(CH2)3(C6H5); r is an integer from 1 to 15; s is an integer from 0 to 6; t is an integer from 0 to 6; u is an integer from 3 to 8; v is an integer from 5 to 15; XR2is -N([CH2]7CH3)C(0)NH(CH2)7CH3, -N([CH2]6CH3)C(0)NH(CH2)6CH3, -NH(CH2)qCH3, -NH(C6H4)0(C6H5), -N(CH3)(CH2)5CH3, -NHCH[(CH2)3CH3]2, -NHCH(CH3)[CH2]5CH3, or -N([CH2]7CH3)2; q is an integer from 6 to 15; and R3 is H, -CH3, -CH2OCH3 or C3-C10 cycloalkyl. 12. The compound as claimed in claim 11, having the structure: (Structure Removed) wherein, R, is H, -(CH2)3CH3, -(CH2)sCH3, -(CH2)6CH3, -(CH2)7CH3) -(CH2)9CH3, -(CH2),,CH3, -CH(CH3)2, -CH(CH3)CH2C(CH3)3, -CH(CH3)(CH2)3C(=C H2)C H3, -CH(CH3)(CH2)3C(CH3)20C(0)CH3, -CH(CH3)[CH2]3C(CH3)20CH3, -CH2(C6H5), -(CH2)2(C6H5), -(CH2)3(C6H5), -(CH2)4(C6H5), -(CH2)5(C6H5), -C(0)OH, -C(0)NHCH3, -C(0)NHCH2CH3, -C(0)NH(CH2)3CH3, -C(0)OCH2(C6H5), -C(0)0(CH2)5CH3, -C(0)0(CH2)6CH3, -C(0)0(CH2)7CH31, -C(0)OCH[(CH2)3CH3\|2, -C(0)NH(CM2)sCH3t, -C(0)NM(CH2)7Cllt, -C(0)NH(CII2)yCH3, -C(0)NH(CH2)2CH3,, -C(0)NH(CH2)isCH3, -C(0)N(CH3)2, -C(0)NHCH2(C6H5). -C(0)NHCH2(C5H4N), -C(0)N\|(CH2)3CH32, -C(0)N[(CH2)5CH3]2, -C(0)N[(CH2)7CH,\|2, -C(0)NH(C6H,,), -C(0)(NC4H8N)CH2(C6H5), -C(0)(NCSH9)CH2(C6H5), -C(0)NH(CH2)30(C6H5), -C(0)NHCH[(CH2)3CH3]2, -C(0)NH(CH2)3N(CH3)2, -C(0)NHCH2C(0)OCH2(C6H5), -C(0)N(CH3)CH2(C5H3N[CH3]), -C(0)NH(CH2)2(C5H4N), -C(0)N(CH2CH3)(CH2)2(C5H4N), -C(0)NHCH2(C4H30), -C(O)(NC4H8N)[CH2]2(NC5HI0), -C(0)NHCH2CH(CH3)2, -C(0)NHCH2(C5H4N), -C(0)NHCH2C(CH3)3, -C(0)(NC4H8N)CH2C(0)NHCH(CH3)2, -C(0)(NC9H8)[OCH3]2, -C(0)NHCH2(C6H3[OCH3]2), -C(0)NHCH2(C7H502), -C(0)NH(CH2)20(C6H5), -C(0)NH(CH2)2OCH3, -C(0)NH(CH2)3OCH3, -C(0)NH(CH2)4(Cl,Hs), or -C(0)NH(CH2),(C()Hs); XR2 is -N([CH2j7CH3)C(0)NII(CH2)7CH3 -N([CH2]6CH3)C(())NH(CH!)(,CHl, -NH(CH2)()CCH3, -NH(CH2)7CH3, -NH(CH2)CH3, -NH(CH2),13CH,, -NH(CH2),sCH,, -NH(C6H4)0(C6H5), -N(CHj)(CII2)5CH3, -NHCH[(CII2)3CH,]2, -NHCI l(CI l3)[CH2\|5CH3, or -N([CH2]7CH3)2; and R3 is H, -CH3 or -CH2OCH3. 13. The compound as claimed in any one of claims 1 to 12, wherein any heterocyclic or heteroaryl ring, if present, is a piperazine, piperidine, (l,4)diazepan, pyrazine, pyridine, pyrrolidine, pyrazole, pyrimidine, thiophene, imidazole, azetidine, pyrrole, benzothiazole, benzodioxolane, dithiolane, oxathiine, imidazolidine, quinoline, isoquinoline, dihydroisoquinoline, indole, isoindole, triazaspiro[4.5]decane, morpholine, furan or an isothiazole ring. 14. The compound as claimed in any one of claims 1 to 12, wherein any substituent, if present, is halogen, hydroxyl, straight chain (C1-C30)alkyl, branched chain (C3- C30)alkyl, (C3-C10)cycloalkyl, straight chain(C1-C30)alkylcarbonyloxy, branched chain (C3-C30)alkylcarbonyloxy, arylcarbonyloxy, straight chain(C1-C30)alkoxycarbonyloxy, branched chain(C3-C3o)alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, straight chain(C1-C30)alkylcarbonyl, branched chain (C3-C30)alkylcarbonyl, straight chain (C1- C3o)alkoxycarbonyl, branched chain (C1-C30)alkoxycarbonyl, aminocarbonyl, straight chain (C1-C30)alkylthiocarbonyl, branched chain (CVC\to)alkylthiocarbonyl, straight chain (C1-C30)alkoxyl, branched chain (C1-C30)alkoxyl, phosphate, phosphonato, cyano, amino, straight chain (C1-C30)alkylamino, branched chain ((.VC'm)alkylamino, straight chain (Cj-C3o)dialkylamino, branched chain (C3-C30)dialkylamino, arylamino, diarylamino, straight chain (C1-C30)alkylarylarhino, branched chain (C3- C3o)alkylarylamino, acylamino, straight chain (C1-C30)alkylearbonylamino, branched chain (C3-C30)alkylcarbonylamino, arylcarbonylamino, carbamoyl, urcido, amidino, imino, sulfhydryl, straight chain (C1-C30))alkylthio, branched chain (C1-C30)alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sullamoyl, sullbnamido, nitro, trifluoromethyl, azido, 4-10 membered hetcrocyclyl, straight chain (C1-C30)alkylaryl, branched chain (C3-C30)alkylaryl, benzo( l,3)dioxole, or an aromatic or 5-6 membered heteroaromatic moiety, which substituent may be further substituted by any of the above. 15. An in vitro method of inhibiting the hydrolytic activity of pancreatic lipase enzymes in a cell, comprising contacting the cell with an amount of the compound of any one of claims I, 2, 7, 8, 10, 11 or 12 which is effective in inhibiting the hydrolytic activity of pancreatic lipase enzymes. 16.A process of manufacturing a compound having the structure: (Structure Removed) wherein, X is O, S or CH2; R1 is H, substituted C1-C15 alkyl, unsubstituted C2-C15 alkyl, C1-C8 alkylaryl, -C(0)OR4, -C(0)NR4R5, -CR6R6 OR,, -CR6R6, OC(0)R4, -CR6R6 OC(0)NHR7, -C(0)NR8R9, -C(0)NR8R9NR8R9, -N(R5)C(0)NHR5, or CH2R4; R2 is a substituted or unsubstituted, straight chain C1-C30 alkyl or branched C3-C30 alkyl, aryl, alkylaryl, arylalkyl, heteroarylalkyi or cycloalkyi; R3 is H, -CH3, -CH2OCH3 or cycloalkyi; R4 is H or a substituted or unsubstituted, straight chain or branched, C6-C30 alkyl, aryl, -CH2-aryl, arylalkyl, heteroarylalkyi or cycloalkyi; R5 is H or a substituted or unsubstituted, straight chain or branched, C6-C30 alkyl, arylalkyl, heteroarylalkyi or cycloalkyi; R6 and R6 are each independently H, substituted or unsubstituted C1-C6 alkyl, dialkyl or cycloalkyi or together form a 3-7 membered cycloalkyi or aryl group; R7 is H or substituted or unsubstituted C1-C12 alkyl or cycloalkyi; R8 and R9 are each independently H, substituted or unsubstituted C1-C6 alkyl, C1-C6 alkoxy, C\|-C6 alkylaryl, or NR8R9 together form a substituted piperazine or piperidine ring or a dihydro-lH-isoquinoIine ring system, or XR2is -N([CH2]7CH3)C(0)NH(CH2)7CH3, -N([CH2]6CH3)C(0)NH(CH2)6CH3, -NH(CH2)qCH3, -NH(C6H4)0(C6H5), -N(CH3)(CH2)5CH3, -NHCH[(CH2)3CH3]2, -NHCH(CH3)[CH2]5CH3, or -N([CH2]7CH3)2; q is an integer from 6 to 15; R1 is H, substituted or unsubstituted C1-C15 alkyl, or unsubstituted C2-C15 alkyl, C1- C8 alkylaryl, -C(0)OR4, -C(0)NR4R5, -CR6R6OR4, -CR6R6 OC(0)R4, - CR6R6 OC(0)NHR7, -C(0)NR8R9, -C(0)NR8R9NR8R9, -N(R5)C(0)NHR5, or CH2R4; R2 is a substituted or unsubstituted, straight chain C1-C30 alkyl or branched C3-C30 alkyl, aryl, alkylaryl, arylalkyl, heteroarylalkyl or cycloalkyl; R3 is H or substituted or unsubstituted C\|-C6 alkyl-CH3, -CH2OCH3 or cycloalkyl; R4 is H or a substituted or unsubstituted, straight chain or branched, C6-C30alkyl, aryl, -CH2-aryl, arylalkyl, heteroarylalkyl or cycloalkyl; R5 is H or a substituted or unsubstituted, straight chain or branched, C6-C30 alkyl, aryl C1-C30 alkyl, heteroarylalkyl or cycloalkyl; R6 and R6- are each independently H, substituted or unsubstituted C1-C6 alkyl, dialkyi or cycloalkyl or together form a 3-7 membered cycloalkyl or aryl groupring system; R7 is H or substituted or unsubstituted C1-C12 alkyl or cycloalkyl; R8 and R9 are each independently H, substituted or unsubstituted C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylaryl, or NR8R9 together form a substituted piperazine or piperidine ring or a dihydro-lH-isoquinoline ring system, comprising (a) reacting (Structure Removed) in the presence of sulfur, a base and solvent to produce: (Structure Removed) (b) reacting the product of step (a) with (Structure Removed) in the presence of a base to produce: (Structure Removed) (c) reacting the product of step (b) with trifluoroacetic acid (TFA) in the presence of solvent to produce: (Structure Removed) (d) reacting the product of step (c) with SOCI2 in the presence of solvent to produce the compound. 17. The process as claimed in claim 16, wherein the intermediates having the structure: (Structure Removed) wherein, R10 is H or substituted or unsubstituted C1-C15 alkyl, C1-C15 alkylaryl, or -C(0)R14, wherein R11 is hydroxyl, or a substituted or unsubstituted C1-C30 alkyl, alkylamino, dialkylamino, alkoxy, benzyloxy, cycloalkyl, alkylheteroaryl, alkylaryl, or a heterocyclic, heteroaryl or aryl ring; R11 is hydrogen or methyl; R12 is hydrogen or tert/-butyl; and R11 is hydrogen or -C(0)ZR15, wherein Z is CH2, O or N and R15 is substituted or unsubstituted C1-C15 alkyl or aryl. 18. The process as claimed in claim 16, wherein the base in step (a) is triethyl amine and the solvent is dimethylformamide (DMF). 19. The process as claimed in claim 16 or 18, wherein the solvent in step (c) is dichloromethane. 20. The process as claimed in claim 16 or 19, wherein the solvent in step (d) is pyridine:CH2Cl2.

Full Text

PANCREATIC LIPASE INHIBITOR
COMPOUNDS. THEIR SYNTHESIS AND USE
This application claims priority of U.S. Provisional Application No. 60/342,617, filed
December 20, 2001, and U.S. Provisional Application No. 60/357,015, filed February
13, 2002, the entire contents of which are hereby incorporated by reference.
Throughout this application, various publications are referenced by full citations. The
disclosures of these publications in their entireties are hereby incorporated by
reference into this application in order to more fully describe the state of the art as
known to those skilled therein as of the date of the invention described and claimed
herein.
Background of the Invention
During the last 20 years, obesity has become an increasingly common problem in
the populations of developed countries. The increased incidence of obesity is partly
due to the adoption of a westernised diet in many developed countries - which
contains many foods with high fat and low fiber concentrations - and partly due to the
lifestyle of westernized society. Obesity is known to increase the risk of contracting
disorders such as diabetes, cardiovascular disease and hypertension.
Pharmacological approaches to the treatment of obesity either try to increase the
body's energy expenditure, thereby burning more fat, or reduce the body's energy
intake. The latter approach has stimulated the development of a variety of drugs
which attempt to reduce the body's ability to absorb fat. These drugs target the
enzymes responsible for the digestion of fat in the human digestive cycle. The most
important enzymes in the digestion of fat are hydrolytic enzymes. The most
significant of these enzymes are lipases, pancreatic lipase in particular. Orlistat, a
derivative of lipstatin, a lipase inhibitor, is disclosed as an anti-obesity drug in
European Patent Application No. EP129748. Other lipase inhibitors are disclosed in
PCT International Publication Nos. WO 00/40569 and WO 00/40247, respectively.
Summary of the Invention
The subject invention provides a compound having the structure:
wherein,
X is O, S, CH2 or NR5;
Y is O or S;
R! is H, substituted or unsubstituted d-Cis alkyl, CrC8 alkylaryl,
-C(0)OR4, -C(0)NR4R5, -CReRe-ORA, -CReReOC(O)R4, -CR6R6-OC(O)NHR7l
-C(O)NR10Rn, -C(O)NR8R9 NR8R9, -N(R5)C(O)NHR5, or CH2R4;
R2 is a substituted or unsubstituted, straight chain CrCao alkyl or
branched C3-C30 alkyl, aryl, alkylaryl, arylalkyi, heteroarylalkyl or cycloalkyl;
and,
R3 is H or substituted or unsubstituted CrCe alkyl or C3-Cio
cycloalkyl,
wherein
R4 is H or a substituted or unsubstituted, straight chain or
branched, C6-C30 alkyl, aryl, -CH2-aryl, aryl -CrC3o alkyl,
heteroaryl-Ci-C30 alkyl or C3-Cio cycloalkyl;
Rs is H or a substituted or unsubstituted, straight chain or
branched, Ce-C3o alkyl, aryl Ci-C30alkyl, heteroarylalkyl or
cycloalkyl;
Re and R6- are each independently H, substituted or
unsubstituted d-C6 alkyl, dialkyl or C3-Ci0 cycloalkyl or together
form a 3-7 membered ring system;
R7 is H or substituted or unsubstituted Ci-Ci2 alkyl or C3-
C10 cycloalkyl; and
R8 and Rg are each independently H, substituted or
unsubstituted d-Ce alkyl, CrC6 alkoxy, CrC6 alkylaryl, or
NR8Rg together form a substituted piperazine or piperidine ring
or a dihydro-1H-isoquinoline ring system,
or a specific enantiomer thereof, or a specific tautomer, or a
pharmaceutically acceptable salt thereof.
The subject invention also provides a compound having the structure:
Q
wherein,
Rio is H or substituted or unsubstituted Ci-Ci5 alkyl, d-Ci5
alkylaryl, or -C(O)R14,
wherein R14 is hydroxyl, or a substituted or unsubstituted
CrCso alkyl, alkylamino, dialkylamino, alkoxy, benzyloxy, cycloalkyl,
alkylheteroaryl, alkylaryl, or a heterocyclic, heteroaryl or aryl ring;
Rn is hydrogen or methyl;
R12 is hydrogen or fert-butyl; and
Ria is hydrogen or -C(O)ZRi5,
wherein Z is CH2, O or N and R15 is substituted or
unsubstituted CrCi5 alkyl or aryl.
The subject invention also provides a method for treating obesity in a subject in
need of such treatment, comprising administering to the subject a therapeutically
effective amount of a compound of the invention so as to thereby treat obesity in
the subject.
The subject invention also provides a method for treating diabetes in a subject in
need of such treatment, comprising administering to the subject a therapeutically
effective amount of a compound of the invention so as to thereby treat diabetes in
the subject.
The subject invention also provides a method of inhibiting the hydrolytic activity of
pancreatic lipase enzymes in a cell, comprising contacting the cell with an
amount of a compound of the invention which is effective in inhibiting the
hydrolytic activity of pancreatic lipase enzymes.
Detailed Description
The subject invention provides compounds having the structure:
o
wherein,
X is O, S, CH2 or NR5;
YisOorS;
RI is H, substituted or unsubstituted CrCi5 alkyl, CrC8 alkylaryl,
-C(O)OR4l -C(O)NR4R5, -CR6R6-OR4) -CR6R6'OC(O)R4, -CR6R6'OC(O)NHR7,
-C(O)NRioRn, -C(O)NR8R9NR8R9, -N(R5)C(O)NHR5l or CH2R4;
R2 is a substituted or unsubstituted, straight chain Ci-C30 alkyl or
branched C3-C3o alkyl, aryl, alkylaryl, arylalkyi, heteroarylalkyl or cycloalkyi;
and
RS is H or substituted or unsubstituted d-Ce alkyl or Cs-Cio
cycloalkyi,
wherein
R4 is H or a substituted or unsubstituted, straight chain or
branched, C6-C30 alkyl, aryl, -CH2-aryl, aryl -CrC3oalkyl,
heteroaryl-CrCao alkyl or C3-Cio cycloalkyi;
R5 is H or a substituted or unsubstituted, straight chain or
branched, C6-C3o alkyl, aryl CrC30alkyl, heteroarylalkyl or
cycloalkyi;
R6 and R6- are each independently H, substituted or
unsubstituted CrC6 alkyl, dialkyl or C3-Ci0 cycloalkyi or together
form a 3-7 membered ring system;
R7 is H or substituted or unsubstituted CrCi?. alkyl or C3-
Cio cycloalkyi; and
R8 and R9 are each independently H, substituted or
unsubstituted CrC6 alkyl, d-Ce alkoxy, CrC6 alkylaryl, or
NRaRg together form a substituted piperazine or piperidine ring
or a dihydro-1 H-isoquinoline ring system,
or a specific enantiomer thereof, or a specific tautomer, or a
pharmaceutically acceptable salt thereof.
In one embodiment, the compound has the structure:
O
wherein,
X is O, S or NR5;
Y is O or S;
R1 is H, -C(O)OR4, -C(O)NR4R5, -CR6R6'OR4, -CR6R6'OC(O)R4,
-CR6R6OC(O)NHR7, or CHaR-iI
Ra is a substituted or unsubstituted, straight chain or branched,
C6-C3o alkyl, arylalkyl, heteroarylalkyl or cycloalkyi; and
R3 is H or substituted or unsubstituted Ci-C6 alkyl or cycloalkyi,
wherein,
R4 is H or a substituted or unsubstituted, straight chain or
branched, Ce-Cao alkyl, arylalkyl, heteroarylalkyl or cycloalkyi;
RS is H or a substituted or unsubstituted, straight chain or
branched, C$-C30 alkyl, arylalkyl, heteroarylalkyl or cycloalkyi;
Re and R6' are each independently H, substituted or
unsubstituted Cr.CB alkyl, dialkyl or cycloalkyi or together form a
3-7 membered ring system; and
R7 is H or substituted or unsubstituted CrCi2 alkyl or
cycloalkyi.
In a further embodiment, the compound has the structure:
o
wherein,
X is O, S or NR5;
Ri is H, -C(O)OR4l -C(O)NR4R5, -CR6R6'OR4, -CR6R6OC(O)R4,
-CR6R6'OC(O)NHR7, or CH2R4;
R2 is a substituted or unsubstituted, straight chain or branched
C6-C3o alkyl, arylalkyl, heteroarylalkyl or cycloalkyi; and
R3 is H or substituted or unsubstituted CrCe alkyl or cycloalkyi,
wherein,
R4 is H or a substituted or unsubstituted, straight chain or
branched, C6-C30 alkyl, arylalkyl, heteroarylalkyl or cycloalkyi;
R5 is H or a substituted or unsubstituted, straight chain or
branched, Ce-Cso alkyl, arylalkyl, heteroarylalkyl or cycloalkyi;
R6 and R6' are each independently H, substituted or
unsubstituted CrC6 alkyl, dialkyi or cycloalkyi or together form a
3-7 membered ring system; and
R7 is H or substituted or unsubstituted CrCi2 alkyl or
cycloalkyi.
In a further embodiment of the above compound,
X is O or NR5;
R! is -C(O)O-(C6-C30) alkyl, -C(O)NH-(C6-C30) alkyl or
-C(0)OCH2(C6H5);
R2 is C6-C30 alkyl; and
R3 is CrC6 alkyl.
In a further embodiment, R3 is H or CH3.
In a further embodiment, X is O.
In a further embodiment, R3 is methyl.
In a further embodiment, X is N.
In a further embodiment, R3 is methyl.
In a further embodiment, the compound has the structure:
o
SN XR2
wherein,
Y is 0 or S;
Ri is H, -(CH2)rCH3> -CH(CH3)2, -CH(CH3)CH2C(CH3)3,
-CH(CH3)(CH2)3C(=CH2)CH3,
-CH(CH3)(CH2)3C(CH3)2OC(O)CH3,
-CH(CH3)[CH2]3C(CH3)20CH3l -CHs(C6H5), -C(O)OH,
-C(O)NH(CH2)tCH3l-C(O)O(CH2)uCH3,
-C(O)OCH[(CH2)3CH3]2)-C(O)NH(CH2)VCH3,
-C(0)N(CH3)2, -C(O)NHCH2(C6H5),
-C(0)NHCH2(C5H4N),-C(0)N[(CH2)3CH3]2)
-C(0)N[(CH2)5CH3]2, -C(0)N[(CH2)7CH3]2) -C(O)NH(C6Hn),
-C(O)(NC4H8N)CH2(C6H5),-C(O)(NC5H9)CH2(C6H5),
-C(0)NH(CH2)30(C6H5),-C(O)NHCH[(CH2)3CH3]2,
-C(0)NH(CH2)3N(CH3)2,-C(O)NHCH2C(0)OCH2(C6H5),
-C(0)N(CH3)CH2(C5H3N[CH3])1-C(0)NH(CH2)2(C5H4N))
-C(0)N(CH2CH3)(CH2)2(C5H4N),-C(0)NHCH2(C4H30),
-C(O)(NC4H8N)[CH2]2(NC5H10),-C(O)NHCH2CH(CH3)2)
-C(0)NHCH2(C5H4N),-C(0)NHCH2C(CH3)3,
-C(O)(NC4H8N)CH2C(O)NHCH(CH3)2,-C(O)(NC9H8)[OCH3]2,
-C(0)NHCH2(C6H3[OCH3]2), -C(O)NHCH2(C7H5O2),
-C(O)NH(CH2)2O(C6H5),-C(O)NH(CH2)2OCH3,
-C(0)NH(CH2)3OCH3, -C(O)NH(CH2)4(C6H5), or
-C(0)NH(CH2)3(C6H5);
r is an integer from 1 to 15;
s is an integer from 0 to 6;
t is an integer from 0 to 6;
u is an integer from 3 to 8;
v is an integer from 5 to 15;
XR2 is -(CH2)nCH3, -O(CH2)mCH3) -OCH(CH3)2,
-OCH(CH3)(CH2)5CH3, -OCH2CH(CH3)2, -O(CH2)2OCH3)
-0(CH2)2OCH2(C6H5), -0(CH2)P(C6H5), -OCH2(C6H4[(CH2)3CH3]),
-0(C6H4[(CH2)3CH3]), -O(CH2)2(C6H4[CH3]), -O(CH2)3OCH2(C6H5),
-O(CH2)4OCH2(C6H5), -N([CH2]7CH3)C(O)NH(CH2)7CH3,
-N([CH2]6CH3)C(O)NH(CH2)6CH3l-NH(CH2)qCH3,
-NH(C6H4)0(C6H5), -N(CH3)(CH2)5CH3, -NHCH[(CH2)3CH3]2,
-NHCH(CH3)[CH2]5CH3, or -N([CH2]7CH3)2;
n is an integer from 6 to 15;
m is an integer from 1 to 15;
p is an integer from 0 to 6;
q is an integer from 6 to 15; and
R3 is H, -CH3 or -CH2OCH3.
In a further embodiment, the compound has the structure:
o
_ XR2
wherein,
Y is O or S;
Ri is H, -(CH2)3CH3) -{CH2)5CH3, -(CH2)6CH3) -(CH2)7CH3,
-(CH2)9CH3l -(CH2)nCH3> -CH(CH3)2, -CH(CH3)CH2C(CH3)3,
-CH(CH3}(CH2)3C(=CH2)CH3,
-CH(CH3)(CH2)3C(CH3)2OC(O)CH3,
-CH(CH3}[CH2]3C(CH3)20CH3, -CH2(C6H5), -(CH2)2(C6H5),
-(CH2)3(C6H5), -(CH2)4(C6H5), -(CH2)5(C6H5), -C(O)OH,
-C(O)NHCH3, -C(O)NHCH2CH3, -C(0)NH(CH2)3CH3l
-C(O)OCH2(C6H5), -C(O)O(CH2)SCH3, -C(O)O(CH2)6CH3,
•€(0)O(CH2)7CH3l-C(O)OCH[(CH2)3CH3]2,
-C(O)NH(CH2)5CH3> -C(O)NH(CH2)7CH3l
-C(0)NH(CH2)9CH3, -C(0)NH(CH2)nCH3)
-C(0}NH(CH2)i5CH3, -C(0)N(CH3)2l -C(O)NHCH2(C6H5),
-C(O)NHCH2(C5H4N),-C(O)N[(CH2)3CH3]2l
-C{0)N[(CH2)5CH3]2, -C(0)N[(CH2)7CH3]2, -C(O)NH(CeHn),
-C(0)(NC4HBN)CH2{C6H5),-C(0)(NC5H9)CH2(C6H5),
-C(O)NH(CH2)3O(C6H5)I-C(0)NHCH[(CH2)3CH3]2l
-C(O)NH(CH2)3N(CH3)2)-C(O)NHCH2C(O)OCH2(C6H5),
-C(0)N(CH3)CH2(C5H3N[CH3]))-C(0)NH(CH2)2(C5H4N)I
-C(O)(NC4H8N)[CH2l2(NC5Hio),-C(0)NHCH2CH(CH3)2l
-C(O)NHCH2(C5H4N)!-C(O)NHCH2C(CHS.)3)
-C(O)(NC4H8N)CH2C(0)NHCH(CH3)2, -C(O)(NC9H8)[OCH332,
-C(O)NHCH2(C6H3[OCH3]2), -C(O)NHCH2(C7H5O2),
-C(O)NH(CH2)20(C6H5)1 -C(O)NH(CH2)2OCH3l
-C(0)NH(CH2)3OCH3l -C(O)NH(CH2)4(C6H5), or
-C(0)NH(CH2)3(C6H5);
XR2 is -(CH2)6CH3, -(CH2)i0CH3l -(CH2)i4CH3,
-0(CH2)3CH3l -0(CH2)5CH3) -O(CH2)6CH3, -0(CH2)7CH3,
-0(CH2)9CH3, -CKCHsOnCHa, -O(CH2)15CH3, -OCH(CH3)2)
-OCH(CH3)(CH2)5CH3l -OCH2CH(CH3)2) -O(CH2)2OCH3,
-0(CH2)2OCH2(C6H5), -0(CH2)4(C6H5), -O(CH2)3(C6H5),
-0(CH2)2(C6H5), -0(CeH5), -OCH2(C6H5),
-OCH2(C6H4[(CH2)3CH3]),-0(C6H4[(CH2)3CH3]),
-0(CH2)J(C6H4[CH3]),-0(CH2)30CH2(C6H5),
-O(CH2)4OCH2(C6H5), -N([CH2]7CH3)C(O)NH(CH2)7CH3>
-N([CH2]6CH3)C(0)NH(CH2)6CH3,-NH(CH2)6CH3)
-NH(CH2)7CH3l -NH(CH2)nCH3) -NH(CH2)i3CH3,
-NH(CH2)i5CH3) -NH(C6H4)0(C6H5), -N(CH3)(CH2)5CH3,
-NHCH[(CH2)3CH3]2, -NHCH(CH3)[CH2]5CH3) or
-N([CH2]7CH3)2; and
R3 is H, -CH3 or -CH2OCH3.
In a further embodiment, the compound is selected from the group consisting of:
6-Heptyl-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one;
6-Hexyl-2-octyloxy-thieno[2,3-d][1)3]oxazin-4-one;
2-Octyloxy-6-(1)3l3-trimethyl-butyl)-thieno[2,3-d][1,3]oxazin-4-one;
6-Butyl-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one;
6-Heptyl-2-octylamino-thieno[2,3-d][1,3]oxazin-4-one;
6-Butyl-2-octylamino-thieno[2,3-d][1,3]oxazin-4-one;
6-Benzyl-2-octylamino-thieno[2,3-d][1,3]oxazin-4-one;
6-Heptyl-2-undecyl-thieno[2,3-d][1,3]oxazin-4-one;
6-(5-Methoxy-1,5-dimethyl-hexyl)-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-
one;
6-( 1.5-Dimethyl-hex-4-enyl)-2-octyloxy-thieno[2:3-d][1,3]oxazin-4-one;
6-(1,5-Dimethyl-hex-5-enyl)-2-octyloxy-thieno[2,3-d][1,31oxazin-4-one;
Trifluoro-acetic acid 1,1-dimethyl-5-(2-octyloxy-4-oxo-4H-thieno[2,3-
d][1,3]oxazin-6-yl)-hexyl ester;
2-(2-Benzyloxy-ethoxy)-6-decyl-thieno[2,3-d][1,3]oxazin-4-one;
6-Heptyl-5-methyl-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one;
6-Methyl-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one;
2-Octyloxy-6-phenethyl-thieno[2,3-d][1,3]oxazin-4-one;
2-Octyloxy-6-(3-phenyl-propyl)-thieno[2,3-d][1,3]oxazin-4-one;
2-Octyloxy-6-(4-phenyl-butyl)-thieno[2,3-d][1,3]oxazin-4-one;
2-Octyloxy-6-(5-phenyl-pentyl)-thieno[2,3-d][1,3]oxazin-4-one;
6-Decyl-2-(2-methoxy-ethoxy)-thieno[2,3-d][1,3]oxazin-4-one;
2-(4-Butyl-phenoxy)-6-decyl-thieno[2,3-d][1,3]oxazin-4-one;
2-(3-Benzyloxy-propoxy)-6-decyl-thieno[2,3-d][1,3]oxazin-4-one;
2-(3-Benzyloxy-butyloxy)-6-decyl-thieno[2,3-d][1,3]oxazin-4-one;
6-lsopropyl-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one;
6-Octyl-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one;
6-Dodecyl-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one;
2-Benzyloxy-6-Decyl-thieno[2,3-d][1,3]oxazin-4-one;
2-(4-Butylbenzyloxy)-6-Decyl-thieno[2,3-d][1j3]oxazin-4-one;
6-Decyl-2-(2-p-tolyl-ethoxy)-thieno[2,3-d][1,3]oxazin-4-one;
6-Decyl-2-phenethyloxy-thieno[2,3-d][1,3]oxazin-4-one;
3-Methyl-6-octyl-2-octyloxy-5H-thieno[2,3-b]pyridin-4-one;
2-Butoxy-6-octyl-5H-thieno[2,3-b]pyridin-4-one;
2-Hexyloxy-6-octyl-5H-thieno[2,3-b]pyridin-4-one;
2-Dodecyloxy-6-octyl-5H-thieno[2,3-b]pyridin-4-one;
6-Decyl-2-phenoxy-5H-thieno[2,3-b]pyridinr4-one;
2-Decyloxy-6-octyl-5H-thieno[2,3-b]pyridin-4-one;
e-Benzyl^-octyloxythieno^.S-cdll.Sloxazin^-one;
6-Decyl-2-octyloxythienot2,3-d][1,3]oxazin-4-one;
6-Decyl-2-(1 -methylheptyloxy)thieno[2,3-cd[1,3joxazin-4-one;
6-Heptyl-2-(1 -methylheptyloxy)thieno[2,3-c(l[1,3]oxazin-4-one;
e-Decyl-2-(4-phenylpropoxy)thieno[2,3-c(|[1,3]oxazin-4-one; and
6-Decyl-2-(4-phenylbutoxy)thieno[2,3- !3
The subject invention also provides compounds having the structure:
o
wherein,
RIO is H or substituted or unsubstituted CrC15 alkyl, CrC15
alkylaryl, or -C(O)Ri4,
wherein R^ is hydroxyl, or a substituted or unsubstituted
CrC30 alkyl, alkylamino, dialkylamino, alkoxy, benzyloxy, cycloalkyl,
alkylheteroaryl, alkylaryl, or a heterocyclic, heteroaryl or aryl ring;
Rn is hydrogen or methyl;
Ria is hydrogen or te/t-butyl; and
Ria is hydrogen or -C(O)ZR15,
wherein Z is CH2, O or N and RIB is substituted or
unsubstituted Crds alkyl or aryl.
The subject invention also provides a method for treating obesity in a subject in
need of such treatment, comprising administering to the subject a therapeutically
effective amount of a compound of the invention so as to thereby treat obesity in
the subject.
The subject invention also provides a method for treating diabetes in a subject in
need of such treatment, comprising administering to the subject a therapeutically
effective amount of a compound of the invention so as to thereby treat diabetes in
the subject.
The subject invention also provides a method of inhibiting the hydrolytic activity of
pancreatic lipase enzymes in a cell, 'comprising contacting the cell with an
amount of a compound of the invention which is effective in inhibiting thb
hydrolytic activity of pancreatic lipase enzymes.
The above method may contact the cell either in vitro or in vivo.
The subject invention also provides a pharmaceutical composition comprising the
a compound or the invention and a pharmaceutically acceptable carrier.
In one embodiment, the pharmaceutical composition is formulated for oral,
topical, parenteral, or nasal administration. ,
The subject invention also provides a process for the manufacture of a
pharmaceutical composition comprising admixing a compound of the invention
with a pharmaceutically acceptable carrier.
The subject invention also provides an article of manufacture comprising
packaging material;
the above pharmaceutical composition; and ,
instructions for use of the pharmaceutical composition in the treatment
of obesity.
The subject invention also provides a process of manufacturing a compound
having the structure:
N XR2
wherein,
X is 0, S, CH2 or NR6;
RI is H, substituted or unsubstituted CrCi5alkyl, CrC6 alkylaryl,
-C(0)OR4, -C(O)NR4R5, -CR6R6.OR4, -CR6R6.OC(O)R4,
-CReR6OC(O)NHR7, -C(O)NR8R9, -
-N(R5)C(0)NHR5, or CH2R4;
R2 is a substituted or unsubstituted, straight chain CrCso alkyl or
branched C3-C30 alkyl, aryl, alkylaryl, arylalkyi, heteroarylalkyi or cycloalkyi;
R3 is H or substituted or unsubstituted d-C6 alkyl or cycloalkyi;
R4 is H or a substituted or unsubstituted, straight chain or
branched, Ce-Cso alkyl, aryl, -CH2-aryl, arylalkyi, heteroarylalkyi
or cycloalkyi;
R5 is H or a substituted or unsubstituted, straight chain or
branched, Ce-Cso alkyl, arylalkyi, heteroarylalkyi or cycloalkyi;
R6 and R6* are each independently H, substituted or
unsubstituted CrC6 alkyl, dialkyi or cycloalkyi or together form a
3-7 membered ring system;
R7 is H or substituted or unsubstituted CrC12 alkyl or
cycloalkyi;
R8 and R9 are each independently H, substituted or
unsubstituted CrC6 alkyl, C-i-Ce alkoxy, d-C6 alkylaryl, or
NR8R9 together form a substituted piperazine or piperidine ring
or a dihydro-1 H-isoquinoline ring system,
comprising
(a) reacting
o
NC and
Rin
the presence of sulfur, a base and solvent to produce:
o
H
(b) reacting the product of step (a) with
0
c
in the presence of a base to produce:
(c) reacting the product of step (b) with trifluoroacetic acid (TFA) in the presence
of solvent to produce:
Q
(d) reacting the product of step (c) with SOCI2 in the presence of solvent to
produce the compound.
In one embodiment of the above process, the base in step (a) is triethyl amine
and the solvent is dimethylformamide (DMF).
In a further embodiment, the solvent in step (c) is dichloromethane,
In a further embodiment, the solvent in step (d) is pyridine:CH2CI2.
The subject invention also provides a compound produced by the above process.
The subject invention also provides the use of the compounds of the invention for
manufacturing a medicament useful for treating obesity in a subject.
The subject invention also provides the use of the compounds of the invention
for manufacturing a medicament useful for treating diabetes in a subject.
The subject invention also provides the use of the compounds of the invention
for manufacturing a medicament useful for inhibiting the hydrolytic activity of
pancreatic lipase enzymes in a cell.
The inhibition of the cell may be effected either in vitro or in vivo.
The subject invention also provides the above compounds, wherein any
heterocyclic or heteroaryl ring, if present, is a piperazine, piperidine,
(1,4)diazepan, pyrazine, pyridine, pyrrolidine, pyrazole, pyrimidine, thiophene,
imidazole, azetidine, pyrrole, benzothiazole, benzodioxolane, dithiolane,
oxathiine, imidazolidine, quinoline, isoquinoline, dihydroisoquinoline, indole,
isoindole, triazaspiro[4.5]decane, morpholine, furan or an isothiazole ring.
The subject invention also provides any of the above compounds, wherein any
substituent, if present, is halogen, hydroxyl, straight chain (CrC3o)alkyl,
branched chain (C3-C30)alkyl, (C3-Ci0)cycloalkyl, straight chatn(Ci
C30)alkylcarbonyloxy, branched chain (C3-C3o)alkylcarbonyloxy, arylcarbonyloxy,
straight chain(Ci-C3o)alkoxycarbonyloxy, branched chain(C3-
C3o)alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, straight chain(d-
C3o)alkylcarbonyl, branched chain (C3-C3o)alkylcarbonyl, straight chain (d-
C30)alkoxycarbonyl, branched chain (C3-C3o)alkoxycarbonyl, aminocarbonyl,
straight chain . (d-CsoJalkylthiocarbonyl, branched chain (C3-
C3o)alkylthiocarbonyl, straight chain (C-rC3o)alkoxyl, branched chain (Cr
C3o)alkoxyl, phosphate, phosphonato, cyano, amino, straight chain (Cr
C3o)alkylamino, branched chain (C3-C30)alkylamino, straight chain (d-
C3o)dialkylamino, branched chain (C3-C3o)dialkylamino, arylamino, diarylamino,
straight chain (Ci-C30)alkylarylamino, branched chain (Cs-C^alkylarylamino,
acylamino, straight chain (CrC3o)alkylcarbonylamino, branched chain (C3-
C3o)alkylcarbonylamino, arylcarbonylamino, carbamoyl, ureido, amidino, imino,
sulfhydryl, straight chain (Ci-C30)alkylthio, branched chain (C3-C30)alkylthio,
arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro,
trifluoromethyl, azido, 4-10 membered heterocyclyl, straight chain (d-
C30)alkylaryl, branched chain (C3-Cx)alkylaryl, benzo(1,3)dioxole, or an aromatic
or 5-6 membered heteroaromatic moiety,
which substituent may be further substituted by any of the above.
The number of carbons when represented as "(CrC30)" or "(C3-C3o)M is intended to
mean any incremental whole number between 1 and 3 and 30, e.g. 1, 2, 3, 4, 5 ... or
30.
Additional embodiments of the compounds of this invention are described below.
Entry structure MW k
0-3.S-1
Ymax % inhibit MP
399.5
CH,
H.C
455.6
511.7
-o V 393.6
Crt,
429.! 0.649
485.7
541.8 0.779
H,C CH,
415.E 1.052
451J 0.924 0.286 58.5-60.2
10 rY 423J 1.349
11
PH
339.4 0.547
12 381.5 0.438 47.5-48.0
13 583.8 0.414
14 555.7 0.459
15 450.', 1.548
16 OH,
428.6 1.711 153.5-154.Q
17 414.5 1,74
18 449.7 1.036 18.03% 152.0-152.8
19
:«, p
506.6 0.981
20 450. 0.922
21
H.I
427.6 1.079
22
CH,
365.5 0.537
23 295.4 0.893
24 505.8 1.849 137.1-138.C
25 533.8 1.629 145.0-145.8
26 561.9 1.709 146.3-147.0
•Vv
27 421.6 2.577
28 477; 0.998
29 505.8 0.797
•A*
30 61.9 0.433
31 351.5 0.777 152.5-158
32 ,
f
393.6 2.447
33
rNH
CH,
365.5 0.547
34 ^ H"
428.6 0.864
35 428.6 1.544 148-150
36 449.7
CH,
0.146 0.616
514.7 0.574 0.211
193.5-195
(decomp)
p
o
CO
T— CM
CD
O)
CO co
CM
O>
CO
CO
in
CO in CM
I-;
CD
en co
O
i—
T— d
r-.
cd 01
oi
n
06
oco
oino
CO in
in •*
CM
CM
d
CO
CM
00
in
CM
coo
en8
d
in at •>*•
CO
co
CO
or-. iv
CD
r-.
CO
CO
CM coq
d
cq
co
47 CM, 449.7 0.191 0.943
48 485.6 0.440 147-149
49 456.6 0.022
50 442.6 0.719
51 CH,
H3C 470.6 0.012
52 417.5 1.257
53 517. 0.166
,CH,
54 393.6 0.702
55 428. 0.754
56 444.6 0.114
57
K,C 0
414.5 0.070 86-88
58 407.6 0.723 173-174.5
59 442.6 0.222 136-138
60 540.8 0.013
61 378.6 0.247 0.460 89-91
62 370.5 0.103 1.901 123.0-124.0
63 336.5 0.074 10.091 93.0-94.0
64 505.7 0.176 3.917
65
,-CH,
513.7 0.284 0.339 77-80
66
Hfl
fiV^O
K.C-O"
487.6 1.027 0.118 159.0-163,
67 405.7 0.064 10.973 oil
68 ,CM, 379.6 5.825 0.020 78.94% oil
69
H,o
471.6 1.137 0.112 149-152
70 ,« -^ 457.6 1.999 0.140
71 428.6 0.086
H,C O
14.657
72 395.5 1.102 0.185
H.O-0
73 Y 409.i 0.794 1.594
74 393.6 0.422 0.982
75 n,c 337.5 2.219 0.054 oil
76 H3C 323.5 1.288 0.161 oil
77 371.5 0.392 0.482 oil
78 379.6 1.315 0.126 17.86% oil
79 469.7 69.49% 153-154
80 455.6 66.27% 139-141
81 391.6 66.46% oil
82 491.6 84.90% oil
83
o
H.C-0
423.6 36.93% Oil
84 365.5 3.033 0.029 71.26% Oil
85 393.6 96.13% oil
86 421.6 73.58% oil
87 407.6 27.91% 36
88 449.7 74.21%
89 OY"-^—^C
c«» 429.5 -14.14% oil
90 421.7
CM.
15.03% oil
91 379.6 12.44% Oil
92 397.6
O CH,
oil
93 411.6 oil
94 H.C 365. 83.03% oil
95 337.5 60.26% oil
96 367.5 38-41
97 443.6 oil
98
H,C
441.6 oil
99
H.C
427.6 oil
100 449.7 Oil
101
yo
o / 357.5 oil
102 441.6 55-58
10C 385.! oil
HO'
1.1.
ou
601-
801
901-
9'668 JO I.
9'66e
'HO'
113 429,5
K,C O
114
•0 /
Hi 395.5
'-3
"k" and "Ymax" in the above table correspond to values inn the equation appearing
on page 159. All compounds listed as oils were oils at room temperature.
The language "therapeutically effective amount" of the compounds of the invention,
described infra, refers to that amount of a therapeutic compound necessary or
sufficient to perform its intended function within a mammal. An effective amount of
the therapeutic compound can vary according to factors such as the amount of the
causative agent already present in the mammal, the age, sex, and weight of the
mammal, and the ability of the therapeutic compounds of the present invention to
affect the desired result in the mammal. One of ordinary skill in the art would be able
to study the aforementioned factors and make a determination regarding the
effective amount of the therapeutic compound without undue experimentation. An in
vitro or in vivo assay also can be used to determine an "effective amount" of the,
therapeutic compounds described infra. The ordinarily skilled artisan would select
an appropriate amount of the therapeutic compound for use in the aforementioned
assay or as a therapeutic treatment.
A therapeutically effective amount preferably diminishes at least one symptom or
effect associated with the disorder being treated by at least about 20%, (more
preferably by at least about 40%, even more preferably by at least about 60%, and
still more preferably by at least about 80%) relative to untreated subjects. Assays
can be designed by one skilled in the art to measure the diminishment of such
symptoms and/or effects. Any art recognized assay capable of measuring such
parameters are intended to be included as part of this invention.
The term "animal" includes any organism with adenosine receptors. Examples of
animals include yeast, mammals, reptiles, and birds. It also includes transgenic
animals.
The term "mammal" is art recognized and is intended to include an animal, more
preferably a warm-blooded animal, most preferably cattle, sheep, pigs, horses, dogs,
cats, rats, mice, and humans. Mammals susceptible to obesity associated disorders
are included as part of this invention.
33
The term "alky!" refers to the radical of saturated aliphatic groups, including straightchain
alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl
substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. In preferred
embodiments, a straight chain or branched chain alkyl has 30 or fewer carbon atoms
in its backbone (e.g., Ci-C30 for straight chain, C3-C3o for branched chain), and more
preferably 20 or fewer. Likewise, preferred cycloalkyls have from 4-10 carbon atoms
in their ring structure, and more preferably have 5, 6 or 7 carbons in the ring
structure.
The term "substituted alkyl", refers to alkyl moieties having substituents replacing a
hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents
can include, for example, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy,
alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl,
aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato,
cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and
alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino,
carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate,
sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido,
heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. It will be understood
by those skilled in the art that the moieties substituted on the hydrocarbon chain can
themselves be substituted, if appropriate. Cycloalkyls can be further substituted,
e.g., with the substituents described above. An "alkylaryl" moiety is an alkyl
substituted with an aryl (e.g., phenylmethyl (benzyl)). The term "alkyl" also includes
unsaturated aliphatic groups analogous in length and possible substitution to the
alkyls described above, but that contain at least one double or triple bond
respectively.
The term "aryl" as used herein, refers to the radical of aryl groups, including 5- and
6-membered single-ring aromatic groups that may include from zero to four
heteroatoms, for example, benzene, pyrrole, furan, thiophene, imidazole,
benzoxazole, benzothiazole, triazole, tetrazole, pyrazole, pyridine, pyrazine,
pyridazine and pyrimidine, and the like. Aryl groups also include polycyclic fused
aromatic groups such as naphthy', quinolyi, indolyl, and the like. Those aryl groups
having heteroatoms in the ring structure may also be referred to as "aryl
heterocycles", "heteroaryls" or ' heteroaromatics". The aromatic ring can be
substituted at one or more ring positions with such substituents as described above,
as for example, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy,
alkoxycarbonyloxy, aryloxycarbonyioxy, carboxylate, alkylcarbonyl, alkoxycarbonyl,
aminocarbonyl, alkylthiocarbonyi, phosphate, phosphonato, phosphinato, cyano,
amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and
alkylarylamino), acylamino (incUding alkylcarbonylamino, arylcarbonylamino,
carbamoyi and ureido), amidino, irruno, sulfhydryl, alkylthio, arylthio, thiocarboxylate,
suifates, sulfonato, sulfamoyl, suifonamido, nitro, trifluoromethyl, cyano, azido,
heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. Aryl groups can also
be fused or bridged with alicyclic or heterocyclic rings which are not aromatic so as
to form a polycycle (e.g., tetralin).
The terms "alkenyl" and "alkynyl" refer to unsaturated aliphatic groups analogous in
length and possible substitution to the alkyls described above, but that contain at
least one double or triple bond respectively. For example, the invention
contemplates cyano and propargyl groups.
Unless the number of carbons is otherwise specified, "lower alky!" as used herein
means an alkyl group, as defined above, but having from one to ten carbons, more
preferably from one to six carbon atoms in its backbone structure, even more
preferably one to three carbon atoms in its backbone structure. Likewise, "lower
alkenyl" and "lower alkynyl" have similar chain lengths.
The terms "alkoxyalkyl", "polyaminoalkyl" and "thioalkoxyalkyl" refer to alkyl groups,
as described above, which further include oxygen, nitrogen or sulfur atoms replacing
one or more carbons of the hydrocarbon backbone, e.g., oxygen, nitrogen or sulfur
atoms.
The terms "poiycyclyl" or "polycyclic radical" refer to the radical of two or more cyclic
rings (e.g., cycloalkyls, cycloalkenyls, c.ycloalkynyls, aryls and/or heterocyclyls) in
which two or more atoms are common to two adjoining rings, e.g., the rings are
"fused rings". Rings that are joined through non-adjacent atoms are termed
"bridged" rings. Each of the rings of the polycycle can be substituted with such
substituents as described above, as for example, halogen, hydroxyl,
alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy,
carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl,
phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino,
dialkylamino, arylarnino, diarylamino, and alkylarylamino), acylamino (including
alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino,
sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl,
sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkyl, alkylaryl, or an
aromatic or heteroaromatic moiety.
The term "heteroatom" as used herein means an atom of any element other than
carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, sulfur and
phosphorus.
i"
The term "heterocycle" or "heterocyclic system" as used herein is intended to mean a
stable 5, 6 or 7-membered monocyclic or 7, 8, 9, 10 or 11- membered bicyclic
heterocyclic ring which is saturated or partially unsaturated.
The terms "carbocyclic" or "heterocyclic" further include spiro compounds, which
denote a bicyclic compound in which the two rings have one atom in common and
the atom may be carbon or a heteroatom.
The term "amino acids" includes naturally and unnaturally occurring amino acids
found in proteins such as glycine, alanine, valine, cysteine, leucine, isoleucine,
serine, threonine, methionine, glutamic acid, aspartic acid, glutamine, asparagine,
lysine, arginine, proline, histidine, phenylalanine, tyrosine, and tryptophan. Amino
acid analogs include amino acids with lengthened or shortened side chains or variant
side chains with appropriate functional groups. Amino acids also include D and L
stereoisomers of an amino acid when the structure of the amino acid admits of
stereoisomeric forms. The term "dipeptide" includes two or more amino acids linked
together. Preferably, dipeptides are two amino acids linked via a peptide linkage.
Particularly preferred dipeptides include, for example, alanine-alanine and glycinealanine.
It will be noted that the structure of some of the compounds of this invention includes
asymmetric carbon atoms and thus occur as racemates and racemic mixtures, single
enantiomers, diastereomeric mixtures and individual diastereomers. All such
isomeric forms of these compounds are expressly included in this invention. Each
stereogenic carbon may be of the R or S configuration. It is to be understood
accordingly that the isomers arising from such asymmetry (e.g., all enantiomers and
diastereomers) are included within the scope of this invention, unless indicated
otherwise. Such isomers can be obtained in substantially pure form by classical
separation techniques and by stereochemically controlled synthesis.
The invention further pertains to pharmaceutical compositions for treating obesity
and obesity associated disorders in a mammal. The pharmaceutical composition
includes a therapeutically effective amount of a compound of the invention and a
pharmaceutically acceptable carrier. It is to be understood, that all of the
compounds described below are included for therapeutic treatment. It is to be
further understood that the compounds of the invention can be used alone or in
combination with other compounds of the invention or in combination with additional
therapeutic compounds, such as antibiotics, antiinflammatories, or anticancer
agents, for example.
The term "antibiotic" is art recognized and is intended to include those substances
produced by growing microorganisms and synthetic derivatives thereof, which
eliminate or inhibit growth of pathogens and are selectively toxic to the pathogen
while producing minimal or no deleterious effects upon the infected host subject.
Suitable examples of antibiotics include, but are not limited to, the principle classes
of aminoglycosides, cephalosporins, chloramphenicols, fuscidic acids, macrolides,
penicillins, polymixins, tetracyclines and streptomycins.
The term "antiinflammatory" is art recognized and is intended to include those agents
which act on body mechanisms, without directly antagonizing the causative agent of
the inflammation such as glucocorticoids, aspirin, ibuprofen, NSAIDS, etc.
The term "anticancer agent" is art recognized and is intended to include those agents
which diminish, eradicate, or prevent growth of cancer cells without, preferably,
adversely affecting other physiological functions. Representative examples include
cisplatin and cyclophosphamide.
When the compounds of the present invention are administered as Pharmaceuticals,
to humans and mammals, they can be given per se or as a pharmaceutical
composition containing, for example, 0.1 to 99.5% (more preferably, 0.5 to 90%) of
active ingredient in combination with a pharmaceutically acceptable carrier.
The phrase "pharmaceutically acceptable carrier" as used herein means a
pharmaceutically acceptable material, composition or vehicle, such as a liquid or
solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying
or transporting a compound(s) of the present invention within or to the subject such
that it can performs its intended function. Typically, such compounds are carried or
transported from one organ, or portion of the body, to another organ, or portion of the
body. Each carrier must be "acceptable" in the sense of being compatible with the
other ingredients of the formulation and not injurious to the patient. Some examples
of materials which can serve as pharmaceutically acceptable carriers include:
sugars, such as lactose, glucose and sucrose; starches, such as corn starch and
potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose,
ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc;
excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil,
cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols,
such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and
polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering
agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid;
pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer
solutions; and other non-toxic compatible substances employed in pharmaceutical
formulations.
As set out above, certain embodiments of the present compounds can contain a
basic functional group, such as amino or alkylamino, and are, thus, capable of
forming pharmaceutically acceptable salts with pharmaceutically acceptable acids.
The term "pharmaceutically acceptable salts" in this respect, refers to the relatively
non-toxic,inorganic and organic acid addition salts of compounds of the present
invention. These salts can be prepared in situ during the final isolation and
purification of the compounds of the invention, or by separately reacting a purified
compound of the invention in its free base form with a suitable organic or inorganic
acid, and isolating the salt thus formed. Representative salts include the
hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate,
oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate,
maleate, fumarate, succinate, tartrate, napthylate, mesylate, glucoheptonate,
lactobionate, and laurylsulphonate salts and the like. (See, e.g., Berge et al. (1977)
"Pharmaceutical Salts", J. Pharm. Sci. 66:1-19).
In other cases, the compounds of the present invention may contain one or more
acidic functional groups and, thus, are capable of forming pharmaceutically
acceptable salts with pharmaceutically acceptable bases. The term
"pharmaceutically acceptable salts" in these instances refers to the relatively nontoxic,
inorganic and organic base addition salts of compounds of the present
invention. These salts can likewise be prepared in situ during the final isolation and
purification of the compounds, or by separately reacting the purified compound in its
free acid form with a suitable base, such as the hydroxide, carbonate or bicarbonate
of a pharmaceutically acceptable metal cation, with ammonia, or with a
pharmaceutically acceptable organic primary, secondary or tertiary amine.
Representative alkali or alkaline earth salts include the lithium, sodium, potassium,
calcium, magnesium, and aluminum salts and the like. Representative organic
amines useful for the formation of base addition salts include ethylamine,
diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the
like.
The term "pharmaceutically acceptable esters" refers to the relatively non-toxic,
esterified products of the compounds of the present invention. These esters can be
prepared in situ during the final isolation and purification of the compounds, or by
separately reacting the purified compound in its free acid form or hydroxyl with a
suitable esterifying agent. Carboxylic acids can be converted into esters via
treatment with an alcohol in the presence of a catalyst. Hydroxyl containing
derivatives can be converted into esters via treatment with an esterifying agent such
as alkanoyl halides. The term is further intended to include lower hydrocarbon
groups capable of being solvated under physiological conditions, e.g., alkyl esters,
methyl, ethyl and propyl esters. (See, for example, Berge era/., supra.)
The invention further contemplates the use of prodrugs which are converted in vivo
to the therapeutic compounds of the invention (see, e.g., R.B. Silverman, 1992, "The
Organic Chemistry of Drug Design and Drug Action", Academic Press, Chapter 8).
Such prodrugs can be used to alter the biodistribution (e.g., to allow compounds
which would not typically enter the reactive site of the protease) or the
pharmacokinetics of the therapeutic compound. For example, a carboxylic acid
group, can be esterified, e.g., with a methyl group or an ethyl group to yield an ester.
When the ester is administered to a subject, the ester is cleaved, enzymatically or
non-enzymatically, reductively or hydrolytically, to reveal the anionic group. An
anionic group can be esterified with moieties (e.g., acyloxymethyl esters) which are
cleaved to reveal an intermediate compound which subsequently decomposes to
yield the active compound. In another embodiment, the prodrug is a reduced form of
a sulfate or sulfonate, e.g., a thiol, which is oxidized in vivo to the therapeutic
compound. Furthermore, an anionic moiety can be esterified to a group which is
actively transported in vivo, or which is selectively taken up by target organs. The
ester can be selected to allow specific targeting of the therapeutic moieties to
particular reactive sites, as described below for carrier moieties.
The compounds of the invention may comprise water-soluble prodrugs which are
described in WO 99/33815, International Application No. PCT/US98/04595, filed
March 9, 1998 and published July 8, 1999. The entire content of WO 99/33815 Is
expressly incorporated herein by reference. The water-soluble prodrugs are
metabolized in v/Voto an active drug, e.g., by esterase catalyzed hydrolysis.
Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and
magnesium stearate, as well as coloring agents, release agents, coating agents,
sweetening, flavoring and perfuming agents, preservatives and antioxidants can also
be present in the compositions.
Examples of pharmaceutically acceptable antioxidants include: water soluble
antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium
metabisulfite, sodium sulfite and the like; oil-soluble antioxidants, such as ascorbyl
palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin,
propyl gallate, alpha-tocopherol, and the like; and metal chelating agents, such as
citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric
acid, and the like.
Formulations of the present invention include those suitable for oral, nasal, topical,
transdermal, buccal, sublihgual, rectal, vaginal and/or parenteral administration. The
formulations may conveniently be presented in unit dosage form and may be
prepared by any methods well known in the art of pharmacy. The amount of active
ingredient which can be combined with a carrier material to produce a single dosage
form will generally be that amount of the compound which produces a therapeutic
effect. Generally, out of one hundred per cent, this amount will range from about 1
per cent to about ninety-nine percent of active ingredient, preferably from about 5 per
cent to about 70 per cent, most preferably from about 10 per cent to about 30 per
cent.
Methods of preparing these formulations or compositions include the step of bringing
into association a compound of the present invention with the carrier and, optionally,
one or more accessory ingredients. In general, the formulations are prepared by
uniformly and intimately bringing into association a compound of the present
invention with liquid carriers, or finely divided solid carriers, or both, and then, if
necessary, shaping the product.
Formulations of the invention suitable for oral administration may be in the form of
capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose
and acacia or tragacanth), powders, granules, or as a solution or a suspension in an
aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion,
or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and
glycerin, or sucrose and acacia) and/or as mouth washes and the like, each
containing a predetermined amount of a compound of the present invention as an
active ingredient. A compound of the present invention may also be administered as
a bolus, electuary or paste.
In solid dosage forms of the invention for oral administration (capsules, tablets, pills,
dragees, powders, granules and the like), the active ingredient is mixed with one or
more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium
phosphate, and/or any of the following: fillers or extenders, such as starches,
lactose, sucrose, glucose, mannitol, and/or silicic acid; binders, such as, for example,
carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or
acacia; humectants, such as glycerol; disintegrating agents, such as agar-agar,
calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and
sodium carbonate; solution retarding agents, such as paraffin; absorption
accelerators, such as quaternary ammonium compounds; wetting agents, such as,
for example, acetyl alcohol and glycerol monostearate; absorbents, such as kaolin
and bentonite clay; lubricants, such a talc, calcium stearate, magnesium stearate,
solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and coloring
agents. In the case of capsules, tablets and pills, the pharmaceutical compositions
may also comprise buffering agents. Solid compositions of a similar type may also
be employed as fillers in soft and hard-filled gelatin capsules using such excipients
as lactose or milk sugars, as well as high molecular weight polyethylene glycols and
the like.
A tablet may be made by compression or molding, optionally with one or more
accessory ingredients. Compressed tablets may be prepared using binder (for
example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent,
preservative, disintegrant (for example, sodium starch glycolate or cross-linked
sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets
may be made by molding in a suitable machine a mixture of the powdered
compound moistened with an inert liquid diluent.
The tablets, and other solid dosage forms of the pharmaceutical compositions of the
present invention, such as dragees, capsules, pills and granules, may optionally be
scored or prepared with coatings and shells, such as enteric coatings and other
coatings well known in the pharmaceutical-formulating art. They may also be
formulated so as to provide slow or controlled release of the active ingredient therein
using, for example, hydroxypropylmethyl cellulose in varying proportions to provide
the desired release profile, other polymer matrices, liposomes and/or microspheres.
They may be sterilized by, for example, filtration through a bacteria-retaining filter, or
by incorporating sterilizing agents in the form of sterile solid compositions which can
be dissolved in sterile water, or some other sterile injectable medium immediately
before use. These compositions may also optionally contain opacifying agents and
may be of a composition that they release the active ingredient(s) only, or
preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed
manner. Examples of embedding compositions which can be used include polymeric
substances and waxes. The active ingredient can also be in micro-encapsulated
form, if appropriate, with one or more of the above-described excipients.
Liquid dosage forms for oral administration of the compounds of the invention
include pharmaceutically acceptable emulsions, microemulsions, solutions,
suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage
forms may contain inert dilutents commonly used in the art, such as, for example,
water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol,
isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate,
propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn,
germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene
glycols and fatty acid esters of sorbitan, and mixtures thereof.
Besides inert clHutents, the oral compositions can also include adjuvants such as
wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring,
perfuming and preservative agents.
Suspensions, in addition to the active compounds, may contain suspending agents
as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and
sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agaragar
and tragacanth, and mixtures thereof.
Formulations of the pharmaceutical compositions of the invention for rectal or vaginal
administration may be presented as a suppository, which may be prepared by mixing
one or more compounds of the invention with one or more suitable nonirritating
excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a
suppository wax or a salicylate, and which is solid at room temperature, but liquid at
body temperature and, therefore, will melt in the rectum or vaginal cavity and release
the active compound.
Formulations of the present invention which are suitable for vaginal administration
also include pessaries, tampons, creams, gels, pastes, foams or spray formulations
containing such carriers as are known in the art to be appropriate.
Dosage forms for the topical or transderrnal administration of a compound of this
invention include powders, sprays, ointments, pastes, creams, lotions, gels,
solutions, patches and inhalants. The active compound may be mixed under sterile
conditions with a pharmaceutically acceptable carrier, and with any preservatives,
buffers, or propellants which may be required.
The ointments, pastes, creams and gels may contain, in addition to an active
compound of this invention, excipients, such as animal and vegetable fats, oils,
waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols,
silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
Powders and sprays can contain, in addition to a compound of this invention,
excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium sii'cate?
and polyamide powder, or mixtures of these substances. Sprays can additionally
contain customary propellants, such as chlorofluorohydrocarbons and volatile
unsubstituted hydrocarbons, such as butane and propane.
Transdermal patches have the added advantage of providing controlled delivery of a
compound of the present invention to the body. Such dosage forms can be made by
dissolving or dispersing the compound in the proper medium. Absorption enhancers
can also be used to increase the flux of the compound across the skin. The rate of
such flux can be controlled by either providing a rate controlling membrane or
dispersing the active compound in a polymer matrix or gel.
An appropriate buffer system (e.g., sodium phosphate, sodium acetate or sodium
borate) may be added to prevent pH drift under storage conditions.
Pharmaceutical compositions of this invention suitable for parenteral administration
comprise one or more compounds of the invention in combination with one or more
pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions,
dispersions, suspensions or emulsions, or sterile powders which may be
reconstituted into sterile injectable solutions or dispersions just prior to use, which
may contain antioxidants, buffers, bacteriostats, solutes which render the formulation
isotonic with the blood of the intended recipient or suspending or thickening agents.
Examples of suitable aqueous and nonaqueous carriers which may be employed in
the pharmaceutical compositions of the invention include water, ethanol, polyols
(such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable
mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such
as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating
materials, such as lecithin by the maintenance of the required particle size in the
case of dispersions, and by the use of surfactants.
These compositions may also contain adjuvants such as preservatives, wetting
agents, emulsifying agents and dispersing agents. Prevention of the action of
microorganisms may be ensured by the inclusion of various antibacterial and
antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the
like. It may also be desirable to include isotonic agents, such as sugars, sodium
chloride, and the like into the compositions. In addition, prolonged absorption of the
injectable pharmaceutical form may be brought about by the inclusion of agents
which delay absorption such as aluminum monostearate and gelatin.
In some cases, in order to prolong the effect of a drug, it is desirable to slow the
absorption of the drug from subcutaneous or intramuscular injection. This may be
accomplished by the use of a liquid suspension of crystalline or amorphous material
having poor water solubility. The rate of absorption of the drug then depends upon its
rate of dissolution which, in turn, may depend upon crystal size and crystalline form.
Alternatively, delayed absorption of a parenterally-administered drug form is
accomplished by dissolving or suspending the drug in an oil vehicle.
Injectable depot forms are made by forming microencapsule matrices of the subject
compounds in biodegradable polymers such as polylactide-polyglycolide. Depending
on the ratio of drug to polymer, and the nature of the particular polymer employed,
the rate of drug release can be controlled. Examples of other biodegradable
polymers include poly(orthoesters) and poly(anhydrides). Depot injectable
formulations are also prepared by entrapping the drug in liposomes or
microemulsions which are compatible with body tissue.
The preparations of the present invention may be given orally, parenterally, topically,
or rectally. They are of course given by forms suitable for each administration route.
For example, they are administered in tablets or capsule form, by injection,
inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion
or inhalation; topical by lotion or ointment; and rectal by suppositories. Oral
administration is preferred.
The phrases "parenteral administration" and "administered parenterally" as used
herein means modes of administration other than enteral and topical administration,
usually by injection, and includes, without limitation, intravenous, intramuscular,
intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal,
intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular,
subcapsular, subarachnoid, intraspinal and ihtrasternal injection and infusion.
The phrases "systemic administration," "administered systematically/1 "peripheral
administration" and "administered peripherally" as used herein mean the
administration of a compound, drug or other material other than directly into the
central nervous system, such that it enters the patient's system and, thus, is subject
to metabolism and other like processes, for example, subcutaneous administration.
These compounds may be administered to humans and other animals for therapy by
any suitable route of administration, including orally, nasally, as by, for example, a
spray, rectally, intravaginally, parenterally, intracisternally and topically, as by
powders, ointments or drops, including buccally and sublingually.
Regardless of the route of administration selected, the compounds of the present
invention, which may be used in a suitable hydrated form, and/or the pharmaceutical
compositions of the present invention, are formulated into pharmaceutically
acceptable dosage forms by conventional methods known to those of skill in the art.
Actual dosage levels of the active ingredients in the pharmaceutical compositions of
this invention may be varied so as to obtain an amount of the active ingredient which
is effective to achieve the desired therapeutic response for a particular patient,
composition, and mode of administration, without being toxic to the patient.
The selected dosage level will depend upon a variety of factors including the activity
of the particular compound of the present invention employed, or the ester, salt or
amide thereof, the route of administration, the time.of administration, the rate of
excretion of the particular compound being employed, the duration of the treatment,
other drugs, compounds and/or materials used in combination with the particular
compound employed, the age, sex, weight, condition, general health and prior
medical history of the patient being treated, and like factors well known in the
medical arts.
A physician or veterinarian having ordinary skill in the art can readily determine and
prescribe the effective amount of the pharmaceutical composition required. For
example, the physician or veterinarian could start doses of the compounds of the
invention employed in the pharmaceutical composition at levels lower than that
required in order to achieve the desired therapeutic effect and gradually increase the
dosage until the desired effect is achieved.
In general, a suitable daily dose of a compound of the invention will be that amount
of the compound which is the lowest dose effective to produce a therapeutic effect.
Such an effective dose will generally depend upon the factors described above.
Generally, intravenous and subcutaneous doses of the compounds of this invention
for a patient, when used for the indicated analgesic effects, will range from about
0.0001 to about 200 mg per kilogram of body weight per day, more preferably from
about 0.01 to about 150 mg per kg per day, and still more preferably from about 0.2
to about 140 mg per kg per day.
If desired, the effective daily dose of the active compound may be administered as
two, three, four, five, six or more sub-doses administered separately at appropriate
intervals throughout the day, optionally, in unit dosage forms.
While it is possible for a compound of the present invention to be administered
alone, it is preferable to administer the compound as a pharmaceutical composition.
The present invention also pertains to packaged pharmaceutical compositions for
treating obesity or obesity associated disorders in a mammal. The packaged
pharmaceutical compositions include a container holding a therapeutically effective
amount of at least one compound of the invention and instructions for using the
compound for treating obesity or an obesity associated disorder in the mammal.
The features and details of the invention will now be more particularly described and
pointed out in the claims. It is to be understood that the particular embodiments of
the invention are shown by way of illustration and not as limitations of the invention.
The principle features of this invention can be employed in various embodiments
without departing from the scope of the invention.
The invention is further illustrated by the following examples which in no way should
be construed as being further limiting. The contents of all references, pending patent
applications and published patent applications, cited throughout this application,
including those referenced in the background section, are hereby incorporated by
reference. It should be understood that the models used throughout the examples
are accepted models and that the demonstration of efficacy in these models is
predictive of efficacy in humans.
This invention will be better understood from the Experimental Details which follow.
However, one skilled in the art will readily appreciate that the specific methods and
results discussed are merely illustrative of the invention as described more fully in
the claims which follow thereafter.
Compounds in the examples are labeled with whole numbers if the compound
appears in the table above and as X.Y, where X is the example number and Y is an
index starting at 1 in each example, if they do not appear in the above table.
•rt
Experimental Details
All non-aqueous reactions requiring anhydrous conditions were performed
under a positive pressure of nitrogen (N£) in oven-dried glassware, which had been
cooled under N£. All solvents for anhydrous reactions were purchased from Aldrich.
The removal of solvents refers to evaporation in vacua on a rotary evaporator
followed by evacuation to constant sample weight ( chromatography were purchased HPLC grade. All reagents employed were of
American Chemical Society (ACS) grade or finer. Air sensitive reagents were
handled under an atmosphere of dry N2-
Where possible all reactions were followed by thin layer chromatography
(TLC) and visualized using UV fluorescence, 3% KMnO4 (aqueous) staining, and/or
dodecamolybdophosphoric acid. Commercial thin layer and preparative layer
chromatography plates were Si250F and SiSOOF, respectively, from J. T. Baker.
Flash chromatography was performed using 40 urn 'Baker' silica gel from J. T.
Baker. All solvent mixtures are listed as volume ratios.
Melting points are uncorrected and were determined on a Mel-Temp II
(Laboratory Devices, USA) using open capillary tubes. Mass spectra (MS) were
recorded on a Platform 2 Micromass instrument. Nuclear magnetic resonance
(NMR) spectra were measured on a Varian 200 instrument in the specified solvent
with tetramethylsilane (TMS) as internal standard for 1H NMR. For 13C NMR
spectra, the deuterated solvent peak was used as the reference with its position set
relative to TMS.
LCMS Methods: Method A=LC1 method; Method B=Polar method; Method
C=Polar_Short method; Method D=Strong_Nonpolar
General Procedure: Amides/Esters
a. Route A. The aminothiophene was synthesized using a known protocol
(McKibben, B.P., Cartwell, C.H., Castelhano, A.L Tetrahedron Lett. 1999, 40, 5471-
5474). Amide protection with trifluoroacetic anhydride followed by TFA deprotection
and treatment with sodium carbonate generates the amino acid. Attempts to
deprotect with TFA without amide protection results in decarboxylation. The amino
acid was reacted with various acid chlorides, and chloroformates to afford the
thienoxazinones in moderate yields (Scheme 1).
Scheme 1
BnO^-^
Et2NH, pyr Bn0
Bn°
,
Sulfur
1)TFA,DCM
(70%)
DBU.pyr BnO L
95% 20-70%
b. Route B.. In general, reacting the f-Bu protected amino acid directly with a
chloroformate or an isocyanate followed by TFA deprotection of the M3u ester and
treatment with thionyl chloride gives the corresponding thienoxazinones in higher
yields (Scheme 2)
Scheme 2
BnO
6
g I • o
. V^A.,-J 11
3 S^NH. °^ Ll n o S-^MU
N * r* T
/-.^^VTT*- or ° A \ / n
A; 50-80 %
H2,Pd(OH)2
EtOAo (95%)
1) TFA, DCM
1) R,R2YH, EDCI,
HOBt, DMAP, DCM
(95%)
2) TFA, DCM
(95%) CO
A(-h
(90%)
Derivation at the 5-position was achieved through either transesterification of
methyl acetoacetate with various alcohols prior to thiophene formation or benzyl
deprotection of the diester, followed by EDC coupling with various alcohols and
amines to generate esters or amides, respectively.
Example 1: General Procedure tor Amino-Thiophene formation
5-Amino-3-methyl-thiophene-2,4-dicarboxylic acid 2-benzyl ester 4-fert-butyl
ester. (1.1) To a suspension of benzyl acetoacetate (20.0 g, 104.1 mmol), t-butyl
cyanoacetate (14.7 g, 104.1 mmol), sulfur (3.5 g, 109.3 mmol) and pyridine (120 ml)
was added diethyl amine dropwise. After 2 days, the "black solution was
concentrated under reduced pressure, dissolved in EtaO and filtered through silica.
The eluent was then concentrated. Chromatography (silica, 7:1 hexane/EtOAc)
yielded 25.58g (71%)of a orange oil which slowly crystallizes upon standing: 1HNMR
(CDCI3) 1-58 (s, 9H), 2.70 (s, 3H), 5.27 (s, 2H), 7.38 (m, 5H). 1H NMR was
consistent with published data.
5-Amino-3-methyl-thiophene-2,4-dicarboxylic acid 2-heptyl ester 4-fert-butyl
ester. (1.2) The same method as for the preparation of 5-amino-3-methyl-thiophene-
2,4-dicarboxylic acid 2-benzyl ester 4-fert-butyl ester was employed. Thus,
cyclization of fert-butyl cyanoacetate (10.3 mL, 72.0 mmol), heptyl acetoacetate
(13.7 g, 68.0 mrnol), and sulfur (4.4 g, 0.14 mol) in pyridine (80 ml) with added
diethylamine (7.1 ml, 68.0 mmol) afforded 18.4 g thiophene (76%) of an oil after
column Chromatography (10:1; hexanes:EtOAc): 1H NMR (CDCI3) 8 6.47 (bs, 2H),
4.19 (t, 2H, J= 6.6 Hz), 2.67 (s, 3H), 1.80-1.50 (m, 2H), 1.57 (s, 9H), 1.30 (bs, 8H),
0.89 (t,3H, J=6.6Hz).
5-Amino-3-methyl-thiophene-2,4-dicarboxylic acid 2-octyl ester 4-ferf-butyl
ester. (1.3) The same method as for the preparation of 5-amino-3-methyl-thiophene-
2,4-dicarboxylic acid 2-benzyl ester 4-fert-butyl ester was employed. Thus,
cyclization of fert-butyl cyanoacetate (6.2 mL, 43.0 mmol), octyl acetoacetate (8.5 g,
41.0 mmol), and sulfur (2.6 g, 82.0 mmol) in pyridine (50 mL) with added
diethylamine (4.3 ml, 41.0 mmol) afforded 10.3 g thiophene (68%) of an oil after
column chromatography (10:1; hexanes:EtOAc): 1H NMR (CDCI3) 8 6.63 (s, 2H),
4.14 (t, 2H, J= 6.6 Hz), 2.63 (s, 3H), 1.72-1.50 (m, 2H), 1.52 (s, 9H), 1.22 (bs, 10H),
0.83 (t, 3H, J= 6.8 Hz). 13C NMR (CDCI3) 5 165.9, 165.4, 163.0, 147.9, 109.6,
108.0, 81.0, 64.4, 31.7, 29.1, 28.6, 28.4, 25.9, 22.5, 16.2, 14.0.
Example 2: General Procedure for Cyclization From Chloroformate and Aminoacid
2-Dodecyloxy-5-methyl-4-oxo-4H-thieno[2,3-c(l[1,3]oxazine-6-carboxylic acid
benzyl ester (6) To a stirring solution of 5-amino-3-methyl-thiophene-2,4-
dicarboxylic acid 2-benzyl ester (1.00 g, 3.43 mmol) in pyridine (20 ml) was added
dodecyl chloroformate (2.80 ml, 2.56 g, 10.3 mmol). The reaction was stirred at 0
SC for 0.5 h, then solvent was removed under reduced pressure. The product was
purified by column chromatography (10:1; hexanes:EtOAc) to give 169mg (10%) of
a solid: 1H NMR (CDCI3) 8 7.50-7.25 (m, 5H), 5.35 (s, 2H), 4.17 (t, 2H, J = 6.6 Hz),
2.87 (s, 3H), 1.70-1.40 (m, 2H), 1.40-1.00 (m, 18H), 0.88 (t, 3H, J= 6.4 Hz). MS (El):
486.4 (m++H).
5-Methyl-2-octyloxy-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid
benzyl ester (5) The same method as for the preparation of 2-dodecyloxy-5-
methyl-4-oxo-4H-thieno[2,3-dJ[1,3]oxazine-6-carboxylic acid benzyl. ester was
employed: 1H NMR (CDCI3) 8 7.53-7.25 (m, 5H), 5.33 (s, 2H), 4.44 (t, 2H, J= 6.6
Hz), 2.83 (s, 3H), 1.80 (quint, 2H, J = 6.6 Hz), 1.26 (bs, 10H), 0.88 (t, 3H, J = 6.6
Hz).
2-Hexadecyloxy-5-methyl-4-oxo-4H-thienot2,3-d][1,3]oxazine-6-carboxylic acid
benzyl ester (7) The same method as for the preparation of 2-dodecyloxy-5-methyl-
4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid benzyl ester was employed: 1H
NMR (CDCI3) 5 7.50-7.25 (m, 5H), 5.34 (s, 2H), 4.44 (t, 2H, J= 6.6 Hz), 2.83 (s, 3H),
1.80 (quint, 2H, J= 6.6 Hz), 1.26 (bs, 26H), 0.88 (t, 3H, J = 6.6 Hz).
Example 3: General Procedure for Cyclization From Acyl Chloride and Aminoacid
2-Heptyl-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid benzyl
ester (1) To a stirring solution of 5-amino-3-methyl-thiophene-2,4-dicarboxylic acid
2-benzyl ester (200 mg, 0.69 mmol) in pyridine (5 mL) was added octanoyi chloride
(352 |j.L, 2.56 g, 10.3 mmol). The reaction was stirred at 0 BC for 0.5 h, then let
warm to RT and stirred for 3.5 h. The solvent was removed under reduced
pressure. The mixture was diluted in EtOAc, washed with H2O. The organic fraction
was dried (MgSO4), and concentrated in vacuo. The product was purified by column
chromatography (9:1; hexanes:EtOAc) to give 48 mg (18%) of a solid: ): 1H NMR
(CDCla) 6 7.32-7.48 (m, 5H), 5.35 (s, 2H), 2.86 (s, 3H), 2.69 (t, 2H, J = 7.2 Hz), 1.90-
1.70 (m, 2H), 1.45-1.20 (m, 8H), 0.98-0.80 (m, 3H).
5-Methyl-4-oxo-2-pentadecyl-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid
benzyl ester (3) The same method as for the preparation of 2-nepty!-5-methyl-4-
oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid benzyl ester was employed.
Thus, cyclization with hexadecanoyl chloride (476 mL, 2.06 mmol) yielded 56 mg
product (16%) after oil after column chromatography (9:1; hexanes:EtOAc): 1H*NMR
(CDCI3) 6 7.30-7.55 (m, 5H), 5.35 (s, 2H), 2.86 (s, 3H), 2.69 (t, 2H, J = 7.2 Hz), 2.00-
1.70 (m, 2H), 1.50-1.0 (m, 24H), 1.00-0.90 (m, 3H).
2-Undecyl-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid
benzyl ester (2) The same method as for the preparation of 2-heptyl-5-methyl-4-
oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid benzyl ester was employed.
Thus, cyclization with dodecanoyl chloride (476 mL, 2.06 mmol) yielded 77 mg
product (24%) after oil after column chromatography (9:1; hexanes:EtOAc): 1H NMR
(CDCI3) 5 7.30-7.50 (m, 5H), 5.35 (s, 2H), 2.86 (s, 3H), 2.69 (t, 2H, J = 7.2 Hz), 1.90-
1.70 (m, 2H), 1.50-1.20 (m, 16H), 1.00-0.90 (m, 3H).
Example 4: Genera! Procedure for Acylation with Chlorformate of Diester
Ph\-o
3-Methoxymethyl-5-octyloxycarbonylamino-thiophene-2,4-dicarboxylic acid 2-
benzyl ester 4-ferf-butyl ester. (4.1) To a stirring solution of 5-amino-3-
methoxymethyl-thiophene-2,4-dicarboxylic acid 2-benzyl ester 4-fert-butyl ester
(1.16 g, 3.06 mmol) in pyridine (15 ml) was added octyl chloroformate (0.9 mL, 886
mg, 4.6 mmol). The reaction was stirred at 0 9C for 1 h, then solvent was removed
under reduced pressure. The product was purified by column chromatography
(10:1; hexanes:EtOAc) to give 1.27 g (78%) of a solid: 1H NMR (CDCI3) 8 10.51 (s,
1H), 7.32 (m, 5H), 5.12 (s, 2H), 4.19 (t, 2H, J = 6.6 Hz), 3.81 (s, 3H), 3.76 (s, 2H),
1.68 (quint, 2H, J = 6.6 Hz), 1.45 (s, 9H), 1.44-1.21 (m, 10H), 0.89 (t, 3H, J = 5.8
Hz). MS (El): 533.9 (m+).
3-Methyl-5-octyloxycarbonylamino-thiophene-2,4-dicarboxylic acid 4-tert-butyl
ester 2-octyl ester. (4.2) The same method as for the preparation of 3-
methoxymethyl-5-octyloxycarbonylamino-thiophene-2,4-dicarboxylic acid 2-benzyl
ester 4-fert-butyl ester was employed. Thus, acylation with octyl chloroformate
(0.171 ml, 168 mg, 0.87 rnmol) afforded 80 mg of a solid (26%) after column
chromatography (9:1; hexanes:EtOAc): 1H NMR (CDCIa) 8 10.86 (s, 1H), 4.23 (t,
2H, J = 6.6Hz), 2.67 (s, 3H), 1.80-1.40 (m, 4H), 1.57 (s, 9H), 1.42-1.08 (m, 20H),
0.89 (t, 3H, J = 6.6 Hz). MS (El): 526.0 (m+).
3-Methyl-5-heptyloxycarbonylamino-thiophene-2,4-dicarboxylic acid 4-ferfbutyl
ester 2-heptyl ester. (4.3) To a stirring solution of 5-amino-3-methylthiophene-
2,4-dicarboxylic acid 2-heptyl ester 4-tert-butyl ester (5.0 g, 14.0 mmol)
and DBU (5.3 ml, 5.4 g, 35.0 mmol) in CH2CI2 (100 mL) was added heptyl
chloroformate (5.0 ml, 5,0 g, 28.0 mmol). The reaction was stirred at room
temperature for 20 h, and then solvent was removed under reduced pressure. The
product was purified by column chromatography (9:1; hexanes:EtOAc) to give 3.1 g
(45%) of a solid: 1H NMR (CDCI3) 8 10.86 (s, 1H), 4.23 (t, 2H, J = 6.6Hz), 2.67 (s,
3H), 1.80-1.40 (m, 4H), 1.57 (s, 9H), 1.42-1.08 (m, 16H), 0.89 (t, 3H, J= 6.6 Hz).
5-Benzyloxycarbonylamino-3-methyl-thiophene-2,4-dicarboxyllc acid 4-fertbutyl
ester 2-octyi ester. (4.4) The same method as for the preparation of 3-
methyl-5-heptyloxycarbonylamino-thiophene-2,4-dicarboxylic acid 4-tert-butyl ester
2-heptyl ester was employed. Thus, acylation with benzyl chloroformate (0.154 mL,
185 mg, 1.1 mmol) afforded 138 mg of a solid (52%) after column chromatography
(10:1; hexanes:EtOAc): Mp 65.0-66.0 aC; 1H NMR (CDCI3) 6 10.97 (s, 1H), 7.50-
7.30 (m, 5H), 5.28 (d, 2H, J = 4.8 Hz), 4.23 (t, 2H, J = 6.6 Hz), 2.72 (s, 3H), 1.80-
1.55 (m, 2H), 1.58 (s, 9H), 1.28 (bs, 10H), 0.89 (t, 3H, J= 6.6 Hz).
4-Methyl-2-octyIoxycarbonylamino-thiophene-3-carboxylic acid ethyl ester.
(4.5) The same method as for the preparation of 3-methyl-5-
heptyioxycarbonylamino-thiophene-2,4-dicarboxylic acid 4-tert-butyl ester 2-heptyl
ester was employed. Thus, acylation with octyl chlorofbrmate (1.06 ml, 1.04 g, 5.4
mmol) afforded 254 mg of an oil (28%) after column chromatography (9:1;
hexanes:EtOAc): 1H NMR (CDCI3) 6 10.53 (s, 1H), 6.31 (s, 1H), 4.34 (q, 2H, J= 6.8
Hz), 4.12 (t, 2H, J= 6.6 Hz).2.34 (s, 3H), 1.67 (bs, 2H), 1.37 (quint, 3H, J= 6.8 Hz),
1.28 (bs, 10H), 0.88 (t, 3H, J= 6.6 Hz). MS (El): 341.9 (m+).
5-/soPropoxycarbonylamino-3-methyl-thiophene-2,4-dicarboxylic acid 4-fertbutyl
ester 2-octyl ester. (4.6) The same method as for the preparation of 3-
methyl-5-heptyloxycarbonylamino-thiophene-2,4-dicarboxylic acid 4-fert-butyl ester
2-heptyl ester was employed. Thus, acylation with /so-propy! chloroformate in
toluene (0.54 mL, 0.54 mmol) afforded 117 mg of a solid (95%) after column
chromatography (9:1; KexanesrEtOAc): 1H NMR (CDCl3) 8 10.82 (s, 1H), 5.30 (s,
1H), 5.08 (sept, 1H, J = 6.2 Hz), 4.23 (t, 2H, J = 6.6 Hz), 2.73 (s, 3H), 1.80-1.60 (m,
2H), 1.60 (s, 9H), 1.34 (d, 6H, J= 6.2 Hz), 1.28 (bs, 10H), 0.88 (t, 3H, J= 6.6 Hz).
5-/so-Butoxycarbonylamino-3-methyl-thiophene-2,4-dicarboxylic acid 4-fertbutyl
ester 2-octyl ester. (4.7) The same method as for the preparation of 3-
methyl-5-heptyloxycarbonylamino-thiophene-2,4-dicarboxylic acid 4-tert-butyl ester
2-heptyl ester was employed. Thus, acylation with /so-butyl chloroformate (0.07 mL,
74.0 mg, 0.54 mmol) afforded 98 mg of a solid (77%) after column chromatography
(9:1; hexanes:EtOAc): 1H NMR (CDCI3) 8 10.86 (s, 1H), 4.23 (t, 2H, J = 6.6 Hz),
4.04 (d, 2H, J = 6.6 Hz), 2.73 (s, 3H), 2.02 (nonet, 1H, J = 6.6 Hz), 1.80-1.50 (m,
2H), 1.06 (s, 9H), 1.28 (bs, 10H), 1.00 (d, 6H, J = 6.6 Hz), 0.88 (t, 3H, J= 6.2 Hz).
Example 5: General Procedure for Acylation with Isocyanate of Diester
Reaction
O H
3-Methyl-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid 4-tert-butyl ester 2-
octyl ester. (5.1) To a stirring solution of 5-amino-3-methyl-thiophene-2,4-
dicarboxylic acid 2-octyl ester 4-tert-butyl ester (348 mg, 0.94 mmol) and DBU (0.35
mL, 360 mg, 2.4 mmol) in CH2CI2 (10 mL) was added octyl isocyanate (0.166 mL,
146 mg, 0.94 mmol). The reaction was stirred RT for 16 h, and then solvent was
removed under reduced pressure. The product was purified by column
chromatography (5:1; hexanes:EtOAc) to give 431 mg of a solid (87%): Mp 92.0-
94.0 BC; 1H NMR (CDCI3) 5 12.30 (s, 1H), 8.64 (s, 1H), 5.30 (t, 1H, J= 6.0 Hz), 4.25
(t, 2H, J = 6.4 Hz), 3.29 (q, 2H, J = 6.0 Hz), 2.74 (s, 3H), 1 .90-1 .50 (m, 4H), 1 .61 (s,
9H), 1 .28 (bs, 20H), 0.88 (m, 6H). MS (El): 525.1 (m+).
o
3-Methyl-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid 2-benzyl ester 4-
fert-butyl ester. (5.2) The same method as for the preparation of 3-methyl-5-(3-
octyl-ureido)-thiophene-2,4-dicarboxylic acid 4-fert-butyl ester 2-octyl ester was
employed. Thus, acylation with octyl isocyanate (3.83 mL, 3.37 g, 21.7 mmol)
afforded 3.42 g of a solid (38%) after column chromatography (9:1; hexanes:EtOAc):
Mp 119.0-120.0SC; 1H NMR (CDCI3) 8 11.03 (s, 1H), 7.50-7.20 (m, 5H), 5.27 (s, 2H),
5.03 (vt, 1H), 3.29 (q, 2H, J = 6.6 Hz), 2.71 (s, 3H), 1.63-1.40 (m, 2H), 1.57 (s, 9H),
1.26 (bs, 10H), 0.87 (t, 3H, J- 6.6 Hz). MS (El): 502.8 (m+).
o
3-Methyl-5-(3-tetradecyl-ureido)-thiophene-2,4-dicarboxylic acid 2-benzyl ester
4-tert-butyl ester. (5.3) The same method as for the preparation of 3-methyl-5-(3-
octyl-ureido)-thiophene-2,4-dicarboxylic acid 4-fert-butyl ester 2-octyl ester was
employed. Thus, acylation with tetradecyl isocyanate (0.33 ml, 287 mg, 1.2 mmol)
afforded 253 mg of a solid (36%) after column chromatography (9:1;
hexanes:EtOAc): Mp 104.5-106.0SC; 1H NMR (CDCI3) 6 11.04 (s, 1H), 7.50-7.20 (m,
5H), 5.27 (S, 2H), 5.14 (t, 1H, J = 6.2 Hz), 3.29 (q, 2H, J = 6.2 Hz), 2.71 (s, 3H),
1.65-1.40 (m, 2H), 1.57 (s, 9H), 1.25 (bs, 22H), 0.88 (t, 3H, J = 6.0 Hz). MS (El):
587.1 (m+).
5-(3-Hexadecyl-ureido)-3-methyl-thiophene-2,4-dicarboxylic acid 2-benzyl
ester 4-fert-butyl ester. (5.4) The same method as for the preparation of 3-methyl-
5-(3-octyl-ureido)-thiophene-2,4-dicarbQxylic acid 4-tert-butyl ester 2-octyl ester was
employed. Thus, acylation with hexadecyl isocyanate (0.37 mL, 321 mg, 1.2 mmol)
afforded 218 mg of a solid (30%) after column chromatography (9:1;
hexanes-.EtOAc): Mp 104.0-105.09C; 1H NMR (CDCI3) 8 11.04 (s, 1H), 7.50-7.20 (m,
5H), 5.27 (s, 2H), 5.14 (t, 1H, J = 6.2 Hz), 3.29 (q, 2H, J = 6.2 Hz), 2.71 (s, 3H),
1.65-1.40 (m, 2H), 1.57 (s, 9H), 1.25 (bs, 26H), 0.88 (t, 3H, J= 6.0 Hz). MS (El):
615.1 (m*).
5-(3-Dodecyl-ureido)-3-methyl-thiophene-2,4-dicarboxylic acid 2-benzyl ester
4-tert-butyl ester. (5.5) The same method as for the preparation of 3-methyl-5-(3-
octyl-ureido)-thiophene-2,4-dicarboxylic acid 4-fert-butyl ester 2-octyl ester was
employed. Thus, acylation with decyl isocyanate (0.29 mL, 254 mg, 1.2 mmol)
afforded 265 mg of a solid (40%) after column chromatography (9:1;
hexanes-.EtOAc): Mp 106.8-108.0SC). 1H NMR (CDCI3) 8 11.04 (s, 1H), 7.45-7.26
(m, 5H), 5.27 (s, 2H), 5.24 (t, 1H, J= 5.6 Hz), 3.28 (q, 2H, J= 6.6 Hz), 2.72 (s, 3H),
1.60-1.40 (m, 2H), 1.57 (s, 9H), 1.25 (bs, 18H), 0.88 (t, 3H, J = 6.4 Hz). MS (El):
559.0 (m+).
Example 6: General Procedure TFA Deprotection at C-2
Ph,v-o
3-Methoxymethyl-5-octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-
benzyl ester. (6.1) To a stirring solution of 3-methoxymethyl-5-
octyloxycarbonylamino-thiophene-2,4-dicarboxylic acid 2-benzyl ester 4-fert-butyl
ester (0.60 mg, 0.11 mmol) in CH2CI2 (1.0 ml) was added TFA (1.0 ml). The
reaction was stirred at room temperature for 12 hrs, then solvent was removed
under reduced pressure to give a solid. The product was taken on without further
purification: 1H NMR (CDCI3) 8 11.98 (s, 1H), 10.09 (s, 1H), 7.45-7.20 (m, 5H), 5.14
(s, 2H), 4.22 (t, 2H, J = 6.6 Hz), 3.85 (s, 3H), 3.82 (s, 2H), 1.70 (quint, 2H, J = 6.6
Hz), 1.28 (bs, 10H), 0.88 (t, 3H, J = 5.6 Hz).
o
(,0
3-Methoxymethyl-5-octyloxycarbonylamino-thiophene-2,4-dicarboxylic acid 2-
octyl ester. (6.2) The same method as for the preparation of 3-methoxymethyl-5-
octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester was
employed. Thus, deprotection with TFA afforded 64 mg of a solid (68%) aftei
column chromatography (5:1; hexanes:EtOAc): 1H NMR (CDCI3) 5 10.56 (s, 1H),
4.27 (t, 2H, J = 6.5 Hz), 4.25 (t, 2H, J = 6.5 Hz), 2.81 (s, 3H), 1.80-1.53 (m, 4H),
1.50-1.15 (m, 20H), 0.89 (t, 3H, J = 6.5 Hz). MS (El): 469.9 (m+).
5-Heptyloxycarbonylamino-3-methoxymethyl-thiophene-2,4-dicarboxylic acid
2-heptyl ester. (6.3) The same method as for the preparation of 3-methoxymethyl-
5-octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester was
employed. Thus, deprotection with TFA afforded 2.7 g of a solid (96%) after
tritration with hexanes: 1H NMR (CDCI3) 5 10.53 (s, 1H), 4.26 (t, 4H, J = 6.6 Hz),
2.81 (s, 3H), 1.90-1.58 (m, 4H), 1.60-1.12 (m, 16H), 0.89 (t, 3H, J= 6.6 Hz). MS (El):
441.9 (m+).
5-Benzyloxycarbonylamino-3-methyl-thiophene-2,4-dicarboxylic acid 2-octyl
ester. (6.4) The same method as for the preparation of 3-methoxymethyl-5-
octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester was
employed. Thus, deprotection with TFA afforded a solid, which was used without
purification: Mp 148.0-149.5 BC; 1H NMR (CDCI3) 8 10.56 (bs, 2H), 7.50-7.30 (m,
5H), 5.30 (d, 2H, J = 4.8 Hz), 4.25 (t, 2H, J = 6.6 Hz), 2.79 (s, 3H), 1.83-1.60 (m,
2H), 1.29 (bs, 10H), 0.89 (t, 3H, J= 6.6 Hz).
0
5-/SD-Propoxycarbonylamino-3-methyl-thiophene-2,4-dicarboxylic acid 2-octyl
ester. (6.5) The same method as for the preparation of 3-methoxymethyl-5-
octy!oxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester was
employed. Thus, deprotection with TFA afforded a solid, which was taken forward
without further purification: Mp 152.0-153.0 SC; 1H NMR (CDCI3) 6 10.45 (s, 1H),
5.12 (sept, 1H, J= 6.6 Hz), 4.25 (t, 2H, J = 6.6 Hz), 2.82 (s, 3H), 1.73 (quint, 2H, J =
6.6 Hz), 1.38 (d, 6H, J = 6.6 Hz), 1:28 (bs, 10H), 0.89 (t, 3H, J = 6.6 Hz).
o
5-;soButoxycarbonylamino-3-methyl-thiophene-2,4-dicarboxylic acid 2-octyl
ester. (6.6) The same method as for the preparation of 3-methoxymethyl-5-
octyloxycarbonylamino-thiophene[2;4]dicarboxylic acid 2-benzyl ester was
employed. Thus, deprotection with TFA afforded a solid, which was used without
purification: 1H NMR (CDCI3) 6 10.53 (bs, 2H), 4.26 (t, 2H, J= 6.2 Hz), 4.08 (d, 2H, J
= 6.6 Hz), 2.82 (s, 3H), 2.06 (nonet, 1H, J = 6.6 Hz), 1.71 (quint, 2H, J = 6.6 Hz),
1 .29 (bs, 1 0H), 1 .00 (d, 6H, J = 6.6 Hz), 0.89 (t, 3H, J = 6.6 Hz).
o
4-Methyl-5-octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid.
(6.7) The same method as for the preparation of 3-methoxymethyl-5-
octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester was
employed. Thus, deprotection with TFA afforded a solid, which was used without
purification: 1H NMR (CDCl3) 6 10.90 (bs, 2H), 5.82-5.62 (m, In), 5.76-5.60 (m, 1H),
3.33 (q, 4H, J = 6.6 Hz), 2.61 (s, 3H), 1.70-1.40 (m, 4H), 1.27 (bs, 20H), 0.88 (m,
6H).
3-Methyl-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid 2-octyl ester. (6.8)
The same method as for the preparation of 3-methoxymethyl-5-
octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester was
employed. Thus, deprotection with TFA afforded a solid, which was used without
purification: 1H NMR (CDCl3) 5 12.30 (s, 1H), 10.91 (bs, 2H), 5.30 (t, 1H, J== 6.0 Hz),
4.25 (t, 2H, J = 6.4 Hz), 3.29 (q, 2H, J = 6.0 Hz), 2.74 (s, 3H), 1.90-1.50 (m, 4H),
1.28 (bs, 20H), 0.88 (m, 6H). MS (El): 468.9 (m+).
BnNH
5-Ben2ylcarbamoyl-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid.
(6.9) The same method as for the preparation of 3-methoxymethy!-5-
octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester was
employed. Thus, deprotection with TFA afforded a solid, which was used without
purification: 1H NMR (CDCI3) 8 11.16 (s, 1H), 7.40-7.10 (m, 5H), 6.19 (t, 1H, J= 5.4
Hz), 4.56 (d, 2H, J = 5A Hz), 3.25 (q, 2H, J = 6.6 Hz), 2.63 (s, 3H), 1.60-1:40 (m,
2H), 1.26 (bs, 10H), 0.86 (t, 3H, J = 6.2 Hz). MS (El): 445.9 (m+).
5-DimethylcarbamoyI-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid.
(6.10) The same method as for the preparation of 3-methoxymethyl-5-
octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester was
employed. Thus, deprotection with TFA afforded a solid, which was used without
purification: 1H NMR (CDCI3) 8 10.89 (s, 2H), 5.39 (t, 1H, J= 6.6 Hz), 3.27 (q, 2H, J
= 6.6 Hz), 3.05 (s, 6H), 2.28 (s, 3H), 1.65-1.45 (m, 2H), 1.26 (s, 10H), 0.87 (t, 3H, J
= 6.2 Hz). MS (El): 383.9 (m+).
o
O H
3-Methyl-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid 2-benzyl ester.
(6.11) The same method as for the preparation of 3-methoxymethyl-5-
octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester was
employed. Thus, deprotection with TFA afforded a solid, which was used without
purification: 1H NMR (CDCU) 5 10.57 (s, 1H), 7.45-7.25 (m, 5H), 5.30 (s, 1H), 4.26 (t,
2H, J= 6.6 Hz), 2.81 (s, 3H), 1.72 (quint, 2H, J= 6.6 Hz), 1.28 (bs, 10H), 0.88 (t, 3H,
J=6.6Hz).
4-Methyl-5-octylcarbamoyl-2-(3-tetradecyl-ureido)-thiophene-3-carboxylic acid.
(6.12) The same method as for the preparation of 3-methoxymethyl-5-
octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester was
employed. Thus, deprotection with TFA afforded a solid, which was used without
purification.
2-(3-Hexadecyl-ureido)-4-methyl-5-octylcarbamoyl-thiophene-3-carboxylic
acid. (6.13) The same method as for the preparation of 3-methoxymethyl-5-
octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester was
employed. Thus, deprotection with TFA afforded a solid, which was used without
purification: MS (El): 580.2 (m"").
2"(3-Dodecyl-ureIdo)-4-methyl-5-octylcarbamoyl-thiophene-3-carboxylic acid.
(6.14) The same method as for the preparation of 3-methoxymethyl-5-
octyloxycarbonylamino-thiophene[2,4]cicarboxylic acid 2-benzyl ester was
employed. Thus, deprotection with TFA afforded a solid, which was used without
purification: MS (El): 524.1 (m+).
Example 7: Extra TFA Deportection
o
3-Methyl-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid. (7.1) To a stirring
solution of 3-methyl-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid 4-tert-butyl
ester (50.0 mg, 0.13 mmol) in CH2Cl2 (1 ml) was added TFA (1 mL). The reaction
was stirred at RT for 2 h, and then solvent was removed under reduced pressure to
give a solid. The product was dissolved in EtOAc, washed with sat. NaHCOs (aq.),
and brine. The organic layer was dried with MgSO4, filtered, and concentrated
under reduced pressure to give 10.0 mg of a solid (22%): 1H NMR (CDCI3) 8 10.45
(bs, 1H), 6.27 (bs, 1H), 5.00 (bs, 1H), 3.50-3.20 (m, 2H), 2.37 (s, 3H), 1.70-1.40 (m,
2H), 1.26 (bs, 10H), 0.88 (t, 3H, J= 6.2 Hz). MS (El): 312.9 (m+-COOH).
Example 8: Ethyl Ester Hydrolysis
4-Methyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid. (8.1) To a
stirring solution of 4-methyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid
ethyl ester (254 mg, 0.74 mmol) in ethanol (2 mL) and THF (2 mL) was added LiOHH2O
(31 mg, 0.74 mmol). The reaction was stirred at RT for 5 days, and then
solvent was removed under reduced pressure to give a solid. The product was
taken on without further purification: 1H NMR (CDCl3) 8 6.02 (s, 1H), 4.07 (t, 2H, J =
6.6 Hz), 2.32 (s, 3H), 1.60-1.40 (m, 2H), 1.27 (bs, 10H), 0.86 (t, 3H, J= 6.6 Hz).
Example 9: General Procedure for Hydrogenolysis at C-6
"
5-Methyl-2-octyloxy-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid (11)
To a stirring solution of 2-dodecyloxy-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-
carboxylic acid benzyl ester (50 mg, 0.10 mmol) in EtOAc (2 mL) was added 10%
Pd/C (5 mg, 10 wt%). The reaction was charged with H2 and stirred at RT for 1 h.
The reaction slurry was filtered through a plug of Celite, and the solvent was
removed in vacuo. The product was taken on without further purification: 1H NMR
(CDCI3) 8 4.47 (t, 2H, J= 6,2 Hz), 4.19 (bs, 1H), 2.85 (s, 3H), 1.80 (quint, 2H, J= 6.2
Hz), 1.27 (bs, 18H), 0.88 (t, 3H, J= 6.6 Hz). MS (El): 395.4 (m+).
3-i\Tiethyi-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid 4-ferf-butyl ester.
(9.1) The same method as for the preparation of 2-dodecyloxy-5-methyl-4-oxo-4/-/-
thieno[2,3-dl[1,3]oxazine-6-carboxylic acid was employed. Thus, hydrogenolysis
afforded a solid, which was used without purification: 1H NMR (CDCIa) 8 11.06 (s,
1H), 5.14 (vt, 1H), 3.30 (q, 2H, J= 6.0 Hz), 2.71 (s, 3H), 1.70-1.40 (m, 2H), 1.59 (s,
9H), 1.27 (bs, 10H), 0.87 (t, 3H, J= 6.6 Hz). MS (El): 412.8 (m+).
5-(3-Dodecyl-ureido)-3-methyl-thiophene-2,4-dicarboxylic acid 4-fert-butyl
ester. (9.2) The same method as for the preparation of 2-dodecyloxy-5-methyl-4-
oxo^H-thieno^.S-c/ltl.Sloxazine-e-carboxylic acid was employed. Thus,
hydrogenolysis afforded 0.198 g of a solid (98%), which was used without
purification: Mp 187.0-188.52C; 1H NMR (CDCI3) 8 11.06 (s, 1H), 5.21 (bs, 1H), 3.31
(q, 2H, J= 5.8 Hz), 2.72 (s, 3H), 1.65-1.40 (m, 2H), 1.60 (s, 9H), 1.26 (bs, 18H),
0.88 (t, 3H, J= 6.6 Hz). MS (El): 469.0 (m+).
3-Methyl-5-(3-tetradecyl-ureido)-thiophene-2,4-dicarboxylic acid 4-fert-butyl
ester. (9.3) The same method as for the preparation of 2-dodecyloxy-5-methyl-4-
oxo-4/:/-thieno[2,3-dl[1,3]oxazine-6-carboxylic acid was employed. Thus,
hydrogenolysis afforded 123 mg of a solid (58%), which was used without
purification: Mp 176.0-178.09C; 1H NMR (CDCI3) 8 11.06 (s, 1H), 7.35 (t, 1H, J= 6.2
Hz), 5.20 (bs, 1H), 3.30 (q, 2H, J= 6.2 Hz), 2.72 (s, 3H), 1.70-1.45 (m, 2H), 1.59 (s,
9H), 1.25 (bs, 22H), 0.88 (t, 3H, J= 6.6 Hz). MS (El): 497.0 (m*).
o
5-(3-Hexadecyl-ureido)-3-methyl-thiophene-2,4-dicarboxylic acid 4-fert-butyl
ester. (9.4) The same method as for the preparation of 2-dodecyloxy-5-methyl-4-
oxo-4/-/-thieno[2,3-d][1,3]oxazine-6-carboxylic acid was employed. Thus,
hydrogenolysis afforded a solid, which was used without purification: Mp 187.5-
189.02C; 1H NMR (CDCI3) 5 11.07 (s, 1H), 5.18 (bs, 1H), 3.29 (q, 2H, J= 6.2 Hz),
2.72 (s, 3H), 1.70-1.45 (m, 2H), 1.60 (s, 9H), 1.25 (bs, 26H), 0.88 (t, 3H, J= 6.6 Hz).
MS (El): 525.0 (m*).
Example 10: General Procedure for Amide/Ester Formation at C-6
o
4-Methyl-5-octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid tertbutyl
ester. (10.1) To a stirring solution of 3-methyl-5-(3-octyl-ureido)-thiophene-
2,4-dicarboxylic acid 4-fert-butyl ester (185 mg, 0.46 mmol) and octyl amine (0.112
ml, 87.3 mg, 0.69 mmol) in CH2CI2 (10 mL) was added EDO (133 mg, 0.69 mmol)
and DMAP (2.8 mg, 0.02 mmol). The reaction was stirred at RT for 16 h, washed
with H2O, 0.5N citric acid, sat. NaHCOs, and brine. The organic fraction was dried
(MgSC>4), filtered, and concentrated in vacua. The residue was purified by column
chromatography (9:1; hexanes:EtOAc) to give 290 mg of a solid (99%): 1H NMR
(CDCI3) 8 10.89 (s, 1H), 5.82-5.62 (m, 1H), 5.78-5.60 (m, 1H), 3.33 (q, 4H, J = 6.6
Hz), 2.61 (s, 3H), 1.70-1.40 (m, 4H), 1.55 (s, 9H), 1.27 (bs, 20H), 0.88 (m, 6H). MS
(El): 524.1 (m+).
BnNH
O
5-Benzylcarbamoyl-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid
fert-butyl ester. (10.2) The same method as for the preparation of 4-methyl-5-
octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid fert-butyl ester was
employed. Thus, coupling with benzyl amine (0.061 mL, 60 mg, 0.56 mmol)
afforded 202 mg of a solid (99%) after by column chromatography (95:5;
CHCI3:MeOH): 1H NMR (CDCI3) 8 10.90 (s, 1H), 7.40-7.20 (m, 5H), 6.05 (t, 1H, J =
5.4 Hz), 5.33 (t, 1H, J - 6.6 Hz), 4.55 (d, 2H, J = 5.4 Hz), 3.26 (q, 2H, J = 6.6 Hz),
2.63 (s, 3H), 1.65-1.40 (m, 2H), 1.56 (s, 9H), 1.26 (bs, 10H), 0.87 (t, 3H, J = 6.2 Hz).
MS (El): 502.0 (m+).
o
5-Dimethylcarbamoyl-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid
ferf-butyl ester. (10.3) The same method as for the preparation of 4-methyl-5-
octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid fert-butyl ester was
employed. Thus, coupling with a 40% solution of dimethyl amine in HaO (0.063 ml_,
0.56 mmol) afforded 174 mg of a solid (99%) after by column chromatography (95:5;
CHCI3:MeOH): 1H NMR (CDCI3) 5 10.78 (s, 1H), 5.39 (t, 1H, J = 6.6 Hz), 3.27 (q,
2H, J= 6.6 Hz), 3.05 (s, 6H), 2.28 (s, 3H), 1.65-1.45 (m, 2H), 1.56 (s, 9H), 1.26 (s,
10H), 0.87 (t, 3H, J= 6.2 Hz). MS (El): 440.0 (m+).
2-(3-Dodecyl-ureido)-4-methyl-5-octylcarbamoyl-thlophene-3-carboxylic acid
fert-butyl ester. (10.4) The same method as for the preparation of 4-methyl-5-
octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid te/t-butyl ester was
employed. Thus, coupling with octyl amine (0.111 mL, 87.0 mg, 0.69 mmol)
afforded 205 mg of a solid (81%) after by column chromatography (9:1;
hexanes:EtOAc): 1H NMR (CDCI3) 8 10.90 (s, 1H), 5.74 (t, 1H, J = 5.4 Hz), 5.47 (t,
1H, J = 6.2 Hz), 3.32 (vsext, 4H, J = 6.6 Hz), 2.61 (s, 3H), 1.70-1.40 (m, 4H), 1.55
(s, 9H), 1.26 (bs, 28H), 0.88 (t, 6H, J= 6.6 Hz). MS (El): 580.2 (m+).
o
4-Wlethyl-5-octylcarbamoyl-2-(3-tetradecyl-ureido)-thiophene-3-carboxylic acid
ferf-butyl ester. (10.5) The same method as for the preparation of 4-methyl-5-
octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid fert-butyl ester was
employed. Thus, coupling with octyl amine (0.112 mL, 87.3 mg, 0.69 mmol)
afforded 290 mg of a solid (99%) after by column chromatography (9:1;
hexanes:EtOAc): 1H NMR (CDCI3) 8 10.90 (s, 1H), 5.74 (t, 1H, J = 5.4), 5.44 (bs,
1H), 3.33 (vsext, 4H, J= 6.2 Hz), 2.61 (s, 3H), 1.60-1.40 (m, 4H), 1.56 (s, 9H), 1.26
(bs, 32H), 0.88 (t, 6H, J= 6.6 Hz). MS (El): 608.1 (m+).
o
2-(3-Hexadecyl-ureido)-4-methyl-5-octylcarbamoyl-thiophene-3-carboxylic acid
tert-butyl ester. (10.6) The same method as for the preparation of 4-methyl-5-
octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid terf-butyl ester was
employed. Thus, coupling with octyl amine (0.080 mL, 62.0 mg, 0.50 mmol)
afforded 195 mg of a solid (93% from BnOOC) after by column chromatography
(9:1; hexanes:EtOAc): 1H NMR (CDCI3) 8 10.90 (s, 1H), 5.73 (t, 1H, J= 5.4), 5.35
(bs, 1H), 3.33 (vsext, 4H, J= 6.2 Hz), 2.61 (s, 3H), 1.65-1.40 (m, 4H), 1.56 (s, 9H),
1.26 (bs, 36H), 0.88 (t, 6H, J = 6.6 Hz). MS (El): 636.2 (m+).
2-Heptyl-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid hexyl
ester (4) The same method as for the preparation of 4-methyl-5-octylcarbamoyl-2-
(3-octyl-ureido)-thiophene-3-carboxylic acid fert-butyl ester was employed. Thus,
coupling with octyl alcohol (0.125 mL, 1.50 mmol) afforded 20 mg of a solid (21%)
after by Prep. TLC (9:1; hexanes:EtOAc): 1H NMR (CDCI3) 5 4.29 (t, 2H, J= 6.6 Hz),
2.84 (s, 3H), 2.87 (t, 2H, J= 7.2 Hz), 2.00-1.60 (m, 4H), 1.15-1.60 (m, 24H), 1.15-
0.70 (m, 6H).
Example 11: General Procedure for Cyclization with EDCI
Ph,
\-0
5-Methoxy-2-octyloxy-4-oxo-4H-thieno[2,3-c/l[1,3]oxazine-6-carboxylic acid
benzyl ester (112) To a stirring solution of 3-methoxymethyl-5-
octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester (27 mg, 0.056
mmol) in CH2CI2 (1,0 ml) was added EDC (16.0 mg, 0.084 mmol). The reaction
was stirred at RT for 16 h, washed with H2O and brine. The organic fraction was
dried (MgSO4), filtered, and concentrated in vacua. The residue was purified by
column chromatography (5:1; hexanes:EtOAc) to give 7.0 mg of a solid (27%): 1H
NMR (CDCI3) 5 7.42-7.27 (m, 5H), 5.16 (s, 2H), 4.38 (t, 2H, J= 6.6 Hz), 3.89 (s, 3H),
3.85 (s, 2H), 1.78 (quint, 2H, J = 6.6 Hz), 1.50-1.10 (m, 10H), 0.89 (t, 3H, J = 6.6
Hz). MS(EI):461.9(m+H+).
5-Methyl-2-octyloxy-4-oxo-4H-thieno[2,3-c/][1,3]oxazine-6-carboxylic acid octyl
ester (9) The same method as for the preparation of 5-methoxy-2-octyloxy-4-oxo-
4H-thieno{2,3-d)[1I3]oxazine-6-carboxylic acid benzyl ester was employed. Thus,
cyclization afforded 15 mg of a solid (24%) after by column chromatography (9:1;
hexanes:EtOAc): Mp 58.5-60.22C; 1H NMR (CDCI3) 5 4.45 (t, 2H, J = 6.6 Hz), 4.29
(t, 2H, J= 6.6 Hz), 2.80 (s, 3H), 1.88-1.70 (m, 4H), 1.29 (bs, 20H), 0.89 (t, 6H, J =
6.6 Hz). MS(EI):451.8(m+).
Example 12: General Procedure for Cyclization with SOCI2
5-Methyl-2-heptyloxy-4-oxo-4H-thieno[2,3-dJ[1,3]oxazine-6-carboxylic acid
heptyl ester (10) To a stirring solution of 5-heptyloxycarbonylamino-3-
methoxymethyl-thiophene-2,4-dicarboxylic acid 2-heptyl ester (2.7 g, 6.1 mmol) in
pyridine (65 ml_) was added thionyl chloride (0.88 ml_, 1.4 g, 12.0 mmol). The
reaction was stirred RT for 0.5 h, and concentrated in vacuo. The residue was
dissolved in CHCI3, washed with H2O, 0.5 N citric acid, sat. NaHC03, and brine.
The organic fraction was dried (MgSO4), filtered, and concentrated in vacuo. The
residue was purified by column chromatography (20:1; hexanes:EtOAc) to give 2.6 g
of a solid (99%): 1H NMR (CDCI3) 6 4.45 (t, 2H, J = 6.6 Hz), 4.29 (t, 2H, J= 6.6 Hz),
2.80 (s, 3H), 1.78 (dquint, 4H, J= 13.2, 6.6 Hz), 1.58-1.18 (bs, 16H), 0.90 (t, 6H, J =
7.0 Hz); 13C NMR (CDCI3) 5 168.9, 162.1, 158.3, 154.0, 144.1, 121.4, 113.9, 71.1,
65.4, 31.6, 31.6, 28.8, 28.7, 28.6, 28.2, 25.9, 25.5, 22.5, 14.6, 14.0; MS (El): 423.9
2-Benzyloxy-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid
octyl ester (113) The same method as for the preparation of 5-methyl-2-heptyloxy-
4-oxo-4H-thieno[2,3-c(l[1,3]oxazine-6-carboxylic acid heptyl ester was employed.
Thus, cyclization afforded 11.0 mg of a solid (10%) after by column chromatography
(20:1; hexanes:EtOAc): 1H NMR (CDCI3) 8 7.55-7.30 (m, 5H), 5.48 (s, 2H), 4.29 (t,
2H, J= 6.6 Hz), 2.82 (s, 3H), 1.75 (quint, 2H, J= 6.6 Hz), 1.29 (bs, 10H), 0.89 (t, 3H,
J=6.6Hz).
2-/so-Propoxy-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid
octyl ester (12) The same method as for the preparation of 5-methyl-2-heptyloxy-4-
oxo-4H-thieno[2,3-cf)[1,3]oxazine-6-carboxylic acid heptyl ester was employed.
Thus, cyclization afforded 108 mg of a solid (98%) after by column chromatography
(20:1; hexanes:EtOAc): Mp 47.5-48.0sC; 1H NMR (CDCI3) 5 5.31 (sept, 1H, J = 6.2
Hz), 4.29 (t, 2H, J= 6.6 Hz), 2.81 (s, 3H), 1.75 (quint, 2H, J = 6.6 Hz), 1.44 (d, 6H, J
= 6.2 Hz), 1.29 (bs, 10H), 0.89 (t, 3H, J = 6.4 Hz); MS (El): 381.9 (m+).
2-/so-Butoxy-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid
octyl ester (114) The same method as for the preparation of 5-methyl-2-hepty!oxy-
4-oxo-4H-thieno[2,3-dj[1,3]oxazine-6-carboxylic acid heptyl ester was employed.
Thus, cyclization afforded 15 mg of a solid (25%) after by column chromatography
(20:1; hexanes:EtOAc): 1H NMR (CDCI3) 6 4.31 (q, 2H, J= 6.6 Hz), 4023 (d, 2H, J =
6.6 Hz), 2.82 (s, 3H), 2.13 (nonet, 1H, J= 6.6 Hz), 1.73 (quint, 2H, J = 6.6 Hz), 1.29
(bs, 10H), 1.03 (d, 6H, J= 6.6 Hz), 0.89 (t, 3H, J= 6.6 Hz); MS (El): 395.9 (m+).
5-Methyl-2-octyloxy-thieno[2,3-d][1,3]oxazln-4-one (23) The same method as for
the preparation of 5-methyl-2-heptyloxy-4-oxo-4H-thieno[2,3-o][1,3]oxazine-6-
carboxylic acid heptyl ester was employed. Thus, cyclization afforded 44 mg of an
oil (20%) after by column chromatography (20:1; hexanes:EtOAc): 1H NMR (CDCI3)
8 6.59 (s, 1H), 4.41 (t, 2H, J = 6.6 Hz), 2.46 (s, 3H), 1.80 (quint, 2H, J = 6.6 Hz),
1.29 (bs, 10H), 0.89 (t, 3H, J= 6.6 Hz); MS (El): 295.9 (m+).
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid
octyl amide (18) The same method as for the preparation of 5-methyl-2-heptyloxy-4-
oxo-4/-/-thieno[2,3-d][1,3]oxazine-6-carboxylic acid heptyl ester was employed.
Thus, cyclization afforded 106 mg of a solid (52% from 4-methyl-5-octylcarbamoyl-2-
(3-octyl-ureido)-thiophene-3-carboxylic acid tert-butyl ester) after by column
chromatography (95:5; CHCI3:MeOH): Mp 152.0-152.8SC; 1H NMR (CDCI3) 8 5.70
(bs, 1H), 5.06 (bs, 1H), 3.42 (q, 6H, J = 6.2 Hz), 2.71 (s, 3H), 1.70-1.42 (m, 4H),
1.54 (s, 9H), 1.28 (bs, 20H), 0.89 (t, 6H, J= 6.6 Hz); MS (El): 450.5 (m+1).
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid
octyl ester (20) The same method as for the preparation of 5-methyl-2-heptyloxy-4-
oxo-4H-thieno[2,3-c(][1,3]oxazine-6-carboxylic acid heptyl ester was employed.
Thus, cyclization afforded 229 mg of a solid (67% from t-Bu ester) after by column
chromatography (20:1; hexanes:EtOAc): 1H NMR (CDCI3) 5 5.20 (bs, 1H), 4.26 (t,
2H, J= 6.6 Hz), 3.51-3.40 (m, 2H), 2.78 (s, 3H), 1.85-1.48 (m, 4H), 1.28 (bs, 20H),
1.00-0.80 (m, 6H); MS (El): 451.0 (m+).
BnNH
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid
benzylamide (21) The same method as for the preparation of 5-methyl-2-
heptyloxy-4-oxo-4H-thieno[2,3-d|[1,3]oxazine-6-carboxylic acid heptyl ester was
employed. Thus, cyclization afforded 75.0 mg of a solid (49% from 3-methyl-5-(3-
octyl-ureido)-thiophene-2,4-dicarboxylic acid 4-tert-butyl ester) after by column
chromatography (95:5; CHCI3:MeOH): 1H NMR (CDCI3) 6 7.40-7.26 (m, 5H), 6.03 (t,
1H, J= 5.4 Hz), 5.20 (bs, 1H), 4.62 (d, 2H, J= 5.4 Hz), 3.50-3.30 (m, 2H), 2.72 (s,
3H), 1.73-1.43 (m, 2H), 1.28 (bs, 10H), 0.88 (t, 3H, J = 6.6 Hz). MS (El): 427.9 (m+).
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxa2ine-6-carboxylic acid
dimethylamide (22) The same method as for the preparation of 5-methyl-2-
heptyloxy-4-oxo-4H-thieno[2,3-c(l[1,3]oxazine-6-carboxylic acid heptyl ester was
employed. Thus, cyclization afforded 17.0 mg of a solid (13% from 3-methyl-5-(3-
octyl-ureido)-thiophene-2,4-dicarboxylic acid 4-tert-butyl ester) after by column
chromatography (1:1 to 1:5; hexanes:EtOAc): 1H NMR (CDCI3) 5 5.22 (bs, 1H), 3.41
(q, 2H, J= 5.4 Hz), 3.08 (s, 6H), 2.41 (s, 3H), 1.62 (quint, 2H, J =6.6 Hz), 1.28 (bs,
10H), 0.88 (t, 3H, J= 6.2 Hz); MS (El): 365.9 (m'+).
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxyllc acid
benzyl ester (16) The same method as for the preparation of 5-methyl-2-heptyloxy-
4-oxo-4H-thieno[2,3-cfl[1l3]oxazine-6-carboxylic acid heptyl ester was employed.
Thus, cyclization afforded 108 mg of a solid (63% from 3-methyl-5-(3-octyl-ureido)-
thiophene-2,4-dicarboxylic acid 2-benzyl ester 4-tert-butyl ester) after by column
chromatography (9:1; hexanes:EtOAc): Mp 153.5-154.05C; 1H NMR (CDCI3) 8 7.50-
7.30 (m, 5H), 5.44 (bs, 1H), 5.32 (s, 2H), 3.42 (q, 2H, J= 6.2 Hz), 2.79 (s, 3H), 1.78-
1.50 (m, 2H), 1.27 (bs, 10H), 0.88 (t, 3H, J = 6.4 Hz); MS (El): 428.9 (m+).
2-Heptylamino-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid
benzyl ester (17) The same method as for the preparation of 5-methyl-2-heptyloxy-
4-oxo-4H-thieno[2,3-o(j[1,3]oxazine-6-carboxylic acid heptyl ester was employed.
Thus, cyclization afforded 12 mg of a solid; 1H NMR (CDCI3) 8 7.50-7.30 (m, 5H),
5.32 (s, 2H), 5.24 (bs, 1H), 3.42 (q, 2H, J= 6.2 Hz), 2.79 (s, 3H), 1.78-1.50 (m, 2H),
1.27 (bs, 8H), 0.88 (t, 3H, J= 6.4 Hz); MS (El): 414.8 (m+).
2-Dodecylamino-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid
octylamide (24) The same method as for the preparation of 5-methyl-2-heptyloxy-4-
oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid heptyl ester was employed.
Thus, cyclization afforded 56 mg of a solid (32% from 2-(3-decyl-ureido)-4-methyl-5-
octylcarbarnoyl-thiophene-3-carboxylic acid ferf-butyl ester) after by column
chromatography (9:1 to 5:1; hexanes:EtOAc): Mp 137.1-138.0eC; 1H NMR (CDCI3)
6 5.74 (bs, 1H), 5.30 (bs, 1H), 3.42 (q, 4H, J= 6.6 Hz), 2.71 (s, 3H), 1.75-1.45 (m,
4H), 1.27 (bs, 28H), 0.89 (t, 6H, J= 6.0 Hz); MS (El): 506.1 (m+).
5-Methyl-4-oxo-2-tetradecylamino-4H-thieno[2,3-d]t1,3]oxazine-6-carboxylic
acid octylamide (25) The same method as for the preparation of 5-methyl-2-
heptyloxy^-oxo^H-thieno^.S-cfJtl.Sloxazine-e-carboxylic acid heptyl ester was
employed. Thus, cyclization afforded 25 mg of a solid (19% from 4-methyl-5-
octylcarbamoyl-2-(3-tetradecyl-ureido)-thiophene-3-carboxylic acid ferf-butyl ester)
after by column chromatography (5:1; hexanes:EtOAc): Mp145.0-145.89C; 1H NMR
(CDCla) 6 5.74 (bs, 1H), 5.30 (bs, 1H), 3.42 (q, 4H, J= 6.6 Hz), 2.71 (s, 3H), 1.75-
1.45 (m, 4H), 1.27 (bs, 32H), 0.89 (t, 6H, J = 6.0 Hz); MS (El): 534.1 (m4).
2-Hexadecylamino-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxync
acid octylamide (26) The same method as for the preparation of 5-methyl-2-
heptyloxy-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid heptyl ester was
employed. Thus, cyclization afforded 24 mg of a solid (14% from 2-(3-hexadecylureido)-
4-methyl-5-octylcarbamoyl-thiophene-3-carboxylic acid ferf-butyl ester) after
by column chromatography (5:1; hexanes:EtOAc): Mp 146.3-147.OeC; 1H NMR
(CDClg) 8 5.74 (bs, 1H), 5.30 (bs, 1H), 3.42 (q, 4H, J = 6.6 Hz), 2.71 (s, 3H), 1.75-
1.45 (m, 4H), 1.27 (bs, 36H), 0.89 (t, 6H, J= 6.0 Hz); MS (El): 562.1 (m+).
N H
5-MethyI-4-oxo-2-(4-phenoxy-phenylamino)-4H-thieno[2,3-d][1,3]oxazine-6-
carboxylic acid octyl ester (19) The same method as for the preparation of 5-
methyl-a-heptyloxy^-oxo^H-thieno^.S-c/in.SJoxazine-e-carboxylic acid heptyl ester
was employed. Thus, cyclization afforded a solid, which was purified by
recrystalization from EtOAc/Hexanes to give 25 mg of a solid (24%): 1H NMR
(CDClg) 6 7.50 (d, 2H, J= 8.8 Hz), 7.25-7.45 (m, 2H), 7.40-6.90 (m, ,5H), 4.27 (t, 2H,
J = 6.6 Hz), 2.81 (s, 3H), 1.73 (dt, 2H, J = 6.6 Hz), 1.27 (m, 10H), 0.89 (t, 3H, J = 6.0
Hz).
2-Heptyloxy-5-methyl-4-oxo-4H-thieno[2,3-dJ[1,3]oxazine-6-carboxylic acid
benzyl ester (8) The same method as for the preparation of 5-methyl-2-heptyloxy-4-
oxo-4H-thieno[2,3-ad[1,3]oxazine-6-carboxylic acid heptyl ester was employed.
Thus, cyclization afforded 116 mg of a solid (63%) after by column chromatography
(4:1; hexanes:EtOAc): 1H NMR (CDCl3) 6 7.50-7.30 (m, 5H), 5.33 (s, 2H), 4.44 (t,
2H, J = 6.2 Hz), 1.90-1.70 (m, 2H), 1.45-1.15 (m, 10H), 1.00-0.80 (m, 3H).
5-Wlethyl-2-octyloxy-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid
octylamlde (15) The same method as for the preparation of 5-methyl-2-heptyloxy-4-
oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid heptyl ester was employed.
Thus, cyclization afforded 44.0 mg of a solid (44%) after by column chromatography
(4:1; hexanes:EtOAc): 1H NMR (CDCI3) 5 5.90-5.70 (m, 1H), 4.43 (t, 2H, J = 6.6 Hz),
3.42 (q, 2H, J = 6.6 Hz), 2.72 (s, 3H), 1.90-1.70 (m, 2H), 1.70-1.50 (m, 2H), 1.50-
1.15 (m, 20H), 0.95-0.80 (m, 6H).
Example 13: Carbamate/Urea Intermediates
4-Wlethyl-2-(3-octyl-ureido)-5-[(pyridin-4-ylmethyl)-carbamoyl]-thlophene-3-
carboxylic acid tert-butyl ester (13.1) The compound was purified by column
chromatography (100% EtOAc) to yield 175 mg (70%) of a white foam.: (70%). 'H
NMR (CDCI3, 200MHz) 8 0.86 (m, 3H), 1.25 (brs, 10H), 1.56 (brs, 11H), 2.64 (s,
3H), 3.28 (dt, 2H, J= 6.2Hz, J = 6.6Hz), 4.56 (d, 2H, J= S.BHz), 5.16 (t, 1H, J=
5.4Hz), 6.17 (t, 1H, J= 5.8HZ), 7.24 (d, 2H, J= 5.8Hz), 8.54 (d, 2H, J= 5.8Hz), 10.94
4-Methyl-5-[methyl-(6-methyl-pyridin-2-ylmethyl)-carbamoyl]-2-(3-octyl-ureido)-
thiophene-3-carboxylic acid tert-butyl ester (13.2): (84%). 'H NMR (CDCI3,
200MHz) 8 0.87 (m, 3H), 1.25 (brs, 10H), 1.56 (brs, 11H), 2.32 (s, 3H), 2.52 (s, 3H),
3.01 (s, 3H), 3.28 (dt, 2H, J= 6.2Hz, J = 6.6Hz), 4.74 (s, 2H), 4.95 (t, 1H, J= 5.4Hz),
7.03 (d, 2H, J=7.8Hz), 7.55 (t, 1H, J=7.6Hz), 10.75 (s, 1H)
5-[Ethyl-(2-pyridin-2-yl-ethyl)-carbamoyl]-4-methyl-2-(3-octyl-ureido)-
thiophene-3-carboxylic acid tert-butyl ester (13.3): (99%). 'H NMR (CDCI3,
200MHz) 8 0.87 (m, 3H), 1.11 (t, 3H, J= 7.0Hz), 1.25 (brs, 10H),.1.56 (brs, 11H),
2.20 (s, 3H), 3.09 (t, 2H, J= 7.0Hz), 3.26 (m, 4H), 3.80 (t, 2H, J= 7.0Hz), 5.08 (t, 1H,
J= 5.0HZ), 7.15 (m, 2H), 7.59 (ddd, 1H, J= 7.6Hz, J= 7.6Hz, J= 1.4Hz), 8.51 (d, 1H,
J=4.4Hz), 10.76 (S.1H)
5-(Benzyloxycarbonylmethyl-carbamoyl)-4-methyl-2-(3-octyl-ureldo)-thiophene-
3-carboxylic acid tert-butyl ester (13.4): (95%). 1H NMR (CDCI3l 200MHz) 8 0.86
(m, 3H), 1.25 (brs, 10H), 1.58 (brs, 11H), 2.56 (s, 3H), 3.25 (dt, 2H, J= 6.2Hz, J =
6.6Hz), 4.21 (d, 2H, J= 5.4Hz), 5.21 (s, 2H), 5.49 (brs, 1H), 6.51 (t, 1H, J= 5.6Hz),
7.36(8, 5H), 10.71 (s,1H)
5-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinoline-2-carbonyl)-4-methyl-2-(3-octylureido)-
thiophene-3-carboxylic acid tert-butyl ester (13.5): (97%). 'H NMR
(CDCl3, 200MHz) 8 0.87 (brs, 3H), 1.27 (brs, 10H), 1.57 (s, 11H), 2.30 (s, 3H), 2.83
(t, 2H, J= 5.8Hz), 3.29 (dt, 2H, J= 6.2Hz, J= 6.6Hz), 3.80 (m, 8H), 4.69 (s, 2H), 4.87
(t, 1H, J=5.6Hz), 6.55 (s, 1H), 6.60 (s, 1H), 10.83 (s, 1H)
5-(3,4-Dimethoxy-benzylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophener3-
carboxylic acid tert-butyl ester (13.6): (97%). 'H NMR (CDCI3, 200MHz) 5 0.86
(brs, 3H), 1.25 (brs, 10H), 1.56 (s, 11H), 2.63 (s, 3H), 3.25 (dt, 2H, J= 6.2Hz, J=
6.6H2), 3.86 (s, 6H), 4.47 (d, 2H, J= 5.6Hz), 5.05 (t, 1H, J= 5.8Hz), 5.95 (t, 1H, J=
S.OHz), 6.84 (m, 3H), 10.90 (s, 1H)
5-(2-Acetylamino-ethylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-
carboxylic acid tert-butyl ester (13.7): (58%). 'H NMR (CDCI3, 200MHz) 8 0.87
(s, 3H), 1.27 (brs, 10H), 1.57 (brs, 11H), 2.04 (s, 3H), 2.60 (s, 3H), 3.29 (dt, 2H, J=
6.2Hz, J= 6.6Hz), 3.50 (m, 4H), 4.90 (brs, 1H), 6.29 (brm, 2H), 10.92 (s, 1H)
5-[4-(lsopropylcarbamoyl-methyl)-piperazine-1-carbonyl]-4-methyl-2-(3-octylureido)-
thiophene-3-carboxylic acid tert-butyl ester (13.8): (61%). 'H NMR
(CDCI3, 200MHz) 5 0.86 (brs, 3H), 1.10-1.28 (m, 16H), 1.56 (s, 11H), 2.29 (s, 3H),
2.51 (s, 4H), 2.99 (s, 3H), 3.27 (dt, 2H, J= 6.2Hz, J= 6.6Hz), 3.63 (s, 4H), 4.10 (m,
1H), 5.05 (brs, 1H), 6.81 (d, 1H, J= S.OHz), 10.79 (s, 1H)
3-Methyl-5-(3-octyl-thioureido)-thiophene-2,4-dicarboxylic acid 2-benzyl ester
4-tert-butyl ester (13.9): 'H NMR (CDCI3l 200MHz) 6 0.88 (m, 3H), 1.28 (brs,
10H), 1.59 (m, 11H), 2.72 (s, 3H), 3.47 (m, 2H), 5.30 (s, 2H), 6.31 (brs, 1H), 7.36 (m,
5H).
4-Methyl-2-(3-octyl-ureido)-5-[(pyridin-3-yl-methyl)-carbamoyl]-thiophene-3-
carboxylic acid tert-butyl ester (13.10). The reaction was passed through a plug
of silica gel with ethyl acetate to yield 13.10, 3.42 g (94% crude yield) of an off white
solid.
5-[(Furan-2-ylmethyl)-carbamoyl]-4-methyl-2-(3-octyl-ureido)-thiophene-3-
carboxylic acid tert-butyl ester (13.11) white solid (97% yield): 'H NMR (CDCI3,
200MHz) 5 0.86 (t, 3H, J= 6.6 Hz), 1.24-1.27 (m, 10H), 1.54 (bs, 11H), 2.61 (s, 3H),
3.26 (dt, 2H, J= 6.4, 5.8 Hz), 4.54 (d, 2H, J= 5.4 Hz), 5.31 (bs, 1H), 6.02 (t, 1H, J =
5.3 Hz), 6.27 (1H, dd, J= 11.4, 3.2 Hz), 6.30, (d, 1H, J = 3.2 Hz), 7.34 (s, 1H), 10.89
(bs, 1H). UC NMR (CDCIa) 6 14.0, 16.0, 22,6, 26.8, 28.4, 29.1, 29.2, 29.9, 31.7,
36.9, 40.8, 82.3, 107.6, 110.4, 112.9, 118.7, 140.5, 142.3, 151.0, 152.7, 153.6,
163.2, 166.4. MS (ES+) 491.95 (M+1), 493.00 (M+2).
4-Wlethyl-2-(3-octyl-ureido)-5-[(2-pyridin-3-yl-ethyl)-carbamoyl]-thiophene-3-
carboxylic acid tert-butyl ester (13.12) white solid (73% yield): 'H NMR (CDCI3)
200MHz) 8 0.85 (t, 3H, J= 6.6 Hz), 1.21-1.28 (m, 10H), 1.52 (bs, 11H), 2.54 (s, 3H),
2.89 (t, 2H, J= 6.9 Hz), 3.27 (dt, 2H, J= 6.4, 6.2 Hz), 3.61 (dt, 2H, J= 6.6, 6.2 Hz),
5.69 (bs, 1H), 5.92 (t, 1H, J= 5.9 Hz), 7.23 (dd, 1H, J = 6.2, 5.2 Hz), 7.55, (ddd, 1H,
J = 7.6, 1.8, 1.8 Hz), 8.46 (d,1H,J = 4.8 Hz), 8.47(8, 1H), 10.81 (bs, 1H). 13C NMR
(CDCI3) 5 14.0, 15.9, 22.6, 26.8, 28.3, 29.1, 29.2, 29.9, 31.7, 33.0, 40.7, 40.9, 82.2,
112.7, 118.9, 123.5, 134.4, 136.3, 139.9, 147.9, 150.1, 152.6, 153.6, 163.7, 166.3.
MS (ES+) 516.98 (M+1), 518.05 (M+2).
4-Methyl-2-(3-octyl-ureido)-5-[4-(2-piperidin-1-yl-ethyl)-piperazine-1-carbonyl]-
thiophene-3-carboxylic acid tert-butyl ester (13.13) yellow oil (80% yield): 'H.
NMR (CDCI3, 200MHz) 5 0.84 (t, 3H, J = 6.4 Hz), 1.22 (bs, 12H), 1.53 (m, 15H),
2.25, (s, 3H), 2.33-2.52 (m, 8H), 3.23 (dt, 2H, J = 6.6, 6.4 Hz), 3.57 (bs, 2H), 5.63
(bs, 1H), 10.73 (bs, 1H). MS (ES+) 592.07 (M+1), 593.13 (M+2).
5-(3-Hexyl-3-methyl-ureido)-3-methyl-thiophene-2,4-dicarboxylic acid 2-benzyl
ester 4-tert-butyl ester (13.14). 1H NMR (CDCI3, 200MHz) 8 0.87 (t, 3H, J = 6.4
Hz), 1.25-1.32 (m, 6H), 1.58 (s, 11H), 2.72 (s, 3H), 3.04 (s, 3H), 3.36 (t, 2H, J = 7.7
Hz), 5.26 (s, 2H), 7.27-7.43 (m, 5H), 11.53 (bs, 1H). I3C NMR (CDCI3) 8 13.9, 15.8,
22.5, 26.3, 27.7, 28.3, 31.4, 34.4, 49.3, 65.8, 82.3, 113.1, 115.2, 127.9, 128.4, 136.1,
145.5,153.6,156.6,163.0, 166.7. MS (ES+) 557 (M+68).
5-[3-(1 -Butyl-pentyl)-ureido]-3-methyl-thiophene-2,4-dicarboxylic acid 2-benzyl
ester 4-tert-butyl ester (13.15). 'H NMR (CDCI3, 200MHz) 80.86 (t, 6H, J = 6.6
Hz), 1.25-1.31 (m, 12H), 1.55 (s, 9H), 2.70 (s, 3H), 3.58-3.78 (m, 1H), 5.04 (bd, 1H, J
= 8.8 Hz), 5.25 (S, 2H), 7.27-7.41 (m, 5H), 10.98 (bs, 1H). "C NMR (CDCI3) 8 13.9,
14.0, 15.8, 22.6, 22.7, 28.0, 28.1, 28.3, 35.1, 35.6, 65.9, 82.3, 112.8, 115.2, 127.9,
128.4,136.1,145.5,153.1,156.3, 163.0,166.4,186.4. MS (ES+) 585 (M+68).
5-(3,3-Dioctyl-ureido)-3-methyl-thiophene-2,4-dicarboxylic acid 2-benzyl ester
81
4-fert-butyl ester (13.16). 'H NMR (CDCI3l 200MHz) 80.87 (t, 6H, J = 6.6 Hz),
1.26-1.30 (m, 20H), 1.58 (bs, 13H), 2.72 (s, 3H), 3.32 (t, 4H, J = 7.7 Hz), 5.25 (s,
2H), 7.28-7.43 (m, 5H), 11.58 (bs, 1H). 13C NMR (CDCI3) 8 14.0, 15.8, 22.6, 26.9,
28.3, 28.5, 29.2, 29.3, 31.8, 47.9, 65.9, 82.3, 113.0, 115.1, 127.9, 128.0, 128.5,
136.1, 145.6, 153.3, 156.7, 163.0, 166.7.
5-lsobutylcarbamoyl-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid
tert-butyl ester (13.17). MS (ES): m/z 467.9 [MH+]. 1H NMR (CDCI3, 200 MHz): 8
= 0.83 (m, 9H), 1.26-1.57 (m, 20H), 1.87 (m, 1H, 6.6 Hz), 2.62 (s, 3H), 3.16-3.30 (m,
4H), 5.11 (brs, 1H), 5.64 (m, 1H).
5-(2,2-Dimethyl-propylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-
carboxylic acid tert-butyl ester (13.18). MS (ES): m/z 481.7 [MH+]. 1H NMR
(CDCI3, 200 MHz): 5 = 0.83 (m, 9H), 1.26-1.57 (m, 23H), 2.62 (s, 3H), 3.16-3.30 (m,
4H), 5.11 (brs, 1H), 5.64 (m, 1H).
5-[(2,3-Dihydro-benzofuran-5-ylmethyl)-carbamoyl]-4-methyl-2-(3-octyl-ureido)-
thiophene-3-carboxylic acid tert-butyl ester (13.19). MS (ES): m/z 543.87 [MH+].
4-Methyl-2-(3-octyl-ureido)-5-[(pyridin-2-ylmethyl)-carbamoyl]-thiophene-3-
carboxylic acid tert-butyl ester (13.20) The same method as for the preparation of
4-methyl-5-octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid tert-butyl
ester was employed. Thus, coupling with 2-(aminomethyl)pyridine (31.5 mg, 0.36
mmol) afforded 86.9 mg of a solid (71%) after by column chromatography (EtOAc):
1H NMR (CDCI3) 8 0.87 (m, 3H), 1.45-1.20 (m, 10H), 1.70-1.45 (m, 11H), 2.64 (s,
3H), 3.29 (dt, 4H, J = 6.7, 6.6 Hz), 4.68 (d, 2H, J = 5.8H.Z), 4.91 (m, TH), 7.02 (m,
1H), 7.35-7.10 (m, 1H), 7.65 (t, 1H, J = 8.0Hz), 8.53 (d, 1H, J = 5.0 Hz), 10.92 (s,
1H); MS (El): cal'd 502.86, exp 502.94 (MH+).
4-Methyl-2-(3-octyl-ureido)-5-[(pyridin-3-ylmethyl)-carbamoyl]-thiophene-3-
carboxylic acid tert-butyl ester (13.21) The same method as for the preparation of
4-methyl-5-octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid tert-butyl
ester was employed. Thus, coupling with 3-(aminomethyl)pyridine (31.5 mg, 0.36
mmol) afforded 93.1 mg of a solid (76%) after by column chromatography (EtOAc):
1H NMR (CDCl3) 5 0.87 (m, 3H), 1.45-1.20 (m, 10H), 1.70-1.45 (m, 11H), 2.65 (s,
3H), 3.29 (dt, 4H, J= 6.7, 6.6 Hz), 4.57 (d, 2H, J = 5.6Hz), 4.89 (m, 1H), 6.05 (t, 1H,
J = 7.0, 5.0HZ), 7.68 (d, 1H, J = 7.0Hz), 8.53 (d, 1H, J = 5.0 Hz), 8.58 (s, 1H), 10.92
(s, 1H); MS (El): cal'd 502.86, exp 502.94 (MH+).
5-Dibutylcarbamoyl-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid
tert-butyl ester (13.22) The same method as for the preparation of 4-methyl-5-
octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid fert-butyl ester was
employed. Thus, coupling with dibutylamine (37.6 mg, 0.36 mmol) afforded 56.9 mg
of a solid (45%) after by column chromatography (8:2; hexanes:EtOAc): 1H NMR
(CDCI8) 5 0.87 (m, 9H), 1.18-1.40 (m, 14H), 1.45-1.68 (m, 15H), 2.23 (s, 3H), 3.20-
3.46 (m, 6H), 5.11 (m, 1H), 10.74 (s, 1H); MS (El): caPd 523.77, exp 524.02 (MH+).
5-(4-Benzyl-piperidine-1-carbonyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-
carboxylic acid tert-butyl ester (13.23): 'H NMR (CDCI3, 200MHz) 8 0.87 (s, 3H),
1.26 (brs, 11H), 1.56 (bra, 15H), 2.27 (s, 3H), 2.54 (d, 2H, J = 6.6Hz), 2.80 (m, 2H),
3.27 (dt, 2H, J = 6.2Hz, J = 6.6Hz), 4.20 (m, 2H), 5.06 (t, 1H, J = 5.2Hz), 7.05-7.30
(m, 5H), 10.77 (s, 1H); MS (ES) 570.1 (M+1)
8
3-Methyl-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid 4-tert-butyl ester 2-
(1-butyl-pentyl) ester (13.24): (60%). 'H NMR (CD3OD, 200MHz) 5 0.89 (s, 9H),
1.32 (s, 18H), 1.60 (s, 15H), 2.69 (s, 3H), 3.19 (t, 2H, J = 6.4Hz), 5.00 (p, 1H, J =
6Hz), 10.95 (s, 1H); MS (ES) 539.2 (M+1)
4-Methyl-2-(3-octyl-ureido)-5-(3-phenoxy-propylcarbamoyl)-thiophene-3-
carboxylic acid tert-butyl ester (13.25): (55%).'H NMR (CDCI3, 400MHz) 5 0.88
(m, 3H), 1.27 (m, 10H), 1.55 (m, 11H), 2.07 (m, 2H), 2.62 (s, 3H), 3.30 (dt, 2H, J =
5.6Hz, J = 7.2Hz), 3.59 (dt, 2H, J = 5.6Hz, J = 6.4Hz), 4.07 (t, 2H, J = 5.6Hz), 4.82
(brs, 1H), 6.14 (brs, 1H), 6.95 (m, 3H), 7.25 (m, 2H), 10.95 (s, 1H); MS (ES) 545.95
(M)
5-(1-Butyl-pentylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic
acid tert-butyl ester (13.26): (92%). 'H NMR (CDCI3, 200MHz) 8 0.87 (m, 9H),
1.29 (m, 18H), 1.56 (s, 11H), 2.61 (s, 3H), 3.29 (dt, 2H, J = 6.6Hz, J = 6.6Hz), 4.02
(brs, 1H), 5.04 (t, 1H, J = 5.6Hz), 5.40 (d, 1H, J = 8.8Hz), 10.91 (s, 1H)
5-[(Furan-2-ylmethyl)-carbamoyl]-4-methyl-2-(3-octyl-ureido)-thiophene-3-
carboxylic acid ferf-butyl ester (13.27): MS (ES+) 491.88 (M+1).
4-Methyl-2-(3-octyl-ureido)-5-(thlazol-2-ylcarbamoyl)-thlophene-3-carboxylic
acid ferf-butyl ester (13.28): MS (ES+) 494.84 (M+1).
4-Methyl-2-(3-octyl-ureido)-5-(2-pyridin-3-yl-ethylcarbamoyl)-thiophene-3-
carboxylic acid ferf-butyl ester (13.29): MS (ES+) 516.93 (M+1).
4-Methyl-2-(3-octyl-ureido)-5-[4-(2-piperidin-1-yl-ethyl)-piperazine-1-carbonyl]-
thiophene-3-carboxylic acid fert-butyl ester (13.30): MS (ES+) 592.04 (M+1).
4-Methyl-2-(3-octyl-ureido)-5-(4-phenyl-plperazine-1-carbonyl)-thlophene-3-
carboxylic acid ferf-butyl ester (13.31): MS (ES+) 556.94 (M+1).
5-([1,4']Bipiperidinyl-1'-carbonyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-
carboxylic acid tert-butyl ester (13.32): MS (ES+) 563.01 (M+1).
5-(3-lmidazol-1-yl-propylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-
carboxylic acid terf-butyl ester (13.33): MS (ES+) 519.95 (M+1),
5-Dihexylcarbamoyi-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid
tert-butyl ester (13.34): (40%). 1H NMR (CD3CI, 200MHz) 8 0.85 (s, 9H), 1.24 (s,
22H), 1.56 (s, 15H), 2.24 (s, 3H), 3.31 (m, 6H), 4.83 (t, 1H, J = 5.2Hz), 10.76 (S, 1H);
MS(ES) 580.21 (M+1)
5-Dioctylcarbamoyl-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid
tert-butyl ester (13.35): (65%). 'H NMR (CD3Cl, 200MHz) 8 0.86 (m, 9H), 1.23 (s,
32H), 1.56 (s, 15H), 2.25 (s, 3H), 3.31 (m, 6H), 4.80 (t, 1H, J = 5.6Hz), 10.77 (s, 1H);
MS (ES) 637.00 (M+1)
5-Cyclohexylcarbamoyl-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic
acid tert-butyl ester (13.36): (75%). 1H NMR (CD3CI, 200MHz) 8 0.87 (t, 3H, J =
6.4Hz), 1.26 (m, 16H), 1.56 (m, 15H), 2.60 (s, 3H), 3.28 (dt, 2H, J = 6.6Hz, J =
6.2Hz), 3.88 (m, 1H), 4.97 (t, 1H, J = 5.4Hz), 5.57 (d, 1H, J = 7.2Hz), 10.78 (s, 1H);
MS (ES) 494.12 (M+1)
5-(4-Benzyl-piperazine-1-carbonyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-
carboxylic acid tert-butyl ester (13.37): (72%). 'H NMR (CD3CI, 200MHz) 80.87
(m, 3H), 1.26 (brs, 10H), 1.56 (brs, 11H), 2.28 (s, 3H), 2.44 (brs, 4H), 3.27 (dt, 2H, J
= 6.6Hz, J = 6.6Hz), 3.52 (s, 2H), 3.60 (brs, 4H), 4.88 (t, 1H, J = 5.0Hz), 7.30 (brs,
5H), 10.78 (s, 1H); MS (ES) 571.16 (M--1)
4-Methyl-2-(3-octyl-ureido)-5-[(pyridin-3-ylmethyl)-carbamoyl]-thiophene-3-
carboxylic acid tert-butyl ester (13.38). The crude solid was then flashed through
a plug of silica gel with ethyl acetate to yield 13.38, 3.84g (98% crude yield) of a tan
solid.
5-(3-DimethyIamino-propylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-
carboxylic acid tert-butyl ester (13.39): MS (ES+) 496.95 (M+1).
3-Methyl-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid 2-benzyl ester 4-
lerf-butyl ester (13.40). Mp 11 9.0-1 20.09C; 1H NMR (CDCI3) 8 11.03 (s, 1H), 7.50-
7.20 (m, 5H), 5.27 (s, 2H), 5.03 (vt, 1H), 3.29 (q, 2H, J = 6.6 Hz), 2.71 (s, 3H), 1.63-
1.40 (m, 2H), 1.57 (s, 9H), 1.26 (bs, 10H), 0.87 (t, 3H, J = 6.6 Hz). MS (El): 502.8
3-Methyl-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid 4-ferf-butyl ester 2-
octyl ester (13.41) Mp 92.0-94.0 eC; 1H NMR (CDCI3) 6 12.30 (s, 1H), 8.64 (s, 1H),
5.30 (t, 1H, J = 6.0 Hz), 4.25 (t, 2H, J = 6.4 Hz), 3.29 (q, 2H, J = 6.0 Hz), 2.74 (s,
3H), 1.90-1.50 (m, 4H), 1.61 (s, 9H), 1.28 (bs, 20H), 0.88 (m, 6H). MS (El): 525.1
4-Methyl-5-octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid fertbiityl
ester (13.42). 1H NMR (CDCI3) 8 10.89 (s, 1H), 5.82-5.62 (m, 1H), 5.78-5.60
(m, 1H), 3.33 (q, 4H, J = 6.6 Hz), 2.61 (s, 3H), 1.70-1.40 (m, 4H), 1.55 (s, 9H), 1.27
(bs, 20H), 0.88 (m, 6H). MS (El): 524.1 (m+).
4-Methyl-2-(3-octyl-ureido)-5-(4-phenyl-butylcarbamoyl)-thiophene-3-carboxylic
acid tert-butyl ester (13.43): 'H NMR (CDCI3l 200MHz) 8 0.87 (m, 3H), 1.21-1.43
(m, 10H), 1.57 (s, 15H), 2.60 (m, 5H), 3.24-3.43 (m, 4H), 5.22 (brs, 1H), 5.70 (t, 1H,
J = 5.0HZ), 7.25 (m, 5H), 10.90 (s, 1 H).
4-Methyl-2-(3-octyl-ureido)-5-(3-phenyl-propylcarbamoyl)-thiophene-3-
carboxylic acid tert-butyl ester (13.44) 'H NMR (CDCI3l 200MHz) 8 0.87 (m, 3H),
1.21-1.45 (m, 10H), 1.57 (s, 11H), 1.89 (tt, 2H, J = 7.4Hz, J = 7.6Hz), 2.65 (m, 5H),
3.24-3.45 (m, 4H), 5.14 (brs, 1H), 5.73 (t, 1H, J = 5.2Hz), 7.17-7.31 (m, 5H), 10.90
4-Methyl-2-(3-octyl-ureido)-5-(2-phenoxy-ethylcarbamoyl)-thiophene-3-
carboxylic acid tert-butyl ester (13.45): 'H NMR (CDCl3, 200MHz) 8 0.87 (m, 3H),
1.22-1.49 (m, 10H), 1.56 (s, 11H), 2.61 (s, 3H), 3.28 (dt, 2H, J = 6.2Hz, J = 6.6Hz),
3.78 (dt, 2H, J = 5.2Hz, J = 5.4Hz), 4.09 (t,'2H, J = 5.2Hz), 5.08 (t, 1H, J = S.OHz),
6.21 (t, 1 H, J = 5.4HZ), 6.29 (m, 3H), 7.28 (m, 2H), 1 0.91 (s, 1 H).
5-(2-Methoxy-ethylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-
carboxylic acid tert-butyl ester (13.46): 'H NMR (CDCI3, 200MHz) 8 0.87 (m, 3H),
1.27-1.45 (m, 10H), 1.57 (brs, 11H), 2.60 (s, 3H), 3.24-3.37 (m, 5H), 3.54 (m, 4H),
5.05 (t, 1H, J = 5.2Hz), 6.12 (brs, 1H), 10.88 (s, 1H).
5-(3-Methoxy-propylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-
carboxylic acid tert-butyl ester (13.47): 'H NMR (CDCI3, 200MHz) 8 0.87 (m, 3H),
1.21-1.49 (m, 10H), 1.57 (brs, 11H), 1.83 (tt, 2H, J = 5.8Hz, J = 6.2Hz), 2.60 (s, 3H),
3.24-3.35 (m, 5H), 3.49 (m, 4H), 5.13 (t, 1H, J = 5.6Hz), 6.31 (t, 1H, J = 5.6Hz),
10.90(s,
5-((Benzo(1,3)dioxol-5-ylmethyl)-carbamoyl)-4-methyl-2-(3-octyl-ureido)-
thiophene-3-carboxyHc acid tert-butyl ester (13.48): 'H NMR (CDCI3, 200MHz) 8
0.87 (m, 3H), 1.26-1.43 (brs, 10H), 1.57 (brs, 11H), 2.63 (s, 3H), 3.27 (dt, 2H, J=
6.2HZ, J= 6.6HZ), 4.44 (d, 2H, J = 5.6Hz), 4.92 (t, 1H, J = 5.6Hz), 5.94 (s, 2H), 6.76
(s, 2H), 6.81 (s, 1H), 10.91 (s, 1H).
3-Methyl-5-(1-methylheptyloxycarbonylamino)thiophene-2,4-dicarboxylic acid
2-benzyl ester 4-tert-butyl ester (13.49)
Light brownish oil in 82% yield as mixture of two rotatmers (2:1 ratio).
'H NMR (CDCI3, 200MHz): 8 7.35-7.40 (m, 5H), 6.49 (brs, 1H), 5.25 and 5.28 (s, 2H),
4.70-4.80 and 4.80-5.05 (m, 1H), 2.68 and 2.73 (s, 3H), 1.50-1.61 (m, 9H), 1.20-1.40
(m, 8H), 0.87(m, 3H).
3-Methyl-5-[3-(1-methylheptyl)ureido]thiophene-2,4-dicarboxylic acid 2-benzyl
ester 4-fert-butyl ester (13.50)
Light yellow oil in 99% yield as mixture of two rotatmers.
'H NMR (CDCIS, 200MHz): 5 11.00 (brs, 1H), 7.29-7.43 (m, 5H), 5.24 and 5.26 (s,
2H), 4.60 and 4.68 (brs, 1H), 3.80-3.95 (brs, 1H), 3.45-3.90 (m, 1H), 2.65 and 2.70
(s, 3H), 1.55 and 1.57 (s, 9H), 1.40-1.50(m, 2H), 1.20-1.40 (m, 8H), 1.17 (d, 2H, J =
6.6Hz), 1.09(d, 1H, J= 6.2HZ), 0.80-0.95(m, 3H).
Example 14: Acid Intermediates
4-Methyl-2-(3-octyl-ureido)-5-[(pyridin-4-ylmethyl)-carbamoyl]-thiophene-3-
carboxylic acid (14.1): (99%). 'H NMR (CD3OD, 200MHz) 8 0.86 (m, 3H), 1.25
(brs, 10H), 1.56 (m, 2H), 2.64 (s, 3H), 3.28 (m, 2H), 4.56 (d, 2H, J= 5.8Hz) 7.24 (d,
2H, J= 5.8HZ), 8.54 (d, 2H, J= 5.8Hz)
4-Methyl-5-[methyl-(6-methyl-pyridin-2-ylmethyl)-carbamoyl]-2-(3-octyl-ureido)-
thiophene-3-carboxylic acid (14.2): (99%). 'H NMR (CD3OD, 200MHz) 6 0.86 (m,
3H), 1.28 (brs, 10H), 1.50 (brs, 2H), 2.38 (s, 3H), 2.50 (s, 3H), 3.04 (s, 3H), 3.17
(brs, 2H), 4.74 (s, 2H), 7.15 (m, 2H), 7.55 (t, 1 H, J= 7.6Hz)
5-[Ethyl-(2'pyridin-2-yl-ethyl)-carbamoyl]-4-methyl-2-(3-octyl-ureido)-
thiophene-3-carboxylic acid (14.3): (99%). 'H NMR (CD3OD, 200MHz) 8 0.85 (m,
3H), 1.20 (brs, 13H), 1.49 (brs, 2H), 2.20 (s, 3H), 3.19 (m, 4H), 3.41 (m, 2H), 3.83
(brs, 2H), 7.38 (m, 2H), 7.84 (t, 1 H, J= 7.2Hz), 8.49 (d, 1 H, J= 3.6Hz)
5-(Benzyloxycarbonylmethyl-carbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-
3-carboxylic acid (14.4): (99%). 1H NMR (CD3OD, 200MHz) 6 0.86 (m, 3H). 1.28
(brs, 10H), 1.50 (brs, 2H), 2.57 (s, 3H), 3.18 (m, 2H), 4.09 (s, 2H), 7.31 (brs, 5H)
3-Methyl-5-(3-octyl-thioureido)-thiophene-2,4-dicarboxylic acid 2-benzyl ester
(14.5): (99%). 'H NMR (CD3OD, 200MHz) 8 0.89 (brs, 3H), 1.29 (brs, 10H), 1.61
(brs, 2H), 2.74 (s, 3H), 3.48 (brs, 2H), 5.29 (s, 2H), 7.38 (m, 5H).
4-Wlethyl-2-(3-octyl-ureido)-5-[(pyridin-3-yl-methyl)-carbamoyI]-thiophene-3-
carboxylic acid (14.6) Thiophene (3.42 g, 6.8 mmol) was dissolved in 40 mL
CH2CI2. Trifluoroacetic acid (10 mL) was added slowly and the reaction was stirred
for 4h at rt. The reaction was concentrated in-vacuo. The residue was dissolved in
methanol and saturated NaHCO3 was added until pH~7. The solution was
concentrated in vacuo and then resuspended in hot ethyl acetate. The insoluble
salts were filtered and the filtrate was concentrated in vacuo to yield 14.6, 2.19 g
(72% crude yield) of a tan solid.
5-[(Furan-2-yl-methyl)-carbamoyl]-4-methyl-2-(3-octyl-ureido)-thiophene-3-
carboxylic acid (14.7) white solid (73% yield): 'H NMR (CD3OD, 200MHz) 8 0.90
(t, 3H, J= 6.4 Hz), 1.30-1.39 (m, 10H), 1.50-1.60 (m, 2H), 2.56 (s, 3H), 3.20 (t, 2H, J
= 6.9 Hz), 4.49 (s, 2H), 6.27 (1H, d, J = 3.0 Hz), 6.35 (dd, 1H, J = 3.2, 1.8 Hz), 7.34
(d, 1H, J =1.8 Hz). MS (ES+) 435.76 (M+1), 436.66 (M+2).
4-Methyl-2-(3-octyl-ureido)-5-[(2-pyridin-3-yl-ethyl)-carbamoyl]-thiophene-3-
carboxylic acid (14.8) light pink solid (100% yield): 'H NMR (CD3OD, 200MHz) 8
0.90 (t, 3H, J= 9.9 Hz), 1.32 (bs, 10H), 1.51-1.60 (m, 2H), 2.58 (s, 3H), 2.96 (t, 2H, J
= 7.0 Hz), 3.20 (t, 2H, J = 6.7 Hz), 3.59 (t, 2H, J = 7.0 Hz), 7.39 (dd, 1 H, J = 7.8, 4.8
Hz), 7.78 (d, 1H, J=7.8 Hz), 8.39 (d, 1H, J=4.8 Hz), 8.46 (s, 1H). MS (ES-) 458.92
(M-1).
4-Methyl-2-(3-octyl-ureido)-5-[4-(2-piperidin-1-yl-ethyl)-piperazine-1-carbonyl]-
thiophene-3-carboxylic acid (14.9) peach solid (80% yield): MS (ES-) 534.04 (M-
1).
5-(3-Hexyl-3-methyl-ureido)-3-methyl-thiophene-2,4-dicarboxyi«c ackti 2-benzyl
ester (14.10) light pink solid (100% yield): 'H NMR (CDCI3, 200MHz) 8 0.87 (t, 3H, J
= 6.4 Hz), 1.25-1.31 (m, 6H), 1.58-1.62 (m, 2H), 2.78 (s, 3H), 3.05 (s, 3H), 3.36 (t,
13C 2H, J = 7.5 Hz), 5.29 (s, 2H), 7.29-7.44 (m, 5H), 10.39 (bs, 1H), 11.18 (bs, 1H).
NMR (CDCI3) 5 13.9, 15.4, 22.4, 26.3, 27.7, 31.4, 34.7, 49.7, 66.4, 110.8, 116.4,
127.9, 128.1, 128.5, 135.7, 146.1, 153.5, 158.6, 162.9, 171.3. MS (ES+) 432.74
(M+1).
5-(3,3-Dioctyl-ureido)-3-methyl-thiophene-2,4-dicarboxylic acid 2-benzyl ester
(14.11) light pink solid (84% yield): 1H NMR (CDCI3, 200MHz) 6 0.86 (t, 6H, J = 6.6
Hz), 1.26-1.30 (m, 20H), 1.63 (bs, 4H), 2.80 (s, 3H), 3.33 (t, 4H, J = 7.0 Hz), 5.28 (s,
2H), 7.30-7.43 (m, 5H), 11.20 (s, 1H), 11.92 (bs, 1H).
5-lsobutylcarbamoyl-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid
(14.12). MS (ES): m/z411.8 [MH+].
5-(2,2-Dimethyl-propylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-
carboxylic acid (14.13). MS (ES): m/z 425.8 [MH+]. 1H NMR (CDCI3) 200 MHz): D
= 1.26-1.57 (m, 23H), 2.62 (s, 3H), 3.16-3.30 (m, 4H), 5.11 (brs, 1H), 5.64 (m, 1H).
O
4-Methyl-2-(3-octyl-ureido)-5-[(pyridin-2-ylmethyl)-carbamoyl]-thiophene-3-
carboxylic acid (14.14) The same method as for the preparation of 3-
methoxymethyl-5-octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl
ester was employed. Thus, deprotection with TFA afforded a solid, which was used
without purification: 1H NMR (CDCI3 + 1 drop of CD3OD) 8 0.86 (m, 3H), 1.32-1.20
(m, 10H), 1.60-1.32 (m, 2H), 2.59 (s, 3H), 3.22 (dt, 4H, J= 6.7, 6.6 Hz), 4.76 (s, 2H),
7.40-7.15 (m, 2H), 7.76 (t, 1H, J = 7.9Hz), 8.53 (d, 1H, J = 5.0 Hz).
4-Methyl-2-(3-octyl-ureido)-5-[(pyridin-3-ylmethyl)-carbamoyl]-thiophene-3-
carboxylic acid (14.15) The same method as for the preparation of 3-
methoxymethyl-5-octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl
ester was employed. Thus, deprotection with TFA afforded a solid, which was used
without purification: 1H NMR (CDCI3+1 drop of CD3OD) 8 0.82 (m, 3H), 1.45-1.20 (m,
10H), 1.70-1.45 (m, 2H), 2.02 (m, 3H), 2.92 (m, 2H), 4.39 (m, 1H), 7.11 (m, 1H), 7.55
(m, 1H), 8.31 (m, 1H), 8.49 (m, 1H).
5-(4-Benzyl-piperidine-1-carbonyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-
carboxylic acid (14.16): (100%). 'H NMR (CD3OD, 200MHz) 8 0. 87 (s, 3H), 1.26
(brs, 11H), 1.56 (brs, 6H), 2.27 (s, 3H), 2.54 (d, 2H, J = 6.6Hz), 2.90 (m, 2H), 3.27 (t,
2H, J = 6.6Hz), 4.20 (brs, 2H), 7.05-7.30 (rn, 5H)
3-Methyl-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid 2-(1-butyl-pentyl)
ester (14.17): (95%). 1H NMR (CD3OD, 400MHz) 8 0.89 (m, 9H), 1.33 (m, 18H),
1.50-1.70 (m, 6H), 2.73 (s, 3H), 3.19 (t, 2H, J = 6.6Hz), 5.02 (m, 1H)
5-(1-Butyl-pentylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thlophene-3-carboxylic
acid (14.18): (100%). 'H NMR (CDCI3, 200MHz) S 0.87 (m, 9H), 1.29 (m, 18H),
1.56 (s, 6H), 2.52 (s, 3H), 3.35 (t, 2H, J = 6.6Hz), 3.90 (brs, 1H)
4-Methyl-2-(3-octyl-ureido)-5-(3-phenoxy-propylcarbamoyl)-thiophene-3-
carboxylic acid (14.19): (100%). 1H NMR (CD3OD, 200MHz) 8 0.89 (m, 3H), 1.32
(s, 10H), 1.55 (brs, 2H), 2.06 (tt, 2H, J = 6.0Hz, J = 6.0Hz), 2.55 (s, 3H), 3.19 (t, 2H,
J = 7.0Hz), 3.51 (t, 2H, J = 6.8Hz), 6.90 (m, 3H), 7.24 (m, 2H).
4-Methyl-2-(3-octyl-ureido)-5-(pyridin-3-ylmethyl)-carbamoyl)-thiophene-3-
carboxyllc acid (14.20):. 14.20,110 mg (100% crude yield) of a tan solid.
5-(3-Dimethylamino-propylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-
carboxylic acid (14.21): MS (ES-) 438.70 (M-1).
5-[(Furan-2-ylmethyl)-carbamoyl]-4-methyl-2-(3-octyl-ureido)-thiophene-3-
carboxylic acid (14.22): MS (ES-) 434.03 (M-1).
4-Methyl-2-(3-octyl-ureido)-5-(thiazol-2-ylcarbamoyl)-thiophene-3-carboxylic
acid (14.23): MS (ES-) 436.23 (M-1).
4-Methyl-2-(3-octyl-ureido)-5-(2-pyridin-3-yl-ethylcarbamoyl)-thiophene-3-
carboxylic acid (14.24): MS (ES-) 459.03(M-1).
4-Methyl-2-(3-octyl-ureido)-5-[4-(2-piperidin-1-yl-ethyl)-piperazine-1-carbonyl]-
thiophene-3-carboxylic acid (14.25): MS (ES-) 534.20 (M-1).
4-Methyl-2-(3-octyl-ureido)-5-(4-phenyl-piperazine-1-carbonyl)-thiophene-3-
carboxylic acid (14.26): MS (ES-) 499.03 (M-1).
5-([1,4']Bipiperidinyl-1'-carbonyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-
carboxylic acid (14.27): MS (ES-) 505.08 (M-1).
5-(3-lmida2ol-1-yl-propylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-
carboxylic acid (14.28): MS (ES-) 462.09 (M-1).
3-Methyl-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid 4-fert-butyl ester
(14.29) 1H NMR (CDCI3) 8 11.06 (s, 1H), 5.14 (vt, 1H), 3.30 (q, 2H, J= 6.0 Hz), 2.71
(s, 3H), 1.70-1.40 (m, 2H), 1.59 (s, 9H), 1.27 (bs, 10H), 0.87 (t, 3H, J= 6.6 Hz). MS
(El): 412.8 (m+).
2-Dodecyloxy-5-methyl-4-oxo-4W-thieno[2,3-cf][1,3]oxazine-6-carboxylic acid
(14.30) 1H NMR (CDCIa) 6 4.47 (t, 2H, J= 6.2 Hz), 4.19 (bs, 1H), 2.85 (s, 3H), 1.80
(quint, 2H, J= 6.2 Hz), 1.27 (bs, 18H), 0.88 (t, 3H, J= 6.6 Hz). MS (Ei): 395.4 (m+).
4-Methyl-5-octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid
(14.31) 1H NMR (CDCh) 8 10.90 (bs, 2H), 5.82-5.62 (m, 1H), 5.78-5.60 (m, 1H),
3.33 (q, 4H, J = 6.6 Hz), 2.61 (s, 3H), 1.70-1.40 (m, 4H), 1.27 (bs, 20H), 0.88 (m,
6H).
3-Methoxymethyl-5-octvioxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-
benzyl ester (14.32) 1H NMR (CDCI3) 8 11.98 (s, 1H), 10.09 (s, 1H), 7.45-7.20 (m,
5H), 5.14 (s, 2H), 4.22 (t, 2H, J = 6.6 Hz), 3.85 (s, 3H), 3.82 (s, 2H), 1.70 (quint, 2H,
J = 6.6 Hz), 1.28 (bs, 10H), 0.88 (t, 3H, J = 5.6 Hz).
5-(4-(lsopropylcarbamoyl-methyl)-piperazine-1-carbonyl)-4-methyl-2-(3-octylureido)-
thiophene-3-carboxylic acid (14.33): 'H NMR (CDCI3) 200MHz) 8 0.89
(brs, 3H), 1.15-1.34 (m, 16H), 1.56 (m, 2H), 2.37 (s, 3H), 3.05-3.49 (m, 10H), 3.95
(m, 1H).
5-((Benzo(1,3)dioxol-5-ylrr,ethyl)-carbamoyl)-4-methyl-2-(3-octyl-ureido)-
thiophene-3-carboxylic acid (14.34): 'H NMR (CDCI3, 200MHz) 8 0.86 (m, 3H),
.1.32-1.45 (m, 10H), 1.53 (rr, 2H), 2.56 (s, 3H), 3.19 (m,2H), 4.4 (d, 2H, J = 6.0Hz),
5.91 (s, 2H), 6.80 (m, 3H).
5-(3,4-Dlmethoxy-benzylcarbamoyl)-4-methylT2-(3-octyl-ureido)-thiophene-3-
carboxylic acid (14.35): 'H NMR (CDCI3, 200MHz) 8 0.88 (brs, 3H), 1.31-1.45 (m,
10H), 1.56 (m, 2H), 2.56 (s, SH), 3.18 (dt, 2H, J= 6.2Hz, J= 6.6Hz), 3.80 (s, 3H), 3.82
(s, 3H), 4.43 (s, 2H), 6.89 (s, 2H), 6.97 (s, 1H).
S-te^-Dimethoxy-S^-dihydro-IH-isoquinoline^-carbonylH-methyl^-ta-octylureido)-
thiophene-3-carboxylic acid (14.36): 'H NMR (CDCI3l 200MHz) 8 0.89
(m, 3H), 1.31-1.45 (m, 10H), 1 51 (brs, 2H), 2.31 (s, 3H), 2.85 (t, 2H, J = 6.0Hz), 3.18
(t, 2H, J = 7.0Hz), 3.79 (m, 8H), 6.71 (s, 1H), 6.74 (s,1H).
4-Methyl-2-(3-octyl-ureido)-5-(4-phenyl-butylcarbamoyl)-thiophene-3-carboxylic
acid (14.37): 'H NMR (CDCI3) 200MHz) 8 0.89 (brs, 3H), 1.26-1.45 (m, 10H), 1.59
(m, 6H), 2.54 (s, 3H), 2.65 (t, 2H, J = 7.0Hz)', 3.19 (m, 4H), 7.21 (m, 5H).
4-Methyl-2-(3-octyl-ureldo)-5-(3-phenyl-propylcarbamoyl)-thiophene-3-
carboxylic acid (14.38): 'H NMR (CDCI3, 200MHz) 8 0.89 (m, 3H), 1.25-1.45 (m,
10H), 1.57 (brs, 2H), 1.89 (tt, 2H, J = 7.4Hz, J = 7.6Hz), 2.55 (s, 3H), 3.17-3.39 (m,
4H), 7.23 (m, 5H).
4-Methyl-2-(3-octyl-ureido)-5-(2-phenoxy-ethylcarbamoyl)-thiophene-3-
carboxylic acid (14.39): 'H NMR (CDCI3, 200MHz) 8 0.87 (m, 3H), 1.25-1.41 (m,
10H), 1.56 (brs, 2H), 2.56 (s, 3H), 3.19 (dt, 2H, J = 6.2Hz, J = 6.6Hz), 3.71 (dt, 2H, J
= 5.2HZ, J = 5.4Hz), 4.12 (t, 2H, J = 5.2Hz), 6.95 (m, 3H), 7.25 (m, 2H).
5-(2-Methoxy-ethylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-
carboxylic acid (14.40): 'H NMR (CDCI3l 200MHz) 5 0.89 (brs, 3H), 1.25-1.43 (m,
10H), 1.53 (m, 2H), 2.56 (s, 3H), 3.19 (t, 2H, J =7.0Hz), 3.37 (s, 3H), 3.51 (m, 4H).
5-(3-Methoxy-propylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-
carboxylic acid (14.41): 'H NMR (CDCI3, 200MHz) 8 0.89 (brs, 3H), 1.27-1.44 (m,
10H), 1.51 (brs, 2H), 1.84 (tt, 2H, J = 6.2Hz, J = 6.6Hz), 2.56 (s, 3H), 3.19 (t, 2H, J =
7.0Hz), 3.34 (s, 3H), 3.39 (t, 2H, J = 7.0Hz), 3.49 (t, 2H, J = 6.2Hz).
0 O
5-Methyl-2-(1-methyiheptyloxy)-4-pxo-4H-thieno[2,3-c/Ioxa2ine-6-carboxylic
acid benzyl ester (14.42)
Light yellow oil in 32% yield.
'HNMR (CDCI3, 200MHz): 8 10.70 (brs, 1H), 8.31 (brs, 2H), 7.29-7.43 (m, 5H), 5.27
(S, 2H), 3.45-3.90 (m, 1H), 2.75 (s, 3H), 1.40-1.60(m, 2H), 1.10-1.40 (m, 11H), 0.85
(t, 3H, J=6.6Hz).
3-Methyl-5-[3-(1-methylheptyl)ureido]thiophene-2,4-dicarboxylic acid 2-benzyl
ester (14.43)
Light brownish solid in 99% yield.
'HNMR (CDCI3, 200MHz): 8 10.52 (s, 1H), 9.00(brs, 1H), 7.35-7.39 (m, 5H), 5.28 (s,
2H), 4.70-5.05 (m, 1H), 2.79 (s, 3H), 1.42-1.62(m, 2H), 1.10-1.40 (m, 8H), 0.87(t, 3H,
J= 6.6Hz), MS (ES) [M'-l] 444.96.
5-(4-Benzyl-piperazine-1-carbonyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-
carboxylic acid (37) 1H NMR (DMSO, 200MHz) 8 0.83 (brm, 3H), 1.18-1.41 (brm,
12H), 2.26 (s, 3H), 2.33 (brs, 4H), 2.99 (dt, 2H, J = 5.8Hz, J = 5.8Hz), 3.29 (s, 2H),
3.43 (brm, 4H), 7.21-7.41 (m, 5H)
Example 15: Thienoxazinones
[(5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carbonyl)-
amino]-acetic acid benzyl ester (48): 'H NMR (CDCI3) 200MHz) 6 0.88 (m, 3H),
1.30 (brs, 10H), 1.61 (m, 2H), 2.74 (s, 3H), 3.42 (dt, 2H, J= 6.2Hz, J= 7.0Hz), 4.25
(d, 2H, J= 5.0Hz), 5.08 (brs, 1H), 5.23 (s, 2H), 6.29 (brs, 1H), 7.37 (s, 5H)
O
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid
(pyridin-4-ylmethyl)-amide (55): (15%). 'H NMR (CDCI3, 200MHz) 5 0.88 (brs,
3H), 1.25 (brs, 10H), 1.55 (brs, 2H), 2.75 (s, 3H), 3.38 (dt, 2H, J= 6.4Hz, J= 6.6Hz),
4.60 (d, 2H, J= 5.8Hz), 6.17 (s, 1H), 7.24 (s, 2H), 8.54 (d, 2H, J= 5.8Hz)
5-iv"iethyi-2-ociyiamhio-4-oxo-4K-thieno[2,3-d][1,3]oxazine-6-carboxylic acid
methyl-(6-methyl-pyridin-2-ylmethyl)-amide (49): (20%). 'H NMR (CDCI3,
200MHz) 5 0.86 (m, 3H), 1.26 (brs, 10H), 1.58 (m, 2H), 2.45 (s, 3H), 2.52 (s, 3H),
3.06 (s, 3H), 3.38 (dt, 2H, J= 6.4Hz, J= 6.6Hz), 4.73 (s, 2H), 5.28 (brs, 1H), 7.05 (d,
2H, J= 7.6Hz), 7.56 (t, 1H, J= 7.8Hz)
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxyllc acid
ethyl-(2-pyridin-2-yl-ethyl)-amide (51): (58%). 'H NMR (CDCI3, 200MHz) 5 0.87
(m, 3H), 1.14 (t, 3H, J= 7.0Hz), 1.26 (brs, 10H), 1.59 (m, 2H), 2.31 (s, 3H), 3.10 (t,
2H, J= 7.0HZ), 3.38 (dt, 4H, J= 6.2Hz, J= 7.0Hz), 3.84 (t, 2H, J= 7.6Hz), 5.26 (brs,
1H), 7.14 (m, 2H), 7:59 (ddd, 1H, J= 7.4Hz, J= 7.6Hz, J= 1.6Hz), 8.52 (d, 1H, J=
4.4HZ)
5-Methyl-2-octy!amino-4-oxo-4H-thieno[2,3-d][1,3]thiazlne-6-carboxylic acid
benzyl ester (56): 'H NMR (CD3OD, 200MHz) 6 0.87 (brs, 3H), 1.27 (brs, 10H),
1.61 (m, 2H), 2.82 (s, 3H), 3.45 (dt, 2H, J= 6.2Hz, J= 6.6Hz), 5.31 (s, 2H), 5.42 (brs,
1H), 7.35 (m,5H)
2-(Hexyl-methyl-amino)-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-
carboxylic acid benzyl ester (57): 'H NMR (CDCI3, 200MHz) 5 0.89 (t, 3H, J= 6.6
Hz), 1.30 (bs, 6H), 1.58-1.64 (m, 2H), 2.77 (s, 3H), 3.11 (s, 3H), 3.47-3.50 (m, 2H),
5.29 (s, 2H), 7.30-7.44 (m, 5H). MS (ES+) 414.70 (M+1).
2-(1-Butyl-pentylamino)-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-
carboxylic acid benzyl ester (59). 'H NMR (CDCI3, 200MHz) 8 0.89 (t, 6H, J = 6.4
Hz), 1.22-1.40 (bs, 8H), 1.48-1.66 (m, 4H), 2.79 (s, 3H), 3.90-4.00 (m, 1H), 5.32 (s,
2H), 5.77 (d, J= 8.4 Hz), 7.31-7.45 (m, 5H).
0
2-Dioctylamino-5-methyl-4-oxo-4H-thleno[2,3-d][1,3]oxazine-6-carboxylic acid
benzyl ester (60) 'H NMR (CDCI3, 200MHz) 8 0.88 (t, 6H, J = 6.6 Hz), 1.26-1.37 (m,
20H), 1.58-1.64 (m, 4H), 2.79 (s, 3H), 3.39-3.53 (m, 4H), 5.31 (s, 2H), 7.29-7.45 (m,
5H).oo \—/ \_N
0
0
5-Methyl-2-octylamino-6-[4-(2-piperidm-1-yl-ethyl)-piperazine-1-carbonyllthleno[
2,3-d][1,3]oxazin-4-one (53) MS (ES): m/z 517.9 [MH+]. 1H NMR (CDCI3,
200 MHz): 5 = 0.87-1.59 (m, 9H), 1.18-1.59 (m, 14H), 2.54 (s, 3H), 2.23-2.51 (rff,
4H), 3.34 (dt, 2H, J = 7 Hz), 3.61 (m, 3H), 5.21 (brs, 1H)
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid
(furan-2-ylmethyl)-amide (52) MS (ES): nVz417.3 [MH+].
1H NMR (CDCI3, 200 MHz): 5 = 1.18-1.41 (m, 14H), 2.67 (s, 3H), 3.43 (t, 2H, J = 8.4
Hz), 4.48 (m, 2H, J = 5.6 Hz), 5.12 (brs, 1H), 6.02-6.57 (m, 3H).
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxyIic acid (2-
pyridin-3-yl-cthyl)-amide (50) MS (ES): m/z 443.5 [MH+]. 1H NMR (CDCI3, 200
MHz): 8 = 1.25-1.68 (m, 14H), 2.60 (s, 3H), 2.99 (t, 2H, J = 7.4 Hz), 3.39 (dt, 2H, J =
6.6 Hz), 5.25 (brs, 1H), 5.77 (s, 1H), 7.25 (m, 2H), 7.61 (d, 1H, J = 19.4 Hz), 8.51 (m,
1H).
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid
isobutyl-amide (54). MS (ES): m/z 393.8 [MH+].
1H NMR (CDCIs, 200 MHz): 6 = 0.84-0.88 (m, 20H), 0.95-0.99(d, 6H, ), 1.41 (m,
14H), 2.67 (s, 3H), 3.43 (t, 2H, J = 8.4 Hz), 4.48 (m, 2H, J = 5.6 Hz), 5.12 (brs, 1H).
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-dl[1,3]oxazine-6-carboxylic acid
(2,2-dimethyl-propyl-amide (58). MS (ES): m/z 407.86 [MH+]. 1H NMR (CDCI3, 200
MHz): 8 = 0.84-0.93 (m, 14H), 0.96 (s, 9H), 2.72 (s, 3H), 3.24 (s, 2H), 3.42 (m, 2H, J
= 6.2 Hz), 5.12 (brs, 1H), 5.76 (brs, 1H).
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid
dibutylamide (36). The same method as for the preparation of 5-methyl-2-
heptyloxy-4-oxo-4H-thieno[2,3-c(][1,3]oxazine-6-carboxylic acid heptyl ester was
employed. Thus, cyclization afforded 20 mg of a solid after column chromatography
(7:3; hexanes:EtOAc) (40% from tert-butyl ester): 1H NMR (CDCI3) 5 0.88 (m, 9H),
1.18-1.40 (m, 14H), 1.45-1.68 (m, 6H), 2.37 (s, 3H), 3.30-3.46 (rn, 6H), 5.19 (br s,
1H); MS (El): caPd 449.66, exp 449.95 (MH+).
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid
(pyridin-3-ylmethyl)amide (35). The same method as for the preparation of 5-
methyl-2-heptyloxy-4-oxo-4H-thieno[2,3-afl[1,3]oxazine-6-carboxylic acid heptyl ester
was employed. Thus, cyclization afforded 46 mg of a solid (36.6% from tert-butyl
ester) after tritration: 1H NMR (CDCI3) 6 0.87 (m, 3H), 1.42-1.20 (m, 10H), 1.68-1.45
(m, 2H), 2.72 (s, 3H), 3.41 (dt, 4H, J= 6.7, 6.6 Hz), 4.62 (d, 2H, J = 6.0Hz), 5.15 (m,
fOt)
1H), 6.07 (m, 1H), 7.38-7.20 (m, 1H), 7.70 (d, 1H, J = 8.6Hz), 8.65-8.52 (m, 2H);
(El): cal'd 428.56, exp 428.88 (MH+).
5-Methyl-2-octyIamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid
(pyridin-2-ylmethyl)amide (34). The same method as for the preparation of 5-
methyl-2-heptyloxy-4-oxo-4H-thieno[2,3-ad[1,3]oxazine-6-carboxylic acid heptyl ester
was employed. Thus, cyclization afforded 46 mg of a solid (36.6% from tert-butyl
ester) after tritration: 1H NMR (CDCI3) 6 0.87 (m, 3H), 1.45-1.20 (m, 10H), 1.80-1.50
(m, 2H), 2.79 (s, 3H), 3.41 (dt, 4H, J= 6.7, 6.6 Hz), 4.72 (d, 2H, J = 4.4Hz), 5.25 (m,
1H), 7.45-7.18 (m, 2H), 7.69 (t, 1H, J = 7.6Hz), 8.55 (d, 1H, J = 4.6 Hz); MS (El):
cal'd 428.56, exp 428.88 (MH+).
6-(4-Ben2yl-piperidine-1-carbonyl)-5-methyl-2-octylamino-thieno[2,3-
d][1,3]oxazin-4-one (43)
1H NMR (CDCIs, 200MHz) 6 0.88 (brs, 3H), 1.27 (brs, 11H), 1.54-1.70 (m, 6H),
2.40 (s, 3H), 2.57 (d, 2H, J = 7'.OHz), 2.86 (m, 2H), 3.40 (dt,. 2H, J = 6.4Hz, J =
6.4Hz), 4.20 (brs, 2H), 5.09 (s, 1H), 7.11-7.35 (m, 5H); MS (ES) 496.69 (M+1).
fet
5-Methyl-2-octyIamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid 1 -
butyl-pentyl ester (39): (73%). 'H NMR (CDCI3, 200MHz) 6 0.89 (s, 9H), 1.31 (s,
18H), 1.61 (m, 6H), 2.78 (s, 3H), 3.42 (dt, 2H, J = 6.2Hz, J = 6.6Hz), 5.00-5.20 (m,
2H); MS(ES) 465.67 (M+1)
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid (1 -
butyl-pentyl)-amide (45): (28%). 'H NMR (CDCI3, 200MHz) 5 0.87 (m, 9H), 1.29
(m, 18H), 1.56 (s, 2H), 2.65 (s, 3H), 3.40 (dt, 2H, J = 6.6Hz, J = 6.6Hz), 4.02 (brs,
1H), 5.04 (brs, 1H), 5.40 (d, 1H, J = 8.8Hz); MS (ES) 464.6 (M+1)
-octyl
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid (3-
phenoxy-propyl)-amide (44): (22%). 'H NMR (CDCI3, 200MHz) 6 0.88 (m, 3H),
1.27 (m, 10H), 1.55 (m, 2H), 2.07 (m, 2H), 2.62 (s, 3H), 3.40 (dt, 2H, J = 5.6Hz, J =
7.2Hz), 3.65 (dt, 2H, J = 5.6Hz, J = 6.4Hz), 4.12 (t, 2H, J = 5.6Hz), 5.05 (brs, 1H),
6.30 (brs, 1H), 6.95 (m, 3H), 7.25 (m, 2H); MS (ES) 471.81 (M+1)
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid
cyclohexylamide (38): (21%). 'H NMR (CDCIa, 400MHz) 8 0.87 (s, 3H), 1.26 (m,
16H), 1.56 (m, 6H), 2.60 (s, 3H), 3.40 (dt, 2H, J = 6.6Hz, J = 6.2Hz), 3.88 (m, 1H),
5.07 (brs, 1H), 5.57 (d, 1H, J = 7.2Hz); MS (ES) 420.12 (M+1)
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid
dioctylamide (41): (61%). 'H NMR (CDCI3l 400MHz) 6 0.87 (m, 9H), 1.25 (brs,
30H), 1.58 (m, 6H), 2.38 (s, 3H), 3.39 (m, 6H), 5.12 (brs, 1H); MS (ES) 562.15
(M+1)
103
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid
dihexylamide (42): (56%). 1H NMR (CDCI3l 400MHz) 8 0.87 (m, 9H), 1.27 (brs,
22H), 1.56 (m, 6H), 2.38 (s, 3H), 3.40 (m, 6H), 5.05 (brs, 1H); MS (ES) 506.03
(M+1).
O
6-(4-Benzyl-piperazine-1-carbonyl)-5-methyl-2-octylamino-thieno[2,3-
d][1,3]oxazin-4-one (40): (67%). 1H NMR (CD3CI, 200MHz) 8 0.87 (t, 3H, J =
5Hz), 1.27 (brs, 10H), 1.58 (brs, 2H), 2.40 (s, 3H), 2.46 (t, 4H, J = 4.8Hz), 3.39 (dt,
2H, J = 6.6Hz, J = 6.6Hz), 3.52 (s, 2H), 3.62 (brs, 4H), 5.19 (brs, 1H), 7.30 (s, 5H);
MS (ES) 497.11 (M+1)
5-Methyl-2-octyiamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid
methylamide (31): (70%, off-white solid). 'H NMR (CDCI3, 200MHz) 8 0.88 (m,
3H), 1.25-1.4 (m), 1.59-1.65 (m), 2.71 (s, 3H), 2.99 (d, 3H (J=5.2)), 3.41 (q, 2H, J=7
Hz), 5.32 (bs, 1H), 5.76 (bs, 1H). MS (ES+) 351.93 (M+1), 352.99 (M+2).
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxyIic acid
ethylamide (33): (off-white solid). 'H NMR (CDCI3, 200MHz) 6 0.88 (t, 3H, J=6.5
Hz), 1.21-1.31 (m, 13H), 1.59-1.65 (m, 2H), 2.71 (s, 3H), 3.36-3.53 (m, 4H), 5.27 (bs,
1H), 5.72 (bs, 1H). MS (ES+) 365.95 (M+1), 367.01 (M+2).
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid
butylamide (32): (off-white solid). 1H NMR (CDCI3, 200MHz) 8 0.85-1.00 (m, 6H),
1.28-1.50 (m, 12H), 1.53-1.63 (m, 4H), 2.70 (s, 3H), 3.41-3.43 (m, 4H), 5.53 (bs, 1H),
5.78 (bs, 1H). MS (ES+) 393.98 (M+1), 395.05(M+2).
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid
hexylamide (27): (off-white solid). 'H NMR (CDCI3, 200MHz) 6 0.88-0.89 (m, 6H),
1.27-1.32 (m, 16H), 1.61 (bs, 4H), 2.70 (s, 3H), 3.41 (2xdt, 4H), 5.44 (bs, 1H), 5.76
(bs, 1H). MS (ES+) 422.05 (M+1), 423.13 (M+2).
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid
decylamide (28): (off-white solid). 'H NMR (CDCI3| 200MHz) 5 0.85-0.88 (m, 6H),
1.26-1.31 (m, 24H), 1.61 (bs, 4H), 2.70 (s, 3H), 3.41 (2xdt, 4H), 5.27 (bs, 1H), 5.73
(bs, 1H). MS (ES+) 478.08 (M+1), 479.10 (M+2).
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid
dodecylamide (29): (off-white solid). 'H NMR (CDCI3, 200MHz) 8 0.85-0.91 (m,
6H), 1.26-1.31 (m, 24H), 1.61 (bs, 4H), 2.70 (s, 3H), 3.41 (2xdt, 4H), 5.30 (bs, 1H),
5.73 (bs, 1H). MS (ES+) 506.14 (M+1), 507.14 (M+2).
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid
hexadecylamide (30): (off-white solid). 'H NMR (CDCI3, 200MHz) 6 0.84-0.91 (m,
6H), 1.26-1.32 (m, 34H), 1.61 (bs, 4H), 2.70 (s, 3H), 3.41 (2xdt, 4H), 5.21 (bs, 1H),
5.72 (bs, 1H). MS (ES+) 562.19 (M+1), 563.22 (M+2).
J-00
6-(6,7"Dimethoxy-3,4-dihydro-1H-isoquinoline-2-carbonyl)-5-methyl-2-
octylamino-thieno(2,3-d)(1,3)oxazln-4-one (65): 1H NMR (CDCI3, 200MHz) 5 0.88
(brs, 3H), 1.28-1.45 (m, 10H), 1.62 (m, 2H), 2.43 (s, 3H), 2.85 (t, 2H, J = 5.6Hz), 3.41
(dt, 2H, J = 6.6Hz, J = 6.6Hz), 3.84 (m, 8H), 4.69 (s, 2H), 5.20 (brs, 1H), 6.56 (s, 1H),
6.63 (s,1H).
5-Methyl-2-octylamino-4-oxo-4H-thieno(2,3-d)(1,3)oxazine-6-carboxylic acid (2-
(3,4-dimethoxy-phenyl)-methyl)-amldc (66): !H NMR (CDCI3, 200MHz) 6 0.88
(brs, 3H), 1.28-1.43 (m, 10H), 1.59 (m, 2H), 2.71 (s, 3H), 3.41 (dt, 2H, J = 6.6Hz, J =
6.6Hz), 3.88 (s, 6H), 4.55 (d, 2H, J = 5.4Hz), 5.10 (brs, 1H), 5.96 (brs, 1H), 6.88 (m,
3H).
N-lsopropyl-2-(4-(5-methyl-2-octylamino-4-oxo-4H-thieno(2J3-d)(1,3)oxazine-6-
carbonyl)-piperazin-1-yl)-acetamide (64): 'H NMR (CDCI3, 200MHz) 8 0.88 (m,
3H), 1.28-1.45 (m, 16H), 1T,60 (m, 2H), 2.41 (s, 3H), 2.54 (m, 4H), 3.25 (s, 2H), 3.40
(dt, 2H, J = 6.6Hz, J = 6.6Hz), 3.59 (m, 4H), 4.61 (m, 1H), 5.08 (brs, 1H).
O
5-Methyl-2-octylamlno-4-oxo-4H-thieno(2,3-d)(1,3)oxazine-6-carboxy!ic acid (2-
benzo(1,3)dioxol-5-yl-methyl)-amide (69): 'H NMR (CDCI3> 200MHz) 6 0.88 (t,
3H, J = 7.0Hz), 1.27-1.45 (m, 10H), 1.60 (m, 2H), 2.71 (s, 3H), 3.44 (dt, 2H, J =
6.4Hz, J = 6.4Hz), 4.51 (d, 2H, J = 5.6Hz), 5.08 (brs, 1H), 5.96 (s, 3H), 6.79 (m, 3H).
0
5-Methyl-2-octylamino-4-oxo-4H-thieno(2,3-d)(1,3)oxazine-6-carboxylic acid (2-
phenoxy-ethyl)-amlde (70): 'H NMR (CDCI3, 200MHz) 8 0.88 (t, 3H, J = 7.0Hz),
1.27-1.42 (m, 10H), 1.60 (m, 2H), 2.72 (s, 3H), 3.41 (dt, 2H, J = 6.6Hz, J = 6.6Hz),
3.84 (dt, 2H, J = 5.0HZ, J = 5.2Hz), 4.15 (t, 2H, J = 5.0Hz), 5.08 (brs, 1H), 6.25 (brs,
1H),6.93(m, 3H), 7.30 (m, 2H).
0
5-Methyl-2-octylamino-4-oxo-4H-thieno(2,3-d)(1,3)oxazine-6-carboxylic acid (2-
methoxy-ethyl)-amide (72): 'H NMR (CDCI3, 200MHz) 8 0.88 (t, 3H, J = 6.8Hz),
1.28-1.45 (m, 10H), 1.61 (m, 2H), 2.71 (s, 3H), 3.93 (m, 5H), 3.58 (m, 4H), 5.08 (brs,
1H), 6.15 (brs, 1H).
5-Methyl-2-octylamino-4-oxo-4H-thieno(2,3-d)(1,3)oxazine-6-carboxylic acid (3-
methoxy-propyl)-amide (73): 'H NMR (CDCI3( 200MHz) 6 0.88 (t, 3H, J = 6.8Hz),
1.28-1.44 (m, 10H), 1.61 (m, 2H), 1.87 (tt, 2H, J = 5.8Hz, J = 6.0Hz), 2.70 (s, 3H),
3.40 (m, 5H), 3.57 (m, 4H), 5.09 (brs, 1H), 6.77 (brs, 1H).
5-Methyl-2-octylamino-4-oxo-4H-thieno(2,3-d)(1,3)oxazlne-6-carboxyllc acid (4-
phenyl-butyl)-amide (79): 'H NMR (CDCI3, 200MHz) 8 0.88 (t, 3H, J = 6.6Hz),
1.28-1.45 (m, 10H), 1.66 (m, 6H), 2.69 (m, 5H), 3.43 (m, 4H), 5.07 (brs, 1H), 5.68
(brs, 1H), 7.20 (m,5H).
5-Methyl-2-octylamino-4-oxo-4H-thieno(2,3-d)(1,3)oxazine-6-carboxylic acid (3-
phenyl-propyl)-amide (80): 'H NMR (CDCI3, 200MHz) 8 0.88 (t, 3H, J = 6.6Hz),
1.27-1.44 (m, 10H), 1.58 (m, 2H), 1.96 (tt, 2H, J = 7.0Hz, J = 7.4Hz), 2.72 (m, 5H),
3.43 (m, 4H), 5.71 (brs, 1 H), 7.22 (m, 5H).
1C13
o N O
5-Methyl-2-(1 -methyl heptyloxy)-4-oxo-4H-thieno[2,3-cf|[1,3]oxazine-B-carboxyUc
acid benzyl ester (89)
Light yellow oil in 22% yield.
'H NMR (CDCIj, 200MHz): 6 7.31-7.50 (m, 5H), 5.34 (s, 2H), 5.18 (tq, 1H, J = 6.2,
6.2Hz), 2.82 (s, 3H), 1.58-1.83(m, 2H), 1.40(d, 3H, J = 6.2Hz), 1.10-1.34 (m, 8H),
0.88 (t, 3H, J=6.6Hz).
O
O
H
5-Methyl-2-(1-methylheptylamino)-4-oxo-4H-thleno[2,3-cQ[1,3]oxazine-6-
carboxylic acid benzyl ester (71)
Light yellow oil in 40% yield.
'H NMR (CDCI,, 200MHz): 8 7.31-7.43 (m, 5H), 5.32 (s, 2H), 5.13 (d, 1H, J = 6.2Hz),
4.00 (m, 1H), 2.79 (s, 3H), 1.42-1.62(m, 2H), 1.10-1.40 (m, 8H), 0.87 (t, 3H, J =
6.6Hz). MS (ES) [M++1] 429.10.
ooi
2-(1,3-Dioctyl-ureido)-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic
acid benzyl ester (13): 1H NMR (CDCI3, 200MHz): 8 9.25 (m, -1H), 7.31-7.43 (m,
5H), 5.32 (s, 2H), 3.99 (m, 2H), 3.35 (dt, 2H, J= 5.6, 5.6 Hz), 2.83 (s, 3H), 1.70-1.5
(m, 4H), 1.50-1.20 (m, 20H), 0.87 (m, 6H, J= 6.6Hz). MS (ES) [M++1] 583.99.
2-(1,3-Diheptyl-ureido)-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-
carboxylic acid benzyl ester (14): 'H NMR (CDCI,, 200MHz): 6 9.25 (m, 1H), 7.31-
7.43 (m, 5H), 5.32 (s, 2H), 3.99 (m, 2H), 3.35 (dt, 2H, J = 5.6, 5.6 Hz), 2.83 (s, 3H),
1.70-1.5 (m, 4H), 1.50-1.20 (m, 16H), 0.87 (m, 6H, J = 6.6Hz). MS (ES) [M++1]
555.97.
114-
5-Methyl-3-octyl-1H-thieno[2,3-d]pyrimidine-2,4-dione-6-carboxylic acid
octylamide (47): Compound 18 (100 mg, 0.22 mmol) was dissolved in 1.8 mL
absolute ethanol. Sodium ethoxide (21% by wt in ethanol, 1.1 ml, 2.9 mmol) was
added and the solution was refluxed for 1h. Once cooled to room temperature, the
solution was poured into 10 ml of a 1N HCI solution. The resultant precipitate was
filtered to provide 47 (116 mg) as an off-white solid (100% yield). 'H NMR (CDCI3,
200MHz) 6 0.87 (m, 6H), 1.27-1.32 (m, 20H), 1.54-1.70 (m, 4H), 2.78 (s, 3H), 3.44
(dt, 2H, J = 7.0, 6.2 Hz), 3.97 (t, 2H, J = 7.7 Hz), 5.86 (t, 1H, J = 5.4 Hz), 10.39 (s,
1H).
Example 16; Procedure for reduction of carboxylic acid: 5-Hydroxymethyl-4-
methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid tert-butyl ester (2) 3-
Methyl-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid 4-tert-butyl ester (1.0g,
2.40 mmol) was dissolved in 25 mL of CH2CI2 and 0.25 ml_ of DMF. Thionyl chloride
added as a 2M solution in CH2CI2 (1.2 ml, 2.4 mmol) and the reaction was stirred for
2h. The reaction was rotovaped to a white solid, which was dissolved in 20 mL of
dioxane. Sodium borohydride (910 mg, 24.0 mmol) added and the reaction stirred
for 2h. The reaction was poured into 100 mL of H2O and extracted with EtOAc. The
organic layer was washed with 1N HCI (aq), H2O, dried with MgSO4) and the solvent
rotovaped off. The residue was recrystalized from EtOAc/Hexanes to give 600 mg of
the title compound.: (62%). 1H NMR (CDCI3, 200MHz) 8 0.87 (m, 3H), 1.26 (brs,
10H), 1.57 (brs, 11H), 2.30 (s, 3H), 3.28 (dt, 2H, J= 6.2Hz, J = 6.6Hz), 4.64 (s, 2H),
4.74 (t, 2H, J = 5.6Hz), 10.77 (s, 1H)
Scheme 3
OH
oxalyl chloride
DMSO, NEt3
CH2CI2
-78aC-»rt
S, NEt3
DMF
rt
2 days
rNH,
| SOCI2
OH pyr:CH2CI2
-R1 or
NHRbase,
CH2CI2
X
.R'
Example 17: Aldehyde Intermediates
For a general procedure to synthesize non-commercial aldehydes 17.1-17.4 see
Yoshisuke, Tsuda et al, Chem. Pharm. Bull. 1991, 39(1), 18-22
4-Phenyi-butyraldehyde (17.1) clear liquid (860 mg, 87% yield) 'H NMR (CDCI3,
200MHz) 6 1.99 (tt, 2H, J= 7.8, 7.4Hz), 2.45 (dt, 2H, J= 7.0, 1.2Hz), 2.67 (t, 2H, J-.
7.4Hz), 7.26 (m, 5H), 9.76 (t, 1H, J= 1.4Hz).
115
5-Phenyl-pentanal (17.2) clear liquid (470 mg, 48% yield) 'H NMR (CDCI3, 200MHz)
6 1.67 (m, 4H), 2.45 (dt, 2H, J = 4.8, 1.8Hz), 2.64 (brs, 2H), 7.25 (m, 5H), 9.75 (t, 1H,
J=1.8Hz).
6-Phenyl-hexanal (17.3) pale yellow oil (2.49 g, 84% yield) 1H NMR (CDCI3,
200MHz) 5 1.20-1.43(m, 4H), 1.44-1.76(m, 4H), 2.41 (dt, 2H, J=7.0, 7.6 Hz), 2.60(t,
2H, J = 7.2 Hz), 7.06-7.35(m, 5H), 9.75(t, 1H, J = 1.8 Hz); MS (ES) No ionization
and no LC was found
5-Phenyl-heptanal (17.4) pale yellow oil (401 mg, 81% yield) 1H NMR (CDCI3,
200MHz) 6 1.20-1.50(m, 2H), 1.50-1.80(m, 4H), 2.41 (dt, 2H, J = 7.0, 7.4 Hz), 2.61 (t,
2H, J = 7.4 Hz), 7.00-7.20(m, 5H), 9.75(t, 1H, 2 Hz), MS (ES) No ionization and no
LC was found.
Example 18: Aminothlophenes
2-Amino-5-methyl-thiophene-3-carboxylic acid tert-butyl ester (18.1): 1H NMR
(CDCIs) 51.54 (s, 9H), 2.24 (s, 3H), 5.65 (br d, 2H), 7.25 (s, 1H); MS (El): cal'd
213.70,exp213.96(MH+).
2-Amino-5-heptyl-thiophene-3-carboxyllc acid fert-butyl ester (18.2) yellow oil
(5.808 g, 46% yield): 0.88 (t, 3H, J = 6.4 Hz), 1.24-1.32 (m, 8H), 1.54-1.57 (m,
11H), 2.56 (t, 2H, J = 7.5 Hz), 5.69 (bs, 2H), 6.56 (s, 1H). MS (ES+) 297.
For a general procedure to synthesize 2-amino-5-alkyl-thiophene-3-carboxylic acid
tert-butyl esters from aldehydes, see Tinney, F. J.; et al. J. Med. Chem. 1981, 24,
878-882.
2-Amino-5-butyl-thiophene-3-carboxylic acid ferf-butyl ester (18.3) yellow oil
(372 mg, 41% yield): 'H NMR (CDCI3, 200MHz) 6 0.91 (t, 3H, J= 7.1 Hz), 1.26-1.41
(m, 4H), 1.53 (bs, 9H), 2.56 (t, 2H, J = 7.3 Hz), 5.77 (bs, 2H), 6.56 (t, 1H, J= 1.1 Hz).
"C NMR (CDCI3, 50MHz) 8 13.7, 22.0, 28.4, 29.3, 33.2, 79.7, 107.7,121.8,126.3,
160.4,164.9. MS (ES+) 340.4 (M+1).
NH.
2-Amino-5-decyl-thiophene-3-carboxylic acid tert-butyl ester (18.4) yellow oil
(11.32 g, 79% yield): 'H NMR (CDCI3, 400MHz) 8 0 88 (t, 3H, J = 6.8 Hz), 1.26-1.30
(m, 14H), 1.52-1.55 (m, 11H), 2.56 (t, 2H, J = 7.4 Hz), 5.68 (bs, 2H), 6.56 (s, 1H).
2-Arnino-5-benzyl-thiophene-3-carboxylic acid fert-butyl ester (18.5) yellow oil
(520 mg, 51% yield): 'H NMR (CDCI3, 200MHz) 6 1.53 (s, 9H), 3.89 (s, 2H), 5.71
(bs, 2H), 6.66 (t, 1H, J= 1.1 Hz), 7.16-7.33 (m, 5H). 13C NMR (CDCI3, 50MHz) 5
28.4, 35.9, 79.9, 107.8, 123.4, 124.7, 126.5, 128.4, 128.5, 140.0, 161.3, 164.9. MS
(ES+) 289.9 (M+1).
2-Amino-5-(1,3,3-trlmethyl-butyl)-thiophene-3-carboxylic acid fert-butyl ester
(18.6) yellow oil (846 mg, 79% yield): 'H NMR (CDCI3, 200MHz) 8 0.89 (s, 9H), 1.22
(d, 3H, J = 7.0 Hz), 1.39 (dd, 1 H, J = 13.8, 4.6 Hz), 1.54 (s, 9H), 1.59 (dd, 1 H, J =
14.0, 7.0 Hz), 2.80-2.96 (m, 1H), 5.67 (bs, 2H), 6.55 (s, 1H).
2-Amino-5-(5-methoxy-1,5-dimethyl-hexyl)-thiophene-3-carboxylic acid tertbutyl
ester (18.7) yellow oil (2.328 g, 80% yield): 'H NMR (CDCI3, 200MHz) 8 1.12
(s, 6H), 1.22 (d, 3H, J= 6.8 Hz), 1.22-1.54 (m, 18H), 2.74 (dq, 1H, J= 7.0, 6.2 Hz),
3.16 (s, 3H), 5.70 (bs, 2H), 6.57 (s, 1H). MS (ES+) 341.93 (M+1).
£16
2-Amino-5-(1,5-dimethyl-hex-4-enyl)-thiophene-3-carboxylic acid fert-butyl
ester (18.8) yellow oil (2.029 mg, 77% yield): 'H NMR (CDCl3, 200MHz) 5 1.21 (d,
3H, J = 6.6 Hz), 1.51-1.54 (m, 11 H), 1.57 (s, 3H), 1.68 (s, 3H), 1.96 (dt, 2H, J = 7.2,
7.0 Hz), 2.75 (tq, 1H, J = 7.0, 6.6 Hz), 5.08 (t, 1H, J= 6.4 Hz), 5.69 (bs, 2H), 6.56 (s,
1H). MS (ES+) 309.9 (M+1).
2-Amino-5-phenethyl-thiophene-3-carboxylic acid fe/t-butyl ester (18.9) yellow
solid (1.5 g, 85% yield) 1H NMR (CDCI3) 200MHz) 8 1.53 (s, 9H), 2.88 (s, 4H), 5.70
(s, 2H), 6.59 (S, 1H), 7.26 (m, 5H)
2-Amino-5-(3-phenyl-propyl)-thiophene-3-carboxyllc acid ferf-butyl ester
(18.10) yellow oil (440 mg, 48% yield) 1H NMR (CDCI3, 200MHz) 8 1.54 (s, 9H),
1.90 (tt, 2H, J= 7.8,7.2Hz), 2.62 (m, 4H), 5.70 (s, 2H), 6.58 (s, 1H), 7.26 (m, 5H)
2-Amino-5-(4-phenyl-butyl)-thiophene-3-carboxylic acid fert-butyl ester (18.11)
yellow oil (1.22 g, 67% yield) 'H NMR (CDCI3l 200MHz) 8 0.88 (bt, 2H, J= 6.6 Hz),
1.16-1.31 (m, 2H), 1.54 (s, 9H), 1.57-1.74 (m, 2H), 2.52-2.70 (m, 2H), 5.69(bs, 2H),
6.56 (t, 1H, J= 1.2 Hz), 7.11-7.22 (m, 3H), 7.22-7.34 (m, 2H); MS (ES) No
lonization (M+1), ^method D) = 9.11min.
2-Amino-5-(5-phenyl-pentyl)-thiophene-3-carboxylic acid ferf-butyl ester (18.12)
yellow oil (638 mg, 36% yield) 1H NMR (CDCI3, 200MHz) 8 1.21-1.50 (m, 2H), 1.50-
1.76 (m, 14H), 2.44-2.72 (m, 4H), 5.69(bs, 2H), 6.56 (t, 1H, J= 1.2 Hz), 7.07-7.37
(m, 5H); MS (ES) No lonization (M+1), t^method D)= No LC trace observed
2-Amino-5-butyl-thiophene-3-carboxylic acid tert-butyl ester (18.13): 1H NMR
(CDCI3, 200 MHz): 8 = 0.91 (t, J = 7.1 Hz, 3H), 1.10-1.80 (m, 13H), 2.56 (td, J = 0.8,
7.4 Hz, 2H), 5.68 (brs, 2H), 6.56 (t, J = 1.1 Hz, 1H).
2-Amino-5-isopropyl-thiophene-3-carboxylic acid tert-butyl ester (18.14): 1H
NMR (CDCI3, 200 MHz): 8 = 1.23 (dd, J = 2.2, 6.8 Hz, 6H), 1.54 (s, 9H), 2.78-3.02
(m, 1H), 5.68 (brs, 2H), 6.57 (d, J = 1.2 Hz, 1H).
2-Amino-5-octyl-thiophene-3-carboxylic acid tert-butyl ester (18.15): 1H NMR
(CDCI3, 200 MHz): 8 = 0.88 (t, J = 6.6 Hz, 3H), 1.14-1.43 (m, 10H), 1.44-1.68 (m,
11H), 2.56 (t, J = 7.1 Hz, 2H), 5.67 (bra, 2H), 6.56 (s, 1H).
2-Amino-5-dodecyl-thiophene-3-carboxylic acid tert-butyl ester (18.16): 1H
NMR (CDCI3, 200 MHz): 8 = 0.88 (t, J = 6.6 Hz, 3H), 1.16-1.42 (m, 18H), 1.46-1.68
(m, 11 H), 2.55 (t, J = 7.5 Hz, 2H), 5.68 (brs, 2H), 6.55 (t, J = 1.2 Hz, 1 H).
2-Amino-5-heptyl-4-methyl-thiophene-3-carboxylic acid tert-butyl ester (18.17):
9.561 g (61%). 1H NMR (CDCI3, 200 MHz): 8 0.87 (t, J = 6.6 Hz, 3H), 1.16-1.40 (m,
10H, 1.55 (s, 9H), 2.12 (s, 3H), 2.41 (t, J = 7.4 Hz, 2H).
2-Amino-5-octyl-4-methyl-thiophene-3-carboxylic acid tert-butyl ester (18.18):
10.202 g (63%). 1H NMR (CDCI3, 200 MHz): 8 0.87 (t, J = 6.8 Hz, 3H), 1.20-1.38
(m, 12 H), 1.55 (s, 9H), 2.12 (s, 3H), 2.41 (t, J = 7.2 Hz, 2H).
113
2-Amino-6-benzylthiophene-3-carboxylic acid f-butyl ester (18.19)
Light yellow oil in 62% yield.
'H NMR (CDCI3, 200MHz): 6 7.18-7.38 (m, 5H), 6.66 (t, 1H, J= 1.0Hz), 5.70 (brs,
2H), 3.90 (s, 2H), 1 .54(s, 9H).
H
S" ^NH2
2-Amino-6-decylthiophene-3-carboxylic acid f-butyl ester (18.20)
Dark brownish oil in 74% yield.
'H NMR (CDCI3> 200MHz): 5 6.56 (t, 1H, J= 1.2Hz), 5.68 (brs, 2H), 2.56 (dt, 2H,
7.6, 1.2Hz), 1.54(s, 9H), 1.20-1.40 (m, 8H), 0.89 (t, 3H, J = 7.6Hz).
2-Amino-6-hexylthiophene-3-carboxylic acid f-butyl ester (18.21)
Dark brownish oil in 99% yield.
'H NMR (CDCI,, 200MHz): S 6.56 (t, 1H, J= 1.2Hz), 5.68 (brs, 2H), 2.55 (dt, 2H, J =
8.0, 1.2Hz), 1.54(s, 9H), 1.20-1.40 (m, 16HO, 0.88 (t, 3H, J = 7.0Hz).
Example 19: Carbamate/Urea Intermediates
5-Heptyl-4-methyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid tertbutyl
ester (19.1): 1H NMR (CDCI3) 50.83-0.92 (m, 6H), 1.20-1.40 (m, 18H), 1.50-
1.60 (m, 11H), 1.64-1.72 (m, 2H), 2.20 (s, 3H), 2.62 (t, 2H, J = 7.6 Hz), 4.19 (t, 2H, J
= 7.2 Hz); MS (El): cal'd 467.72, exp, did not ionize.
5-Methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid tert-butyl ester (19.2):
1H NMR (CDCIa) 80.87 (t, 3H, J = 7.2 Hz), 1.20-1.42 (m, 10H), 1.45-1.68 (m, 11H),
2.32 (s, 3H), 3.27 (dt, 2H, J = 7.2, 7.2 Hz), 4.79 (m, 1H), 6.70 (s, 1H), 10.2 (br s, 1H);
MS (El): cal'd 368.5, exp 368.87 (MH+).
5-Methyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid tert-butyl ester
(19.3): 1H NMR (CDCI3) 80.88 (t, 3H, J = 7.2 Hz), 1.20-1.42 (m, 10H), 1.55 (s, 9H),
1.62-1.72 (m, 2H), 2.34 (s, 3H), 4.19 (t, 2H, J = 6.8 Hz), 6.74 (s, 1H), 10.12 (br s,
1H); MS (El): cal'd 369.5, exp,.did not ionize.
General Procedure for urea formation (19.4-19.6):
5-Heptyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid fe/t-butyl ester (19.4)
Amino-thiophene 18.2 (200 mg, 0.67 mmol) was dissolved in 3 ml_ CH2Cl2 and
cooled to 0 SC. Under N2 atmosphere, DBU (0.25 ml, 1.68 mmol) was added slowly
followed by octyl isocyanate (104mg, 0.67mmol). The reaction slowly warmed to rt
and was stirred at room temperature for 5h. The reaction was then diluted with 20
mL CHaCIa and washed with 1N HCI and brine. The organic solution was then dried
with MgSCXj and concentrated in vacua. The crude mixture purified by silica gel
chromatography (15:1 hexanes: ethyl acetate) to yield 19.4, 73 mg (24% yield) of an
off-white solid: 1H NMR (CDCI3, 200MHz) 8 0.88 (t, 6H, J = 6.4 Hz), 1.27-1.29 (m,
18H), 1.54-1.58 (m, 13H), 2.64 (t, 2H, J = 7.5 Hz), 3.26 (dt, 2H, J = 7.0, 5.8 Hz),
4.85 (t, 1H, J = 5.7 Hz), 6.69 (s, 1H), 10.25 (s, 1H). MS (ES+) 453.1 (M+1).
O
5-Butyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid ferf-butyl ester (19.5) offwhite
solid (353 mg, 59% yield): 'H NMR (CDCI3, 200MHz) 8 0.87 (t, 3H, J = 7.1 Hz),
0.90 (t, 3H, J= 7.1 Hz), 1.25-1.41 (m, 12H), 1.53-1.64 (m, 13H), 2.64 (t, 2H, J = 7.5
Hz), 3.27 (dt, 2H, J = 7.0, 6.2 Hz), 5.29 (t, 1H, J ~ 5.7 Hz), 6.69 (s, 1H), 10.27 (bs,
1H). 13C NMR (CDCIs, 50MHz) 8 1.3.7, 14.0, 22.1, 22.6, 26.8, 28.3, 29.1, 29.2, 29.3,
30.0, 31.7, 33.4, 40.8, 80.7, 110.7, 119.8, 133.0, 149.9, 153.7, 165.6.
5-Benzyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid ferf-butyl ester (19.6)
pale yellow solid (394 mg, 49% yield): 'H NMR (CDCI3, 200MHz) 8 0.87 (t, 3H, J =
6.4 Hz), 1.27 (bs, 10H), 1.54 (s, 11H), 3.25 (dt, 2H, J = 7.0, 5.8 Hz), 3.97 (s, 2H),
4.88 (t, 1H, J= 5.6 Hz), 6.48 (t, 1H, J= 1.0 Hz), 7.16-7.32 (m, 5H), 10.26 (bs, 1H).
General procedure for amide and carbamate formation (19.7-19.17):
2-Dodecanoylamino-5-heptyl-thiophene-3-carboxylic acid tert-butyl ester (19.7)
Amino-thiophene 18.2 (171 mg, 0.57 mmol) was dissolved in 3 ml_ CHaCIa and 2 ml
pyridine. Under N2 atmosphere, lauroyl chloride (126mg, 0.57mmol) was added and
the reaction was stirred at room temperature for 6h. The reaction was then diluted
with 10 mL CH2CI2 and washed with water, 5% citric acid, and brine. The organic
solution was then dried with MgS04 and concentrated in vacua. The crude mixture
purified by silica gel chromatography (40:1 hexanes: ethyl acetate) to yield 19.7,175
mg (63% yield) of a yellow oil: 'H NMR (CDCI3, 200MHz) 8 0.87 (t, 6H, J = 6.4 Hz),
1.25-1.44 (m, 24H), 1.51-1.73 (m, 13H), 2.45 (t, 2H, J=7.5 Hz), 2.67 (t, 2H, J=7.5
Hz), 6.77 (s, 1H), 10.94 (bs, 1H). 13C NMR (CDCI3, 50MHz) 8 14.0, 14.1, 22.5, 22.6,
25.3, 28.3, 28.9, 29.0, 29.1, 29.2, 29.3, 29.4, 29.5, 29.6, 31.3, 31.7, 31.9, 36.7, 81.2,
113.3, 120.1, 134.8,146.3, 165.1, 169.9.
2-Octyloxycarbonylamino-5-(1.3,3-trimethyl-butyl)-thiophene-3-carboxylic acid
fert-butyl ester (19.8) yellow oil (185 mg, 34% yield): 'H NMR (CDCI3, 200MHz) 8
0.85-0.91 (m, 12H), 1.26-1.76 (m, 26H), 2.90-3.03 (m, 1H), 4.20 (t, 2H, J= 6.8 Hz),
6.73 (s, 1H), 10.15 (bs, 1H). 13C NMR (CDCI3, 50MHz) 8 14.0, 22.6, 25.8, 26.3, 28.3,
28.8, 29.1, 29.2, 29.8, 31.2, 31.8, 32.0, 52.6, 66.3, 81.2, 112.3, 118.9, 142.1, 147.7,
153.3,164.9.
5-(5-Methoxy-1,5-methyl-hexyl)-2-octyloxycarbonylamino-thiophene-3-
carboxyiic acid fert-butyl ester (19.9) pale yellow oil: 'H NMR (CDCI3> 200MHz) 5
0.89 (t, 3H, J= 6.4 Hz), 1.11 (s, 6H), 1.26-1.48 (m, 19H), 1.50-1.71 (m, 11H), 2.74
(dq, 1H, J = 7.0, 7.0 Hz), 3.15 (s, 3H), 4.20 (t, 2H, J= 6.6 Hz), 6.74 (s, 1H), 10.17 (s,
1H). "C NMR (CDCI3l 50MHz) 8 14.0, 21.5, 22.5, 22.6, 24.9, 25.7, 28.2, 28.7, 29.1,
31.7, 35.1, 39.3, 39.5, 48.9, 60.2, 66.2, 74.3, 81.. 1, 112.2, 119.3, 139.7, 147.9,
153.1, 164.8.
CT 0
5-(1,5-Dimethyl-hex-4-enyl)-2-octyloxycarbonylamino-thiophene-3-carboxylic
acid terf-butyl ester (19.10) brown oil (630 mg, 90% yield): 1H NMR (CDCI3,
200MHz) 8 0.89 (t, 3H, J = 6.6 Hz), 1.26-1.42 (m, 13H), 1.55-1.73 (m, 19H), 1.96
(dt, 2H, J = 7.8, 7.2 Hz), 2.86 (tq, 1H, J = 7.2, 6.6 Hz), 4.20 (t, 3H, J= 6.6 Hz), 5.08
(t, 1H, J= 7.2 Hz), 6.74 (s, 1H), 10.16 (bs, 1H).
H
2-Octyloxycarbonylamino-5-phenethyl-thiophene-3-carboxylic acid ferf-butyl
ester (19.11) white solid (740 mg, 98% yield) 'H NMR (CDCI3, 200MHz) 8 0.88 (t,
3H, J= 6.6Hz), 1.28 (brs, 10H), 1.56 (s, 9H), 1.68 (m, 2H), 2.96 (s, 4H), 4.20 (t, 2H, J
= 6.6Hz), 6.75 (s, 1H), 7.26 (m, 5H), 10.15 (s, 1H)
2-Octyioxycarbonylamino-5-(3-phenyl-propyi)-ihiophene-3-carboxyiic aciu ierfbutyl
ester (19.12) yellow oil (270 mg, 90% yield) 'H NMR (CDCI3, 200MHz) 8 0.88
(t, 3H, J= 6.6Hz), 1.28 (brs, 10H), 1.64 (brs, 11H), 1.97 (tt, 2H, J = 7.8, 7.2Hz), 2.69
(m, 4H), 4.20 (t, 2H, J= 6.6 Hz), 6.76 (s, 1H), 7.26 (m, 5H), 10.15 (s, 1H)
2-Octyloxycarbonylamino-5-(4-phenyl-butyl)-thiophene-3-carboxylic acid tertbutyl
ester (19.13) clear colorless oil (401 mg, 88% yield) 1H NMR (CDCI3, 200MHz)
8 0.88 (bt, 3H, J = 6.2 Hz), 1.15-1.42 (m, 11H), 1.56 (s, 9H), 1.61-1.80 (m, 6H),
2.52-2.80 (m, 4H), 4.20 (t, 2H, J = 6.6 Hz), 6.74 (s, 1H), 7.09-7.35 (m, 5H), 10.15 (s,
1H); MS (ES) no ionization or LC was observed.
2-Octyloxycarbonylamino-5-(5-phenyl-pentyl)-thiophene-3-carboxylic acid tertbutyl
ester (19.14) clear/colorless oil (331 mg, 75% yield) 1H NMR (CDCI3,
200MHz), 8 0.88 (bt, 3H, J= 6.2 Hz), 1.20-1.50 (m, 14H), 1.50-1.75 (m, 15H), 2.50-
2.75 (m, 4H), 4.19 (t, 2H, J = 7.0 Hz), 6.74 (t, 1H, J = 1.0 Hz), 7.08-7.36 (m, 5H); MS
(ES) No LC trace and no ionization came out.
5-Decyl-2-(2-methoxy-ethoxycarbonylamino)-thiophene-3-carboxylic acid tertbutyl
ester (19.15) pale yellow oil (307 mg, 76% yield) 1H NMR (CDCI3, 200MHz) 8
0.88 (bt, 3H, J = 6.2 Hz), 1.16-1.43 (m, 14H), 1.55 (s, 9H), 1.57-1.73 (m, 2H), 2.66
(t, 2H, J = 7.8 Hz), 3.41 (s, 3H), 3.58-3.70 (m, 2H), 4.25-4.44 (m, 2H), 6.74 (s, 1H),
10.27 (bs, 1H); MS (ES) 442.64 (M+1), t^method D) = 12.91min.
2-(4-Butyl-phenoxycarbonylamino)-5-decyl-thiophene-3-carboxylic acid tertbutyl
ester (19.16) Amino thiophene 18.4 ( 300 mg, 0.92 mmol) was dissolved in
anhydrous THF (4 ml_). Under a nitrogen atmosphere was added 4-nitrophenyl
chloroformate (184 mg, 0.92 mmol) and was stirred overnight at room temperature.
Without any isolation of the 4-nitrophenyl carbamate intermediate the sodium salt of
4-butyl phenol (200 mg, 1.26 mmol) was dropwise added to the solution of the
intermediate and was stirred at room temperature for 2 hours followed by heating to
40 BC for an additional hour. The sodium salt of the phenol was prepared by
dissolving 4-butyl phenol (174 mg, 1.16 mmol) in anhydrous THF (3 mL) and cooling
to 0 SC. Then NaH(60% dispersion in mineral oil) (45 mg, 1.16 mmol) was added to
reaction mixture and stirred at 0 BC for Vfe hour and was used as stated above. The
reaction mixture was partitioned between CHCI3 and H20 and separated. The H20
layer was extracted again with CHCI3 (3x) and separated. The combined CHCI,
layers was washed with 2M NaOH (1x), 1M HCI (1x), brine (1x) and dried with
Na2SO4 filtered and concentrated resulting in 490 mg of a dark orange oil. The crude
material was further purified by flash silica chromatography (2% EtOAc in Hexanes)
which resulted in 241 mg of a yellow oil (50% yield). 1H NMR (CDCI3, 200MHz) 8
0.83-0.93 (m, 6H), 1.19-1.45 (m, 18H), 1.47-1.72 (m, 14H), 2.55-2.75 (m, 4H), 6.80
(s, 1H), 7.11 (d, 2H, J=8.8Hz), 7.19 (d, 2H, J = 8.8Hz), 10.58 (s, 1H).
5-Decyl-2-(4-phenyl-butoxycarbonylamino)-thiophene-3-carboxylic acid tertbutyl
ester (19.17) pale yellow oil (241 mg, 89% yield) 1H NMR (CDCI3, 200MHz) 5
0.88 (t, 3H, J = 6.6 Hz), 1.26-1.38 (m, 14H), 1.56-1.70 (m, 11H), 1.99 (tt, 2H, J =
12.6, 6.2 Hz), 2.66 (t, 2H, J = 7.5 Hz), 3.58 (t, 2H, J = 6.2 Hz), 4.34 (t, 2H, J = 6.2
Hz), 4.50 (s, 2H), 6.75 (s, 1H), 7.24-7.34 (m, 5H), 10.16 (s, 1H). UC NMR (CDCI3,
50MHz) 8 14.04, 22.60, 28.26, 28.97, 29.19, 29.23, 29.27, 29.45, 29.48, 29.51,
31.25, 31.82, 63.35, 66.35, 72.96, 81.09, 112.53, 120.60, 127.48, 127.53, 128.28,
133.87,138.21, 147.97, 152.97, 164.77.
Example 20: Tert-butyl Ester Intermediates
5-Butyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid tert-butyl ester
(20.1): 1H NMR (CDCI3, 200 MHz): 8 = 0.80-1.00 (m, 6H), 1.18-1.49 (m, 12H),
1.50-1.79 (m, 13H), 2.67 (t, J = 7.3 Hz, 2H), 4.19 (t, J = 6.6 Hz, 2H), 6.74 (t, J = 0.9
Hz, 1H), 10.14 (brs, 1H).
5-lsopropyl-2-octyloxycarbonylamJno-thlophene-3-carboxylic acid tert-butyl
ester (20.2): 1H NMR (CDCI3, 200 MHz): 8 = 0.88 (t, J = 6.6 Hz, 3H), 1.16-1.46 (m,
16H), 1.50-1.76 (m, 11H), 2.90-3.16 (m, 1H), 4.20 (t, J = 6.6 Hz, 2H), 6.75 (d, J =
1.0Hz, 1H), 10.15 (brs, 1H).
cr o
5-Octyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid tert-butyl ester
(20.3): 1H NMR (CDCI3, 200 MHz): 6 = 0.79-0.98 (m, 6H), 1.18-1.46 (m, 20H),
1.51-1.78 (m, 13H), 2.66 (td, J = 0.8, 7.5 Hz, 2H), 4.19 (t, J = 6.6 Hz, 2H), 6.74 (t, J
= 1.1 Hz, 1H), 10.14 (brs, 1H).
CT O
5-Dodecyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid tert-butyl
ester (20.4): 1H NMR (CDCI3, 200 MHz): 6 = 0.80-0.98 (m, 6H), 1.15-1.46 (m,
28H), 1.52-1.78 (m, 13H), 2.66 (t, J = 7.3 Hz, 2H), 4.20 (t, J = 6.8 Hz, 2H), 6.74 (s,
1H), 10.14 (brs, 1H).
2-Benzyloxycarbonylamino-5-decyi-thiophene-3-carboxylic acid tert-butyl ester
(20.5): 1H NMR (CDCI3, 200 MHz): 8 = 0.88 (t, J = 6.4 Hz, 3H), 1.18-1.42 (m, 14H),
1.48-1.72 (rn, 11H), 2.66 (t, J = 7.5 Hz, 2H), 5.24 (s, 2H), 6.74 (s, 1H), 7.31-7.47 (m,
5H), 10.25 (brs, 1H).
General procedure for the preparation of tert-butyl esters 20.6-20.8 from
aminothiophene 18.4 and the corresponding commercially available alcohols:
To a solution of 4-butylbenzyl alcohol (0.30 mL, 1.76 mmol) in CH2Cl2 (10 ml) was
added saturated NaHC03 (10 ml) and then diphosgene (0.25 ml, 2.07 mmol)
dropwise. The mixture was allowed to stir vigorously at ambient temperature for 45
min, and aminothiophene 18.4 (283 mg, 0.83 mmol) was added in one portion. After
stirring vigorously for 2 h, the reaction mixture was diluted with EtaO (100 ml), and
the organic layer was washed with saturated NaHCOs (2x20 mL), and brine (40 mL).
The organic layer was dried over Na2S04 and then filtered. The filtrate was
concentrated and the resulting residue was purified by flash column chromatography
(40:1 Hexanes/EtOAc) to give tert-butyl ester 20.6 as a light yellow oil (416 mg,
95%).
2-(4-Butylbenzyloxycarbonylamino)-5-decyl-thiophene-3-carboxylic acid tertbutyl
ester (20.6): 1H NMR (CDCI3, 200 MHz): 6 = 0.82-1.00 (m, 6H). 1.18-1.46
(m, 16H), 1.48-1.72 (m, 13H), 2.54-2.73 (m, 4H), 5.20 (s, 2H), 6.73 (s, 1H), 7.13-
7.38 (m,4H), 10.23 (brs, 1H).
5-Decyl-2-(2-p-tolyl-ethoxycarbonylamino)-thiophei'ie-3-carboxyi!c acid tertbutyl
ester (20.7): 1H NMR (CDCI3, 200 MHz): 8 = 0.88 (t, J = 6.4 Hz, 3H), 1.17-
139
1.42 (m, 14H), 1.49-1.72 (m, 11H), 2.32 (s, 3H), 2.66 (t, J = 7.3 Hz, 2H), 2.96 (t, J =
7.1 Hz, 2H), 4.39 (t, J = 7.3 Hz, 2H), 6.74 (s, 1H), 7.08-7.19 (m, 4H), 10.14 (brs, 1H).
0 0
5-Decyl-2-phenethyloxycarbonylamino-thiophene-3-carboxylic acid tert-butyl
ester (20.8): 1H NMR (CDCI3, 200 MHz): 5 = 0.88 (t, J = 6.4 Hz, 3H), 1.18-1.42 (m,
14H), 1.50-1.72 (m, 11H), 2.66 (t, J = 7.3 Hz, 2H), 3.01 (t, J = 7.5 Hz, 2H), 4.42 (t, J
= 7.3 Hz, 2H), 6.74 (s, 1H), 7.18-7.40 (m, 5H), 10.15 (brs, 1H).
O
4-Methyl-5-octyl-2-octyloxycarbonylamino-th1ophene-3-carboxylic acid tertbutyl
ester (20.9): 2.35 g (33%). 1H NMR (CDCI3, 200 MHz): 6 0.87 (t, J = 6.6 Hz,
3H), 0.88 (t, J = 7.6 Hz, 3H), 1.30-1.72 (m, 24H), 1.57 (s, 9H), 2.20 (s, 3H), 2.61 (t, J
= 7.8 Hz, 2H), 4.18 (t, J = 6.6 Hz, 2H), 10.26 (s, 1H); 13C NMR (CDCI3, 75 MHz): 6
12.3, 12.9, 20.9, 24.0, 24.1, 25.4, 26.7, 27.1, 27.3, 27.4, 27.5, 27.6, 29.6, 30.1, 30.1,
64.5, 79.7, 111.2, 126.2, 127.1, 146.7, 151.5, 164.0.
2-Butyloxycarbonylamino-5-octyl-th!ophene-3-carboxylic acid tert-butyl ester
(20.10): 693 mg (92%). 1H NMR (CDCI3> 200 MHz): 8 0.83 (t, J = 6.6 Hz, 3H), 0.94
(t, J =7.0 Hz, 3H), 1.20-1.48 (m, 12H), 1.55 (s, 9H), 1.52-1.75 (m, 4H), 2.65 (t, J =
7.0 Hz, 2H), 4.20 (t, J = 6.6 Hz, 2H), 6.73 (s, 1H), 10.14 (s 1H).
2-Hexyloxycarbonylamino-5-octyl-thiophene-3-carboxylic acid tert-butyl ester
(20.11): 760 mg (98%). 1H NMR (CDCI3, 200 MHz): 80.87 (t, J = 6.6 Hz, 3H), 0.89
(t, J = 6.6 Hz, 3H), 1.18-1.44 (m, 14H), 1.55 (s, 9H), 1.54-1.76 (m, 4H), 2.65 (t, J =
7.0 Hz, 2H), 4.19 (t, J = 6.6 Hz, 2H), 6.73 (s, 1H), 10.14 (s, 1H).
2-Dodecy!oxycarbonylamino-5-octyl-thiophene-3-carboxylic acid tert-butyl
ester (20.12): 831 mg (88%). 1H NMR (CDCI3) 200 MHz): 8 0.87 (t, J = 6.6 Hz, 6H),
1.051-.50 (m, 28H), 1.55 (s, 9H), 1.50-1.75 (m, 4H), 2.65 (t, J = 7.2 Hz, 2H), 4.19 (t,
J = 6.6 Hz, 2H), 6.73 (t, J = 1.2 Hz, 1H), 10.14 (s, 1H).
5-Decyl-2-phenyloxycarbonylamino-thiophene-3-carboxylic acid tert-butyl
ester (20.13): 696 mg (84%). 1H NMR (CDCI3, 200 MHz): 80.88 (t, J = 7.0 Hz, 3H),
1.20-1.36 (m, 14H), 1.52-1.66 (m, 2H), 1.59 (s, 9H), 2.67 (dt, J = 7.4, 1.2 Hz, 2H),
6.78 (t, J = 1.2 Hz, 1H), 7.14-7.48 (m, 5H), 10.55 (s, 1H).
2-Decyloxycarbonylamino-5-octyl-thiophene-3-carboxylic acid ferf-butyl ester
(20.14): 863 mg (91%). 1H NMR (CDCI3) 200 MHz): 5 0.87 (t, J = 6.6 Hz, 6H), 1.14-
1.44 (m, 24H), 1.55 (s, 9H), 1.52-1.76 (m, 4H), 2.65 (t, J = 7.2 Hz, 2H), 4.19 (t, J =
6.6 Hz, 2H), 6.73 (s, 1H), 10.14 (s, 1H).
CT O
6-Benzyl-2-octyloxycarbonylamino)thiophene-3-carboxylic acid f-butyl ester
(20.15)
Light yellow oil in 77% yield.
'H NMR (CDCI3> 200MHz): 5 10.16 (s, 1H), 7.20-7.40 (m, 5H), 6.82 (s, 1H), 4.17 (t,
2H, J= 6.6Hz), 3.99 (s, 2H), 1.64(q, 2H, J= 6.6Hz), 1.55(s, 9H), 1.10-1.50 (m, 10H),
0.88(t,3H, J=6.6Hz).
6-Hexyl-2-(octyloxycarbonylamino)thiophene-3-carboxylic acid f-butyl ester
(20.16)
Light yellow oil in 86% yield.
1H NMR (CDCI3, 200MHz): 8 10.14 (brs, 1H), 6.74 (s, 1H), 4.19 (t, 2H, J = 6.6Hz),
2.66 (t, 2H, J = 7.6Hz), 1.60-1.75(m, 2H), 1.56 (s, 9H), 1.10-1.40 (m, 18H), 0.80-
0.95(m, 6H).
CT O
6-Decyl-2-(octyloxycarbonylamino)thiophene-3-carboxylic acid f-butyl ester
(20.17)
Light yellow oil in 99% yield.
'H NMR (CDCI3, 200MHz): 8 10.14 (brs, 1H), 6.74 (s, 1H), 4.19 (t, 2H, J = 6.6Hz),
2.66 (t, 2H, J = 8.0Hz), 1.60-1.75(m, 2H), 1.56 (s, 9H), 1.08-1.40 (m, 26H), 0.80-
0.95(m, 6H).
O O
6-Decyl-2-(1-methylheptyloxycarbonylamino)thiophene-3-carboxylic acid tbutyl
ester (20.18)
Light yellow oil in 99% yield.
'H NMR (CDCI3, 200MHz): 8 10.10 (brs, 1H), 6.73 (s, 1H), 4.82-5.00 (m, 1H), 2.65 (t,
2H, J = 7.4Hz), 1.50-1.83(m, 15H), 1.08-1.50 (m, 23H), 0.80-1.00(m, 6H).
6-Heptyl-2-(1-methylheptyloxycarbonylamino)thiophene-3-carboxylic acid rbutyl
ester (20.19)
Light yellow oil in 78% yield.
133
'H NMR (CDCI,, 200MHz): 6 10.01 (brs, 1H), 6.73 (s, 1H), 4.80-5.00 (m, 1H), 2.65 (t,
2H, J= 7.4Hz), 1.50-1.83(m, 13H), 1.08-1.50 (m, 17H), 0.80-1.00 (m, 6H).
5-Decyl-2-(4-phenylbutoxycarbonylamino)thiophene-3-carboxylic acid f-butyl
ester (20.20)
Light brownish oil in 99% yield.
1H NMR (CDCI3, 400MHz): 5 10.12 (s, 1H), 7.26-7.31 (m, 2H), 7.19-7.26 (m, 3H), 6.75
(s, 1H), 4.23 (t, 2H, J = 6.4Hz), 2.73 (t, 2H, J= 7.6Hz), 2.66 (t, 2H, J= 7.2Hz), 1.98-
2.07(m, 2H), 1.59-1.65(m, 2H), 1.52-1.57 (m, 11H), 1.26-1.30 (m, 12H), 0.88(t, 3H, J
= 6.4Hz).
5-Decyl-2-(4-phenylbutoxycarbonylamino)thiophene-3-carboxylic acid f-butyl
ester (20.21)
Light brownish oil in 98% yield.
'H NMR (CDCI3I 400MHz): 5 10.11 (s, 1H), 7.26-7.31 (m, 2H), 7.18-7.26 (m, 3H), 6.74
(S, 1H), 4.26 (brs, 2H), 2.67-2.70 (m, 4H), 1.70-1.80(m, 4H), 1.50-1.70(m, 11H),
1.18-1.40 (m, 16H), 0.88(t, 3H, J = 6.8Hz).
Example 21: Acid Intermediates
5-Heptyl-4-methyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid (21.1):
May contain -10% other isomer; 1H NMR (CDCI3) 6 0.82-0.94 (m, 6H), 1.20-1.46 (m,
18H), 1.50-1.66 (m, 2H), 1.66-1.80 (m, 2H), 2.28 (s, 3H), 2.64 (t, 2H, J = 7.2 Hz),
4.22 (t, 2H, J = 7.0 Hz). There was another peak at 2.79 (t, J = 7.0 Hz), which may
be from other isomer; MS (El): cal'd 411.61, exp, did not ionize.
5-Methyl-2-octyloxycarbonylamino-th!ophene-3-carboxylic acid (21.2): 1H NMR
(CDCI3) 80.88 (t, 3H, J = 7.2 Hz), 1:20-1.45 (m, 10H), 1.65-1.75 (m, 2H), 2.37 (s,
3H), 4.23 (t, 2H, J = 6.8 Hz), 6.84 (s, 1H), 9.89 (s, 1H); MS (El): cal'd 313.41, exp.
5-Heptyl-2-(3-octyl-ureldo)-thiophene-3-carboxylic acid (21.3) tan solid (51 mg,
80% yield): 'H NMR (CDCI3, 200MHz) 8 0.87 (t, 6H, J = 5.7 Hz), 1.26 (bs, 18H),
1.54-1.61 (m, 4H), 2.63 (t, 2H, J = 7.5 Hz), 3.26 (dt, 2H, J = 7.0, 7.0 Hz), 5.95 (bs,
1H), 6.77 (s, 1H), 10.10 (s, 1H), 11.36 (bs, 1H). "C NMR (CDCIg, 50MHz) 5 14.0,
22.6, 26.8, 29.0, 29.2, 29.3, 29.4, 29.7, 31.1, 31.7, 31.8, 41.0, 88.4, 108.9, 119.6,
134.2,151.9, 154.1,169.9.
5-Butyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid (21.4) purple oil (308 mg,
100% yield): 'H NMR (CDCI3> 200MHz) 6 0.87 (t, 6H, J= 5.7 Hz), 1.26 (bs, 18H),
1.54-1.61 (m, 4H), 2.63 (t, 2H, J = 7.5 Hz), 3.26 (dt, 2H, J = 7.0, 7.0 Hz), 5.95 (bs,
1 H), 6.77 (s, 1 H), 10.10 (s, 1 H), 11.36 (bs, 1 H).
5-Benzyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid (21.5) tan solid (450 mg): 'H
NMR (CDCIg, 200MHz) 5 0.87 (t, 3H, J= 6.4 Hz), 1.26 (bs, 10H), 1.51 (tt, 2H, J = 12.2, 6.5
Hz), 3.21 (dt, 2H, J= 6.6, 6.0 Hz), 3.96 (s, 2H), 6.33 (bs, 1H), 6.82 (s, 1H), 7.14-7.32 (m,
5H), 10.16 (bs,1H).
8 NH
2-Dodecanoylamino-5-heptyl-thiophene-3-carboxylic acid (21.6) dark brown
solid (185 mg, 100% yield): 'H NMR (CDCI3, 200MHz) 6 0.85-0.90 (m, 6H), 1.26-
1.40 (m, 24H), 1.54-1.79 (m, 4H), 2.52 (t, 2H, J = 7.5 Hz), 2.71 (t, 2H, J = 7.5 Hz),
6.91 (s, 1 H), 10.53 (bs, 1 H), 10.75 (s, 1 H). MS (ES-) 421.86 (M-1).
5-Heptyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid (21.7) pale
yellow solid (76 mg, 54% yield): 'H NMR'(CDCI3, 200MHz) 8 0.85-0.91 (m, 6H),
1.30 (bs, 18H), 1.58-1.75 (m, 4H), 2.69 (t, 2H, J = 7.5 Hz), 4.24 (t, 2H, J = 6.6 Hz),
6.86 (s, 1H), 9.90 (s, 1H). MS (ES-) 395.93 (M-1).
O
2-Octyloxycarbonylamino-5-(1,3,3-trimethyl-butyl)-thiophene-3-carboxylic acid
(21.8) waxy tan solid (190 mg, 100% yield): 'H NMR (CDCI3, 200MHz) 6 0.88-0.89
(m, 12H), 1.28-1.76 (m, 17H), 2.90-3.09 (m, 1H), 4.24 (t, 2H, J= 6.6 Hz), 6.87 (s,
1H), 9.85 (S, 1H), 10.34 (bs, 1H).
2-(2-BenzyIoxy-ethoxycarbonylamino)-5-decyl-thiophene-3-carboxylic acid
(21.9) tan solid (142 mg): 'H NMR (CDCI3, 200MHz) 8 0.89 (t, 3H, J = 6.5 Hz), 1.23-
1.27 (m, 14H), 1.58-1.69 (m, 2H), 2.69 (t, 2H, J = 7.3 Hz), 3.76 (t, 2H, J = 4.6 Hz),
4.43 (t, 2H, J = 4.6 Hz), 4.61 (s, 2H), 6.88 (s, 1H), 7.28-7.38 (m, 5H), 9.99 (s, 1H),
10.48. (bs, 1 H). MS (ES-) 460.06 (M-1).
2-Octyloxycarbonylamino-5-phenethyl-thiophene-3-carboxylic acid (21.10)
white solid (203 mg, 97% yield): 1H NMR (CDCI3, 200MHz) 8 0.88 (t, 3H, J= 6.8Hz),
1.28 (brs, 10H), 2.98 (s, 4H), 4.23 (t, 2H, J= 7.0Hz), 6.84 (s, 1H), 7.22 (m, 5H), 9.96
13?
0
2-Octyloxycarbonylamino-5-(3-phenyl-propyl)-thiophene-3-carboxylic acid
(21.11) yellow solid (175 mg, 99% yield): 'H NMR (CDCI3, 200MHz) 8 0.88 (t, 3H, J
= 6.8Hz), 1.28 (brs, 10H), 1.68 (m, 2H), 1.98 (tt, 2H, J= 7.8Hz, 7.2Hz), 4.23 (t, 2H, J
= 7.0HZ), 6.87 (s, 1H), 7.26 (m, 5H), 9.93 (1H)
o
2-Octyloxycarbonylamino-5-(4-phenyl-butyl)-thiophene-3-carboxylic acid
(21.12) white waxy solid (303 mg, 92% yield): 1H NMR (CD3OD, 400MHz) § 0.90 (bt,
3H, J= 6.8 Hz), 1.21-1.48 (m, 12H), 1.57-1.76 (m, 6H), 2.57-2.77 (m, 4H), 4.20 (t,
2H, J = 6.4 Hz), 6.82 (s, 1H), 7.08-7.32 (m, 5H). MS (ES) 430.35 (M-1), tfi(method
D) = 7.74min
2-Octyloxycarbonylamino-5-(5-phenyl-pentyl)-thiophene-3-carboxylic acid
(21.13) off-white solid (331 mg, 90% yield): 1H NMR (CD3OD, 400MHz) 6 0.90 (bt,
3H, J = 6.4 Hz), 1.23-1.45 (m, 14H), 1.58-1.75 (m, 6H), 2.59 (t, 2H, J = 7.6 Hz),
2.68 (t, 2H, J = 7.2 Hz), 4.20 (t, 2H, 6.8 Hz), 6.81 (bs, 1H), 7.07-7.18 (m, 3H), 7.19-
7.27 (m, 2H). MS (ES) 443.58 (M-1), tn(method D) = 8.58min
5-Decyl-2-(2-methoxy-ethoxycarbonylamino)-thiophene-3-carboxylic acid
(21.14) off-white solid (256 mg, 95% yield): 1H NMR (CDCI3, 200MHz) 8 0.88 (bt,
3H, J = 6.2 Hz), 1.11-1.44 (m, 14H), 1.47-1.73 (m, 2H), 2.69 (t, 2H, J = 7.8 Hz),
3.43 (s, 3H), 3.62-3.75 (m, 2H), 4.31-4.47 (m, 2H), 6.86 (s, 1H), 10.00 (s, 1H). MS
(ES) 384.52 (M-1), t^method D) = 6.28min.
2-(4-Butyl-phenoxycarbonylamino)-5-decyl-thiophene-3-carboxylic acid (21.15)
tan solid (214 mg, 97% yield) 'H NMR (CD3OD, 400 MHz) 8 0.891 (bt, 3H, J = 6.8
Hz), 0.949 (t, 3H, J= 7.2 Hz), 1.21-1.43 (m, 16H), 1.54-1.71 (m, 4H), 2.63 (t, 2H, J
= 7.6 Hz), 2.70 (t, 2H, J= 7.2 Hz), 6.87 (s, 1H), 7.12 (d, 2H, J= 8.4 Hz), 7.23 (d, 2H,
J= 8.8 Hz); MS (ES) no ionization (M-1), tR(method D) = no peak
2-(3-phenoxy-propoxycarbonylamlno)-5-decyl-thiophene-3-carboxylic acid
(21.16) off-white solid (137 mg, 80% yield): 1H NMR (CDCI3l 200MHz) 8 0.88 (t, 3H,
J= 6.4 Hz), 1.26-1.38 (m, 14H), 1.64 (tt, 2H, J= 12.4, 7.0 Hz), 2.02 (tt, 2H, J= 12.4,
6.2 Hz), 2.68 (t, 2H, J = 7.3 Hz), 3.60 (t, 2H, J = 6.2 Hz), 4.37 (t, 2H, J = 6.2 Hz),
4.53 (s, 2H), 6.87 (s, 1H), 7.25-7.34 (m, 5H), 9.88 (s, 1H), 10.85 (bs, 1H).
2-(4-Benzyloxy-butoxycarbonylamino)-5-decyl-thiophene-3-carboxylic acid
(21.17) off-white solid (55 mg, 55% yield): 1H NMR (CDCI3, 200MHz) 8 0.88 (t, 3H, J
= 6.3 Hz), 1.26-1.38 (m, 14H), 1.61-1.82 (m, 6H), 2.68 (t, 2H, J= 7.4 Hz), 3.53 (t,
2H, J = 5.8 Hz), 4.27 (t, 2H, J = 5.8 Hz), 4.50 (s, 2H), 6.86 (s, 1H), 7.25-7.33 (m,
5H), 9.92(s, 1H).
5-Pentyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid (21.18): 1H
NMR (CDCI3, 200 MHz): 8 = 0.78-1.02 (m, 6H), 1.14-1.50 (m, 12H), 1.52-1.82 (m,
4H), 2.69 (t, J = 7.5 Hz, 2H), 4.23 (t, J = 6.8 Hz, 2H), 6.59 (s, 1H), 9.88(brs, 1H).
5-lsopropyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid (21.19): 1H
NMR (CDCI3, 200 MHz): 8 = 0.88 (t, J = 6.4 Hz, 3H), 1.16-1.50 (m, 16H), 1.60-1.82
(m, 2H), 2.90-3.18 (m, 1H), 4.24 (t, J = 6.8 Hz, 2H), 6.87 (d, J = 1.2 Hz, 1H), 9.81
(brs, 1H), 9.86 (brs, 1H).
O
5-Octyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid (21.20): 1H NMR
(CDCI3, 200 MHz): 6 = 0.78-1.00 (m, 6H), 1.12-1.49 (m, 20H), 1.54-1.82 (m, 4H),
2.68 (t, J = 7.3 Hz, 2H), 4.23 (t, J = 6.6 Hz, 2H), 6.86 (s, 1H), 9.89 (brs, 1H).
5-Dodecyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid (21.21): 1H
NMR (CDCI3, 200 MHz): 8 = 0.78-0.96 (m, 6H), 1.12-1.46 (m, 28H), 1.52-1.78 (m,
4H), 2.68 (t, J = 7.3 Hz, 2H), 4.23 (t, J = 6.8 Hz, 2H), 6.85 (s, 1H), 9.90 (brs, 1H).
2-Benzyloxycarbonylamino-5-decyl-thlophene-3-carboxylic acid (21.22): 1H
NMR (CDCI3, 200 MHz): 6 = 0.88 (t, J = 6.4 Hz, 3H), 1.14-1.44 (m, 14H), 1.50-1.74
(m, 2H), 2.68 (t, J = 7.1 Hz, 2H), 5.26 (s, 2H), 6.85 (s, 1H), 7.33-7.49 (m, 5H), 9.95
(brs, 1H).
2-(4-Butylbenzyloxycarbonylamino)-5-decyl-thiophene-3-carboxylic acid
(21.23): 1H NMR (CDCI3, 200 MHz): 8 = 0.78-1.02 (m, 6H), 1.10-1.46 (m, 16H),
1.48-1.76 (m, 4H), 2.52-2.80 (m, 4H), 5.23 (s, 2H), 6.84 (s, 1H), 7.13-7.40 (m, 4H),
9.93 (brs, 1H).
cr o'
5-Decyl-2-(2-p-tolyl-ethoxycarbonylamino)-thiophene-3-carboxylic acid (21.24):
1H NMR (CDCIa, 200 MHz): 8 = 0.88 (t, J = 6.4 Hz, 3H), 1.16-1.46 (m, 14H), 1.52-
1.78 (m, 2H), 2.33 (s, 3H), 2.69 (t, J = 7.5 Hz, 2H), 3.00 (t, J = 7.3 Hz, 2H), 4.43 (t, J
= 7.3 Hz, 2H), 6.87 (s, 1H), 7.08-7.22 (m, 4H), 9.91 (brs, 1H).
H
( T O
5-Decyl-2-phenethyloxycarbonylamino-thiophene-3-carboxylic acid (21.25): 1H
NMR (CDCI3, 200 MHz): 8 = 0.88 (t, J = 6.4 Hz, 3H), 1.16-1.46 (m, 14H), 1.52-1.76
(m, 2H), 2.69 (t, J = 7.3 Hz, 2H), 3.05 (t, J = 7.3 Hz, 2H), 4.46 (t, J = 7.5 Hz, 2H),
6.87 (s, 1H), 7.18-7.42 (m, 5H), 9.92 (brs, 1H).
4-Methyl-5-octyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid (21.26):
520 mg (69%). 1H NMR (CDCI3, 200 MHz): S 0.87 (t, J = 6.6 Hz, 6H), 1.16-1.62 (m,
24), 2.28 (s, 3H), 2.64 (t, J = 7.2 Hz, 2H), 4.18 (t, J = 6.6 Hz, 2H), 10.26 (s, 1H).
o
2-Butyloxycarbonylamino-5-octyl-thiophene-3-carboxylic acid (21.27): 366 mg
(67%). 1H NMR (CDCIs, 200 MHz): 6 0.87 (t, J = 6.6 Hz, 3H), 0.96 (t, J = 7.4 Hz,
3H), 1.14-1.82 (m, 16H), 2.67 (t, J = 7.4 Hz, 2H), 4.24 (t, J = 6.6 Hz, 2H), 6.85 (s,
1H), 9.89(8, 1H).
2-Hexyloxycarbonylamino-5-octyl-thiophene-3-carboxyiic acid (21.28): 395 mg
(60%). 1H NMR (CDCI3, 200 MHz): 8 0.87 (t, J = 7.0 Hz, 3H), 0.90 (t, J = 6.4 Hz,
3H), 1.12-1.52 (m, 16H), 1.50-1.82 (m, 4H), 2.68 (t, J = 7.2 Hz, 2H), 4.23 (t, J = 7.0
Hz, 2H), 6.68 (s, 1H), 9.88 (s, 1H).
2-Dodecyloxycarbonylamlno-5-octyl-thiophene-3-carboxylic acid (21.29): 541
mg (80%). 1H NMR (CDCIg, 200 MHz): 5 0.87 (t, J = 6.4 Hz, 6H), 1.12-1.50 (m,
28H), 1.50-1.80 (m, 4H), 2.68 (t, J = 7.4 Hz, 2H), 4.23 (t, J = 6.6 Hz, 2H), 6.85 (s,
1H), 9.89 (s, 1H).
cr o
5-Decyl-2-phenyloxycarbonylamino-thiophene-3-carboxylic acid (21.30): 469
mg (80%). 1H NMR (CDCI3) 200 MHz): 50.87 (t, J = 6.6 Hz, 3H), 1.18-1.44 (m,
14H), 1.54-1.76 (m, 2H), 2.70 (t, J = 7.2 Hz, 2H), 6.91 (s, 2H), 7.17-7.48 (m, 5H),
10.27 (s,1H).
Cr 0
2-Decyloxycarbonylamino-5-octyl-thiophene-3-carboxylic acid (21.31): 603 mg
(86%). 1H NMR (CDCI3, 200 MHz): 8 0.87 (t, J = 6.2 Hz, 6H), 1.32-1.50 (m, 24H),
1.52-1.82 (m, 4H), 2.67 (t, J = 7.4 Hz, 2H), 4.23 (t, J = 6.6 Hz, 2H), 6.85 (s, 1H),
9.89 (S.1H).
6-Benzyl-2-octyloxycarbonylamino)thiophene-3-carboxylic acid (21.32)
Light yellow solid in 100% yield.
'H NMR (CDCI3, 200MHz): 5 9.86 (s, 1H), 7.22-7.34 (m, 5H), 7.00(brs, 1H), 6.87 (t,
1H, J= 1.0HZ), 4.21 (t, 2H, J= 6.6Hz), 4.01 (s, 2H), 1.67(q, 2H, J = 7.0Hz), 1.15-
1.45 (m, 10H), 0.88(t, 3H, J = 7.0Hz).
6-Hexyl-2-(octyloxycarbonylamino)thiophene-3-carboxylic acid (21.33)
Light yellow oil in 74% yield.
'H NMR (CDCI3, 200MHz): 5 10.87 (brs, 1H), 9.83 (s, 1H), 6.86 (s, 1H), 4.24 (t, 2H, J
= 6.6Hz), 2.68 (t, 2H, J = 7.2Hz), 1.60-1.80(m, 4H), 1.10-1.45 (m, 20H), 0.80-0.95(m,
6H).
6-Decyl-2-(octyloxycarbonylamino)thiophene-3-carboxylic acid (21.34)
Light yellow solid in 100% yield.
'H NMR (CDCI3, 200MHz): 5 9.89 (brs, 1H), 8.00 (brs, 1H), 6.85 (s, 1H), 4.23 (t, 2H, J
= 6.6Hz), 2.68 (t, 2H, J = 7.0Hz), 1.60-1.80(m, 4H), 1.08-1.40 (m, 24H), 0.80-0.95(m,
6H).
6-Decyl-2-(1-methylheptyloxycarbonylamino)thiophene-3-carboxylic
(21.35)
Light yellow solid in 98% yield.
acid
'H NMR (CDCI,, 200MHz): 6 9.80 (brs, 1H), 8.24(brs, 1H), 6.73 (s, 1H), 4.82-5.00 (m,
1H), 2.65 (t, 2H, J = 7.4Hz), 1.50-1.83(m, 15H), 1.08-1.50 (m, 23H), 0.80-1.00(m,
6H).
( T O
acid 6-Heptyl-2-(1-methylheptyloxycarbonylamino)thiophene-3-carboxylic
(21.36)
Light yellow oil in 100% yield.
'H NMR (CDCI3> 200MHz): 5 9.80 (brs, 1H), 8.24(brs, 1H), 6.85 (s, 1H), 4.90-5.00 (m,
1H), 2.68 (t, 2H, J = 7.6Hz), 1.50-1.83(m, 4H), 1.08-1.50 (m, 20H), 0.80-1.00 (m,
6H).
O O
5-Decyl-2-(4-phenylpropoxycarbonylamino)thiophene-3-carboxylic acid (21.37)
Light brownish solid in 100% yield.
'H NMR (CDCI,, 400MHz): 5 10.4 (brs, 1H), 9.88 (s, 1H), 7.26-7.31 (m, 2H), 7.18-7.21
(m, 3H), 6.87 (s, 1H), 4.27 (t, 2H, J= 6.4Hz), 2.74 (t, 2H, J = S.OHz), 2.68 (t, 2H, J =
7.6Hz), 2.02-2.07(m, 2H), 1.59-1.66(m, 2H), 1.18-1.40 (m, 14H), 0.88 (t, 3H, J =
6.0Hz).
5-Decyl-2-(4-phenylbutoxycarbonylamino)thiophene-3-carboxylic acid (21.38)
Light brownish solid in 100% yield.
!H NMR (CDCI3, 400MHz): 8 12.0 (brs, 1H), 9.90 (s, 1H), 7.26-7.31 (m, 2H), 7.17-7.21
(m, 3H), 6.87 (s, 1H), 4.26 (t, 2H, J= 6.4Hz), 2.67-2.70 (m, 4H), 1.70-1.80(m, 4H),
1.50-1.70(m, 2H), 1.18-1.40 (m, 16H), 0.88(t, 3H, J = 6.8Hz).
Example 22: Thienoxazinones
6-Heptyl-5-methyl-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one (74) (May contain
-10% other isomer); Mp 29-31 SC; 1H NMR (CDCI3) 6 0.82-0.96 (m, 6H), 1.20-1.50
(m, 18H), 1.50-1.68 (m, 2H), 1.68-1.86 (m, 2H), 2.36 (s, 3H), 2.70 (t, 2H, J = 6.8 Hz),
4.38 (t, 2H, J = 6.6 Hz) Another peak at 2.83 (t, J = 6.7 Hz), which may be from other
isomer; MS (El): cal'd 393.59, exp, did not ionize.
6-Methyl-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one (22.1): 1H NMR (CDCI3)
80.88 (t, 3H, J = 7.2 Hz), 1.20-1.45 (m, 10H), 1.55 (s, 9H), 1.70-1.84 (m, 2H), 2.46
(s, 3H), 4.39 (t, 2H, J = 6.6 Hz), 6.93 (s, 1H); MS (El): cal'd 295.5, exp.
6-Heptyl-2-octylamino-thieno[2,3-d][1,3]oxazin-4-one (61): off-white solid (38 mg,
801% yield): 'H NMR (CDCI3, 200MHz) 5 0.87 (t, 6H, J = 6.4 Hz), 1.27-1.30 (m,
18H), 1.58-1.67 (m, 4H), 2.71 (t, 2H, J= 7.3 Hz), 3.38 (dt, 2H, J= 7.0, 6.2 Hz), 5.45
(68,11-0,6.84(8,1^.
6-Butyl-2-octylamino-thieno[2,3-d][1,3]oxazin-4-one (63): off-white solid (162 mg,
55% yield): mp 93.0-94.0 eC. 'H NMR (CDCI3, 200MHz) 5 0.88 (t, 3H, J= 6.4 Hz),
0.93 (t, 3H, J = 7.3 Hz), 1.27-1.48 (m, 12H), 1.56-1.71 (m, 4H), 2.72 (t, 2H, J = 7.5
Hz), 3.39 (dt, 2H, J = 7.0, 6.2 Hz), 5.73 (bs, 1H), 6.§5 (t, 1H, J= 1.1 Hz). MS (ES+)
337.23 (M+1).
6-Benzyl-2-octylamino-thieno[2,3-d][1,3]oxazin-4-one (62): off-white solid (182
mg, 55% 2-step yield): mp 123.0-124.0 BC. 'H NMR (CDCI3, 200MHz) 6 0.87 (t, 3H,
J= 6.4 Hz), 1.26-1.28 (m, 10H), 1.51 (tt, 2H, J= 13.6, 6.5 Hz), 3.36 (dt, 2H, J = 7.0,
6.6 Hz), 4.02 (s, 2H), 5.81 (bs, 1H), 6.85 (s, 1H), 7.20-7.35 (m, 5H). MS (ES+)
371.18 (M+1).
6-Heptyl-2-undecyl-thieno[2,3-d][1,3]oxazin-4-one (67): yellow oil (97 mg, 55%
yield): 'H NMR (CDCI3, 200MHz) 5 0.85-0.91 (m, 6H), 1.26-1.32 (m, 24H), 1.66-
1.83 (m, 4H), 2.69 (t, 2H, J= 7.7 Hz), 2.82 (t, 2H, J= 7.5 Hz), 7.06 (s, 1H). 13C NMR
(CDCI3, 50MHz) 8 14.0, 14.1, 22.5, 22.6, 26.2, 28.8, 28.9, 29.0, 29.2, 29.3, 29.4,
29.5, 30.4, 31.0, 31.7, 31.9, 34.7, 117.8, 118.6, 144.3, 155.6, 162.2, 165.2.
6-Heptyl-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one (68): yellow oil (36 mg, 50%
yield): 1H NMR (CDCI3, 200MHz) 8 0.85-0.93 (m, 6H), 1.29-1.48 (m, 18H), 1.61-
1.87 (m, 4H), 2.77 (t, 2H, J = 7.5 Hz), 4.41 (t, 2H, J = 6.6 Hz), 6.97 (t, 1H, J = 1.1
Hz).
2-Octyloxy-6-(1,3,3-trimethyl-butyl)-thIeno[2,3-d][1,3]oxazin-4-one (78): colorless
oil (92 mg, 51% yield): 'H NMR (CDCI3, 200MHz) 8 0.88-0.89 (m, 12H), 1.30-1.83
(m, 17H), 3.04-3.13 (m, 1H), 4.41 (t, 2H, J = 6.6 Hz), 6.98 (s, 1H). "C NMR (CDCI3,
50MHz) 8 14.0, 22.6, 25.6, 26.2, 28.3, 29.1, 29.8, 31.3, 31.7, 32.8, 52.6, 70.5, 113.2,
116.5, 149.4,154.5,156.9,165.3. MS (ES+) 380.01 (M+1).
(83): pale yellow oil (3 mg): 'H NMR (CDCI3, 200MHz) 8 0.89 (t, 3H, J = 6.6 Hz),
1.11 (s, 6H), 1.26-1.67 (m, 19H), 1.77 (dt, 2H, J= 7.0, 6.6 Hz), 2.96 (dq, 1H, J = 7.2,
7.0 Hz), 3.15 (S, 3H), 4.40 (t, 2H, J^ 6.6 Hz), 6.98 (s, 1H). MS (ES+) 424.03 (M+1).
6-(1,5-Dimethyl-hex-4-enyl)-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one and 6-
(1,5-Dimethyl-hex-5-enyl)-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one (2:1 mixture
of isomers) (81): colorless oil (16 mg): MS (ES+) 391.95, 391.97 (M+1).
O
Trifluoro-acetic acid 1,1-dimethyl-5-(2-octyloxy-4-oxo-4H-thieno[2,3-
d][1,3]oxazin-6-yl)-hexyl ester (82): colorless oil (61 mg): 'H NMR (CDCI3,
200MHz) 8 0.89 (t, 3H, J= 6.6 Hz), 1.26-1.69 (m, 8H), 1.76-1.88 (m, 4H), 2.97 (dq,
1H, J = 7.0, 6.8 Hz), 4.41 (t, 2H, J = 6.6 Hz), 6.98 (s, 1H). "C NMR (CDCI3,
100MHz) 8 14.2, 21.5, 22.7, 22.8, 25.7, 25.8, 28.5, 29.3, 31.9, 35.8, 38.7, 40.3, 70.8,
89.1, 113.6, 114.6 (q, CF3, J = 285.9 Hz), 117.3, 117.4, 146.8, 154.7, 156.4 (q,
COCF3, J= 40.9 Hz), 157.3, 165.8. MS (ES+) 505.93 (M+1).
2-(2-Benzyloxy-ethoxy)-6-decy1-thieno[2,3-d][1,3]oxazin-4-one (97): yellow oil
(68 mg, 50% yield): 'H NMR (CDCI3, 400MHz) 8 0.88 (t, 3H, J= 6.8 Hz), 1.26-1.32
(m, 14H), 1.66 (tt, 2H, J = 14, 7.6 Hz), 2.76 (t, 2H, J = 7.6 Hz), 3.81 (t, 2H, J = 4.4
Hz), 4.57 (t, 2H, J = 4.6 Hz), 4.60 (s, 2H), 6.95 (s, 1H), 7.25-7.34 (m, 5H). 13C NMR
(CDCI3l 100MHz) 5 14.0, 22.6, 28.8, 29.2, 29.3, 29.4, 29.5, 30.2, 30.9, 31.8, 67.1,
69.3, 73.3, 113.7, 118.2, 127.6, 127.7, 128.4, 137.6, 141.3, 154.2, 156.7, 165.2.
490
2-Octyloxy-6-phenethyl-thieno[2,3-d][1,3]oxazin-4-one (103): clear oil (84 mg,
88% yield) 'H NMR (CDCI3l 200MHz) 8 0.89 (t, 3h, J = 6.8Hz), 1.28-1.43 (m, 10H),
1.79 (tt, 2H, J = 7.6Hz, J = 7.2Hz), 2.98 (t, 2H, J = 7.2Hz), 3.10 (t, 2H, J = 7.6Hz),
4.39 (t, 2H, J = 6.8Hz), 6.95 (s, 1H), 7.17-7.31 (m, 5H).
2-Octyloxy-6-(3-phenyl-propyl)-thieno[2,3-d][1,3]oxazin-4-one (104): white solid
(72 mg, 75% yield) 'H NMR (CDCI3, 200MHz) 80.88 (t, 3H, J = 6.6Hz), 1.21-1.50 (m,
10H), 1.79 (tt, 2H, J = 7.0Hz, J = 6.6Hz), 2.01 (tt, 2H, J = 7.8Hz, J = 7.2Hz), 2.69 (t,
2H, J = 7.6Hz), 2.80 (t, 2H, J = 7.2Hz), 4.40 (t, 2H, J = 6.6Hz), 6.98 (s, 1H), 7.16-
7.35 (m, 5H).
2-Octyloxy-6-(4-phenyl-butyl)-thieno[2,3-d][1,3]oxazin-4-one (92): pale yellow oil
(218 mg, 78% yield) 'H NMR (CDCI3, 200MHz) 8 0.887 (bt, 3H, 6.2 Hz), 1.08-1.52
(m, 10H), 1.60-1.90 (m, 6H), 2.54-2.72 (m, 2H), 2.72-2.88 (m, 2H), 4.40 (t, 2H, J =
6.6 Hz), 6.95 (s, 1H), 7.09-7.38 (m, 5H); MS (ES) 414.59 (M+1), tn(method D) =
9.71 min.
131
2-Octyloxy-6-(5-phenyl-pentyl)-thieno[2,3-d][1,3]oxazin-4-one (93): Pale yellow
oil (223 mg, 94% yield) 1H NMR (CDCI3, 200MHz) 8 0.887 (bt, 3H, J = 6.2 Hz),
1.20-1.50 (m, 12H), 1.57-1.88 (m, 6H), 2.61 (t, 2H, J = 7,4 Hz), 2.76 (t, 2H, J = 6.8
Hz), 4.40 ( t, 2H, J = 6.6 Hz), 6.95 (t, 1H, J = 1 Hz), 7.08-7.35 (m, 5H); MS (ES)
428.62 (M+1), tfl(method D) = 10.69min.
6-Decyl-2-(2-methoxy-ethoxy)-thieno[2,3-d][1,3]oxazin-4-one (96): off-white
waxy solid (195 mg, 83% yield); m.p. = 38-41 SC; 1H NMR (CDCI3, 200MHz) 8 0.879
(bt, 3H, J = 6.2 Hz), 1.06-1.43 (m, 14H), 1.52-1.78 (m, 2H), 2.76 (t, 3H, J= 7.0 Hz),
3.43 (s, 3H), 3.62-3.82 (m, 2H), 4.44-4.64 (m, 2H), 6.96 (s, 1H); MS (ES) 368.52
(M+1), tfl(method D) = S.OOmin.
2-(4-Butyl-phenoxy)-6-decyl-thieno[2,3-d][1,3]oxazin-4-one (102): light yellow
solid (145 mg, 79% yield); m.p. = 55-58 SC; 1H NMR (CDCI,, 400 MHz) 8 0.878 (t,
3H, J= 6.0 Hz), 0.946 (t, 3H, J = 7.6 Hz), 1.18-1.45 (m, 18H), 1.55-1.71 (m, 4H),
2.64 (t, 2H, J = 7.6 Hz), 2.76 (t, 2H, J = 7.6 Hz), 6.99 (s, 1H), 7.15 (d, 2H, J = 8.4
Hz), 7.24 (d, 2H, J= 8.4 Hz); MS (ES) 442.64 (M+1), t, (method D) = 12.19min.
o
2-(3-Benzyloxy-propoxy)-6-decyI-thieno[2,3-d][1,3]oxazin-4-one (109): colorless
oil (115 mg, 87% yield): 'H NMR (CDCI3, 200 MHz) 8 0.88 (t, 3H, J= 6.6 Hz), 1.26-
1.38 (m, 14H), 1.67 (tt, 2H, J= 14.4, 7.4 Hz), 2.09 (tt, 2H, J= 12.4, 6.2 Hz), 2.76 (t,
2H, J= 7.4 Hz), 3.62 (t, 2H, J = 6.2 Hz), 4.51 (s, 2H), 4.53 (t, 2H, J= 6.4 Hz), 6.96 (t,
1H, J = 1.1 Hz), 7.24-7.33 (m, 5H). "C NMR (CDCI3, 100MHz) 5 14.04, 22.61,
28.78, 28.83, 29.22, 29.23, 29.44, 29.50, 30.25, 30.90, 31.82, 65.93, 67.46, 73.06,
113.59,118.14,127.60,128.31, 133.09,141.18,154.30, 156.73, 165.54.
2-(3-Benzyloxy-butyloxy)-6-decyl-thieno[2,3-d][1,3]oxazin-4-one (111): colorless
oil (19 mg, 36% yield): 'H NMR (CDCI3, 200 MHz) 8 0.88 (t, 3H, J = 6.4 Hz), 1.26-
1.38 (m, 14H), 1.63-1.99 (m, 14H), 2.76 (t, 2H, J= 7.7 Hz), 3.54 (t, 2H, J= 6.2 Hz),
4.44 (t, 2H, J= 6.2 Hz), 4.51 (s, 2H), 3.96 (t, 1H, J= 1.0 Hz), 7.28-7.35 (m, 5H).
N o
6-Butyl-2-octyloxy-thleno[2,3-d][1,3]oxazln-4-one (75): MS (ES/SIR): m/z 338.49
[MH4]. 1H NMR (CDCI3, 200 MHz): 8 = 0.78-1.03 (m, 6H), 1.15-1.53 (m, 12H),
1.54-1.90 (m, 4H), 2.77 (t, J = 7.5 Hz, 2H), 4.40 (t, J = 6.6 Hz, 2H), 6.96 (t, J = 0.8
Hz, 1H).
6-lsopropy!-2-octy!oxy-thieno[2,3-d][1,3]oxazin-4-one (76): MS (ES/SIR): m/z
324.46 [MH4]. 1H NMR (CDCI3, 200 MHz): 8 = 0.88 (t, J = 6.6 Hz, 3H), 1.18-1.52 (m,
16H), 1.70-1.88 (m, 2H), 2.98-3.22 (m, 1H), 4.40 (t, J = 6.6 Hz, 2H), 6.98 (d, J = 1.0
Hz, 1H).
6-Octyl-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one (85): 1H NMR (CDCI3, 200
MHz): 6 = 0.80-1.00 (m, 6H), 1.12-1.52 (m, 20H), 1.57-1.90 (m, 4H), 2.76 (td, J
1.0, 7.6 Hz, 2H), 4.40 (t, J = 6.6 Hz, 2H), 6.95 (t, J = 1.1 Hz, 1H).
N O
6-Dodecyl-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one (88): 1H NMR (CDCI3> 200
MHz): 5 = 0.80-0.98 (m, 6H), 1.16-1.52 (m, 28H), 1.58-1.88 (m, 4H), 2.76 (t, J = 7.2
Hz, 2H), 4.40 (t, J = 6.6 Hz, 2H), 6.95 (s, 1H).
2-Benzyloxy-6-Decyl-thieno[2,3-d][1,3]oxazin-4-one (105): MS (ES/SIR): m/z
400.56 [MH+].1H NMR (CDCI3, 400 MHz): 8 = 0.88 (t, J = 6.8 Hz, 3H), 1.17-1.42 (m,
14H), 1.67 (quint., J = 7.4 Hz, 2H), 2.77 (t, J = 7.1 Hz, 2H), 5.44 (s, 2H), 6.96 (s, 1H),
7.33-7.49 (m, 5H).
15 *2-(4-Butylbenzyloxy)-6-Decyl-thieno[2,3-d][1,3]oxazin-4-one (106): 1H NMR
(CDCI3, 200 MHz): 8 = 0.78-1.02 (m, 6H), 1.12-1.47 (m, 16H), 1.50-1.77 (m, 4H),
2.62 (t, J = 7.5 Hz, 2H), 2.77 (t, J = 7.6 Hz, 2H), 5.40 (s, 2H), 6.96 (s, 1H), 7.20 (d, J
= 8.0 Hz, 2H), 7.36 (d, J = 8.2 Hz, 2H).
6-Decyl-2-(2-p-tolyl-ethoxyHhieno[2,3-d][1,3]oxazin-4-one (107): 1H NMR
(CDCI3) 200 MHz): 8 = 0.88 (t, J = 6.6 Hz, 3H), 1.14-1.46 (m, 14H), 1.56-1.78 (m,
2H), 2.32 (s, 3H), 2.76 (t, J = 7.4 Hz, 2H), 3.06 (t, J = 7.0 Hz, 2H), 4.58 (t, J = 7.0 Hz,
2H), 6.95 (t, J = 1.1 Hz, 1H), 7.07-7.22 (m, 4H).
6-Decyl-2-phenethyloxy-thieno[2,3-d][1,3]oxazin-4-one (108): 1H NMR (CDCI3,
200 MHz): 8 = 0.88 (t, J = 6.4 Hz, 3H), 1.14-1.46 (m, 14H), 1.56-1.76 (m, 2H), 2.76
(t, J = 7.2 Hz, 2H), 3.11 (t, J = 7.0 Hz, 2H), 4.60 (t, J = 7.0 Hz, 2H), 6.95 (s, 1H),
7.18-7.42 (m,5H).
455
3-Methyl-6-octyl-2-octyloxy-5H-thieno[2,3-b]pyridin-4-one (87): 51 mg (60%).
m.p. 369C. 1H NMR (CDCI3, 200 MHz): 8 0.88 (t, J = 6.6 Hz, 6HO, 1.10-1.94 (m,
24H), 2.35 (s, 3H), 2.69 (t, J = 7.2 Hz, 2H), 4.38 (t, J = 7.0 Hz, 2H); 13C NMR (CDCI3,
75 MHz): 5 11.1, 12.3, 20.9, 23.9, 25.7, 26.6, 27.3, 27.4, 27.5, 27.6, 29.4, 30.0, 30.1,
68.6, 11.5, 126.9, 132.0, 153.1, 155.1, 162.9.
2-Butoxy-6-octyl-5H-thieno[2,3-b]pyridin-4-one (95): 265 mg (93%). 1H NMR
(CDCI3, 200 MHz): 8 0.86 (t, J = 6.6 Hz, 3H), 0.96 (t, J = 7.2 Hz, 3H), 1.14-1.88
(m,16H), 2.74 (t, J = 7.4 Hz, 2H), 4.39 (t, J = 6.6 Hz, 2H), 6.93 (s, 1H); 13C NMR
(CDCI3, 75 MHz): S 11.9, 12.3, 17.2, 20.9, 27.2, 27.4, 27.5, 28.6, 29.2, 30.1, 68.5,
101.9, 116.5, 139.4, 152.7, 155.2, 164.0; MS (SIR): 338.48 (M+1).
2-Hexyloxy-6-octyl-5H-thieno[2,3-b]pyridin-4-one (94): 312 mg (94%). 1H NMR
(CDCI3, 200 MHz): 8 0.86 (t, J = 6.6 Hz, 3H), 0.89 (t, J = 6.6 Hz, 3H), 1.15-1.54 (m,
16H), 1.54-1.88 (m, 4H), 2.74 (t, J = 7.0 Hz, 2H), 4.38 (t, J = 6.6 Hz, 2H), 6.94 (t, J =
1.2 Hz, 1H); 13C NMR (CDCI3, 75 MHz): 8 12.2, 12.3, 20.8, 20.9, 23.6, 26.6, 27.2,
27.4, 27.5, 28.6, 29.2, 29.6, 30.1, 68.8, 101.9, 116.5, 139.4, 152.7, 155.2, 164.0; MS
(SIR): 366.55 (M+1).
2-Dodecyloxy-6-octyl-5H-thieno[2,3-b]pyridin-4-one (100): 322 mg (91%). 1H
NMR (CDCI3, 200 MHz): 8 0.87 (t, J = 6.2 Hz, 6H), 1.04-1.52 (m, 28H), 1.52-1.90
(m, 4H), 2.75 (t, J = 7.0 Hz, 2H), 4.38 (t, J = 6.5 Hz, 2H), 6.94 (s, 1H); 13C NMR
(CDCI3) 75 MHz): 8 12.3, 12.4, 20.9, 21.0, 23.9, 26.6, 27.2, 27.4, 27.5, 27.6, 27.7,
27.8, 27.9, 28.6, 29.2, 30.1, 30.2, 68.8, 11.9, 116.5, 139.4, 152.7, 155.2, 164.0; MS
(SIR): 450.71 (M+1).
6-Decyl-2-phenoxy-5H-thieno[2,3-b]pyridin-4-onc (101): 322 mg (86%). 1H NMR
(CDCI3, 200 MHz): 8 0.87 (t, J = 6.6 Hz, 3H), 1.15-1.45 (m, 14H), 1.55-1.75 (m, 2H),
2.75 (t, J = 7.0 Hz, 2H), 7.0 (t, J = 1 Hz, 1H), 7.22-7.51 (m, 5H); 13C NMR (CDCl3, 75
MHz): 8 12.4, 21.0, 27.2, 27.5, 27.6, 27.6, 27.8, 28.6, 29.2, 30.2, 97.7, 97.7, 102.5,
116.5, 119.4, 124.9, 128.0, 140.7, 149.5, 152.3, 154.5, 163.1; MS (SIR): 358.48
(M+1).
2-Decyloxy-6-octyl-5H-th!eno[2,3-b]pyridin-4-one (110): 313 mg (69%). 1H NMR
(CDCIa, 200 MHz): 8 0.85 (t, J = 6.4 Hz, 6H), 1.16-1.50 (m, 24H), 1.50-1.88 (m, 4H),
2.74 (t, J = 6.8 Hz, 2H), 4.38 (t, J = 6.6 Hz, 2H), 6,93 (s, 1H); 13C NMR (CDCI3, 75
MHz): 8 12.3, 20.9, 20.9, 23.9, 26.6, 27.2, 27.4, 27.5, 27.6, 27.7, 27.8, 28.6, 29.2,
30.1, 30.1, 68.8, 111.9,116.5, 139.3, 152.6,155.2,164.0.
6-Benzyl-2-octyloxythieno[2,3-dl[1,3]oxazin-4-one (77)
Light yellow oil in 53% yield.
'H NMR (CDCI3, 200MHz): 5 7.20-7.40 (m, 5H), 6.98 (t, iH, J= 1.0Hz), 4.38 (t, 2H, J
=. 6.6Hz), 4.09 (s, 2H), 1.76(q, 2H, J= 7.2Hz), 1.10-1.50 (m, 10H), 0.88 (t, 3H, J =
7.0Hz). MS (ES) [M*+l] 372.51.
6-Hexyl-2-octyloxythieno[2,3-cQ[1,3]oxazin-4-one (84)
Light yellow oil in 30% yield.
'H NMR (CDCI3, 200MHz): S 6.94 (s, 1H), 4.39 (t, 2H, J = 6.6Hz), 2.76 (t, 2H, J =
7.2Hz), 1.76(q, 2H, J = 7.4Hz), 1.64 (q, 2H, J = 7.6Hz), 1.08-1.50 (m, 14H), 0.80-
0.95 (m, 6H). MS (ES) [M++l] 366.55.
O
6-Decyl-2-octyloxythieno[2,3-c/][1,3]oxazin-4-one (86)
Light yellow oil in 50% yield.
'H NMR (CDCI3) 200MHz): 5 6.94 (s, 1H), 4.39 (t, 2H, J = 6.6Hz), 2.76 (t, 2H, J =
7.2HZ), 1.76(q, 2H, J = 7.4Hz), 1.64 (q, 2H, J = 7.6Hz), 1.08-1.50 (m, 20H), 0.80-
0.95 (m, 6H). MS (ES) [M++l] 422.56
6-Decyl-2-(1-methylheptyloxy)thieno[2,3-d][1,3]oxazin-4-one(90)
Light yellow oil in 22% yield.
!H NMR (CDCI3, 200MHz): 5 6.96 (s, 1H), 5.13 (tq, 1H, J= 5.8, 6.2Hz), 2.76 (t, 2H, J
= 7.6Hz), 1.58-1.83(m, 4H), 1.08-1.50 (m, 26H), 0.80-1.00 (m, 6H). MS (ES) [M++l]
380.57.
6-Heptyl-2-(1-methylheptyloxy)thieno[2,3-cq[1,3]oxazin-4-one(91)
Light yellow oil in 28% yield.
'H NMR (CDCI3, 200MHz): 6 6.96 (s, 1H), 5.13 (tq, 1H, J= 6.2, 6.6Hz), 2.76 (t, 2H, J
= 7.6Hz), 1.58-1.83(171, 4H), 1.08-1.50 (m, 20H), 0.80-1.00 (m, 6H). MS (ES) [M++l]
422.65
6-Decyl-2-(4-phenylpropoxy)thieno[2,3-d][1,3]oxazin-4-one (99)
Light yellow oil in 28% yield.
'H NMR (CDCL, 200MHz): 5 7.17-7.38 (m, 5H), 6.96 (s, 1H), 4.42 (t, 2H, J= 6.6Hz),
2.72-2.85 (m, 4H), 2.05-2.20(m, 2H), 1.50-1.75(m, 2H), 1.20-1.40 (m, 16H), 0.88(t,
3H, J= 6.6Hz). MS (ES) [M++l] 428.62.
6-Decyl-2-(4-phenylbutoxy)thieno[2,3-d][1,3]oxazin-4-one (98)
Light yellow oil in 25% yield.
1H NMR (CDCI3, 200MHz): 8 7.10-7.38 (m, 5H), 6.96 (s, 1H), 4.42 (t, 2H, J= 6.4Hz),
2.60-2.80 (m, 4H), 1.75-1.83(m, 4H), 1.50-1.70(m, 2H), 1.18-1.40 (m, 16H), 0.88(t,
3H, J = 6.4Hz).
Example 23; Pancreatic lipase assay
The use of a pancreatic lipase assay has been described in the literature (Hadvary,
P. et al. Biochem. J. (1988) 256: 357-361; Hadvary, P. et al. Biochem. J. (1991)
266:2021-2027). Pancreatic lipase activity was measured using a 718 Stat Titrino
(Brinkmann) programmed to maintain a pH of 8.0 using 0.1 N NaOH. The substrate
mixture (pH 8) contained 1 mM taurochenodeoxycholate (Sigma), 9 mM
taurodeoxycholate (Sigma), 0.1 mM cholesterol (Sigma), 1 mM phosphatidylcholine
(Sigma), 1.5% BSA, 2 mM Tris base, 100 mM NaCI, 10 mM CaCI2, and 3% triolein
(Sigma). The mixture (5 mL) was emulsified via sonication at room temperature, and
added to the titration vessel with rapid stirring. The Stat Titrino was turned on and
lipase (7.0 nM type VI-S porcine pancreatic lipase (Sigma) dissolved in PBS) was
added to the vessel. After 10 min, inhibitor (700 nM dissolved in 100% DMSO) was
added and the reaction continued for an additional 12.5 min. The k values were
determined for the 12.5 min after the addition of the inhibitor using a one phase
exponential association equation, Y=Ymax*(1-exp(-k*X)), k values for lipase alone
were 0.0004 ± 0.0001 sec. The k values for compounds disclosed herein are
>0.0004 ± 0.0001 sec.
Equivalents
Those skilled in the art will recognize, or be able to ascertain, using no more than
routine experimentation, many equivalents to specific embodiments of the invention
described specifically herein. Such equivalents are intended to be encompassed in
the scope of the following claims.

WE CLAIM:
1. A compound having the structure:
(Formula Removed)
wherein,
X is O, S, or CH2; Y is O or S;
R1 is H, substituted CI-C15 alkyl, unsubstituted C2-C15 alkyl, C1-C8 alkylaryl, -C(0)OR4, -C(0)NR,R,, -CR„R„ OR,,, -CR6R6 OC(0)R4, CR6R6OC(0)NHR7, -QCONR8R9, NR8R9, -N(R5)C(0)NHR5, or CH9R4;
R2 is a substituted or unsubstituted, straight chainC1-C30 alkyl or branched C3-C30 alkyl, aryl, alkylaryl, arylalkyi, hclcroarylalkyi or cycloalkyl; and R3 is H, -CH3, -CI I2OCI l3 or C,-CK, cycloalkyl, wherein
R4 is H or a substituted or unsubstituted, straight chain or branched, C6-C30 alkyl, aryl, -CII2-aryl, aryl -C|-C«> alkyl, heteroaryl-C1-C30alkyl or C3-C10 cycloalkyl;
R5 is H or a substituted or unsubstituted, straight chain or branched, C6-C30 alkyl, aryl C1-C30 alkyl, heteroarylalkyl or cycloalkyl;
R6 and R6' are each independently H, substituted or unsubstituted C1-C6 alkyl, dialkyl or C3-C10 cycloalkyl or together form a 3-7 membered cycloalkyl or aryl group;
R7 is H or substituted or unsubstituted C1-C12 alkyl or C3-C10 cycloalkyl; and
Rg and R9 are each independently H, substituted or unsubstituted C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylaryl, or NR8R9 together form a

substituted piperazine or piperidine ring or a dihydro-lH-isoquinoline ring system, or a specific enantiomer thereof, or a specific tautomer, or a pharmaceutically acceptable salt thereof.
2.The compound as claimed in claim 1, having the structure:
(Structure Removed)
wherein, XisOorS;
R1 is H, -C(0)OR4, -C'(0)NR„Rs, -( R„R()OR,, -C R„R(,-OC(0)R4, -CR6R6-OC(0)NHR7, or CH2R4;
R2 is a substituted or unsubstiluled, straight chain or branched C6-C30 alkyl, arylalkyl, heteroarylalkyl or cycloalkyl; and
R3 is H, -CH3, -CH2OH3, or C3-C10 cycloalkyl, wherein,
R4 is H or a substituted or unsubstiluled, straight chain or branched, C6-C30 alkyl, arylalkyl, heteroarylalkyl or cycloalkyl;
R5 is H or a substituted or unsubstiluled, straight chain or branched, C6-C30 alkyl, arylalkyl, heteroarylalkyl or cycloalkyl;
R6 and R6' are each independently H, substituted or unsubstituted C1-C6 alkyl, dialkyl or cycloalkyl or together form a 3-7 membered cycloalkyl or aryl group; and
R7 is H or substituted or unsubstituted C1-C12 alkyl or cycloalkyl.
3.The compound as claimed in claim 2, wherein X is O;
R1 is -C(0)0-(C6-C30) alkyl, -C(0)NH-(C6-C30) alkyl or -C(0)OCH2(C6H5); R2 is C6-C30 alkyl; and

(Structure Removed)
The compound as claimed in claim 2, wherein R3 is H or -CH3.
5. The compound as claimed in claims 3 or 4, wherein X is O.
6.The compound as claimed in claims 3 to 5, wherein R3 is methyl.

7. The compound as claimed in claim 1, having the structure:

(Structure Removed)
wherein,
Y is O or S;
R, is 1-1, -(CH2)rCH3, -CH(CH3)2, -CH(CH3)CH2C(CH3),, -CH(CH3)(CH2)3C(=CH2)CI I3, -CH(CH)(CH2)3C(CH3)20C(0)CH3, -CH(CH3)[CH2]3C(CH3)2OCH3, -CHS(C6H5), -C(0)OH, -C(0)NH(CH2)tCH3,-C(0)0(CH2)uCH3, -C(0)OCH[(CH2)3CH3]2,-C(0)NH(CH2)vCH3, -C(0)N(CH3)2, -C(0)NHCH2(C6H5), -C(0)NHCH2(C5H4N),-C(0)N[(CH2)3CH3]2, -C(0)N[(CH2)5CH3]2, -C(0)N[(CH2)7CH3]2, -C(0)NH(C6Hn), -C(0)(NC4HgN)CH2(C6H5),-C(0)(NC5H9)CH2(C6H5), -C(0)NH(CH2)30(C6H5))-C(0)NHCH[(CH2)3CH3]2, -C(0)NH(CH2)3N(CH3)2,-C(0)NHCH2C(0)OCH2(C6H5), -e(0)N(CH3)CH2(C5H3N[CH3]),-C(0)NH(CH2)2(C5H4N), -C(0)N(CH2CH3)(CH2)2(C5H4N),-C(0)NHCH2(C4H30), -C(0)(NC4H8N)[CH2]2(NC5H10),-C(0)NHCH2CH(CH3)2, -C(0)NHCH2(C5H4N),-C(0)NHCH2C(CH3)3, -C(0)(NC4H8N)CH2C(0)NHCH(CH3)2,-C(0)(NC9H8)[OCH3]2,

-C(0)NHCH2(C6H3[OCH3]2), -C(0)NHCH2(C7H502), -C(0)NH(CH2)20(C6H5),-C(0)NH(CH2)20CH3) -C(0)NH(CH2)3OCH3, -C(0)NH(CH2)4(C6H5), or -C(0)NH(CH2)3(CH5);
r is an integer from 1 to 15;
s is an integer from 0 to 6;
t is an integer from 0 to 6;
u is an integer from 3 to 8;
v is an integer from 5 to 15; XR2 is -(CH2)nCH3 -O(CH2)mCH3, -OCH(CH3)2 -OCH(CH3)(CH2)5CH3 -OCH2;CH(CH3)2, -O(CH2) 2 OCH3.. -0(CH2)20CH2(C6H5), -0(C'I l2)n(C6H5), -OC'H3(C6H4](CH2)3CH3), -0(CH4|(CH2)3CH3]), -0(CH2)2(6H4](CH3])), -0(CH2)3OCH2(C6H5) or -0(CH2)4OCH2(C6H5);
n is an integer from 6 to 15;
m is an integer from 1 to 15;
p is an integer from 0 to 6;
and R3 is H, -CH3 or -CH2OCH3.

8. The compound as claimed in claim 7, having the structure:
(Structure Removed)
wherein,
Y is O or S;
R, is H, -(CH2)3CH3, -(CH,)SCH3, -(CH2)6CH3, -(CH2)7CH3, -(CH2)9CH3, -(CH2),,CH3, -CH(CH3)2, -CH(CH3)CH2C(CH3)3, -CH(CH3)(CH2)3C(=CH2)CH3, -CH(CH3)(CH2)3C(CH3)20C(0)CH3,
-CH(CH3)[CH2l3C(CH3)20CH3, -CH2(C6H5), -(CH2)2(C6H5), -(CH2)3(C6H5), -(CH2)4(C6H5), -(CH2)5(C6H5), -C(0)OH, -C(0)NHCH3, -C(0)NHCH2CH3, -C(0)NH(CH2)3CH3, -C(0)OCH2(C6H5), -C(0)0(CH2)5CH3, -C(0)0(CH2)6CH3) -C(0)0(CH2)7CH3, -C(0)OCH[(CH2)3CH3]2, -C(0)NH(CH2)5CH3, -C(0)NH(CH2)7CH3, -C(0)NH(CH2)9CH3, -C(0)NH(CH2)i 1CH3, -C(0)NH(CH2)|5CH3, -C(0)N(CH3)2, -C(0)NHCH2(C6H5), -C(0)NHCH2(C5H4N),-C(0)N[(CH2)3CH3]2, -C(0)N[(CH2)5CH3]2, -C(0)N[(CH2)7CH3]2, -C(0)NH(C6H„), -C(0)(NC4H8N)CH2(C6H5),-C(0)(NC5H9)CH2(C6H5), -C(0)NH(CH2)30(C6H5),-C(0)NHCH[(CH2)3CH3]2, -C(0)NH(CH2)3N(CH3)2,-C(0)NHCH2C(0)OCH2(C6H5), -C(0)N(CH3)CH2(C5H3N[CH3]),-C(0)NH(CH2)2(C5H4N), -C(0)N(CH2CH3)(CH2)2(C5H4N),-C(0)NHCH2(C4H30), -C(0)(NC4H8N)[CH2]2(NC5H,o), -C(0)NHCH2CH(CH3)2, -C(0)NHCH2(C5H4N),-C(0)NHCH2C(CH3)3, -C(0)(NC4H8N)CH2C(0)NHCH(CH3)2,-C(0)(NC9H8)[OCH3]2, -C(0)NHCH2(C6H3[OCH3]2),-C(0)NHCH2(C7H502),

2-Octyloxy-6-(3-phenyl-propyl)-thieno[2,3-d][ 1,3]oxazin-4-one; 2-Octyloxy-6-(4-phenyl-butyl)-thieno[2,3-d][ 1,3]oxazin-4-one; 2-Octyioxy-6-(5-phenyl-pentyI)-thieno[2,3-d][l,3]oxazin-4-one; 6-Decyl-2-(2-methoxy-ethoxy)-thieno[2,3-d][ 1,3]oxazin-4-one; 2-(4-Butyl-phenoxy)-6-decyl-thieno[2,3-d|[l,3]oxazin-4-one; 2-(3-Benzyloxy-propoxy)-6-decyl-thieno[2,3-d |[ 1,3 joxazin-4-one; 2-(3-Benzyloxy-butyloxy)-6-decyl-thieno(2,3-d II1,3 |oxazin-4-onc; 6-Isopropyl-2-octyloxy-thieno[2,3-d |[ 1,3 |oxazin-4-onc; 6-Octyl-2-octyloxy-thieno[2,3-d|| 1,3 |oxa/.in-4-one; 6-Dodecyl-2-octyloxy-thieno[2,3-d || 1,3 |oxazin-4-one; 2-Benzyloxy-6-Decyl-thieno[2,3-d || 1,3 |oxazin-4-one; 2-(4-Butylbenzyloxy)-6-Decyl-lhicno[2,3-d|l 1,3|oxazin-4-one; 6-Decyl-2-(2-p-tolyl-ethoxy)-thienol2,3-d|[I,3]oxazin-4-one; 6-Decy 1-2-phenethy loxy-th ieno( 2,3 -d | [ 1,3 joxazin-4-one; 3-Methyl-6-octyl-2-octyloxy-5U-thieno[2,3-b]pyridin-4-one; 2-Butoxy-6-octyl-5H-thieno[2,3-b|pyridin-4-one; 2-Hexyloxy-6-octyl-5H-thieno[2,3-b|pyridin-4-one; 2-Dodecyloxy-6-octyl-5H-thieno[2,3-b]pyridin-4-one; 6-Decyl-2-phenoxy-5H-thieno[2,3-b]pyridin-4-one; 2-Decyloxy-6-octyl-5H-thieno[2,3-b]pyridin-4-one; 6-Benzyl-2-octyloxythieno[2,3-t/][l,3]oxazin-4-one; 6-Decyl-2-octyloxythieno[2,3-d][l,3]oxazin-4-one; 6-Decyl-2-(l-methylheptyloxy)thieno[2,3-d][l,3]oxazin-4-one; 6-Heptyl-2-( 1 -methylheptyloxy)thieno[2,3-d][l ,3]oxazin-4-one; 6-Decyl-2-(4-phenylpropoxy)thieno[2,3-t/][l,3]oxazin-4-one; and 6-Decyl-2-(4-phenylbutoxy)thieno[2,3-c/][l,3]oxazin-4-one.

10. A compound having the structure:
(Structure Removed)
wherein,
Y is O; XR2is -N([CH2]7CH,)C(0)NI I(CH2)7CH3, -N([CH2J6CH3)C(0)NH(CH3)()CH3, -NH(CH2)qCH3, -NH(C6H4)0(C6H5), -N(CH3)(CH2)5CH3, -NHCH[(CH2)3CH3]2, -NHCH(CH3)[CH2]5CH3, or -N([CH2]7CH3)2; q is an integer from 6 to 15;
Ri is H, substituted C1-C15 alkyl, or unsubstituted C2-C15 alkyl, C1-C8 alkylaryl, -C(0)OR4, -C(0)NR4R5, -CR6R6OR4, -CR6R60C(0)R4, CR6R60C(0)NHR7, -C(0)NRgR9NR8R9, -N(R5)C(0)NHR5, or CH2R4; R3 is H, -CH3, -CH2OCH3 or C3-C10 cycloalkyl, wherein
R4 is H or a substituted or unsubstituted, straight chain or branched, C6-C30 alkyl, aryl, -CH2-aryl, aryl -C1-C30 alkyl, heteroaryl-C1-C30alkyl or C3-C10 cycloalkyl; R6 and R6- are each independently H, substituted or unsubstituted C1-C6 alkyl, dialkyl or C3-C10 cycloalkyl or together form a 3-7 membered cycloalkyl or aryl group; R7 is H or substituted or unsubstituted C1-C12 alkyl or C3-C10 cycloalkyl; and

R8 and R9 are each independently H, substituted or unsubstituted C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylaryl, or NR8R9 together form a substituted piperazine or piperidine ring or a dihydro-1 H-isoquinoline ring system,
or a specific enantiomer thereof, or a specific tautomer, or a pharmaceuticaliy
acceptable salt thereof.
11. The compound as claimed in claim 10 having the structure:
(Structure Removed)
wherein,
R1 is H,
-(CH2)rCH3,
-CH(CH3)2,
-CH(CH3)CH2C(CH,)3,
-CH(CH3)(CH2)3C(=CH2)CH3,
-CH(CH3)(CH2)3C(CH3)2OC(0)CH3,
-CH(CH3)[CH2J3C(CH3)2OCH3,
-CHs(C6H5),
-C(0)OH,
-C(0)NH(CH2)tCH3,
-C(0)0(CH2)uCH3,
-C(0)OCH[(CH2)3CH3]2,
-C(0)NH(CH2)vCH3,
-C(0)N(CH3)2,
-C(0)NHCH2(C6H5),
-C(0)NHCH2(C5H4N),
-C(0)N[(CH2)3CH3]2,
-C(0)N[(CH2)5CH3]2,
-C(0)N[(CH2)7CH3]2,

-C(0)NH(C6Hn),
-C(0)(NC4H8N)CH2(C6H5),
-C(0)(NC5H9)CH2(C6H5),
-C(0)NH(CH2)30(C6H5),
-C(0)NHCH[(CH2)3CH3]2,
-C(0)NH(CH2)3N(CH3)2,
-C(0)NHCH2C(0)OCH2(C6H5),
-C(0)N(CH3)CH2(C5H3N[CH3]),
-C(0)NH(CH2)2(C5H4N),
-C(0)N(CH2CH3)(CH2)2(C5H4N),
-C(0)NHCH2(C4H30)7
-C(O)(NC4H8N)[CH2]2(NC5H10),
-C(0)NHCH2CH(CH3)2,
-C(0)NHCH2(C5H4N),
-C(0)NHCH2C(CH3)3,
-C(0)(NC4H8N)CH2C(0)NHCH(CH3)2,
-C(0)(NC9Hg)[OCH,]2,
-C(0)NHCH2(C6H3[OCI I3I2),
-C(0)NHCH2(C7Hs02),
-C(0)NH(CH2)20(C6H5),
-C(0)NH(CH2)2OCH3,
-C(0)NH(CH2)3OCH3,
-C(0)NH(CH2)4(C6H5), or
-C(0)NH(CH2)3(C6H5);
r is an integer from 1 to 15;
s is an integer from 0 to 6;
t is an integer from 0 to 6;
u is an integer from 3 to 8;
v is an integer from 5 to 15; XR2is
-N([CH2]7CH3)C(0)NH(CH2)7CH3, -N([CH2]6CH3)C(0)NH(CH2)6CH3, -NH(CH2)qCH3,

-NH(C6H4)0(C6H5), -N(CH3)(CH2)5CH3, -NHCH[(CH2)3CH3]2, -NHCH(CH3)[CH2]5CH3, or -N([CH2]7CH3)2;
q is an integer from 6 to 15; and R3 is H, -CH3, -CH2OCH3 or C3-C10 cycloalkyl.
12. The compound as claimed in claim 11, having the structure:
(Structure Removed)

wherein,
R, is H,

-(CH2)3CH3, -(CH2)sCH3,
-(CH2)6CH3,
-(CH2)7CH3)
-(CH2)9CH3,
-(CH2),,CH3,
-CH(CH3)2,
-CH(CH3)CH2C(CH3)3,
-CH(CH3)(CH2)3C(=C H2)C H3,
-CH(CH3)(CH2)3C(CH3)20C(0)CH3,
-CH(CH3)[CH2]3C(CH3)20CH3,
-CH2(C6H5),
-(CH2)2(C6H5),
-(CH2)3(C6H5),
-(CH2)4(C6H5),

-(CH2)5(C6H5),
-C(0)OH,
-C(0)NHCH3,
-C(0)NHCH2CH3,
-C(0)NH(CH2)3CH3,
-C(0)OCH2(C6H5),
-C(0)0(CH2)5CH3,
-C(0)0(CH2)6CH3,
-C(0)0(CH2)7CH31,
-C(0)OCH[(CH2)3CH3|2,
-C(0)NH(CM2)sCH3t,
-C(0)NM(CH2)7Cllt,
-C(0)NH(CII2)yCH3,
-C(0)NH(CH2)2CH3,,
-C(0)NH(CH2)isCH3,
-C(0)N(CH3)2,
-C(0)NHCH2(C6H5).
-C(0)NHCH2(C5H4N),
-C(0)N|(CH2)3CH32,
-C(0)N[(CH2)5CH3]2,
-C(0)N[(CH2)7CH,|2,
-C(0)NH(C6H,,),
-C(0)(NC4H8N)CH2(C6H5),
-C(0)(NCSH9)CH2(C6H5),
-C(0)NH(CH2)30(C6H5),
-C(0)NHCH[(CH2)3CH3]2,
-C(0)NH(CH2)3N(CH3)2,
-C(0)NHCH2C(0)OCH2(C6H5),
-C(0)N(CH3)CH2(C5H3N[CH3]),
-C(0)NH(CH2)2(C5H4N),
-C(0)N(CH2CH3)(CH2)2(C5H4N),
-C(0)NHCH2(C4H30),
-C(O)(NC4H8N)[CH2]2(NC5HI0),

-C(0)NHCH2CH(CH3)2,
-C(0)NHCH2(C5H4N),
-C(0)NHCH2C(CH3)3,
-C(0)(NC4H8N)CH2C(0)NHCH(CH3)2,
-C(0)(NC9H8)[OCH3]2,
-C(0)NHCH2(C6H3[OCH3]2),
-C(0)NHCH2(C7H502),
-C(0)NH(CH2)20(C6H5),
-C(0)NH(CH2)2OCH3,
-C(0)NH(CH2)3OCH3,
-C(0)NH(CH2)4(Cl,Hs), or
-C(0)NH(CH2),(C()Hs); XR2 is -N([CH2j7CH3)C(0)NII(CH2)7CH3
-N([CH2]6CH3)C(())NH(CH!)(,CHl,
-NH(CH2)()CCH3,
-NH(CH2)7CH3,
-NH(CH2)CH3,
-NH(CH2),13CH,,
-NH(CH2),sCH,,
-NH(C6H4)0(C6H5),
-N(CHj)(CII2)5CH3,
-NHCH[(CII2)3CH,]2,
-NHCI l(CI l3)[CH2|5CH3, or
-N([CH2]7CH3)2; and R3 is H, -CH3 or -CH2OCH3.
13. The compound as claimed in any one of claims 1 to 12, wherein any heterocyclic or heteroaryl ring, if present, is a piperazine, piperidine, (l,4)diazepan, pyrazine, pyridine, pyrrolidine, pyrazole, pyrimidine, thiophene, imidazole, azetidine, pyrrole, benzothiazole, benzodioxolane, dithiolane, oxathiine, imidazolidine, quinoline, isoquinoline, dihydroisoquinoline, indole, isoindole, triazaspiro[4.5]decane, morpholine, furan or an isothiazole ring.

14. The compound as claimed in any one of claims 1 to 12, wherein any substituent, if
present, is halogen, hydroxyl, straight chain (C1-C30)alkyl, branched chain (C3-
C30)alkyl, (C3-C10)cycloalkyl, straight chain(C1-C30)alkylcarbonyloxy, branched chain
(C3-C30)alkylcarbonyloxy, arylcarbonyloxy, straight chain(C1-C30)alkoxycarbonyloxy,
branched chain(C3-C3o)alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, straight
chain(C1-C30)alkylcarbonyl, branched chain (C3-C30)alkylcarbonyl, straight chain (C1-
C3o)alkoxycarbonyl, branched chain (C1-C30)alkoxycarbonyl, aminocarbonyl, straight
chain (C1-C30)alkylthiocarbonyl, branched chain (CVC\to)alkylthiocarbonyl, straight
chain (C1-C30)alkoxyl, branched chain (C1-C30)alkoxyl, phosphate, phosphonato,
cyano, amino, straight chain (C1-C30)alkylamino, branched chain ((.VC'm)alkylamino,
straight chain (Cj-C3o)dialkylamino, branched chain (C3-C30)dialkylamino, arylamino,
diarylamino, straight chain (C1-C30)alkylarylarhino, branched chain (C3-
C3o)alkylarylamino, acylamino, straight chain (C1-C30)alkylearbonylamino, branched
chain (C3-C30)alkylcarbonylamino, arylcarbonylamino, carbamoyl, urcido, amidino,
imino, sulfhydryl, straight chain (C1-C30))alkylthio, branched chain (C1-C30)alkylthio,
arylthio, thiocarboxylate, sulfates, sulfonato, sullamoyl, sullbnamido, nitro,
trifluoromethyl, azido, 4-10 membered hetcrocyclyl, straight chain (C1-C30)alkylaryl,
branched chain (C3-C30)alkylaryl, benzo( l,3)dioxole, or an aromatic or 5-6 membered
heteroaromatic moiety,
which substituent may be further substituted by any of the above.
15. An in vitro method of inhibiting the hydrolytic activity of pancreatic lipase enzymes in
a cell, comprising contacting the cell with an amount of the compound of any one of
claims I, 2, 7, 8, 10, 11 or 12 which is effective in inhibiting the hydrolytic activity of
pancreatic lipase enzymes.

16.A process of manufacturing a compound having the structure:
(Structure Removed)
wherein,
X is O, S or CH2;
R1 is H, substituted C1-C15 alkyl, unsubstituted C2-C15 alkyl, C1-C8 alkylaryl, -C(0)OR4, -C(0)NR4R5, -CR6R6 OR,, -CR6R6, OC(0)R4, -CR6R6 OC(0)NHR7, -C(0)NR8R9, -C(0)NR8R9NR8R9, -N(R5)C(0)NHR5, or CH2R4;
R2 is a substituted or unsubstituted, straight chain C1-C30 alkyl or branched C3-C30 alkyl, aryl, alkylaryl, arylalkyl, heteroarylalkyi or cycloalkyi; R3 is H, -CH3, -CH2OCH3 or cycloalkyi;
R4 is H or a substituted or unsubstituted, straight chain or branched, C6-C30 alkyl, aryl, -CH2-aryl, arylalkyl, heteroarylalkyi or cycloalkyi;
R5 is H or a substituted or unsubstituted, straight chain or branched, C6-C30 alkyl, arylalkyl, heteroarylalkyi or cycloalkyi;
R6 and R6 are each independently H, substituted or unsubstituted C1-C6 alkyl, dialkyl or cycloalkyi or together form a 3-7 membered cycloalkyi or aryl group;
R7 is H or substituted or unsubstituted C1-C12 alkyl or cycloalkyi;
R8 and R9 are each independently H, substituted or unsubstituted
C1-C6 alkyl, C1-C6 alkoxy, C|-C6 alkylaryl, or NR8R9 together form a
substituted piperazine or piperidine ring or a dihydro-lH-isoquinoIine
ring system,

or

XR2is

-N([CH2]7CH3)C(0)NH(CH2)7CH3, -N([CH2]6CH3)C(0)NH(CH2)6CH3,

-NH(CH2)qCH3, -NH(C6H4)0(C6H5), -N(CH3)(CH2)5CH3, -NHCH[(CH2)3CH3]2, -NHCH(CH3)[CH2]5CH3, or -N([CH2]7CH3)2; q is an integer from 6 to 15;
R1 is H, substituted or unsubstituted C1-C15 alkyl, or unsubstituted C2-C15 alkyl, C1-
C8 alkylaryl, -C(0)OR4, -C(0)NR4R5, -CR6R6OR4, -CR6R6 OC(0)R4, -
CR6R6 OC(0)NHR7, -C(0)NR8R9, -C(0)NR8R9NR8R9, -N(R5)C(0)NHR5, or
CH2R4;
R2 is a substituted or unsubstituted, straight chain C1-C30 alkyl or branched C3-C30
alkyl, aryl, alkylaryl, arylalkyl, heteroarylalkyl or cycloalkyl; R3 is H or substituted or unsubstituted C|-C6 alkyl-CH3, -CH2OCH3 or cycloalkyl; R4 is H or a substituted or unsubstituted, straight chain or branched, C6-C30alkyl,
aryl, -CH2-aryl, arylalkyl, heteroarylalkyl or cycloalkyl; R5 is H or a substituted or unsubstituted, straight chain or branched, C6-C30 alkyl,
aryl C1-C30 alkyl, heteroarylalkyl or cycloalkyl; R6 and R6- are each independently H, substituted or unsubstituted C1-C6 alkyl, dialkyi or cycloalkyl or together form a 3-7 membered cycloalkyl or aryl groupring system; R7 is H or substituted or unsubstituted C1-C12 alkyl or cycloalkyl; R8 and R9 are each independently H, substituted or unsubstituted C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylaryl, or NR8R9 together form a substituted piperazine or piperidine ring or a dihydro-lH-isoquinoline ring system, comprising
(a) reacting

(Structure Removed)
in the presence of sulfur, a base and solvent to produce:
(Structure Removed)
(b) reacting the product of step (a) with
(Structure Removed)
in the presence of a base to produce:

(Structure Removed)

(c) reacting the product of step (b) with trifluoroacetic acid (TFA) in the presence of solvent to produce:
(Structure Removed)

(d) reacting the product of step (c) with SOCI2 in the presence of solvent to produce the compound.
17. The process as claimed in claim 16, wherein the intermediates having the structure:

(Structure Removed)

wherein, R10 is H or substituted or unsubstituted C1-C15 alkyl, C1-C15 alkylaryl, or -C(0)R14,
wherein R11 is hydroxyl, or a substituted or unsubstituted C1-C30 alkyl,
alkylamino, dialkylamino, alkoxy, benzyloxy, cycloalkyl, alkylheteroaryl,
alkylaryl, or a heterocyclic, heteroaryl or aryl ring; R11 is hydrogen or methyl; R12 is hydrogen or tert/-butyl; and R11 is hydrogen or -C(0)ZR15,
wherein Z is CH2, O or N and R15 is substituted or unsubstituted C1-C15 alkyl or
aryl.
18. The process as claimed in claim 16, wherein the base in step (a) is triethyl amine and the solvent is dimethylformamide (DMF).
19. The process as claimed in claim 16 or 18, wherein the solvent in step (c) is dichloromethane.
20. The process as claimed in claim 16 or 19, wherein the solvent in step (d) is pyridine:CH2Cl2.

Documents:

1808-delnp-2004-abstract.pdf

1808-DELNP-2004-Claims-(02-09-2008).pdf

1808-DELNP-2004-Claims-(18-09-2008).pdf

1808-delnp-2004-claims.pdf

1808-DELNP-2004-Correspondence-Others-(02-09-2008).pdf

1808-DELNP-2004-Correspondence-Others-(18-09-2008).pdf

1808-delnp-2004-correspondence-others.pdf

1808-delnp-2004-description (complete)-02-09-2008.pdf

1808-delnp-2004-description (complete).pdf

1808-DELNP-2004-Form-1-(18-09-2008).pdf

1808-delnp-2004-form-1.pdf

1808-delnp-2004-form-13.pdf

1808-DELNP-2004-Form-2-(02-09-2008).pdf

1808-delnp-2004-form-2.pdf

1808-DELNP-2004-Form-26-(02-09-2008).pdf

1808-delnp-2004-form-26.pdf

1808-DELNP-2004-Form-3-(02-09-2008).pdf

1808-delnp-2004-form-3.pdf

1808-delnp-2004-form-5.pdf

1808-delnp-2004-pct-101.pdf

1808-delnp-2004-pct-401.pdf

1808-delnp-2004-pct-408.pdf

1808-delnp-2004-pct-409.pdf

1808-delnp-2004-pct-416.pdf

1808-DELNP-2004-Petition-137-(02-09-2008).pdf

1808-delnp-2004-petition-138.pdf

abstract.jpg

« Previous Patent

Next Patent »

Patent Number

226041

Indian Patent Application Number

1808/DELNP/2004

PG Journal Number

01/2009

Publication Date

02-Jan-2009

Grant Date

05-Dec-2008

Date of Filing

24-Jun-2004

Name of Patentee

OSI PHARMACEUTICALS, INC

Applicant Address

58, SOUTH SERVICE ROAD, MELVILLE, NEW YORK 11747, U.S.A.

Inventors:

#	Inventor's Name	Inventor's Address
1	WITTER, DAVID	12 ARBUTUS ROAD, PUTNAM VALLEY NEW YORK 10579, U.S.A.
2	CASTELHANO, ARLINDO L.	3 EAGLE COURT, NEW CITY NEW YORK 10956 U.S.A.

PCT International Classification Number

C07D 265/12

PCT International Application Number

PCT/US02/41272

PCT International Filing date

2002-12-20

PCT Conventions:

#	PCT Application Number	Date of Convention	Priority Country
1	60/357,015	2002-02-13	U.S.A.
2	60/342,617	2001-12-20	U.S.A.